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Abstract 
Approximately 40% of women will experience at least one urinary tract infection (UTI) in their lifetime 
and 25% of these women will go on to suffer recurrent UTIs. After the menopause, the risk of developing 
a recurrent UTI doubles, which is putatively linked to reduced estrogen levels. Topical vaginal estrogen 
treatment in postmenopausal women has been shown to reduce the incidence of UTIs. However, the 
mechanism by which vaginal estrogen helps to protect against UTIs is not well understood. Antimicrobial 
peptides (AMPs), secreted in response to infection and functioning via bacterial cell lysis, are an important 
component of the host innate immune response to infection. The aim of this project was to investigate 
the effects of estrogen treatment on vaginal epithelial AMP expression and synthesis. 
 
Immortalised vaginal epithelial cells (VK2 E6/E7), used to model the vaginal epithelium, were treated 
with 4nM 17β-estradiol for seven days and then challenged with 50ng/ml flagellin (isolated from 
Escherichia coli clinical UTI isolate) for 24 hours. Combined estrogen pretreatment plus flagellin resulted in 
a 2.3- and 2.1-fold increase in expression of the AMPs human β-defensin 2 (hBD2) and hBD3, 
respectively, above that observed with flagellin challenge alone (p-values <0.001). 
 
Microarray analyses identified upregulation of the AMPs LCN2, RNase 7, S100A7, S100A12, SLPI, by 
estrogen pretreatment plus flagellin in addition to hBD2 and hBD3. Furthermore, several genes relating to 
keratinisation (for example keratin and SPRR genes) and inflammation (for example SERPINB4, S100A8 
and S100A9) were also upregulated suggesting that estrogen pretreatment stimulated multiple protective 
responses in VK2 cells.  
 
A hBD2 luciferase reporter vector containing a 2032bp hBD2 promoter region was used to measure 
hBD2 expression in response to estrogen and flagellin treatments. Reporter activity in VK2 cells 
significantly increased 2.1-fold following seven day estrogen pretreatment (4nM) plus flagellin (50ng/ml) 
challenge compared to flagellin challenge without estrogen pretreatment (p=0.0367). Six estrogen 
response elements (EREs) were identified in the hBD2 promoter and were mutated by site-directed 
mutagenesis. Mutation of each of the EREs abolished hBD2 gene expression potentiation by estrogen 
pretreatment plus flagellin, suggesting that hBD2 is regulated through ER-α or ER-β binding to EREs in 
the hBD2 promoter.  
 
Pathway analysis of the microarray data identified IL-17A as a potential regulator of AMP expression. 
Thus, VK2 cells were challenged with exogenous IL-17A in concentrations ranging from 0.1ng/ml to 
100ng/ml for 24 hours. The expression of hBD2, LCN2, RNase 7, and S100A7 was significantly 
increased between 2- and 21- fold in an IL-17A dose dependent manner (p-values <0.001). In addition, 
estrogen pretreatment of VK2 cells prior to challenge with IL-17A (100ng/ml) plus flagellin (50ng/ml) 
significantly increased the expression of hBD2, hBD3 and S100A7 by between 1.4- and 1.6-fold compared 
to IL-17A plus flagellin without estrogen (p-values <0.05). These data indicated an important role for 
estrogen in AMP expression even in the presence of proinflammatory cytokines, such as IL-17A.  
 
Altogether, these data indicated that estrogen is an important regulator of innate epithelial defences of the 
urogenital tract. These results suggest that estrogen protects against UTIs by augmenting the vaginal 
antimicrobial response to infection and by strengthening the epithelial barrier to infections. Hence, loss of 
estrogen following the menopause leaves postmenopausal women susceptible to repeated UTIs.  
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1 Introduction 
1.1 The urogenital tract 
The urogenital tract consists of the reproductive and urinary systems. These are grouped together 
due to their proximity and use of common pathways, for example the male urethra, which carries 
both urine and semen. The reproductive system consists of the sex organs involved in human 
reproduction. In females this consists of the ovaries, fallopian tubes, uterus, cervix and vagina, 
which function in the development and transportation of oocytes. In males the reproductive 
system consists of the testes, epididymis, vas deferens, seminal vesicles, prostate and urethra, 
which function in the development and transportation of sperm cells. The urinary tract is the 
same in both men and women and consists of the kidneys, ureters, bladder, and urethra. The 
upper urinary tract is responsible for filtering waste products out of the blood to produce urine. 
Urine is transported from the kidneys to the bladder, via the ureters, where it is stored until 
excretion from the body via the urethra. Women are more prone to urinary tract infections 
(UTIs) than men; approximately 50% of women of women experience at least one UTI in their 
lifetime, compared to only 12% of men1. This is largely due to anatomy, as the urethra is shorter 
in women than in men and is much closer to the anus, the source of bacteria that cause UTIs. 
 
1.2 Infections of the urogenital tract 
UTIs occur when bacteria from the gut colonise the urinary tract. Initially the bacteria migrate 
from the bowel to the periurethral area, where the organisms can multiply and establish a 
reservoir. In women the vagina also provides an important reservoir for the invading organisms. 
Nearly 50 years ago Gruneberg (1969) demonstrated that in more than 80% of patients the 
urinary bacterial strain causing an acute symptomatic UTI could also be recovered from and was 
the predominant strain in the rectum, vagina, and periurethral area2. From the periurethral area 
and/or vagina bacteria can colonise the urethral opening and ascend the urethra to infect the 
bladder. In the bladder, the invading bacteria can replicate extracellularly in the bladder lumen, or 
penetrate the bladder epithelium and replicate intracellularly within the superficial umbrella cells3. 
Bacterial infection of the bladder is termed cystitis and is clinically diagnosed by bacterial 
numbers in the urine greater than 5x105 colony forming units (CFU) per millilitre. Typical 
symptoms of cystitis include cloudy urine, urinary urgency and frequency, and pain upon 
urination. In approximately 1% of cystitis patients the bacteria ascend from the bladder into the 
ureters and from here infect the kidneys causing pyelonephritis4. Once the kidneys are infected, 
the bacteria can access the bloodstream and cause bacteraemia, which may be fatal1. Figure 1.1 
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shows the progression of bacteria from the bowel to the kidney. UTIs can also be asymptomatic; 
asymptomatic bacteriuria is the presence of >5x105 CFU/ml bacteria in the urine but without the 
patient experiencing any symptoms. It is not well understood what host or bacterial factors 
contribute to the development of an asymptomatic UTI.  
 
 
Figure 1.1: Bacterial migration in UTIs. UTIs occur when bacteria from the bowel colonise the periurethral 
area/vagina and from here ascend the urethra and infect the bladder. From the bladder the bacteria may ascend the 
ureter to infect the kidney. Diagram adapted from ref 5. 
 
After the initial infection, approximately 25% of cystitis patients will experience a recurrent 
urinary tract infection (rUTI)6. Recurrent UTI is defined as either two episodes of UTI within six 
months or three episodes within twelve months7. A rUTI usually occurs when the bacterial strain 
that caused the initial infection is not successfully cleared from the urogenital tract and residual 
bacteria in the vagina or periurethral area can reinfect the bladder. However, less commonly rUTI 
can occur by reinfection of the urinary tract by a different bacterial strain8.  
 
1.3 UTI prevalence and risk factors 
There are approximately 150 million cases of UTIs worldwide each year and UTIs account for 1-
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3% of all GP visits9. Cost analyses in 1995 revealed the estimated cost of community-acquired 
UTIs in the USA was $1.6 billion per annum10. Limited figures are available for the UK, but an 
investigation into hospital-acquired infections in 1995 showed that hospital-acquired UTIs alone 
cost the NHS £124 million per annum11. More recent figures (from 2010) suggest that diagnosis 
and treatment of an acute UTI costs approximately £33 per patient12.  
 
In women risk factors associated with increased incidence of UTI differ between pre- and 
postmenopausal women. Risk factors for premenopausal women include frequent sexual 
intercourse, use of spermicides as a contraceptive and congenital urinary tract abnormalities10. 
The menopause could be classed as a risk factor in itself, as postmenopausal women are more 
susceptible to UTIs and are twice as likely to experience a rUTI than premenopausal women13. 
Other risk factors for postmenopausal women include incontinence, post-voiding residual urine 
volume and abnormal urine flow14.  
 
1.4 Uropathogenic organisms 
Urinary tract infections may be caused by bacteria, fungi or viruses, although fungal and viral 
UTIs are rare and only seen in immunocompromised or hospitalised patients15,16. Approximately 
75-95% of bacterial UTIs are caused by the Gram-negative microorganism Escherichia coli. Other 
potential but less common causes of bacterial UTIs include Staphylococcus saprophyticus, Klebsiella 
pneumoniae, and Enterococcus faecalis, however, these organisms are more frequent in hospital-
acquired UTIs17,18. As E. coli is the primary cause of community-acquired UTIs this will be the 
focus of discussions in this thesis.  
 
1.4.1 Bacterial virulence factors 
E. coli that infect the urinary tract are called uropathogenic E. coli (UPEC) and display a variety of 
virulence factors to facilitate colonisation of the host (Figure 1.2).  
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Figure 1.2: Virulence factors of uropathogenic E. coli (UPEC). UPEC possess a number of virulence factors to 
facilitate survival within the host. These include fimbriae, flagella, iron acquisition systems, and toxins.  
 
The first of these virulence factors are fimbriae. Fimbriae, also called pili, are short filamentous 
organelles on the bacterial surface that are vital for adherence to cell surfaces. UPEC strains carry 
significantly more fimbrial gene clusters than commensal E. coli isolates19. Although there are 
many different types of fimbriae, type I fimbriae and P fimbriae are the most well characterised. 
Deletion or mutation of the type I fimbrial adhesin fimH gene diminishes the ability of UPEC to 
colonise the urinary tract20,21. The FimH adhesin of type I fimbriae binds to the host glycoprotein 
uroplakin 1a on the bladder epithelium and has an important role in adhesion to and invasion of 
bladder epithelial cells (Figure 1.3)22–24. P fimbriae are unique to UPEC and are associated with 
pyelonephritic UPEC isolates25. The PapG adhesin of P fimbriae recognises and binds to 
glycoproteins found abundantly within the renal epithelium26. However, although some research 
has shown that P fimbriae are required for renal colonisation by UPEC, others have reported that 
deletion of P fimbriae genes does not affect the ability of UPEC to infect the kidney25,27. The 
contribution of P fimbriae to UPEC virulence is, therefore, unclear.  
 
In addition to fimbriae, UPEC also possess flagella, which provide the bacteria with motility. 
Flagella are an important virulence factor with respect to UTIs as ascension of the urinary tract is 
key to colonisation and maximal flagella expression coincides with bacterial ascension of the 
urinary tract28. UPEC must coordinate the expression of fimbriae and flagella, as these perform 
opposing functions. Thus, expression of type I fimbriae to allow adhesion downregulates 
expression of flagellin, the main component of flagella, and hence reduces motility29.   
 
UPEC also secrete toxins to facilitate invasion of the host. Hemolysin A (HlyA) is the most well 
characterised toxin and is encoded by approximately 50% of UPEC isolates30,31. HlyA is a pore-
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forming toxin that has cytolytic activity. Furthermore, expression of HlyA results in shedding of 
the bladder epithelial cells and is associated with increased UTI severity32,33. The HlyA toxin has 
also been reported to stimulate degradation of host signalling pathway components and thus 
reduce the inflammatory response to UPEC34. The toxin cytotoxic necrotising factor 1 (CNF1) is 
produced by approximately 30% of UPEC isolates. CNF1 has been reported to exacerbate UTIs 
by activating Rho family GTPases, which affects many host cell functions. For example, 
activation of the Rho GTPase Rac stimulates ruffling of the host cell membrane which promotes 
bacterial uptake into the cell (Figure 1.3)35. Similarly to HlyA, CNF1 has also been reported to 
cause apoptosis and exfoliation of bladder epithelial cells36. CNF1 deletion in a mouse model of 
UTI resulted in reduced bacteria in the urine and bladder compared to UPEC strains producing 
CNF1, suggesting that CNF1 production confers a survival advantage to UPEC isolates37.  
 
 
Figure 1.3: Role of type I fimbriae and toxins in bladder cell invasion. Binding of type I fimbriae or toxins to 
bladder epithelial cells activates Rho GTPases and causes membrane ruffling and uptake of bacteria into the 
epithelial cell. 
 
Additionally, as iron availability is limited within the host, UPEC require an effective method of 
acquiring iron. UPEC secrete siderophores, which bind to iron and are transported into the 
bacterium by active transport. E. coli can produce up to four siderophores: enterobactin, 
salmochelin, aerobactin, and yersiniabactin. Compared to faecal E. coli strains UPEC produce 
more salmochelin and yersiniabactin suggesting these siderophores confer a survival advantage in 
the urinary tract38. However, deletion of the UPEC siderophore receptor genes revealed that iron 
uptake by aerobactin and yersiniabactin was more important than uptake by enterobactin and 
salmochelin for successful colonisation of the urinary tract39. Thus, UPEC strains regulate 
siderophore production to facilitate iron acquisition in the urinary tract.  
 
Altogether, UPEC possess a variety of virulence factors that promote bacterial survival within the 
urogenital tract and encourage bacterial invasion of epithelial cells. 
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1.5 Host response to infection 
The host detects pathogen invasion through pattern recognition receptors (PRRs), which 
recognise conserved microbial structures called pathogen-associated molecular patterns (PAMPs). 
There are four types of PRR and these are toll-like receptors (TLRs), c-type lectin receptors 
(CLRs), retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and nucleotide-binding 
oligomerisation domain (NOD)-like receptors (NLRs). These receptors bind to a range of 
microbial PAMPs and initiate signalling cascades.  
 
1.5.1 Toll-like receptors 
There are currently ten TLRs (TLR1-10) identified in humans and these bind to bacterial and 
viral PAMPS (Figure 1.4). TLR localisation within the cell corresponds to where the ligand for 
that TLR is likely to be present during an infection. TLR1/2/5/6/10 are localised to the cell 
membrane and are linked to ligands present on the pathogen surface, whereas TLR3/7/8/9 are 
found in endosomes in the cytoplasm and are linked to detection of pathogenic molecular 
material, such as bacterial DNA. TLR4 localises to both the plasma membrane and endosomes. 
The ligand for each of the TLRs is shown in Table 1.1. The ligand for TLR10 has not yet been 
identified, however, homology modelling suggests a similar binding pocket to TLR240. In 
addition, Oosting et al. (2014) reported that TLR10 is an anti-inflammatory PRR that acts to 
inhibit TLR2 mediated responses41. 
 
Interestingly, TLR11 is present in mice and is associated with protection against UTI42. This 
receptor has not been identified in humans and this, therefore, indicates genetic differences 
between mice and humans. This should be taken into account when using mouse models of UTI, 
as the presence of an additional TLR may influence the mouse innate immune response to 
UPEC.  
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Table 1.1: Toll-like receptor (TLR) ligands. The ligand for each TLR is shown. TLR2 dimerises with TLR1 and 
TLR6 to detect bacterial lipopeptides. The ligand for TLR10 remains unknown43–49.  
 
 
The adapter molecule MyD88 is activated downstream of the TLRs, with the exception of TLR3, 
and initiates signalling cascades that result in activation of NF-ĸB, p38 mitogen-activated protein 
(MAP) kinase, AP-1 and JNK transcription factors50–53. These transcription factors upregulate 
proinflammatory cytokines and chemokines, and produce an innate immune response to the 
invading pathogen. As a result of ligand binding to TLR3 and TLR4, MyD88-independent 
signalling pathways can be activated via the adapter protein TRIF, which stimulates the activity of 
the transcription factor IRF3 and causes transcription of interferon-inducible genes54–56.  
 
 
Figure 1.4: Toll-like receptor ligands, localisation, and signalling. The adaptor protein MyD88 is activated 
downstream of TLR1/2/4/5/6/7/8/9/10 and this leads to activation of NF-ĸB and other transcription factors such 
as AP-1. The adapter protein TRIF is activated downstream of TLR3/4 and this activates transcription factor IRF3.  
 
TLR Ligand
TLR1-TLR2 Triacyl lipopeptides
TLR2-TLR6 Diacyl lipopeptides
TLR3 dsRNA
TLR4 Lipopolysaccharide
TLR5 Flagellin
TLR7 ssRNA
TLR8 ssRNA
TLR9 Bacterial DNA
TLR10 Unknown
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The importance of TLR signalling with respect to UTI susceptibility is not well characterised. 
Tabel et al. (2007) studied 124 Turkish children who suffered at least one UTI and found that the 
G2258A mutation in the TLR2 gene occurred more frequently in this group than in 116 healthy 
controls. Furthermore, those carrying the G2258A mutation in the TLR2 gene suffered 
significantly more UTI episodes than non-carriers57. However, a second study by Hawn et al. 
(2009) examining 1261 American adult women did not find any significant difference in UTI 
frequency between women carrying the TRL2 G2258A mutation and non-carriers58. Thus, the 
importance of TLR2 in protecting against UTIs is not clear. Hawn et al. also found that the 
A896G mutation in TLR4 was protective against rUTI. However, other researchers examining 
377 adults (both men and women) reported that this mutation had a higher frequency in patients 
with a rUTI and was associated with increased susceptibility to UTI59. TLR4 expression in 
monocytes was also reported to be lower in rUTI patients than healthy controls. Thus, the role of 
TLR4 in UTI protection is also unclear. Hawn et al. also identified a C1174T mutation in the 
TLR5 gene that was linked to increased rUTI susceptibility. This mutation introduces an early 
stop codon in TLR5 and has since been confirmed to increase susceptibility to UTIs60. TLR5 null 
mice have been shown to have increased susceptibility to UTIs and had significantly more 
bacteria in the bladder and kidneys following transurethral injection of E. coli than wild type 
mice61. Thus, these data demonstrate that flagellin detection by TLR5 is highly important for 
bacterial clearance from the urogenital tract.  
 
1.5.2 Nod-like receptors (NLRs) 
NLRs are cytoplasmic PRRs. The NLRs NOD1 and NOD2 recognise bacterial peptidoglycan. 
NOD1 recognises peptidoglycan containing γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP), 
which is present in most common Gram-negative bacteria, such as E. coli and Bacillus subtilis62. 
Muramyl dipeptide (MDP) is the ligand for NOD2 and this is present in the peptidoglycan of all 
Gram-positive and Gram-negative species63. Activation of NOD1 and NOD2 results in NF-ĸB 
activation, which results in proinflammatory cytokine upregulation64. In addition, the MAP 
kinases p38, ERK, and JNK can be activated by ligand binding to NOD1 and NOD265,66. 
 
NOD1 null mice showed significantly greater burden of UPEC in the kidney following 
inoculation than wild type mice, suggesting NOD1 has a protective role against pyelonephritis67. 
Wang et al. (2014) showed that transgenic mice lacking the NOD2 gene did not have increased 
susceptibility to UTI compared to NOD2 competent mice68. These data suggest that NLRs do 
not have a role in protecting the host from UTI, however, following bladder infection NOD1 
may reduce the bacterial burden in the kidney. 
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1.5.3 Rig-I-like receptors (RLRs) and c-type lectin receptors (CLRs) 
RLRs are cytoplasmic receptors that detect dsRNA from viral pathogens. This may either be the 
dsRNA of the viral genome, or may be produced during replication of a ssRNA virus. Three 
RLRs exist: RIG-I, MDA5, and LGP269–71. RIG-I recognises short dsRNA, up to 1kb in length, 
whereas, MDA5 recognises long dsRNA strands72. It is hypothesised that the third RLR LGP2 
may modify viral RNA or act to unwind complex RNA structures to facilitate binding by RIG-I 
or MDA5. Activation of RLRs results in expression of antiviral interferon-inducible genes. As 
RLRs are involved in antiviral immunity no role for these in defence against UTIs has been 
reported.  
 
CLRs recognise carbohydrate motifs on invading pathogens and are primarily involved in 
recognition of fungal pathogens. Dectin-1 and Dectin-2 are the most well characterised members 
and recognise β-glucans and mannans, respectively, from fungal cell walls73,74. Thus, CLRs are 
unlikely to be involved in the recognition of UPEC in the urogenital tract.  
 
1.5.4 Innate immunity to UTIs 
Pathogen recognition by TLRs activates signalling pathways that trigger an immune response to 
the invading pathogen. An innate immune response is produced immediately and is not specific 
to the invading microorganism. TLR activation by microbial ligands results in the production of 
antimicrobial cytokines and chemokines. Interleukin (IL)-6 and -8 are important for bacterial 
clearance from the urinary tract. IL-6 promotes an acute phase response, which is an early 
inflammatory response to infection, and is elevated in patients with a UTI. IL-8 is also elevated in 
the urogenital tract following infection with UPEC75,76. IL-8 is chemotactic for neutrophils 
through interaction of IL-8 with the IL-8 receptors CXCR1 and CXCR2. Recruitment of 
neutrophils to the site of infection is vital for clearance of UPEC from the urogenital tract77–79. 
Indeed, mice deficient in the IL-8 receptor showed delayed neutrophil migration, increased UTI 
susceptibility and increased bacterial loads in the bladder and kidneys compared to wild type 
mice80.  
 
In addition to neutrophils, other cellular components of the innate immune system also play a 
role in UTI clearance. LY6C macrophages reside within the bladder epithelium and following 
infection secrete cytokines and chemokines that aid in neutrophil recruitment. Natural killer (NK) 
cells and mast cells are also thought to be important to UPEC clearance. The roles of these cells 
is less well understood, but the number of mast cells and NK cells in the urine increases during 
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UTI indicating a role for these cells in bacterial clearance81. NK cells facilitate bacterial killing 
through production of TNF-α, however, UPEC can abrogate this response by secreting the HlyA 
toxin, which causes NK cell death82. Dendritic cells are also recruited to the bladder during a 
UTI, but were dispensable for bacterial clearance in a mouse model of UTI83. Mice depleted of 
dendritic cells prior to transurethral UPEC infection did not demonstrate a significant difference 
in the bacterial CFU of the bladder compared to non-depleted control mice83. 
 
A key part of the host innate immune response to infection is antimicrobial peptide (AMP) 
synthesis. These molecules are vital to bacterial clearance from the urogenital tract and are 
discussed in more detail below.  
 
1.5.5 Antimicrobial peptides 
AMPs have been identified in bacteria, archaea, protists, fungi, plants and animals, suggesting 
they play a fundamental role in organism survival. As of July 2016, 2722 AMPs have been 
identified in total and 2043 of these are in animals, with 113 existing in humans84. The underlying 
principle of AMPs is the ability to form a structure that consists of discrete hydrophilic and 
hydrophobic areas. This amphipathic structure allows insertion of the peptides into bacterial 
membranes to cause cell lysis. The peptides are small, up to 100 amino acids in length, and 
usually carry an overall positive charge. The exact mechanism of action of AMPs is not 
understood, but disruption of the microbial membrane is the key principle. Several models of 
how the peptides interact with membranes have been proposed. These include the barrel and 
stave model, whereby the peptides bore into the bacterial membrane to form a pore through the 
lipid bilayer, and the carpet model, which suggests that AMPs coat the outer bacterial membrane 
in peptides which causes membrane disintegration85.  
 
The positive charge of AMPs ensures preferential binding to microbial membranes over host cell 
membranes (Figure 1.5). Anionic phospholipid head groups, such as phosphatidylglycerol, in the 
lipid bilayer give bacterial cell membranes a negative charge. Whereas, the lipid bilayer of 
mammalian cells consists of neutral phospholipids86. Thus, positively charged AMPs 
preferentially interact with negatively charged microbial membranes. Furthermore, incorporation 
of cholesterol into mammalian membranes hinders AMP binding86,87. Cullen et al. (2015) recently 
reported that commensal bacteria from the gut can survive at higher concentrations of AMPs 
than pathogenic species88. In addition, the authors identified an enzyme, LpxF, present in 
commensal species that removes the negatively charged phosphate group from LPS. This 
neutralises the LPS negative charge and interferes with AMP binding to commensal organisms. 
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Thus, AMP specifically target pathogenic bacterial cell membranes, making AMPs an interesting 
area for development of alternative therapeutics to antibiotics. In humans several groups of 
AMPs exist and are outlined below.  
 
 
Figure 1.5: Mechanism of AMP membrane selection and insertion. (A) AMPs have distinct hydrophobic (blue) 
and hydrophilic (red) areas. This allows insertion into bacterial membranes. Several models exist for how AMPs lyse 
bacteria, and these include the barrel and stave model, where the AMPs form a pore in the membrane, and the carpet 
model, where AMPs coat the bacterial membrane and cause membrane disintegration. (B) Cationic AMPs 
preferentially bind to negatively charged phospholipids of microbial membranes. The presence of cholesterol in 
mammalian membrane also inhibits AMP binding. (A) adapted from ref 89 and (B) adapted from ref 90. 
 
1.5.5.1 Defensins 
The defensins are an important group of AMPs that can be further divided into three categories, 
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α-defensins, β-defensins and θ-defensins, based on the spacing between six cysteine residues and 
the resultant disulphide bridges91.  
 
There are six human α-defensins: HNP1-4 are found primarily within granules of neutrophils and 
HD5 and HD6 are produced in gut Paneth cells92,93. HD5 is also expressed in epithelial cells of 
the respiratory tract, urinary tract and female reproductive tract94–96. These six α-defensins are 29-
35 amino acids long and disulphide bonds are formed between cysteine residues 1 and 6, 2 and 4, 
and 3 and 5.  
 
The θ-defensins only exists in non-human primates. The θ-defensin genes have been identified 
within the human genome; however, these genes encode a premature stop codon. Therefore, 
functional θ-defensins are not synthesised in humans97. 
  
Evolutionarily, the α-defensin and θ-defensin genes descended from β-defensins. Human β-
defensins (hBDs) are produced by epithelial cells and are a vital component of innate immunity at 
epithelial surfaces. Although over 30 gene loci for hBDs are thought to exist, mostly clustered on 
chromosome 8p23, only hBD1-4 have been identified in vivo and studied in detail98. Zhou et al. 
(2013) have shown that deletion of nine murine β-defensin genes in the cluster on chromosome 8 
resulted in reduced sperm motility and infertility in male mice99. This suggests that in mammals 
other β-defensin genes may have alternative functions to AMPs. hBDs are larger than α-
defensins, consisting of 36-47 amino acids. They have little primary sequence homology to α-
defensins, but due to the disulphide bridges between cysteine residues hBDs and α-defensins 
share a similar tertiary structure. In hBDs the disulphide bridges form between cysteine residues 
1 and 5, 2 and 4, and 3 and 6. hBD1 has antimicrobial activity against the Gram-negative bacteria 
E. coli and Pseudomonas aeruginosa, however expression of hBD1 is constitutive and is not induced 
by bacterial PAMPs60,100,101. hBD2 has strong killing activity against Gram-negative bacteria and 
fungi and is bacteriostatic against Gram-positive pathogens102. Similarly, hBD3 has broad-
spectrum activity against Gram-negative, Gram-positive and fungal pathogens103. Expression of 
both hBD2 and hBD3 is induced by bacterial PAMPs during infection60,102–106. hBD4 has been 
shown to be induced by bacteria and has antimicrobial activity against Gram-negative bacteria, 
Gram-positive bacteria, and yeast107,108. However, hBD4 is less well studied than hBD1-3. 
 
1.5.5.2 Cathelicidins 
Like defensins, cathelicidins are cationic, amphipathic peptides. Cathelicidins vary in size, 
sequence and structure, but all share a common cathelin domain at the N-terminal of the 
13 
 
precursor protein. The cathelicidin precursor protein is then processed to release the active 
peptide at the C-terminal. Approximately 30 cathelicidin genes have been identified in mammals. 
Many animals possess multiple cathelicidin genes, for example, eleven cathelicidin genes have 
been identified in the bovine genome109. However, in humans only one cathelicidin gene exists 
(CAMP) and this encodes the AMP LL-37110. LL-37 begins with two leucine resides at the N-
terminus and is 37 amino acids long, hence the name. Expression of LL-37 has been identified in 
many cell types including neutrophils, myeloid bone marrow cells, and epithelial cells111–113. LL-37 
has antimicrobial activity against both Gram-positive and Gram-negative bacteria and can be 
induced by bacterial PAMPs105,114. 
 
1.5.5.3 Antimicrobial proteins 
Antimicrobial proteins are larger than AMPs, typically at 100-200 amino acids in length. As of 
July 2016 there were 17 human antimicrobial proteins in the antimicrobial peptide database84. 
These include several members of the ribonuclease (RNase) A superfamily. The human genome 
contains 13 RNase genes, RNase 1-13, which act to degrade RNA. In ruminants these genes are 
important for digestion of dietary RNA and recovering RNA-nitrogen from the intestinal flora115. 
However, many members of the RNase family have evolved alternative functions, including 
antimicrobial activity. RNase 2, 3, 5, 7 and 8 appear to function in host defence. RNase 2 is an 
eosinophil protein and has antiparasitic and antiviral activity116,117. RNase 3 has recently been 
reported to have activity against mycobacteria118. The antimicrobial role of RNase 5 is unclear as 
although it was initially reported to have antimicrobial activity, a later publication showed the 
antimicrobial activity to be negligable119,120. RNase 7 and 8 are produced by epithelial cells and 
have both been identified as having broad-spectrum antimicrobial activity against Gram-positive 
and Gram-negative bacteria121,122.  RNase 7 is an extremely potent AMP and despite being an 
RNase exerts its antimicrobial activity in the traditional manner for AMPs i.e. through membrane 
disruption and not through interaction with bacterial RNA123. 
 
S100A7, also called psoriasin, is an antimicrobial protein from the S100 protein family and is 101 
amino acids in length. S100 proteins have multiple functions ranging from cell differentiation to 
cancer suppression, but are characterised by the presence of two calcium binding EF-hand 
motifs124–126. S100A7, S100A12, and S100A15 are produced by epithelial cells and have 
antimicrobial activity against E. coli127–129. 
 
Finally, lactoferrin and lipocalin 2 (LCN2) are cationic antimicrobial proteins of 710 and 198 
amino acids, respectively, that are produced by epithelial cells and inhibit bacterial growth 
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through sequestration of iron. Lactoferrin can also interact with bacterial membranes and lyse 
bacteria through membrane damage. Lactoferrin binds iron and prevents uptake by bacterial 
pathogens130,131. However, a number of Gram-negative pathogens, such as Neisseria gonorrhoeae, 
have been reported to overcome iron sequestration by lactoferrin, by inducing a conformational 
change in the lactoferrin molecule and causing release of iron132. LCN2 binds to siderophores, 
primarily enterobactin, and prevents uptake of siderophores by bacteria, thus limiting iron 
intake133. However, as discussed previously, some pathogens can alter their siderophore 
production to favour salmochelin and yersiniabactin, which are not inhibited by LCN238.  
 
It is clear that many AMPs exist in humans and are important in the host immunity to pathogens. 
Expression of many AMPs has been reported in the urogenital tract and the expression pattern 
of these AMPs is summarised in Figure 1.6. 
 
 
Figure 1.6: Antimicrobial peptide expression in the urogenital tract. The antimicrobial peptides that have been 
identified in the vagina, urethra, bladder, ureter and kidneys are shown60,106,129,134,135. Figure adapted from ref 135. 
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1.5.6 Adaptive immunity to UTIs 
Adaptive immunity is characterised by production of antibodies specific to the infecting organism 
and provides the host with an immunological memory of the pathogen. Following antigen 
exposure, T lymphocytes produce cytokines that activate B lymphocytes and stimulate antibody 
production. The cytokine profile produced by T cells determines the nature of the immune 
response produced. Thus, cross-talk between T and B cells is crucial for a robust adaptive 
immune response. The fact that many patients suffer recurrent UTIs caused by the same strain of 
E. coli suggests that an effective adaptive immune response is not mounted. Chan et al. (2013) 
used a mouse model to demonstrate that the kidney produces UPEC-specific antibodies in 
response to pyelonephritis, but that UPEC-specific antibodies are not produced in the bladder in 
response to cystitis136. The authors identified IL-10, secreted from mast cells, as the cause of 
bladder tolerance to infection. Deleting the IL-10 gene in mice resulted in antibody production in 
the bladder following cystitis, which was not seen in IL-10 competent mice. It was demonstrated 
that IL-10 deficient mice had improved dendritic cell activation compared to IL-10 competent 
mice, suggesting that IL-10 drives bladder tolerance to UPEC by reducing dendritic cell 
activation. However, the role of IL-10 in UTI clearance is controversial as Duell et al. (2012) have 
shown that IL-10-depleted mice had higher bacterial loads in the bladder following transurethral 
UPEC injection than wild type mice137. Thus, IL-10 may be important for rapid clearance of 
bacteria from the bladder, but also be detrimental to the adaptive immune response.  
 
Interestingly, Mora-Bau et al. (2015) showed that the adaptive immune response in the bladder is 
improved following macrophage depletion138. In addition, Mora-Bau et al. measured cytokine 
levels following macrophage depletion and demonstrated that the level of IL-10 was not affected, 
showing that macrophage depletion did not indirectly improve adaptive immunity by reducing 
the IL-10 concentration. In fact, the authors demonstrated that macrophage depletion resulted in 
increased phagocytosis of UPEC by dendritic cells. This increased antigen presentation to T and 
B cells and hence, improved the adaptive immune response. Taken together, these results suggest 
that dendritic cell activation is a key step in mounting an adaptive immune response to UPEC. 
However, this does not occur effectively in the bladder in response to UTI and it is not clear 
whether this is due to the presence of macrophages and/or IL-10 secretion from mast cells. 
 
These data show that the adaptive immune response to UTI is not well understood. However, as 
it appears that an adaptive immune response is not properly developed in response to UTI, the 
consensus is that innate immune responses to UTI are key to bacterial clearance.  
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1.6 Treatment of UTIs 
1.6.1 Antibiotic treatment 
Although the majority of UTIs are usually successfully cleared by the immune system, a course of 
antibiotics is usually prescribed to reduce the recovery time. Trimethoprim-sulfamethoxasole 
(TMP-SMX), fluoroquinolones and nitrofurantoin are the first line agents that are commonly 
prescribed. The second line agents, β-lactams and fosfomycin, are mainly used in cases such as 
pregnancy where other antibiotics may not be safe139. Treatment duration can vary from three to 
ten days; five to ten day treatment courses are more effective at eradicating the bacteria than 
three day courses, but are linked to an increased risk of adverse reactions and non-compliance140.  
 
Long-term antibiotic treatment is used for women who regularly suffer from rUTIs. The 2008 
Cochrane review concluded that antibiotic use significantly reduced UTI recurrence in both pre- 
and postmenopausal women when compared to placebo treatment141. However, extended 
antibiotic treatment was associated with adverse events including vaginal candidiasis. There is 
also the major concern that long-term antibiotic use promotes antibiotic resistance. Indeed, UTI 
resistance to TMP-SMX, the antibiotic most commonly used to treat UTIs, is on the increase. 
Current estimates show that approximately 20% of UTI cases are linked to TMP-SMX resistant 
uropathogens142. Furthermore, resistance to TMP-SMX is associated with resistance to other 
antibiotics, including ampicillin and ciprofloxacin, indicating that TMP-SMX resistant strains may 
also be more difficult to treat with other antibiotics143. This emerging resistance demonstrates the 
need for alternative, non-antibiotic based therapies for UTIs. Specifically, research into 
treatments that may be taken long-term to treat rUTIs without causing side effects would be 
extremely valuable.  
 
1.6.2 Vaccination against UTI 
Although adaptive immunity is not thought to play a major role in protection against UTIs some 
vaccination candidates have shown encouraging results. Mouse models of UTI have identified 
several potential vaccine candidates including fimbriae (FimH), flagellin (FliC) and the bacterial 
receptors for the siderophores salmochelin, aerobactin and yersiniabactin, which confer 
protection against UTIs144–149. A FimH vaccine has also been shown to confer protection against 
UTIs in a small group of Cynomolgus monkeys150. Clinical trials have also been performed in 
humans and showed promising results. Bauer et al. (2005) performed a double-blind study where 
women with rUTI were given capsules containing lyophilised E. coli or placebo151. The capsules 
were taken daily for three months and then for ten days in months 7, 8 and 9. In the placebo 
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group 122 patients suffered 276 UTIs in the 12 month follow-up period, whereas, in the 
treatment group 93 patients suffered 185 UTIs. Overall this represented a significant 34% 
reduction in UTI occurrence in the vaccine group. Hopkins et al. (2007) also demonstrated that 
vaginal suppositories containing ten human uropathogenic strains (6 E. coli, 1 K. pneumoniae, 1 E. 
faecalis, 1 Proteus mirabilis and 1 Morganella morganii) were protective against UTIs; women who 
received the vaccine plus boosters had a significantly lower incidence of UTIs caused by UPEC 
than women receiving placebo152. It is worth noting that although these vaccines conferred some 
protection against UTIs, the vaccines were far from 100% effective. The 34% decrease in UTI 
occurrence reported by Bauer et al. is low compared to a near 100% effectiveness for classical 
vaccines such as the measles, mumps, and rubella vaccine. Thus, even with successful UTI 
vaccine development a large number of women could remain unprotected and in need of 
alternative therapeutics.  
 
Only three companies are currently pursuing a UTI vaccine and all three vaccines are in the pre-
clinical stages153. It is thought that as antibiotic treatment is still effective for many UTI patients 
development of a UTI vaccine is not profitable for pharmaceutical companies. Although a large 
number of patients suffer from UTIs and antibiotic resistance is on the increase, it is unlikely that 
a UTI vaccine would be included in national immunisation programmes and thus is unlikely to 
generate enough revenue to entice development from pharmaceutical companies. Hence, a UTI 
vaccine may still be many years from coming to fruition.  
 
1.6.3 Natural agents from the diet 
1.6.3.1 Cranberries 
For decades it has been thought that cranberries can relieve the symptoms of UTIs. The 
mechanism is not fully understood, but evidence suggests that cranberries may inhibit adhesion 
of uropathogens to epithelial cells of the urinary tract, preventing infection154,155. However, a 
review of the published data on this topic by Jepson et al. in 2012 concluded that there is no 
significant reduction in rUTI incidence in women using cranberry products compared to those 
using a placebo treatment156. 
 
1.6.3.2 Vitamin C and D 
In vitro studies of vitamin C showed that it is bacteriostatic in urine due to acidification of the 
urine and generation of nitric oxide, which is toxic to UPEC157. A clinical trial compared 55 
pregnant women receiving vitamin C, along with ferrous sulfate and folic acid, to 55 pregnant 
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women receiving ferrous sulfate and folic acid without vitamin C158. The trial reported that 12.7% 
of the vitamin C group suffered a UTI, whereas 29.1% of the women not taking vitamin C 
suffered a UTI. Thus, vitamin C supplementation significantly reduced the incidence of UTIs in 
pregnant women.  
 
Similarly, low serum vitamin D levels have been associated with increased risk of UTI159. One 
study has compared UTI incidence in patients taking vitamin D to patients taking placebo, 
however, this trial was primarily observing progression from prediabetes to type 2 diabetes 
mellitus160. Therefore, the patients included in the study were not suffering from rUTI and a 
relatively low number of UTIs were recorded throughout the follow-up period (18 patients out of 
116 receiving vitamin D and 34 patients out of 111 in the placebo group). Nevertheless, the 
results showed reduced UTI incidence in patients taking vitamin D. However, more robust 
studies specifically examining pre- and postmenopausal women who regularly suffer UTIs are 
required to properly assess the benefits of vitamin C and D in these patients.  
 
1.6.4 Hormonal treatment 
In certain populations of women estrogen treatment may be effective at reducing the incidence 
of UTIs. Postmenopausal women have an increased risk of developing a rUTI, which has been 
linked to reduced estrogen levels. Evidence suggests that estrogen replacement therapy is 
successful in reducing the incidence of UTIs in postmenopausal women7.  
 
The function of estrogen and its role in protecting against UTIs will now be discussed in more 
detail.  
 
1.7 Estrogen 
Estrogen is a female steroid hormone that is produced by the ovaries and is responsible for 
regulating the menstrual cycle in women. Three forms of estrogen naturally occur in women; 
17β-estradiol is the predominant form, whilst estrone and estriol circulate at much lower levels161. 
The concentration of estrogen in the blood fluctuates throughout the menstrual cycle; the lowest 
estrogen levels occur during the luteal and early follicular phase, ranging between 70 and 510pM 
and the concentration of estrogen peaks before ovulation at a range of 390 to 1480pM162. In 
postmenopausal women estrogen levels drop below 130pM, which is lower than the reported 
estrogen concentration in men (200pM).  
 
Estrogens exert their actions by binding to estrogen receptors (ERs). There are two types of 
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estrogen receptor: genomic, consisting of estrogen receptor alpha and beta (ER-α and –β), and 
non-genomic, consisting of the G protein-coupled estrogen receptor (GPER) also known as G 
protein-coupled receptor 30 (GPR30).  
 
1.7.1 Genomic ERs 
The genomic ERs, ER-α and ER-β, are located in the cytoplasm and are encoded by the ESR1 
and ESR2 genes, respectively. ER-α and –β consist of five domains: the ligand binding domain, 
the dimerisation domain, the nuclear localisation sequence, the N-terminal transactivation 
domain and the DNA binding domain161. Estrogen diffuses through the cell membrane and binds 
to the receptors intracellularly, causing the receptors to dimerise, forming homodimers (α-α or β-
β complexes) or heterodimers (α-β complexes)163,164. The receptor dimers recognise and bind to 
estrogen response elements (EREs) with consensus sequence GGTCAnnnTGACC in the 
promoter region of estrogen responsive genes resulting in transcription of the gene165. The 
mechanism of action of the genomic ERs is shown in Figure 1.7.  
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Figure 1.7: Mechanism of action of genomic estrogen receptors. ER-α and ER-β are localised to the cytoplasm. 
Estrogen diffuses through the cell membrane and binds to the ERs. Upon ligand binding, the ERs dimerise, migrate 
to the nucleus and bind to estrogen response elements (EREs) with consensus sequence GGTCAnnnTGACC to 
initiate gene transcription.  
 
Although the DNA binding domains of ER-α and ER-β are nearly identical, there is only 56% 
amino acid identity in the ligand binding domain166. As a result, certain ligands preferentially bind 
to one receptor over the other. For example, the three naturally occurring estrogens in women 
(17β-estradiol, estriol and estrone) preferentially bind to ER-α, whilst phytoestrogens genistein 
and coumestrol have a higher affinity for the ER-β receptor167. In addition to this, the two 
genomic receptors also differ in their transcriptional potencies, with ER-α being a stronger 
activator of transcription than ER-β168. These distinctions between the receptors mean that 
certain compounds can initiate effects on certain tissues whilst causing a minimal response in 
others; this is already being exploited for treatment of other estrogen-regulated diseases, such as 
breast cancer169.  
 
ER-α and -β are differentially expressed in many cell types and tissues, including the reproductive 
organs, breast tissue, bones and cardiovascular tissue, and are capable of transcribing a multitude 
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of genes170,171. Microarrays on human tissue support the notion that the number of estrogen 
responsive genes in human is in the hundreds172. Thus, it is clear that estrogen is a powerful 
regulator of gene transcription, by activity through ER-α and –β, and the ability to harness and 
manipulate this power may be highly beneficial in development of future therapeutics.  
 
1.7.2 Non-genomic ER 
After the discovery of ER-α and –β, papers were published demonstrating that estrogen can also 
elicit very rapid responses within cells that occur too quickly to be attributed to the 
transcriptional activity of the genomic ERs173,174. As a result, in 2005 a third ER was identified. 
The G protein-coupled receptor 30 (GPR30), previously an ‘orphan’ receptor with unknown 
function, was discovered to bind estrogen and produce non-genomic responses within the cell. 
These include upregulation of intracellular calcium, nitric oxide and receptor tyrosine kinases175. 
The receptor has now been renamed the G protein-coupled estrogen receptor (GPER). Like all 
G protein-coupled receptors GPER is made up of an N-terminal receptor, seven transmembrane 
domains and a C-terminal that activates the associated G protein upon estrogen binding to the 
receptor. Localisation of GPER within the cell is contentious; the receptor has been reported to 
localise to the plasma membrane, the endoplasmic reticulum, the cytoplasm and the nucleus176–179. 
Recently Samartzis et al. (2014) have reported that whilst the localisation is predominantly 
cytoplasmic in one immortalised breast carcinoma cell line (T47D), GPER had nuclear 
localisation in a second immortalised cell line (MCF7)179. Thus this inability to reliably determine 
the subcellular localisation of GPER indicates that the receptor may localise to different places in 
the cell depending on the cell type, function and possibly even disease state.  
 
1.7.3 Estrogen receptor cross-talk 
Although the genomic and non-genomic receptors were identified based on their differing 
functions, there is evidence for cross-talk between the two signalling pathways. For example, 
estrogen binding to GPER can result in phosphorylation of the transcription factors 
CCAAT/enhancer binding protein beta (CEBPB), cAMP response element binding protein 
(CREB) and activator protein 1 (AP-1) by activation of the MAP kinase signalling pathway174,180–
182. Activation of these transcription factors initiates transcription of their target genes. 
Consequently, estrogen interaction with the classical or non-classical estrogen receptors may not 
produce mutually exclusive outcomes, as estrogen binding to the non-genomic receptor, GPER, 
can lead to genomic events.  
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1.7.4 Estrogen protects against UTIs 
In premenopausal women estrogen has an important role in protecting the urinary tract from 
invasion by pathogenic bacteria. In the vagina the presence of estrogen stimulates glycogen 
production183. This promotes the growth of commensal bacteria, such as lactobacilli, that can 
readily metabolise the glycogen. An abundance of commensal organisms within the vagina is 
crucial to preventing uropathogens from establishing a reservoir in this environment. Several 
studies have shown that Lactobacillus species are capable of inhibiting the growth of uropathogens, 
such as E. coli, in a number of ways.  
 
First, the metabolism of glycogen by lactobacilli produces lactic acid. This lowers the pH of the 
vagina so that it is inhospitable to pathogens such as E. coli184. Second, some Lactobacillus species 
also produce hydrogen peroxide. Hydrogen peroxide oxidises halides, such as chloride, when 
combined with a peroxidase, to form oxidants that are toxic to many bacterial species185. One 
study revealed that hydrogen peroxide generating lactobacilli were present in the vagina of 96% 
of premenopausal women186. Peroxidase activity has been detected within the vaginal fluid and 
has been shown to be induced by estrogen in the rat uterus187,188. Therefore, hydrogen peroxide 
production by lactobacilli may be an important system in protecting the vagina from colonisation 
by uropathogens. Finally, cell extracts of Lactobacillus species have been shown to prevent 
adhesion of uropathogens to the urothelium189. These data demonstrate that promotion of 
lactobacilli growth by estrogen helps in preventing colonisation by pathogenic bacteria.  
 
Given the mechanisms by which estrogen potentially protects the urinary tract from 
uropathogens, it is discernible that depleted estrogen levels after the menopause may have a 
knock-on effect on the ability of postmenopausal women to successfully clear a UTI. Lower 
circulating estrogen levels in postmenopausal women reduce the vaginal Lactobacillus population 
resulting in a higher vaginal pH, hence increasing the vaginal susceptibility to colonisation by 
uropathogens. Indeed, women who regularly suffer from UTIs typically have a vaginal pH above 
4.5190. Furthermore, unpublished data from our laboratory has indicated that estrogen may also 
protect the urinary tract from infection by increasing the expression of the AMP hBD2 in the 
vagina60. Thus, it is possible to speculate that these women may have lower expression of certain 
AMPs, further increasing their risk of developing a UTI that they are unable to fully eradicate 
from the urinary tract and surrounding reservoirs.  
 
1.7.5 Efficacy of estrogen treatment of UTIs in postmenopausal women 
Many studies have tested the efficacy of estrogen treatment on the incidence of UTIs and rUTIs 
23 
 
in postmenopausal women. Unfortunately, although the beneficial role of estrogen in urinary 
tract seems clear, clinical studies have failed to fully validate this hypothesis. This ambiguity 
around the usefulness of estrogen as a therapeutic may arise from differences in the method used 
to administer estrogen; estrogen can be delivered orally or directly to the vagina using creams, 
pessaries and rings7. 
 
Studies investigating the effects of oral estrogen on the prevalence of UTIs in postmenopausal 
women unanimously concluded that oral estrogen does not reduce the risk of developing a UTI 
in this population7,191–193. One of these trials supplemented postmenopausal women with 3mg of 
estrogen daily, but no difference in UTI incidence was seen between the estrogen supplemented 
and the placebo group despite this relatively high dose of estrogen191.  
 
Vaginal estrogen creams, however, have shown more promising results. A study conducted by 
Raz & Stamm in 1993 compared the efficacy of estrogen cream versus a placebo cream190. The 
estrogen cream was found to significantly reduce the incidence of UTIs in postmenopausal 
women compared to the placebo treatment. After four months the cumulative likelihood of 
being disease free was 0.95 for the women given estrogen cream, compared to 0.30 for those 
receiving the placebo. Over the course of the study the estrogen treatment group had 12 episodes 
of bacteriuria, whilst the placebo group suffered from 111 episodes. Furthermore, the estrogen 
treatment significantly increased the vaginal lactobacilli colonisation and significantly decreased 
the vaginal pH, compared to the control group. These results are supported by a second study 
showing that vaginal estrogen cream significantly reduced the incidence of UTIs in 
postmenopausal women compared to a group receiving oral antibiotics194. 
 
Other methods of vaginal estrogen application have shown mixed results. One study by Raz et al., 
found that estrogen application using a vaginal pessary resulted in significantly more UTIs during 
the study period than a group receiving the antibiotic, oral nitrofurantoin. Furthermore, this 
method of administering estrogen did not affect the vaginal pH or lactobacilli colonisation195. 
Conversely, a study administering estrogen through a vaginal ring found that estrogen treatment 
significantly reduced the incidence of UTIs compared to the placebo group196. After nine months 
the cumulative event-free survival was 45% in the estrogen treated group compared to 20% in 
the control group. This study did not measure the number of women who were positive for 
lactobacilli in the vagina, but did report a significantly decreased vaginal pH in the estrogen 
treated group after 12 weeks of treatment. Interestingly, this study also used a lower estrogen 
dose than the vaginal pessary study, 2mg of estrogen over 12 weeks compared to 0.5mg estrogen 
given twice weekly. As Raz et al. compared estrogen treatment with antibiotic treatment it cannot 
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be determined whether estrogen, delivered by a vaginal pessary, would have reduced UTI 
incidence compared to a placebo group.  
 
Taken together, the results from these clinical studies indicate that vaginal, as opposed to oral, 
estrogen treatment may reduce the occurrence of UTIs in postmenopausal women, with vaginal 
estrogen creams being particularly promising.  
 
Despite these encouraging findings, two further published papers using ovariectomised mice 
modelling the menopause have reported contrasting results regarding the effect of estrogen on 
the susceptibility of mice to UTIs. One study reported that estrogen treatment promoted an 
ascending UTI, with estrogen treated mice having significantly higher bacterial infection rates in 
the kidney than non-estrogen treated controls197. However, the second study showed that 
ovariectomised mice had significantly higher quiescent intracellular bacterial reservoirs, which can 
seed recurrent infections, 14 days after infection than non-ovariectomised controls. This effect, 
was reversed following estrogen treatment, suggesting that estrogen impairs formation of 
intracellular bacterial reservoirs198.  
 
1.8 Hypothesis and aims 
Many of the aforementioned studies concentrate on the overall effect of estrogen on UTI 
incidence in postmenopausal women, focusing particularly on the changes in vaginal pH and 
lactobacilli colonisation. However, few studies have looked into the effects of estrogen on the 
innate immune defences in the urinary tract134,199. Therefore, the aim of this project was to 
investigate the roles of estrogen on the innate epithelial immune defences in the vagina in 
response to E. coli infection. Investigations were focused on the vagina as this is a key reservoir of 
infection. Understanding the mechanisms involved in effective eradication of bacteria from the 
vagina may prevent progression to UTI. Furthermore, knowledge of the signalling pathways 
involved in estrogen regulation of innate epithelial immunity may aid in the design of novel 
therapeutics that exploit this system in postmenopausal women.  
 
Previous work in our laboratory has shown that the AMP hBD2 is increased in vaginal douches 
of postmenopausal women receiving topical estrogen treatment, compared to postmenopausal 
women not receiving estrogen treatment60. Based on these data, it was hypothesised that estrogen 
treatment of vaginal epithelial cells will result in increased expression of hBD2 and other AMPs 
during infection of the urogenital tract. 
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Therefore, the overarching aim of this project was to investigate the effects of estrogen on the 
innate epithelial defences of the urogenital tract, with specific focus on AMPs.  
 
More specifically, this project aimed to: 
 Investigate the effects of estrogen on the AMPs hBD2 and hBD3, which have been 
previously studied in the bladder by our group, in vaginal epithelial cells. 
 Utilise microarray analyses to identify other components of the innate vaginal epithelial 
defences that are enhanced by estrogen treatment. 
 Examine the signalling pathways involved in estrogen regulation of innate immune 
defences of vaginal epithelial cells.   
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2 Materials and methods 
2.1 Tissue culture 
2.1.1 Vaginal epithelial cell line 
The vaginal keratinocyte cell line VK2 E6/E7 was cultured in tissue culture flasks in 
keratinocyte-SFM (Life Technologies, USA) with 0.1ng/ml epidermal growth factor, 0.05mg/ml 
bovine pituitary extract and 0.2mM of CaCl2. The cells were incubated at 37°C with 5% CO2 and 
passaged once a week when a confluent monolayer was formed. To passage, cells were washed 
with phosphate-buffered saline (PBS, Sigma, USA) before adding 0.1% trypsin (Sigma, USA) and 
incubating at 37°C for approximately 10 minutes, or until the cells detached from the flask 
surface. Trypsin was neutralised by the addition of Dulbecco’s Modified Eagle’s Medium 
(DMEM, Life Technologies) containing 10% fetal calf serum (FCS, Life Technologies, USA) at a 
ratio of 2:1. The cell suspension was centrifuged at 1500rpm for 3 minutes in a MSE Centaur 2 
centrifuge, before being resuspended in keratinocyte-SFM and passed through a needle. The 
Cellometer Auto T4 Cell Viability Counter (Nexcelom, USA) was used to count the cells, before 
seeding a new T75 cell culture flask (Corning, USA) with 1.5x106 cells. The cells were incubated 
at 37°C with 5% CO2 and the medium was replaced every 2-3 days. 
 
2.1.2 Primary vaginal epithelial cell culture 
Vaginal biopsy tissue was collected from women undergoing gynaecological surgery at the Royal 
Victoria Infirmary, Newcastle upon Tyne. Collection and use of biopsy tissue was covered by 
ethics REC reference number: 2003/11. Tissue was stored in Ham’s F12 Nutrient Mix Medium 
(Life Technologies, USA) with 100U/ml penicillin and 100µg/ml streptomycin (Sigma, USA) and 
10% FCS for delivery. Following delivery to the laboratory, the tissue was washed in PBS and any 
excess connective tissue was removed. The tissue was incubated in PBS with 10% 
Penicillin/Streptomycin/Amphotericin B (Lonza, USA) and 2mg/ml Dispase II (Sigma-Aldrich, 
USA) overnight at 4°C to dissociate the epithelial cells from the lamina propria. Epithelial cells 
were removed using tweezers and the cells were incubated in trypsin for 20 minutes at 37°C with 
shaking every 5 minutes. The trypsin was neutralised with DMEM containing 10% FCS, and the 
cell suspension centrifuged at 1200rpm for 5 minutes. The cells were resuspended in EpiLife 
medium (Life Technologies, USA) or DMEM with 10% FCS, passed through a needle to ensure 
a single cell suspension and seeded into 6-well plates. The cells were incubated at 37°C with 5% 
CO2 and the media was renewed every 2 days. 
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2.1.3 Cell challenges 
Cell challenges with both primary and VK2 cells were performed in either 6- or 12-well plates. 
VK2 cells were seeded into 6-well plates at densities between 2.5x105 and 3.5x105 cells/well, and 
12-well plates at a density of 1x105 cells/well. Primary vaginal epithelial cells were seeded into the 
wells at the highest density possible from the number of cells harvested. Once the cells reached 
80% confluency, the medium was removed, cells were washed with PBS and 1ml of cell culture 
medium was added to the cells. The cells were incubated at 37°C with 5% CO2 for 24 hours in 
this medium.  
 
2.1.3.1 Challenge reagents 
The estrogen used for challenges was (2-hydroxypropyl)-β-cyclodextrin encapsulated 17β-
estradiol (Sigma, USA) at a final concentration of 4nM. Encapsulation of estrogen in cyclodextrin 
makes it water-soluble. Initial experiments were carried out using water-treated VK2 cells as the 
control. However, the effects of cyclodextrin were analysed, and cyclodextrin-treated VK2 cells 
were used as the control in later experiments. The water-soluble estrogen consisted of 48.3mg 
17β-estradiol per gram of solid, thus, 4nM estrogen had a cyclodextrin concentration of 14.8nM. 
This concentration of cyclodextrin was, therefore, used for experiments where the control was 
cyclodextrin-treated cells.  
 
The flagellin used was purified by Dr Marcelo Lanz from E. coli clinical isolate 3408 from a 
cystitis patient106. Flagellin was resuspended in PBS and cells were challenged with 50ng/ml 
flagellin (or otherwise stated) or PBS. G-1 and ICI 182,780 were both from Tocris Bioscience, 
UK, and were resuspended in dimethyl sulfoxide (DMSO) to an initial concentration of 1mM. 
Human recombinant IL-17A was purchased from Sigma-Aldrich, USA, and was resuspended to 
an initial concentration of 20µg/ml in 10mM Tris-HCL, pH 7.4 containing 250mM NaCl. 
 
2.1.3.2 Acute estrogen and flagellin challenge 
VK2 cells were treated with 4nM 17β-estradiol (Sigma, USA) and 50ng/ml flagellin or PBS. Each 
of these treatments was performed in triplicate and on three separate occasions. After 0, 8, 12 
and 24 hours the medium was removed, the cells washed with PBS and the RNA extracted. 
 
2.1.3.3 Acute estrogen and flagellin dose response challenge 
VK2 cells were treated with 4nM 17β-estradiol and flagellin at concentrations of 0.0025, 0.025, 
0.25, 2.5, 25 and 50ng/ml, or PBS. Each of these treatments was performed in triplicate and on 
28 
 
two separate occasions. After 24 hours the cells were washed with PBS and the RNA was 
extracted. 
 
2.1.3.4 Estrogen pretreatment and flagellin challenge 
VK2 cells were pretreated with 4nM 17β-estradiol for at least 7 days prior to challenge. The cells 
were seeded into 6-well plates at a density of 3.5x105 cells/well in keratinocyte-SFM 
supplemented with 4nM 17β-estradiol and the medium and estrogen were typically replaced every 
two days. Once the cells reached 80% confluency the cell culture medium was removed, the cells 
were washed with PBS and 1ml keratinocyte-SFM supplemented with 4nM 17β-estradiol was 
added to the wells. The cells were incubated in this medium for approximately 24 hours and then 
challenged with 50ng/ml flagellin, or PBS. After 0, 8, 12 and 24 hours the medium was removed 
and stored at -80°C for analysis by enzyme-linked immunosorbent assays (ELISA), the cells were 
washed with PBS and the RNA was extracted. Primary vaginal epithelial cells were pretreated 
with 4nM 17β-estradiol (4nM) for 5-10 days and then challenged with 50ng/ml flagellin, or PBS. 
After 24 hours the cells were washed with PBS and the RNA extracted. 
 
2.1.3.5 Cyclodextrin and flagellin challenge 
VK2 cells were pretreated with 14.8nM (2-hydroxypropyl)-β-cyclodextrin for 7 days prior to 
challenge. The cells were seeded into 6-well plates at a density of 3.5x105 cells/well in 
keratinocyte-SFM supplemented with 14.8nM cyclodextrin and the medium and cyclodextrin 
were replaced every two days. Once the cells reached 80% confluency the cell culture medium 
was removed, the cells were washed with PBS and 1ml keratinocyte-SFM supplemented with 
14.8nM cyclodextrin was added to the wells. The cells were incubated in this medium for 
approximately 24 hours before challenge with either 50ng/ml flagellin or PBS. Each of these 
treatments was performed in triplicate and on two separate occasions. After 24 hours the 
medium was removed, the cells washed with PBS and the RNA extracted.  
 
2.1.3.6 Fulvestrant and flagellin challenge 
VK2 cells were seeded into 12-well plates at a density of 1x105 cells/well in keratinocyte-SFM 
and were pretreated with either 1µM ICI 182,780 or 0.1% DMSO vehicle, and 4nM 17β-
estradiol, or cyclodextrin vehicle, for at least 7 days prior to challenge. The medium, ICI 182,780 
and 17β-estradiol were replaced every two days. Once the cells reached 80% confluency the 
medium was removed, the cells were washed with PBS and 1ml keratinocyte-SFM supplemented 
with 1µM ICI 182,780 and/or 4nM 17β-estradiol was added to the cells. The cells were incubated 
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in this medium for approximately 24 hours and then challenged with either 50ng/ml flagellin or 
PBS. Each of these treatments was performed in triplicate and on three separate occasions. After 
24 hours the medium was removed, the cells washed with PBS and the RNA extracted.  
 
2.1.3.7 G1 and flagellin challenge 
The cells were seeded into 12-well plates at a density of 1x105 cells/well and were pretreated with 
either 100nM G1 or 0.01% DMSO vehicle for 1, 5 and 7 days prior to challenge. Once the cells 
reached 80% confluency the medium was removed, the cells were washed with PBS and 1ml 
keratinocyte-SFM supplemented with 100nM G1, or 0.01% DMSO, was added to the cells. The 
cells were incubated in this medium for approximately 24 hours and then challenged with 
50ng/ml flagellin, or PBS. Each of these treatments was performed in triplicate and on two 
separate occasions. After 24 hours the medium was removed, the cells washed with PBS and the 
RNA extracted.  
 
2.1.3.8 IL-17A dose response challenge 
VK2 cells were seeded into 12-well plates at a density of 1x105 cells/well. Once they reached 80% 
confluency the medium was removed, the cells were washed with PBS and 1ml keratinocyte-SFM 
medium was added to the cells. The cells were incubated in this medium for 24 hours and then 
challenged with IL-17A (Sigma, USA) at concentrations of 0.1, 1, 10, 100ng/ml or 100µM Tris-
HCL, pH 7.4 with 2.5mM NaCl. Each of these treatments was performed in triplicate and on 
two separate occasions. After 6 and 24 hours the medium was removed and stored at -80°C, the 
cells washed with PBS and the RNA extracted. 
 
2.1.3.9 Estrogen and IL-17A challenge 
VK2 cells were seeded into 12-well plates at a density of 1x105 cells/well in keratinocyte-SFM 
and were pretreated with either 4nM 17β-estradiol or 14.8nM cyclodextrin for at least 7 days 
prior to challenge. The medium, 17β-estradiol and cyclodextrin were replaced every two days. 
Once the cells reached 80% confluency the medium was removed, the cells were washed with 
PBS and 1ml keratinocyte-SFM medium was added to the cells. The cells were incubated in this 
medium for 24 hours and then challenged with 100ng/ml IL-17A (Sigma, USA), or 100µM Tris-
HCL, pH 7.4 with 2.5mM NaCl, and 50ng/ml flagellin, or PBS. Each of these treatments was 
performed in triplicate and on two separate occasions. After 24 hours the medium was removed, 
the cells washed with PBS and the RNA extracted. 
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2.1.4 Cell viability assay 
To measure the effect of 17β-estradiol, ICI 182,780 and G-1 on the growth rate of VK2 cells the 
CellTiter-Blue Cell Viability Assay (Promega, USA) was used. CellTiter-Blue Reagent contains 
highly purified resazurin, which is reduced to resorufin by viable cells. The absorbance maximum 
of resazurin is at 605nm and that of resorufin is at 573nm, therefore measurement of absorbance 
at 573 and 605nm determines the amount of reduction of resazurin. The reduction of resazurin 
to resorufin is directly proportional to the number of viable cells, therefore, the more cells in the 
well, the larger the absorbance value at 573nm. VK2 cells were seeded into 6- or 12-well plates 
and were grown under the same conditions as they were for a challenge. Mitomycin C (1µM, 
Sigma, USA) treated VK2 cells were included as a negative control, as Mitomycin C inhibits 
DNA replication, preventing cell growth. Medium-only wells (no VK2 cells) were also included 
to determine background absorbance values. At each time point growth medium was removed 
from the cells, the cells were washed with PBS, 500 µl keratinocyte-SFM was added to each well 
and the cells were imaged using the EVOS XL Core Cell Imaging System (ThermoFisher 
Scientific, UK). 100µl CellTiter-Blue Reagent was added to each well, and the cells were 
incubated at 37oC for 1 hour. To measure the absorbance, 150µl medium was removed from each 
well and transferred to a white plastic, clear bottom, Costar Assay Plate, 96 well (Corning, USA) 
and the absorbance was measured at 573nm and 605nm using the FLUOstar Omega Microplate 
Reader (BMG Labtech, Germany). To analyse the results the absorbance at 605nm was 
subtracted from the absorbance at 573nm for each sample. To adjust for the background the 
results from the medium-only wells was then subtracted. 
 
2.2 RNA extraction 
RNA was extracted using the Promega SV Total RNA Extraction Kit (Promega, USA). Lysis 
buffer was added to each well, the cells were scraped from the well surface and transferred to a 
microfuge tube. The lysis buffer was passed through a needle and RNA extracted as per the kit 
instructions. Briefly, the RNA was passed through a Spin Column, washed, DNase treated and 
eluted into Milli-Q water. The Thermo Scientific Nanodrop 2000 was used to determine the 
RNA concentration. RNA was stored at -80°C. 
 
2.3 Reverse transcription 
RNA was reverse transcribed into cDNA by mixing 1μg of RNA with Milli-Q water to a volume 
of 25μl. One nanogram of random hexamers (Roche, Switzerland) was added and the reaction 
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was heated at 65°C for 5 minutes. The RNA was immediately placed on ice for 2 minutes, before 
adding the following reagents:  
 
10μl  5x Moloney murine leukaemia virus (MMLV) buffer (Promega, UK)  
12.5μl  2mM dNTPs (Bioline, UK)  
0.5μl  RNase inhibitor (20 units, Promega, UK)  
1μl  Reverse transcriptase (100 units, Promega, UK)  
 
The samples were briefly centrifuged, then incubated at 42°C for 2 hours followed by 70°C for 3 
minutes. cDNA was stored at -80°C. 
 
2.4 End-point polymerase chain reaction 
End-point polymerase chain reaction (PCR) was performed using the following volumes of 
reagents: 
 
0.4μl  25mM MgCl2 (Bioline, UK) 
2μl  10x NH4 buffer (Bioline, UK) 
0.25μl  Taq polymerase (Bioline, UK) 
2.5μl  2mM dNTPs (Bioline, UK) 
1µl 10µM forward primer 
1µl 10µM reverse primer 
7.85μl  MQ water 
5μl  Sample cDNA 
------------------------------ 
20µl Total volume 
 
The samples were briefly centrifuged and PCR was performed under the conditions shown in 
Table 2.1.  
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Table 2.1: Cycling conditions used for end-point PCR. 
 
 
The annealing temperature (Tm) was dependent on the primers used in the reaction and these are 
detailed in Table 2.2. 18S was used as the housekeeping gene. 18S primers were predesigned by 
Life Technologies with a product size of 315bp. 
 
Table 2.2: Table of primers used for end-point PCR. 
 
 
2.5 Gel electrophoresis 
To visualise DNA products, the DNA samples were mixed with 10x Loading Buffer (Bioline, 
UK) in a 9:1 ratio and loaded onto an agarose gel. Agarose gels were prepared using TBE (Tris, 
Boric acid, EDTA, pH 8) buffer with an agarose content between 1-2%. 5µl of SafeView (NBS 
Biologicals, UK) was added per 100ml gel. A DNA ladder solution (Bioline, UK or New England 
Biolabs, USA) was loaded onto the gel and the gel electrophoresed at 60-100V for 60-90 minutes. 
The gel was viewed using the Bio Rad Gel Doc EZ Imager and Image Lab 4.0 software. 
 
Temperature Time
(°C) (min:sec)
Preincubation 95 03:00 1
Denaturation 95 00:30
Annealing Tm 00:30
Elongation 72 00:30
Final elongation 72 10:00 1
Final hold 4 ∞
35
Step Cycles
Temperature Product
(Tm, °C) length (bp)
ER Alpha Forward GGATACGAAAAGACCGAAGAG
ER Alpha Reverse GTCTGGTAGGATCATACTCGG
ER Beta Forward TAGTGGTCCATCGCCAGTTATCAC
ER Beta Reverse GCACTTCTCTGTCTCCGCACAA
GPER Forward GGCTTTGTGGGCAACATC
GPER Reverse CGGAAAGACTGCTTGCAGG
IL17RA Forward GTACTGGTTCATCACGGGCA
IL17RA Reverse AGGCCATCGGTGTATTTGGT
IL17RC Forward AAAAACCTGACTGGACCGCA
IL17RC Reverse TGGCCTTTCAGCAATGGGAA
KRT8 Forward AAGGATGCCAACGCCAAGTT NM_001256282.1, NM_002273.3,
KRT8 Reverse TCATGTTCTGCATCCCAGACTC NM_001256293.1
KRT18 Forward CCAGTCTGTGGAGAACGACAT
KRT18 Reverse TCCTGAGATTTGGGGGCATC
Primer name Sequence Accession number
NM_001122740.1 58 236
NM_001437.2 55 439
56 190
NM_000224.2, NM_199187.1 56 207
NM_014339.6 58 132
NM_153461 58 338
NM_001098201.1 58 680
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2.6 Gel extraction 
To extract DNA products from the gel the bands were excised using a scalpel and the QIAquick 
Gel Extraction Kit (Qiagen, Germany) was used to isolate the DNA. The kit was used as per the 
manufacturers protocol. Briefly, the agarose gel was dissolved in binding buffer, the DNA was 
passed through a Spin Column, washed and eluted in Milli-Q water.  
 
2.7 Quantitative PCR 
Quantitative PCR (qPCR) was performed using both probe-based and SYBR-green-based assays. 
A probe-based assay was initially developed for measuring the expression of hBD2. However, 
this assay was not sensitive for measuring low level gene expression and thus a SYBR-green-
based assay was developed to measure hBD2 expression. The expression of all other genes was 
measured solely by SYBR-green-based qPCR assay. 
 
2.7.1  Probe-based qPCR assay 
Probes-based qPCR involves a DNA probe, consisting of a fluorescent reporter and a quencher, 
which binds to a specific target sequence of the cDNA during the annealing step of the qPCR 
reaction (Figure 2.1). During the elongation step the probe is displaced from the target DNA, 
cleaving the fluorescent reporter from the quencher and resulting in fluorescence being emitted. 
Thus, fluorescence levels are proportional to the amount of probe-specific target cDNA within a 
sample. This differs from SYBR-green, which is not target specific and simply detects all double-
stranded DNA within a sample.  
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Figure 2.1: Mechanism of probes-based qPCR. During the annealing step a DNA probe, consisting of a 
fluorescent reporter (R) and a quencher (Q), binds to a specific sequence in the target gene cDNA. During 
elongation of the PCR product, the probe is displaced and the reporter is cleaved from the quencher. Release of the 
reporter from the quencher produces a fluorescent signal. 
 
Probe-based qPCR was performed by adding the following volumes of reagents into each well of 
a white 96-well PCR microplate (Starlab, UK): 
 
 5µl Lightcycler 480 Probes Master (Roche, Switzerland) 
 0.5µl 5µM primer mix (Integrated DNA Technologies, USA) 
 2µl Milli-Q water 
 2.5µl Sample cDNA 
 ------------------------------ 
 10µl Total volume 
  
The probe-based hBD2 primers for the DEFB4A gene were predesigned by Integrated DNA 
Technologies and the sequences are shown in Table 2.3. 
 
Table 2.3: Table of probe-based primers. 
 
 
Gene Forward primer Reverse primer Product length (bp)
DEFB4A CGCCTATACCACCAAAAACAC TCCTGGTGAAGCTCCCA 106
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After addition of each of the reagents the plate was sealed with StarSeal Advanced Polyolefin 
Film (Starlab, UK) and the plate was briefly centrifuged in a MPS 1000 Mini PCR Plate Spinner 
(Labnet, USA). The plate was loaded into the Lightcycler 480 Instrument II (Roche, Switzerland) 
and qPCR performed as per the cycling conditions shown in Table 2.4. 
 
Table 2.4: Cycling conditions for probe-based qPCR assay. 
 
 
2.7.2 SYBR-green based qPCR 
SYBR-green-based qPCR assays utilise the fluorescent dye SYBR Green I, which binds to all 
double-stranded DNA and fluoresces. Therefore, the amount of fluorescence emitted is directly 
proportional to the amount of amplified cDNA in the sample.  
 
SYBR-green based qPCR was prepared by adding the following volumes of reagents into each 
well of a white 96-well PCR microplate (Starlab, UK): 
  
 5µl Lightcycler 480 SYBR Green I Master (Roche, Switzerland) 
 0.5µl Forward primer 
 0.5µl Reverse primer 
 1.5µl Milli-Q water 
 2.5µl Sample cDNA 
 ------------------------------ 
 10µl Total volume 
 
SYBR-green-based qPCR primers were designed to be approximately 20 base pairs long, have a 
melting temperature between 55°C and 60°C, have a GC content of roughly 50% and produce a 
product size of approximately 100 base pairs. Where possible the primers were also designed to 
span an exon-exon junction to prevent amplification of genomic DNA. The primers used for 
SYBR-green-based qPCR are detailed in Table 2.5. GAPDH and ATP5B were selected as 
housekeeping genes following geNorm analysis performed by Dr Ased Ali60. The primers for 
Temperature Time
(°C) (min:sec)
Preincubation 95 05:00 1
Denaturation 95 00:10
Annealing 60 00:30
Elongation 72 00:01
45
CyclesStep
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GAPDH and ATP5B were predesigned by Primerdesign, UK, and the sequences were not 
provided. 
 
Table 2.5: Table of primers used for qPCR. 
 
 
After addition of each of the reagents the plate was sealed with StarSeal Advanced Polyolefin 
Film (Starlab, UK) and the plate was briefly centrifuged in a MPS 1000 Mini PCR Plate Spinner 
(Labnet, USA). The plate was loaded into the Lightcycler 480 Instrument II (Roche, Switzerland) 
and qPCR performed as per the cycling conditions shown in Table 2.6. 
 
Table 2.6: Cycling conditions for qPCR assays. 
 
 
After each run the results were analysed to calculate the concentration of target cDNA in each 
sample by comparison with a positive control plasmid. The melt curve of each sample was also 
analysed to confirm amplification of a single DNA product. 
 
Temperature Product
(Tm, °C) length (bp)
hBD2 Forward CAGCCATCAGCCATGAGGGT
hBD2 Reverse CCACCAAAAACACCTGGAAGAGG
hBD3 Forward GTGAAGCCTAGCAGCTATGAG
hBD3 Reverse TGATTCCTCCATGACCTGGAA
LCN2 Forward CAAAGACCCGCAAAAGATGT
LCN2 Reverse GGCAACCTGGAAGAAAAGTC
RNase 7 Forward TGACAGCCTAGGAGTGCGT
RNase 7 Reverse CAGGGGTCGCTTTGCG
S100A7 Forward ACACCAGACGTGATGACAAG
S100A7 Reverse CATCGGCGAGGTAATTTGTG
83
NM_018661.4 60 89
NM_005564.4 58 128
Primer name Sequence Accession number
NM_004942.2 58
NM_002963.3 58 114
NM_032572.3 56 83
Temperature Time
(°C) (min:sec)
GAPDH, ATP5B Preincubation 95 10:00 1
Denaturation 95 00:15
Annealing 60 00:30
Elongation 72 00:01
DEFB103A, DEFB4A, Preincubation 95 10:00 1
RNASE7, S100A7 Denaturation 95 00:20
Annealing Tm 00:30
Elongation 72 00:20
LCN2 Preincubation 95 10:00 1
Denaturation 95 00:10
Annealing Tm 00:20
Elongation 72 00:20
45
45
45
CyclesGene Step
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2.7.3 Cloning of qPCR positive control plasmids 
To determine the relative concentration of cDNA in each sample when using qPCR, positive 
control plasmids were produced for each qPCR assay. Positive control plasmids had already been 
made for GAPDH, ATP5B, by Dr Ased Ali, and for hBD2 by Dr Marcelo Lanz60,106. To obtain 
the appropriate PCR product, end-point PCR was performed as outlined in section 2.4 using the 
qPCR primers shown in Table 2.5. The product was gel electrophoresed and the DNA extracted 
from the gel as outlined in sections 2.5 and 2.6. The PCR product was cloned into the pGEM-T 
Easy Vector using the pGEM-T Easy Vector System I (Promega, USA) as per the manufacturer’s 
instructions. Briefly, the PCR product was ligated into the vector, transformed into JM109 
competent cells, and plated out onto LB plates containing 100μg/ml ampicillin with 100mM 
IPTG and 50mg/ml X-GAL for blue/white colony selection. The plates were incubated 
overnight at 37°C and growth of white colonies indicated successful integration of the PCR 
product into the vector. White colonies were picked and used to inoculate 5mls LB/ampicillin 
broth, which was incubated overnight at 37°C with shaking at 200rpm in an Incu-Shake TL6-5R 
rotary shaker (SciQuip, UK). After overnight incubation the plasmid was isolated from the 
cultures using the PureYield Plasmid Miniprep System (Promega, USA). The isolation was carried 
out as per the manufacturer’s instructions, and consisted of pelleting the cultures, lysing the 
bacteria, pelleting the cell debris and proteins, passing the supernatant containing the DNA 
through a Spin Column, washing, and finally eluting into Milli-Q water. The purified plasmid 
DNA was serially diluted and qPCR was performed on each dilution to produce a standard curve. 
 
Positive control plasmids and standard curves were produced using such protocols for DEFB4A, 
LCN2, RNASE7, and S100A7. 
 
2.7.4 qPCR data analysis 
The qPCR results for each gene were analysed using the standard curve method, relative to the 
geometric mean of the two housekeeping genes, GAPDH and ATP5B.  
 
2.8 Protein analysis by enzyme-linked immunosorbent assay 
Sandwich ELISAs were used to measure the concentration of peptides secreted into the cell 
culture medium after challenge. In this type of ELISA a capture antibody was attached to the 
plastic bottom of a 96-well plate. The wells were blocked, samples were bound and a detection 
antibody was added, which bound to any protein bound to the capture antibody. Typically, the 
detection antibody is biotin labelled and binds to streptavidin conjugated to horseradish 
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peroxidase (HRPO). A substrate was added to the well, which reacted with HRPO to cause a 
colour change in the well proportional to the amount of protein bound to the capture antibody. 
 
The ELISA for hBD2 was performed using the Human Beta-Defensin-2 (BD-2) ELISA 
Development Kit (Leinco Technologies, USA). The ELISA for LCN2 was performed using the 
Human Lipocalin-2/NGAL DuoSet ELISA Kit (R&D Systems, USA). Each of these kits 
contained capture antibody, detection antibody, standards and HRPO. No ELISA kit for hBD3 
was available, therefore, the ELISA method for hBD3 was developed and optimised by Dr 
Catherine Mowbray. The concentrations of reagents used for each assay is shown in Table 2.7. 
 
Table 2.7: Reagents used for hBD2, hBD3 and LCN2 ELISAs. 
 
 
To perform the ELISAs the capture antibody was diluted to the required concentration in PBS 
and 100µl was added to each well of a Nunc-Immuno Microwell 96 well plate (Sigma, USA). The 
plate was sealed (ELISA Plate Sealers, R&D Systems, USA) and incubated overnight at room 
temperature. The wells were aspirated to remove the antibody and washed four times with 300µl 
wash buffer. 300µl blocking buffer was added to each well, the plate sealed and incubated at 
room temperature for 1 hour. The wells were aspirated and washed 4 times with wash buffer. 
The standard was serially diluted 1:2 in diluent and 100µl of each standard added to the plate in 
duplicate. 100µl of each sample was added to the plate in duplicate. 100µl of diluent only was 
added to two wells of the plate as a blank. The plate was sealed and incubated for 2 hours at 
room temperature. The wells were aspirated and washed 4 times with wash buffer. The detection 
antibody was diluted to the specified concentration in diluent and 50µl added to each well of the 
hBD2 hBD3 LCN2
Human Beta-Defensin-2 (BD-2) Human Lipocalin-2/NGAL
ELISA Development Kit DuoSet ELISA Kit
Supplier Leinco Technologies R&D Systems
Wash buffer 0.05% Tween 20 in PBS 0.05% Tween 20 in PBS 0.05% Tween 20 in PBS
Blocking buffer 1% BSA in PBS 1% BSA in PBS 1% BSA in PBS
Diluent 0.05% Tween 20, 0.1% BSA in PBS 1% BSA in PBS 1% BSA in PBS
Capture antibody 0.5µg/ml ab109572 (Abcam) 0.25µg/ml
 0.25µg/ml
Standard 7.8125-2000pg/ml 4382-s (Peptide Institute) 19.5313-5000pg/ml
7.8125-1000pg/ml
Detection antibody 0.5µg/ml ab84234 (Abcam) 25ng/ml
1µg/ml
HRPO 1:2000 Ultra Streptavidin-HRPO 1:200
(Life Technologies)
1:400
Substrate solution ABTS Liquid Substrate Solution 1-Step Ultra-TMB ELISA Substrate Reagent
(Leinco Technologies) Substrate Solution (R&D Systems)
(Life Technologies)
Kit name
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plate. The plate was sealed and incubated for 2 hours at room temperature. The wells were then 
aspirated and washed 4 times with wash buffer. HRPO was diluted to the required concentration 
in diluent and 100µl added to each well. The plate was sealed and incubated for 30 minutes at 
room temperature in the dark. The wells were aspirated and washed 4 times with wash buffer. 
100µl substrate solution was added to each well and the plate was sealed and incubated for 20 
minutes at room temperature in the dark. 50µl of 1M sulphuric acid was added to each well to 
stop the reaction. Absorbance was measured at 450nm with wavelength correction at 540nm 
using the FLUOstar Omega Microplate Reader (BMG Labtech, Germany). A standard curve was 
produced using 4-parameter fit to analyse the data and the concentrations of the samples was 
determined. 
 
2.9 Whole transcriptome analysis by microarray 
Microarray analysis was performed to identify other potential genes regulated by estrogen and to 
help determine signalling pathways. VK2 cells that were pretreated with 4nM estrogen for seven 
days followed by 50ng/ml flagellin challenge were analysed by microarray. The 12 and 24 hour 
samples of control, estrogen pretreatment, flagellin, and estrogen pretreatment plus flagellin 
challenged VK2 cells were selected for analysis. Three technical replicates of each treatment were 
analysed, totalling 24 samples. Samples to be analysed were shipped on dry ice to Service XS, The 
Netherlands, who performed RNA quality analysis and carried out the microarray experiments. 
 
2.9.1 RNA quality analysis 
Samples used for microarray analysis must be high quality in order to obtain reliable results. 
Service XS confirmed that the RNA samples were high quality using the Agilent RNA 6000 
Nano Kit and the Agilent 2100 Bioanalyser. The kit analyses the 18S and 28S RNA and calculates 
an RNA integrity number (RIN) between 0 and 10. A RIN above 7 is considered good quality. 
All RNA samples analysed by Service XS had a RIN of 10 and thus could proceed to microarray 
analysis. 
 
2.9.2 Microarray experiments 
Microarrays are useful as they allow analysis of global gene expression changes. This type of 
analysis is not feasible using qPCR. A microarray consists of a chip with thousands of 
oligonucleotides, known as probes, attached. These probes will have a nucleotide sequence 
specific for a given gene and are in a known location on the chip. After exposing cells to a 
specific treatment, the mRNA is extracted and reverse transcribed into cDNA. This cDNA is 
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then labelled with a fluorescent tag before being added to the chip. During the hybridisation step 
the labelled cDNA binds to the complementary probes on the chip and any unbound cDNA is 
subsequently washed off. The fluorescence level of each probe can then be measured to 
determine the level of mRNA of each gene in the sample; as it is the cDNA that is fluorescently 
labelled and not the probe, a probe will only emit fluorescence if cDNA has bound. Binding of 
cDNA to a probe indicates expression of that gene in the sample. Multiple identical probes are 
grouped into ‘spots’ on the chip, and each spot represents a single gene (see Figure 2.2). 
Therefore, increased mRNA of a particular in a sample will result in a higher fluorescent readout 
for that spot. To ensure accurate detection of the cDNA some genes are represented by more 
than one set of probes. 
 
Figure 2.2: Diagram showing multiple identical probes within each spot on a microarray chip200. 
 
Microarrays were carried out using the Illumina HumanHT-12 v4 Expression Beadchip (Illumina, 
USA) for each of the 24 samples sent. The HumanHT-12 v4 chip measures the expression of 
31,000 genes based upon the NCBI RefSeq Release 38 using 50mer probes bound to silica beads. 
 
2.9.3 Analysis of microarray data 
Raw expression data was received from Service XS and analysed in collaboration with the 
Bioinformatics Support Unit, Newcastle University. The raw data was analysed in R using 
Bioconductor using lumi (Methods for Illumina Microarrays) and limma (Linear Models for 
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Microarray Data) packages. The raw data was normalised to the housekeeping genes and 
converted to fold change relative to the control. A fold change in gene expression was considered 
significant if it had a fold change or + or -2 and a p-value <0.05. Venn diagrams were produced 
using the BioVenn software201. Lists of differentially expressed genes were uploaded to Ingenuity 
Pathway Analysis (Qiagen, USA) for pathway analysis. 
 
2.10 Construction of reporter plasmids 
To analyse the regulation of hBD2 and hBD3 by ER-α and –β, a hBD2 promoter reporter 
plasmid was constructed and an attempt was made to construct a hBD3 promoter reporter 
plasmid. 
 
2.10.1 hBD2 reporter plasmid 
The hBD2 promoter reporter plasmid (phBD-2-luc) was constructed by Dr Marcelo Lanz106. The 
plasmid contained the 2000bp hBD2 promoter region upstream of the luciferase gene (Figure 
2.3).  
 
 
Figure 2.3: Diagram of phBD-2-Luc engineered by Dr Marcelo Lanz106. 
 
Analysis of the 2000bp promoter region of hBD2 using PROMO revealed six EREs in the 
promoter, which are transcription factor binding sites for the classical estrogen receptors ER-α 
and –β. Each of these EREs was mutated, in turn, by site-directed mutagenesis in collaboration 
with Tom Powell (MRes student, 2014) using the QuikChange II site-directed mutagenesis kit 
(Agilent, USA) to produce six mutant hBD2 promoter reporter plasmids. Briefly, to perform the 
site-directed mutagenesis mutant strand synthesis was performed by end-point PCR using the 
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primers detailed in Table 2.8. The parental DNA was digested using the restriction enzyme DpnI 
and the mutant DNA was transformed into XL10-Gold Ultracompetent Cells (Agilent, USA) and 
plated out onto LB/ampicillin agar plates. Colonies were picked and inoculated into 5mls 
LB/ampicillin broth and incubated overnight at 37°C with shaking at 200rpm in an Incu-Shake 
TL6-5R rotary shaker (SciQuip, UK). Plasmid DNA was isolated using the PureYield Plasmid 
Miniprep System (Promega, USA) and sequenced to confirm successful mutagenesis (Genevision, 
UK).   
 
Table 2.8: Table of primers used for site-directed mutagenesis of hBD2 promoter plasmid. The ERE site 
mutated at 2 or 3 base pairs is shown in red. 
 
 
2.10.2 hBD3 reporter plasmid 
An attempt was made to construct a hBD3 promoter reporter plasmid in order to examine the 
role of ER-α and –β in hBD3 expression.  
 
2.10.2.1 End-point PCR using KOD polymerase 
End-point PCR was performed on genomic DNA (extracted from vaginal tissue by Dr Catherine 
Mowbray) using primers detailed in Table 2.9 using KOD polymerase (Merck Millipore, 
Germany). KOD polymerase is a high fidelity proofreading polymerase that accurately replicates 
the template DNA without introducing errors. The end-point PCR reaction was set up with the 
following volumes of reagents: 
 
 
 
 
 
 
Primer Sequence Tm (°C)
ERE1 forward GACATGTGCATGGTGAGGCAAATTATCAGCAGCAAGTGAGAGCT
ERE1 reverse AGCTCTCACTTGCTGCTGATAATTTGCCTCACCATGCACATGTC
ERE2 forward TAGCAGTTCTGACAGCATCTATCTCAGCCCTCTCTTTGCATACC
ERE2 reverse GGTATGCAAAGAGAGGGCTGAGATAGATGCTGTCAGAACTGCTA
ERE3 forward GATAGGAGTGTGAAACTAATTTGACCAACATGGCAAAACCCC
ERE3 reverse GGGGTTTTGCCATGTTGGTCAAATTAGTTTCACACTCCTATC
ERE4 forward GTCAAATTGGTCTCACACTCCTATCTTCATGTGATCCACCTGCCT
ERE4 reverse AGGCAGGTGGATCACATGAAGATAGGAGTGTGAGACCAATTTGAC
ERE5 forward GGGTTCTTCAGAACCTGACATTTTAAATGAAGAAATTAGGCAGGTCATGAGGAA
ERE5 reverse TTCCTCATGACCTGCCTAATTTCTTCATTTAAAATGTCAGGTTCTGAAGAACCC
ERE6 forward ATTTTAAATGAAGAGGTCAGGCAAATTATGAGGAAAGCCTCATTGTCCCC
ERE6 reverse GGGGACAATGAGGCTTTCCTCATAATTTGCCTGACCTCTTCATTTAAAAT
78.9
78.9
78.4
79
79.4
78.4
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 2.5µl 10x PCR buffer for KOD polymerase 
 1.5µl 25mM MgSO4 
 2.5µl 2mM dNTPs 
 0.5µl KOD polymerase 
 0.75µl 10µM Forward primer 
 0.75µl 10µM Reverse primer 
 14.5µl Milli-Q water 
 2µl Template DNA 
 -------------------------------- 
 25µl Total volume 
 
The primers were designed to include a restriction enzyme binding site sequence and are detailed 
in Table 2.9. The reactions were briefly centrifuged and PCR was performed as shown in Table 
2.10. The PCR product was gel electrophoresed and the product was extracted from the gel as 
detailed in sections 2.5 and 2.6. 
 
Table 2.9: Table of hBD3 promoter region cloning primers. The restriction binding site is shown in red. 
 
 
 
Table 2.10: Table of PCR cycling conditions for end-point PCR with KOD polymerase. 
 
 
2.10.2.2 Restriction digest 
To clone the hBD3 promoter region into the pGL4.10[luc2] vector (Promega, USA) restriction 
digests were performed on the PCR products and pGL4.10. The pGL4.10 vector is shown in 
Restriction Temperature Product
site (Tm, °C) length (bp)
hBD3 promoter 500bp forward GCGCGAGCTCGTAATCATGCCACTGCACTC SacI 58 513
hBD3 promoter 1KB forward GCGCGGTACCGTCAACCAAATACAACCCATC KpnI 56 1258
hBD3 promoter 2KB forward GCGCGGTACCCGGATTTTGTGTGTCTGGAG KpnI 56 2189
hBD3 promoter reverse GCGCTTCGAAGAACACACCCACTCACTCAG HindIII
Primer name Sequence
Forward primers
Reverse primer
Temperature Time
(°C) (min:sec)
Preincubation 95 02:00 1
Denaturation 95 00:20
Annealing Tm 00:10
Elongation 70 01:20
Final elongation 72 10:00 1
Final hold 4 ∞
35
Step Cycles
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Figure 2.4 and contains the luc2 luciferase gene downstream of a multiple cloning site and the 
ampicillin resistance gene. 
 
 
Figure 2.4: Diagram of pGL4.10 Vector (Promega, USA). 
 
Single and double restriction digests were set up with the following volumes of reagents (all from 
Promega, USA): 
 
pGL4.10 single digest:       pGL4.10 double digest:  Insert double digest: 
3µl 10x Buffer E       3µl      10x Buffer E  3µl 10x Buffer E 
3µl BSA (1µg/µl)       3µl      BSA (1µg/µl)  3µl BSA (1µg/µl)  
1.5µl SacI        1.5µl     SacI   1.5µl SacI 
1.5µl pGL4.10 (1µg/µl)      1.5µl     HindIII   1.5µl HindIII 
21µl Milli-Q water       1.5µl     pGL4.10 (1µg/µl)  10µl Insert DNA 
----------------------------       19.5µl   Milli-Q water  11µl Milli-Q water 
30µl Total volume       -----------------------------  ----------------------------- 
         30µl     Total volume  30µl Total volume 
 
Digestion reactions were incubated at 37°C for up to 5 hours and then heat inactivated at 65°C 
for 15 minutes. The reactions were gel electrophoresed and the digested DNA products were 
extracted from the gel. 
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2.10.2.3 Ligation reaction 
Ligation reactions were performed in order to introduce the hBD3 promoter fragment into the 
pGL4.10 vector. Ligation reactions, including controls, were set up as shown in Table 2.11. 
 
Table 2.11: Table of ligation reactions and reagents. 
 
 
The ligation reactions were incubated overnight at 4°C and transformed the following day. 
 
2.10.2.4 Transformation 
The ligation reactions were transformed into Subcloning Efficiency DH5α Competent Cells 
(Invitrogen, USA) as per the manufacturers protocol. Briefly, 25µl of DH5α cells were gently 
mixed with 5µl of ligation reaction and incubated on ice for 30 minutes. The cells were heat 
shocked at 42°C for 20 seconds, returned to ice for 2 minutes, mixed with 950µl LB medium and 
incubated for 1.5 hours at 37°C with shaking at 200rpm in an Incu-Shake TL6-5R rotary shaker 
(SciQuip, UK). The transformation cultures were plated onto LB plates containing 100μg/ml 
ampicillin and incubated overnight at 37°C to allow colony growth.     
 
2.10.2.5 Colony PCR 
Colonies that grew on the LB/ampicillin plates were picked using a pipette tip, streaked onto a 
fresh LB/ampicillin plate, and then transferred into a PCR tube containing the following 
reagents: 
 
 
 
 
 
 
 
 
Reaction Vector + insert + ligase Vector + ligase Vector only Uncut vector Single digest vector + ligase
Quantifies vector Quantifies undigested Verifies
recircularisation vector transformation
10x Ligase Buffer (Promega, USA) 1µl 1µl 1µl 1µl 1µl
DNA Ligase (Promega, USA) 1µl 1µl 1µl
Double digested vector 1µl 1µl 1µl
Single digested vector 1µl
Uncut vector 1µl
Double digested insert 1µl
Milli-Q water 6µl 7µl 8µl 8µl 7µl
Total volume 10µl 10µl 10µl 10µl 10µl
Reason Cloning reaction Verifies ligation reaction
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2.5µl 10x PCR buffer for KOD polymerase 
 1.5µl 25mM MgSO4 
 2.5µl 2mM dNTPs 
 0.5µl KOD polymerase 
 0.75µl 10µM Forward primer 
 0.75µl 10µM Reverse primer 
 16.5µl Milli-Q water 
 -------------------------------- 
 25µl Total volume 
 
PCR was performed using the cycling conditions described in section 2.10.2.1. PCR products 
were gel electrophoresed, extracted from the gel and sent for sequencing (Genevision, UK) to 
determine whether the hBD3 promoter region was present in the vector.  
 
2.11 Transient transfection of VK2 cells 
To determine the role of each of the EREs in the hBD2 promoter region, the WT hBD2 
promoter plasmid and the six mutant plasmids were transiently transfected into VK2 cells. The 
transfection reaction was optimised for VK2 cells. 
 
2.11.1 Transfection optimisation 
The transfection reaction was optimised to establish which conditions resulted in maximum 
transfection efficiency. For this, the reporter plasmid pGL4.51 (Promega, USA) was used. This 
reporter plasmid consists of a cytomegalovirus (CMV) promoter upstream of the luc2 gene. Thus, 
this plasmid constitutively produced luciferase after transfection. The Attractene transfection 
reagent (Qiagen, USA) was used to transfect VK2 cells as it exhibits very low cytotoxicity. 
Attractene is a lipid based transfection reagent, which incorporates DNA into liposomes that 
then fuse with the cell membrane, introducing the DNA into the cell. 
 
To optimise the transection, 0-0.8µl of Attractene and 150-250ng pGL4.51 DNA was mixed with 
keratinocyte-SFM without BPE, EGF and CaCl2, to a final volume of 50µl and incubated at room 
temperature for approximately 30 minutes while the cells were prepared. VK2 cells were 
trypsinised, centrifuged, counted and seeded into a white plastic, clear bottomed Costar Assay 96 
well plate (Corning, USA) at a density of 5x104 cells/well in 150µl keratinocyte-SFM medium. 
50µl Attractene/DNA/medium mix was added to each well and the cells were incubated with the 
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transfection reagents for 18 hours at 37°C. After this time the medium was removed from each 
well, the cells were washed twice with PBS and 20µl Reporter Lysis 5x Buffer (Promega, USA) 
was added to each well. Air bubbles in the lysis buffer were removed using a needle and the 96-
well plate was incubated at -80°C overnight. Luciferase levels were measured using the Luciferase 
Assay System (Promega, USA) and the FLUOstar Omega Microplate Reader (BMG Labtech, 
Germany) as detailed in section 2.11.2. 
 
Transfection optimisation determined 0.5µl of Attractene and 150ng DNA to be the optimum 
transfection conditions. 
 
2.11.2 Luciferase assay 
The Luciferase Assay System (Promega, USA) was used to measure luciferase levels in each well 
after transfection with a reporter plasmid. The 96-well plate was removed from the -80°C freezer 
and was defrosted at room temperature for at least one hour. The Luciferase Assay Buffer 
(Promega, USA) was defrosted and added to the Luciferase Assay Substrate. The 96-well plate 
and the Luciferase Assay Substrate were placed inside the FLUOstar Omega Microplate Reader 
(BMG Labtech, Germany), which automatically injected 100µl substrate into each well of the 96-
well plate before measuring the luminescence. 
 
2.11.3 Transient transfection of hBD2 reporter plasmid 
To determine the effect of estrogen on hBD2 expression, either untreated VK2 cells or VK2 cells 
pretreated with estrogen for 7 days were transfected with either the hBD-2-luc plasmid or one of 
the hBD-2-luc ERE mutant plasmids. 0.5µl of Attractene Transfection Reagent was mixed with 
150ng plasmid DNA and made up to 50µl total volume with keratinocyte-SFM without BPE, 
EGF and CaCl2. The Attractene/DNA/medium mixture was incubated for approximately 30 
minutes at room temperature to allow complex formation while the VK2 cells were prepared. 
The VK2 cells were trypsinised, centrifuged, resuspended, counted and seeded into a white 
plastic, clear bottomed 96-well plate at a density of 5x104 cells/well in 150µl keratinocyte-SFM 
supplemented with 4nM 17β-estradiol or 14.8nM cyclodextrin. 50µl Attractene/DNA/medium 
mix was added to each well and the cells were incubated for 18 hours at 37°C to allow the cells to 
adhere to the bottom of the well and incorporate the plasmid DNA. After 18 hours the medium 
was removed the cells were washed with PBS and 200µl fresh keratinocyte-SFM supplemented 
with estrogen or cyclodextrin was added to each well and the cells were incubated for another 24 
hours at 37°C. The cells were challenged with either 50ng/ml flagellin (clinical isolate 3408) or 
PBS for 24 hours. After 24 hours the medium was removed, the cells were washed with PBS and 
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20µl of Reporter Lysis 5x Buffer (Promega, USA) was added to each well. Air bubbles were 
removed with a needle and the plate was incubated at -80°C overnight. Luminescence levels were 
determined using the Luciferase Assay System (Promega, USA) as detailed in section 2.11.2. 
 
2.12 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 software (GraphPad Software, USA). 
Following data analysis by one- or two-way ANOVA multiple comparisons were performed 
using Dunnet’s, Sidak’s or Tukey’s post hoc tests. Dunnett’s post hoc test compares each of the 
treatment means to a single control mean. Sidak’s post hoc test performs pairwise comparisons 
between two treatment means. Tukey’s post hoc test compares each treatment mean to every 
other treatment mean.  
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3 Effects of estrogen on hBD2 and hBD3 expression 
3.1 Introduction 
Approximately 50% of postmenopausal women develop a recurrent infection after an initial 
UTI13. This risk is double that of premenopausal women. As circulating estrogen is depleted after 
the menopause, this suggests a role for estrogen in protecting against UTIs. Topical vaginal 
estrogen treatment is used to treat vaginal atrophy in postmenopausal women and has also been 
shown to reduce the incidence of rUTIs in this population190,194. The vagina is a key reservoir of 
UPEC colonisation in women and clearance of pathogenic bacteria from this reservoir helps 
prevent progression to UTI.  
 
In healthy premenopausal women the vaginal epithelium consists of stratified squamous epithelial 
cells. This means there are multiple layers of thin, flat cells that sit on top of the lamina propria – 
a layer of connective tissue. The vaginal epithelium is also keratinised, whereby the outer 
epithelial cells terminally differentiate into cornified cells that lose their nuclei and other 
organelles and are filled with keratin filaments, making the cells hardened and resistant to 
mechanical stress (see Figure 3.1). The outer membrane of these cells is replaced with a cornified 
envelope covalently cross-linked to the keratin filaments. This keratinised outer layer protects the 
underlying epithelial cells202. The keratinised cells are also known as superficial cells and this layer 
is termed the stratum corneum. It is estimated that the outermost layer of the stratum corneum is lost 
every 4 hours203. This sloughing of cells removes any attached pathogens from the vagina, but 
also releases glycogen into the vaginal lumen, which is utilised by lactobacilli to produce lactic 
acid and maintain the vaginal pH.  
 
In postmenopausal women vaginal atrophy occurs, which is thinning of the vaginal epithelium 
due to loss of the superficial epithelial cells. In addition, estrogen depletion results in reduced 
vaginal glycogen and consequently, reduced lactobacilli colonisation and a higher vaginal pH. 
These conditions facilitate vaginal colonisation by UPEC. UPEC in the vagina can readily infect 
the urinary tract, due to the proximity of the urethra to the vagina, and cause repeated UTIs.   
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Figure 3.1: Diagram of the stratified squamous vaginal epithelium. Multiple layers of stratified squamous 
epithelial cells sit on top of the lamina propria – a layer of connective tissue. The outermost epithelial cells lose their 
nuclei and become filled with keratin, creating a hardened outer layer. Figure adapted from ref 204. 
 
Studies investigating the roles of estrogen in UTIs have predominantly focused on the ability of 
estrogen to increase vaginal glycogen levels, which promotes growth of Lactobacillus spp. and 
lowers vaginal pH. However, very few studies have examined the effect of estrogen on the innate 
immune defences of the urogenital tract. 
 
AMPs are a vital component of the innate immune system, especially at epithelial surfaces. AMPs 
have been demonstrated to be important in protecting the urogenital tract from infection. 
Previous work from our laboratory has investigated the AMPs hBD2 and hBD3 and has shown 
that the vaginal concentration of these peptides increases in postmenopausal women receiving 
topical estrogen treatment, compared with non-estrogen treated postmenopausal women60. These 
data suggest that estrogen may also have roles in enhancing the innate immunity to UPEC. 
Following on from previous work in our laboratory, the initial investigations of this thesis, which 
are reported in this chapter, focused on the effect of estrogen on the AMPs hBD2 and hBD3 in 
the vaginal epithelium.  
 
3.2 VK2 cells express estrogen receptors 
It was of interest to study the effects of estrogen on vaginal AMP expression, as effective 
clearance of UPEC from the vagina is thought to prevent progression to UTI. To model the 
vaginal epithelium in vitro the VK2 E6/E7 (VK2) cell line was used. This is an immortalised 
human vaginal epithelial cell line. To determine estrogen receptor expression in VK2 cells, end-
point PCR was performed for each of the receptors (ER-α, ER-β, and GPER). PCR was 
performed on cDNA extracted from untreated VK2 cells, and products representing ER-α, ER-
β, and GPER were detected at 236bp, 439bp, and 680bp, respectively (Figure 3.2). The PCR 
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products were confirmed as ER-α, ER-β, and GPER by sequencing with 99%, 95% and 98% 
identity, respectively, to the basic local alignment search tool (BLAST) database subject sequence. 
This indicated that the VK2 cells were an appropriate cell model to investigate the effects of 
estrogen on vaginal AMP expression. 
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Figure 3.2: VK2 cells express estrogen receptors. End-point PCR was performed on cDNA from VK2 cells for 
(A) ER-α at 236bp, (B) ER-β at 439bp, and (C) GPER at 680bp. The 100bp ladder (New England BioLabs, USA) is 
shown in lane 1 of each gel, and the respective PCR product is shown in lane 2. The PCR products were confirmed 
by sequencing (Genevision, UK) and the nucleotide BLAST alignments are shown. The query sequence is the 
sequence of the PCR product as determined by sequencing and the subject (sbjct) sequence is the BLAST database 
sequence. 
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3.3 Development of qPCR assays 
To measure the effects of estrogen on AMP expression in VK2 cells, qPCR assays were 
developed for AMPs hBD2 and hBD3, in addition to the housekeeping genes GAPDH and 
ATP5B.  
3.3.1 hBD2 qPCR assay 
The qPCR assay for hBD2 was designed as a probes-based qPCR assay and the primers for this 
assay were predesigned by Integrated DNA Technologies (USA). End-point PCR was performed 
for hBD2 using the probes-based hBD2 primers and the PCR product was electrophoresed, 
extracted from the gel and cloned into the pGEM-T Easy vector (Promega, USA) as described in 
the materials and methods. Insertion of the hBD2 qPCR product into the vector was confirmed 
by sequencing (Figure 3.3A) and the inserted product had 100% identity with the BLAST 
database subject sequence. The vector containing the hBD2 PCR product was used to produce 
the standard curve for this assay (Figure 3.3B). The DNA probe of probes-based qPCR assays 
interferes with the melt peak of the PCR product and thus melt peak analysis was not performed 
for this assay. However, the qPCR product was electrophoresed on a TBE gel and only one PCR 
product, with the correct size of 106bp, was detected (Figure 3.3C). 
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Figure 3.3: Sequencing results and standard curve for hBD2 probes-based qPCR assay plasmid. (A) The 
hBD2 PCR product was cloned into the pGEM-T Easy vector (Promega, USA) and confirmed by sequencing. The 
BLAST alignment is shown. The query sequence is the sequence of the PCR product as determined by sequencing 
and the subject (sbjct) sequence is the BLAST database sequence. (B) qPCR was performed using the vector, 
containing the hBD2 PCR product, serially diluted 1:10 to produce a standard curve. (C) The qPCR product was 
electrophoresed with HyperLadder IV (Bioline, USA) in Lane 1 and the 107bp PCR product is shown in Lane 2.  
 
3.3.2 hBD3 qPCR assay 
The hBD3 qPCR assay was a SYBR-green based assay and was established by Dr Marcelo Lanz. 
The hBD3 PCR product was cloned into the pGEM-T Easy vector and confirmed by 
sequencing. This plasmid was used to produce a standard curve for the hBD3 assay and a melt 
peak confirmed only one PCR product was amplified (Figure 3.4)106.  
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Figure 3.4: Standard curve and melt peak of hBD3 qPCR assay. The figure shows the standard curve and melt 
peak of the hBD3 qPCR assay designed by Dr Marcelo Lanz106. The melt peak confirms amplification of a single 
PCR product. 
 
The qPCR results were analysed using the standard curve method relative to the housekeeping 
genes. 
 
3.3.3 Housekeeping gene qPCR assays  
qPCR assays for the housekeeping genes, GAPDH and ATP5B, were designed previously by Dr 
Ased Ali. The primers for these genes were predesigned by Primerdesign (UK). The PCR 
products were cloned into pGEM-T Easy vectors (Promega, USA) to produce a standard curve 
for each assay, as shown in Figure 3.560. Melt peak analyses confirmed that each assay detected 
only one PCR product, as all samples displayed a single melt peak at the same temperature. 
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Figure 3.5: Standard curves and melt peaks for GAPDH and ATP5B qPCR assays. The figure shows the 
standard curves and melt peaks for the (A) GAPDH and (B) ATP5B qPCR assays designed by Dr Ased Ali60. Melt 
peaks confirm that only one PCR product was amplified during each reaction. 
 
The qPCR assays outlined above were used to quantitate the effect of estrogen on hBD2 and 
hBD3 expression. The qPCR results shown in this thesis were analysed using the standard curve 
method, relative to the geometric mean of the two housekeeping genes, GAPDH and ATP5B. 
The results were normalised to the 24 hour flagellin challenge results. This approach was used as 
the AMPs had very low expression in the control samples with cycle numbers between 30 and 35 
recorded. Variability was observed in the cycle numbers reported for the control samples when 
measuring the AMPs, due to the low cycle numbers for these samples. For example, in-plate 
replicates of the control samples were observed as having cycle numbers up to two cycles 
different, indicating a 4-fold difference in the amount of mRNA detected. Thus, as the control 
samples were less reliable the results were not normalised to control, as this would introduce 
uncertainty into all of the results. Instead the results were normalised to 24 hour flagellin 
challenge. As flagellin induced expression of the AMPs, flagellin challenged samples had an 
earlier cycle number than the control. Minimal variability was observed for these samples (cycle 
numbers for in-plate sample replicates were within 1% of each other). Thus, normalisation of the 
results to 24 hour flagellin challenge allowed comparison across different experiments and did 
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not introduce uncertainty into the data. The qPCR results presented in this thesis, therefore, are 
shown as arbitrary units (AU) of expression, with 24 hour flagellin challenge normalised to a 
mean of 100AU for each experiment. 
  
3.4 Effects of acute estrogen on hBD2 and hBD3 expression 
3.4.1 qPCR analyses 
To investigate the effect of estrogen on hBD2 and hBD3 expression VK2 cells were challenged 
with 4nM estrogen with and without 50ng/ml flagellin, or PBS. 4nM estrogen is a relevant 
physiological concentration for premenopausal women162. After 0, 8, 12 and 24 hours the RNA 
was extracted, reverse transcribed into cDNA and analysed for hBD2 and hBD3 expression 
using the qPCR assays described. The qPCR results were analysed relative to the two 
housekeeping genes, GAPDH and ATP5B, using the geometric mean and the resultant values 
were normalised to 24 hour flagellin.  
 
The results, shown in Figure 3.6, indicated that hBD2 expression was significantly induced by 
flagellin challenge. After 8, 12 and 24 hours flagellin challenge hBD2 expression was determined 
as 146AU, 167AU and 100AU, respectively, compared to untreated controls, which had mean 
hBD2 expression of 8AU (p<0.0001, Figure 3.6A). This is representative of a 9.9-, 19- and 22-
fold change at 8, 12 and 24 hours, respectively, relative to the controls.  Estrogen plus flagellin 
challenge also significantly induced hBD2 expression at 8, 12 and 24 hours (p<0.0001), but the 
addition of estrogen did not significantly increase hBD2 expression compared to flagellin 
challenge alone at any of the time points. After 24 hours flagellin challenge hBD3 expression 
increased to 100AU from 46AU in the control, representative of a significant 2.2-fold change in 
hBD3 expression (p<0.0001, Figure 3.6B). This was the only time point where flagellin challenge 
induced a statistically significant increase in hBD3 expression compared to the control. After 24 
hours estrogen plus flagellin challenge hBD3 expression was further increased to 138AU, 
representative of a 3.0-fold change in hBD3 expression relative to the control (p<0.0001) and a 
significant 1.4-fold increase compared to flagellin (p=0.0005). Estrogen plus flagellin did not 
significantly increase hBD3 expression compared to flagellin challenge at any other time point.  
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Figure 3.6: Effects of acute estrogen and flagellin on hBD2 and hBD3 expression in VK2 cells. VK2 cells 
were challenged with 4nM estrogen and/or 50ng/ml flagellin for up to 24 hours. RNA was then extracted and 
analysed by qPCR for (A) hBD2 and (B) hBD3 expression, and results were normalised to 24 hour flagellin. Error 
bars represent standard error. Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. 
ns=not significant, ***=p<0.001. N=3, n=9. 
 
3.4.2 Reporter analyses 
To verify these data, hBD2 promoter activity was also measured using a luciferase reporter assay. 
The phBD-2-Luc reporter plasmid was engineered by Dr Marcelo Lanz and contains a 2032bp 
hBD2 promoter region insert upstream of the luc2 luciferase gene106. Following transfection of 
VK2 cells with the reporter plasmid, expression of hBD2 results in luciferase production. When 
luciferase reacts with the luciferase reporter assay reagent (Promega, USA) light is emitted in the 
form of luminescence in proportion to the amount of luciferase produced by the cells. This 
means that greater hBD2 promoter activity results in higher luminescence. Luciferase expression 
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was quantitated by measurement of luminescence using a plate reader, as detailed in the materials 
and methods. 
  
3.4.2.1 hBD2 reporter assay optimisation 
Transfection of the VK2 cells required optimisation to determine the concentrations of 
transfection reagent and plasmid DNA that yielded the best results. The pGL4.51 vector 
(Promega, USA) was used to optimise the transfection protocol. This vector contains the luc2 
gene downstream of the CMV promoter, which results in constitutive luciferase expression in 
cells that have taken up the plasmid. This is useful for optimisation as the amount of 
luminescence is directly proportional to the amount of plasmid that has been taken up and 
therefore, can be used to determine the optimum transfection conditions. Hence, to optimise the 
transfection reaction, VK2 cells were seeded into a 96-well plate and transfected using 0-
0.8μl/well Attractene transfection reagent and 150-250ng pGL4.51 plasmid DNA. 
 
As shown in Figure 3.7, all of the conditions where 0.2μl or greater of Attractene was used 
resulted in high luminescence levels of approximately 5000AU, compared to the control samples 
without Attractene, which had a mean luminescence of 22AU. Cytotoxic activity was observed at 
higher concentrations of Attractene, reflected by 0.7μl and 0.8μl Attractene data, which showed 
reduced luminescence values of approximately 3500AU. Generally, increasing the concentration 
of plasmid DNA did not increase the luminescence. Therefore, 0.5μl/well Attractene and 150ng 
plasmid DNA were the conditions chosen for further transfection experiments, as this resulted in 
strong luminescence levels of 5033AU, compared to a mean luminescence of 22AU in the 
controls without Attractene, whilst minimising reagent volumes.  
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Figure 3.7: Optimisation of VK2 cell transfection. VK2 cells were seeded into a 96-well plate and transfected 
with 0-0.8μl Attractene (Qiagen, Germany) and 150-250ng pGL4.510 plasmid DNA (Promega, USA) and incubated 
for 18 hours. The cells were then lysed and the Luciferase Assay System (Promega, USA) and FLOUstar Omega 
Microplate Reader were used to measure luciferase production. Error bars represent standard error. N=1, n=3. 
 
3.4.2.2 Effects of acute estrogen on hBD2 promoter activity 
The VK2 cells were transiently transfected with the phBD-2-luc plasmid using the conditions 
determined above and then challenged with 4nM estrogen and/or 50ng/ml flagellin, or PBS, for 
24 hours. Luminescence levels were determined using the Luciferase Assay Kit (Promega, USA) 
and FLOUstar Omega Microplate Reader. 
 
The results of the luciferase assay (Figure 3.8) showed that the 24 hour flagellin challenge 
activated the hBD2 promoter, causing gene transcription. The experimental repeats exhibited 
variation in the fold change induced, with the first repeat showing a 5.9-fold change in promoter 
activity following flagellin challenge, compared to control, and the second repeat showing a 42-
fold change after flagellin challenge. However, this was not observed for other experiments using 
the hBD2 reporter assay and thus was likely to be due to technical differences between 
experimental repeats, such as differences in cell density in the wells at time of challenge. 
Nevertheless, neither repeat showed a significant increase in luminescence following acute 
estrogen plus flagellin challenge, compared to flagellin challenge alone. These data supported the 
qPCR data, showing that acute estrogen treatment did not significantly increase hBD2 
expression.  
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Figure 3.8: Effects of acute estrogen and flagellin on  hBD2 promoter activity. VK2 cells were seeded into 96-
well plates and transiently transfected with the phBD-2-luc plasmid and then treated with 4nM estrogen and/or 
50ng/ml flagellin for 24 hours. The phBD-2-luc plasmid contains a 2032bp hBD2 promoter insert upstream of the 
luc2 gene. The cells were lysed, the Luciferase Assay System (Promega, USA) and FLUOstar Omega Microplate 
Reader were used to determine luminescence, and the results were normalised to the control. (A) and (B) show the 
results for the first and second biological repeat, respectively. Each graph represents N=1, n=3. Error bars represent 
standard error. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. ns=not 
significant.  
 
3.4.3 Effects of acute estrogen with reduced flagellin concentrations on hBD2 and 
hBD3 expression 
To ascertain whether a dose of 50ng/ml flagellin was inducing maximum expression of hBD2 
and hBD3 such that acute estrogen treatment could not further potentiate gene expression, VK2 
cells were challenged with lower concentrations of flagellin, with and without estrogen. It was 
hypothesised that lower concentrations of flagellin would result in a smaller induction of hBD2 
and hBD3 expression, and thus any effects of estrogen would be more marked. VK2 cells were 
challenged with 2.5pg/ml to 50ng/ml flagellin, with and without 4nM estrogen for 24 hours, and 
the RNA was extracted, reverse transcribed and analysed by qPCR for hBD2 and hBD3 
expression. 
 
The results, in Figure 3.9, showed that acute estrogen plus flagellin treatment did not increase 
hBD2 or hBD3 expression compared to flagellin alone, at any of the concentrations of flagellin 
used. The hBD3 expression data suggested a potential increase in gene expression with acute 
estrogen treatment plus 50ng/ml flagellin (135AU), compared to 50ng/ml flagellin without 
estrogen (100AU), however, in this experiment the difference was not significant (p=0.1463) as 
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was seen previously in Figure 3.6. These data indicated that acute estrogen treatment at a 
concentration of 4nM was not sufficient to increase the expression of hBD2 and hBD3 at any of 
the flagellin concentrations tested. Thus, the hypothesis that reducing the flagellin concentration 
may reveal an effect of acute estrogen on hBD2 and hBD3 expression was incorrect. 
Furthermore, these data demonstrated that 25ng/ml and 50ng/ml flagellin induced hBD2 and 
hBD3 expression to comparable levels, whilst flagellin concentrations lower than this resulted in 
lower hBD2 and hBD3 expression. Thus, flagellin at a concentration of 50ng/ml was a strong 
inducer of AMP expression and this concentration was used for subsequent experiments. 
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Figure 3.9: Effects of reduced flagellin concentrations, with and without acute estrogen, on hBD2 and 
hBD3 expression. VK2 cells were challenged with flagellin ranging from 2.5pg/ml-50ng/ml, with and without 4nM 
estrogen, for 24 hours. The RNA was extracted and analysed by qPCR for (A) hBD2 and (B) hBD3 expression. 
Error bars represent standard error. Statistical analysis was performed by two-way ANOVA with Sidak’s post hoc 
test. ns=not significant. N=2, n=6. 
 
3.5 Effects of long-term estrogen treatment on hBD2 and hBD3 expression 
As acute estrogen treatment plus flagellin challenge did not significantly effect hBD2 and hBD3 
expression compared to flagellin alone, the effect of estrogen pretreatment for seven days prior 
to flagellin challenge on hBD2 and hBD3 expression was investigated. Estrogen pretreatment 
more accurately represents physiological exposure to estrogen, as well as topical estrogen 
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treatment, which is applied regularly to the vagina as a prophylactic treatment7. The estrogen 
concentration used in these experiments was representative of physiological estrogen levels, not 
therapeutic levels.  
 
3.5.1 Effects of estrogen pretreatment on VK2 cell growth 
Estrogen has been reported to increase growth of certain cell types205–208. Thus, the effect of 
estrogen pretreatment on VK2 cells was investigated. To do this VK2 cells were seeded at a low 
density into 6-well plates and treated with 4nM estrogen or 1mM Mitomycin C (Sigma, USA) for 
seven days. Mitomycin C inhibits cell growth by inhibiting DNA synthesis. On days one, three, 
five and seven the cells were imaged using an EVOS XL core digital light microscope (AMG, 
USA), and the CellTiter-Blue Cell Viability Assay (Promega, USA) was used to measure cell 
growth. At each time point the medium was removed from the wells, the cells were washed with 
PBS, new medium was added to each well along with CellTiter-Blue Reagent and the cells were 
incubated at 37oC for 1 hour. CellTiter-Blue Reagent contains highly purified resazurin, which is 
reduced to resorufin by metabolically active cells causing a colour change. Resazurin and 
resorufin have distinct absorbance maximums (605nm and 573nm, respectively) and thus 
reduction of resazurin can be determined by measuring absorbance at both of these wavelengths 
on a plate reader. The amount of resazurin reduction is directly proportional to the number of 
cells in the well.  
 
The results showed that untreated control cells and estrogen treated cells grew over the seven day 
period, reaching confluency at day seven (Figure 3.10). However, Mitomycin C treated cells had 
significantly reduced growth at days three, five and seven compared to untreated control cells (p-
values <0.0001). At each time point, the number of cells in the control wells and the estrogen 
treated wells were comparable (Figure 3.10A) and both untreated and estrogen treated wells were 
confluent on day seven (Figure 3.10B). Thus, these data indicated that estrogen pretreatment did 
not affect the growth of VK2 cells. 
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Figure 3.10: Estrogen does not affect the growth of VK2 cells. VK2 cells were seeded into 6-well plates and 
treated with 4nM estrogen or 1mM Mitomycin C for seven days. (A) CellTiter-Blue Cell Viability Assay (Promega, 
USA) was used to measure cell viability after 1, 3, 5 and 7 days of treatment. Error bars represent standard error. 
Statistical analysis was performed by two-way ANOVA with Dunnett’s post hoc test. ns=not significant, **=p<0.01, 
***=p<0.001. N=2, n=6. (B) Images taken on an EVOS XL core digital light microscope (AMG, USA) show the 
cells at each time point for each treatment. Each image was representative of the well. 
 
3.5.2 Effects of estrogen pretreatment on hBD2 and hBD3 expression 
To study the effects of long-term estrogen treatment on AMP expression, VK2 cells were 
pretreated with 4nM estrogen for at least seven days and then challenged with 50ng/ml flagellin 
(Figure 3.11). The cells were typically washed and given fresh culture medium and estrogen every 
other day during the seven day period. Once the cells were confluent at day seven, the cell culture 
medium and estrogen was replaced for the final time, and the cells were incubated in this medium 
for 24 hours prior to challenge with 50ng/ml flagellin, or PBS, on day 8. RNA was extracted at 0, 
(A) 
(B) 
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8, 12, and 24 hours after flagellin challenge and analysed by qPCR for hBD2 and hBD3 
expression.  
 
 
Figure 3.11: Typical timeline of estrogen pretreatment and flagellin challenge of VK2 cells. VK2 cells were 
seeded into 12-well plates and pretreated with estrogen. Every other day the cell culture medium was removed, the 
cells were washed with PBS, and fresh medium and estrogen was added to the cells. The medium and estrogen was 
replaced for the final time 24 hours before flagellin challenge. The RNA was extracted after 0, 8, 12, and 24 hours 
flagellin challenge.  
 
The results for hBD2 are shown in Figure 3.12. After 8 hours challenge hBD2 expression 
increased from 15AU in the control samples to 145AU with flagellin challenge. This represented 
a significant 9.9-fold change in hBD2 expression compared to the control (p=0.035). After 8 
hours estrogen pretreatment plus flagellin challenge hBD2 expression was determined as 290AU, 
representative of a 20-fold increase compared to control (p<0.0001) and a 2.0-fold increase 
compared to flagellin challenge alone (p=0.0374). After 24 hours challenge hBD2 expression 
increased from 4.6AU in the control samples to 100AU with flagellin challenge, representative of 
a 22-fold increase in expression. After 24 hours estrogen pretreatment plus flagellin, hBD2 
expression increased to 233AU, which represented a 50-fold change in hBD2 expression relative 
to the control (p<0.0001) and a 2.3-fold increase compared to flagellin challenge (p<0.0001). 
 
 
 
+E 
Day 1 Day 3 Day 5 Day 7 
+E +E +E +flagellin 
Day 8 
RNA extracted 0, 8, 12, 24 hours 
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Figure 3.12: Effects of estrogen pretreatment and flagellin on hBD2 expression. VK2 cells were pretreated 
with 4nM estrogen for 7 days and then challenged with 50ng/ml flagellin, or PBS. RNA was extracted at 0, 8, 12, and 
24 hours and analysed for hBD2 expression. The results were normalised to 24 hour flagellin. Error bars represent 
standard error. Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. ns=not 
significant, *=p<0.05, ***=p<0.001. At 0, 8 and 12 hour N=3, n=9. At 24 hour N=8, n=24. 
 
The promoter activity of hBD2 was measured once again using the luciferase reporter plasmid, 
this time in response to estrogen pretreatment with flagellin. The results (Figure 3.13) showed 
that estrogen pretreatment plus flagellin challenge alone resulted in a 27-fold change in promoter 
activity compared to control (p<0.0001), which was a significant 2.1-fold increase on the 
promoter activity induced by flagellin treatment (p=0.0367). Thus, these data mirrored the results 
obtained by qPCR and supported the hypothesis that estrogen pretreatment increases hBD2 
expression during infection.  
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Figure 3.13: Effect of estrogen pretreatment and flagellin on hBD2 promoter activity. VK2 cells were 
pretreated with 4nM estrogen for 7 days and then seeded into a 96-well plate and transiently transfected with the 
phBD-2-luc plasmid before being challenged with 50ng/ml flagellin for 24 hours. Promoter activity was determined 
using the Luciferase Assay System (Promega, USA) and luminescence was measured using a plate reader. The results 
were normalised to the control. Error bars represent standard error. Statistical analysis was performed by one-way 
ANOVA with Tukey’s post hoc test. *=p<0.05. N=4, n=8. 
 
Analysis of hBD3 expression by qPCR showed that after 8 hours estrogen pretreatment plus 
flagellin challenge hBD3 expression was induced to 139AU, from 48AU in the control. This 
represented a significant 2.9-fold increase in hBD3 expression relative to control (p=0.0001), and 
a 2.8-fold change compared to flagellin challenge (p=0.0003). Whereas, flagellin challenge did not 
result in a significant increase in hBD3 expression until the 24 hour time point. After 24 hours 
flagellin challenge, hBD3 expression was determined as 100AU, which represented a significant 
2.1-fold increase in expression compared to the controls (47AU, p=0.0003). At this time point, 
estrogen pretreatment plus flagellin resulted in hBD3 expression of 211AU. This represented a 
4.5-fold change in hBD3 expression compared to control (p<0.0001) and a 2.1-fold change 
compared to flagellin challenge alone (p<0.0001). Thus these data showed that estrogen 
pretreatment of VK2 cells prior to flagellin challenge not only resulted in higher expression of 
hBD3, but also induced an earlier hBD3 response than the same challenge without estrogen 
pretreatment. 
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Figure 3.14: Effects of estrogen pretreatment and flagellin on hBD3 expression. VK2 cells were pretreated 
with 4nM estrogen for 7 days, and then challenged with 50ng/ml flagellin. At 0, 8, 12, and 24 hours RNA was 
extracted and analysed by qPCR for hBD3 expression. Error bars represent standard error. Statistical analysis was 
performed by two-way ANOVA with Tukey’s post hoc test. ns=not significant, *=p<0.05, ***=p<0.001. At 0, 8 
and 12 hours N=3, n=9. At 24 hours N=8, n=24. 
 
3.6 Effects of cyclodextrin on AMP expression 
As indicated in the materials and methods section, the estrogen used to pretreat the VK2 cells 
was water-soluble 17β-estradiol (Sigma, USA). To facilitate water solubility the 17β-estradiol is 
encapsulated in 2-hydroxypropyl-β-cyclodextrin (cyclodextrin), which is a compound composed 
of seven sugar molecules that form a ring structure. The inside of the ring is hydrophobic and the 
outside of the ring is hydrophilic, which increases the solubility of the compound that is 
encapsulated. In experiments presented so far within this chapter the cells were pretreated either 
with estrogen or with water, as the estrogen was reconstituted in water. However, it was also 
important to consider whether the observed increases in gene expression were attributed to the 
cyclodextrin that encapsulated the estrogen molecules. The water-soluble estrogen consisted of 
48.3mg 17β-estradiol per gram of solid and thus, 4nM estrogen (the concentration used to 
pretreat the VK2 cells) had a cyclodextrin concentration of 14.8nM. VK2 cells were, therefore, 
treated with 14.8nM cyclodextrin for seven days and then challenged with 50ng/ml flagellin, or 
PBS, for 24 hours. The RNA was extracted and analysed by qPCR for hBD2 expression. 
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Figure 3.15: Effects of cyclodextrin and flagellin on hBD2 expression. VK2 cells were pretreated with 14.8nM 
cyclodextrin or vehicle for 7 days and then challenged with 50ng/ml flagellin for 24 hours. Cells were also treated 
acutely with cyclodextrin (no pretreatment) at the same time as flagellin challenge. RNA was extracted and analysed 
by qPCR for hBD2 expression. Error bars represent standard error. Statistical analysis was performed by one-way 
ANOVA with Tukey’s post hoc test. N=2, n=6. 
 
The results showed that cyclodextrin (given acutely or as a pretreatment) did not affect hBD2 
expression (Figure 3.15). Neither acute cyclodextrin plus flagellin nor cyclodextrin pretreatment 
plus flagellin significantly affected hBD2 expression compared to flagellin treatment without 
cyclodextrin. Thus, these data confirmed that the increases in AMP treatment could be attributed 
to the effects of estrogen, rather than cyclodextrin. 
 
3.7 Effects of estrogen pretreatment and flagellin on hBD2 and hBD3 secretion 
Although it was shown that estrogen increased the expression of hBD2 and hBD3 in VK2 cells 
during a simulated infection, it was also important to examine the effects on hBD2 and hBD3 
peptide concentration. Both hBD2 and hBD3 are secreted from epithelial cells and effectuate 
bacterial killing extracellularly. Thus, the concentration of hBD2 and hBD3 in the cell culture 
medium bathing the VK2 cells during the challenges was collected and measured by ELISA as 
described in the materials and methods. 
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The results for hBD2 showed that control cells displayed a constitutive hBD2 concentration of 
23571pg/ml (standard error of the mean, SEM). Flagellin and estrogen pretreatment plus 
flagellin significantly increased hBD2 concentration by approximately 3-fold (p=0.007, Figure 
3.16A), to 71699pg/ml (SEM) and 69373pg/ml (SEM), respectively. Thus, an increase in 
hBD2 concentration was observed following VK2 cell exposure to flagellin.  
 
In contrast to the mRNA data, the ELISA results for hBD2 did not show an increase in peptide 
concentration with estrogen pretreatment plus flagellin compared to flagellin alone. However, 
significant variability was observed between in-plate repeats of the same sample. For example, the 
concentration of hBD2 in in-plate replicates of one control sample was determined as 300pg/ml 
and 148pg/ml, a more than 2-fold difference. This variability was reflected in the standard curve. 
The standard curve included on each hBD2 ELISA plate consisted of serial 1:2 dilutions of 
recombinant hBD2 peptide from 8pg/ml to 2000pg/ml. A typical standard curve for the hBD2 
ELISA is shown in Figure 3.17, and this showed that the replicates with peptide levels below 
approximately 125pg/ml were variable, limiting the fit of the standard curve and the sensitivity of 
the assay.  
 
The hBD3 ELISA failed to detect any significant increase in hBD3 with any of the treatments, 
compared to the control. All samples showed a hBD3 concentration of around 140pg/ml (Figure 
3.16B). The hBD3 standard curve is shown in Figure 3.18A and demonstrated that the assay was 
functional despite not detecting any increase in hBD3 with the VK2 cell samples. Similarly to the 
hBD2 assay, the hBD3 standard curve replicates (Figure 3.18B) showed that the ELISA was not 
particularly sensitive at hBD3 concentrations below approximately 125pg/ml. Hence the peptide 
data presented here may reflect poor ELISA assays rather than the true data. 
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Figure 3.16: Effects of estrogen pretreatment and flagellin on hBD2 and hBD3 secretion. VK2 cells were 
pretreated with 4nM estrogen for 7 days and then challenged with 50ng/ml flagellin for 24 hours. The medium was 
removed from the cells and analysed by ELISA for (A) hBD2 (N=2, n=6), and (B) hBD3 (N=1, n=3) secretion. 
Error bars represent standard error. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc 
test. **=p<0.01. 
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Figure 3.17: hBD2 ELISA standard curve. A standard curve was included on each hBD2 ELISA plate and 
consisted of recombinant hBD2 serially diluted 1:2 from 2000pg/ml to 8pg/ml. (A) shows the standard curve line of 
best fit. (B) shows the measured concentration of each of the standard replicates. Blanks show where the 
concentration was too low to be determined. 
 
(A) hBD2 standard curve 
(B) hBD2 standard replicates 
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Figure 3.18: hBD3 ELISA standard curve. A standard curve was included on each hBD3 ELISA plate and 
consisted of recombinant hBD3 serially diluted 1:2 from 1000pg/ml to 8pg/ml. (A) shows the standard curve line of 
best fit. (B) shows the measured concentration of each of the standard replicates. Blanks show where the 
concentration was too high to be determined. 
 
3.8 Effects of estrogen pretreatment and flagellin on AMP expression in primary 
vaginal epithelial cells 
It was important to verify the results obtained using VK2 cells in primary vaginal epithelial cells 
(PVECs) as these are more representative of the in vivo vaginal epithelium than the immortalised 
cell line. Vaginal tissue was obtained from women undergoing gynaecological surgery at the Royal 
Victoria Infirmary in Newcastle upon Tyne. PVECs were extracted from the vaginal tissue as 
(A) hBD3 standard curve 
(B) hBD3 standard replicates 
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described in the materials and methods and were seeded into 12-well plates. The cells were fed 
every 2-3 days until confluent (Figure 3.19).  
 
 
Figure 3.19: Primary vaginal epithelial cells at confluency. The image, taken with an EVOS XL Core digital light 
microscope (AMG, USA) at x20 magnification, shows PVECs forming a confluent monolayer. 
 
3.8.1 PVECs express estrogen receptors 
Prior to conducting experiments with the PVECs, it was important to determine the expression 
of the estrogen receptors in these cells. End-point PCR was performed for each of the estrogen 
receptors (ER-α, ER-β, and GPER) to confirm gene expression in PVECs. As shown in Figure 
3.20 PCR products representative of ER-α, -β, and GPER were detected at 236bp, 439bp, and 
680bp, respectively. Thus, PVECs expressed all estrogen receptors.  
 
 
Figure 3.20: Primary vaginal epithelial cells express estrogen receptors. End-point PCR was performed on 
cDNA from PVECs for (A) ER-α at 236bp, (B) ER-β at 439bp, and (C) GPER at 680bp. The 100bp ladder (New 
England BioLabs, USA) is shown in lane 1 of each gel, and the respective PCR product is shown in lane 2. 
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3.8.2 Designing a SYBR-green based hBD2 qPCR assay 
The probes-based hBD2 qPCR assay was not very sensitive at high cycle numbers (when gene 
expression was low). The reported cycle numbers for in-plate replicates of the same sample 
would vary by 2-3 cycle numbers, in samples with cycle numbers above 28 cycles. This meant a 
reported difference of 4-8 fold for the same sample. As only a limited number of epithelial cells 
could be extracted from each patient sample it was important to be able to accurately detect 
mRNA levels in the primary cell samples without needing to repeat the qPCR experiments to 
obtain reliable data. Thus, the hBD2 qPCR assay was redesigned as a SYBR-green based assay, as 
the hBD3 SYBR-green based assay was accurate at high cycle numbers. When designing the 
SYBR-green based hBD2 assay the primers were designed to anneal to a sequence within the 
probes-based assay PCR product. This meant the same positive control plasmid could be used 
with the new assay. A new standard curve was produced using the new primers and SYBR-green 
reagent and a melt peak confirmed that only one PCR product was amplified. This hBD2 qPCR 
assay was used for the remainder of the analyses.  
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Figure 3.21: Standard curve and melt peak for SYBR-green based qPCR assay. A standard curve (A) was 
produced for the SYBR-green based hBD2 qPCR assay. The melt peak (B) confirmed that the assay only amplified 
one PCR product.  
 
3.8.3 Effects of estrogen pretreatment on hBD2 and hBD3 expression in PVECs 
To analyse the effects of estrogen pretreatment on hBD2 and hBD3 expression in PVECs, the 
isolated PVECs were treated with 4nM estrogen, or cyclodextrin vehicle, from seeding to 
confluency, which took between 5-10 days depending on the tissue sample. Once confluent, the 
cells were challenged with 50ng/ml flagellin, or PBS, for 24 hours. Initially PVECs were seeded 
into EpiLife medium (Thermo Fisher Scientific, UK), which is recommended for the growth of 
human keratinocytes and epithelial cells. Data from one patient sample with two replicates is 
shown in Figure 3.22 and demonstrated that hBD2 expression increased from 0.4AU in the 
control to 100AU following 24 hours flagellin challenge. Estrogen pretreatment plus flagellin 
further increased hBD2 gene expression to 157AU, representative of a 1.6-fold compared to 
flagellin alone. 
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Figure 3.22: Effects of estrogen pretreatment and flagellin on hBD2 expression in primary vaginal epithelial 
cells growth in EpiLife medium. PVECs were harvested from vaginal tissue samples and seeded into 6-well plates 
in keratinocyte-SFM. The cells were treated with 4nM estrogen, or cyclodextrin vehicle, for approximately 7 days, 
and then challenged with 50ng/ml flagellin for 24 hours. RNA was extracted and analysed by qPCR for hBD2 
expression. The data represent one patient sample with two replicates.  
 
Results from the same patient sample for hBD3 showed that flagellin challenge increased hBD3 
expression from 12AU in the control to 100AU after flagellin challenge. After estrogen 
pretreatment plus flagellin one replicate exhibited a 20% increase in hBD3 expression, compared 
to flagellin alone, and the second replicate showed a 40% decrease in hBD3 expression, 
compared to flagellin alone (Figure 3.23). Thus, on average hBD3 expression with estrogen 
pretreatment plus flagellin was similar to that with flagellin only (90AU and 100AU, respectively). 
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Figure 3.23: Effects of estrogen pretreatment and flagellin on hBD3 expression in primary vaginal epithelial 
cells growth in EpiLife medium. PVECs were harvested from vaginal tissue samples and seeded into 6-well plates 
in keratinocyte-SFM. The cells were treated with 4nM estrogen, or cyclodextrin vehicle, for approximately 7 days, 
and then challenged with 50ng/ml flagellin for 24 hours. RNA was extracted and analysed by qPCR for hBD3 
expression. The data represent one patient sample with two replicates.  
 
However, although initial results were encouraging, growth of the PVECs in EpiLife medium 
proved difficult. Typically, PVECs would adhere to the plate in small numbers, but not divide 
and grow. Thus, the primary cell culture required optimisation. Growth of the PVECs in 
keratinocyte-SFM, used to culture VK2 cells, was tried, but the results were similar to those using 
EpiLife medium in that cell division and growth did not occur. However, culturing PVECs in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal calf serum (FCS) resulted in good 
growth of the PVECs. Thus, PVECs were seeded into 6- or 12-well plates in DMEM containing 
10% FCS and were treated with 4nM estrogen, or cyclodextrin vehicle, for approximately seven 
days. Before the challenge, the DMEM was removed, cells were washed with PBS and 
keratinocyte-SFM was added to the cells, with estrogen or cyclodextrin. After 24 hours 
incubation in keratinocyte-SFM, the PVECs were challenged with flagellin for 24 hours. The 
RNA was extracted and analysed by qPCR for hBD2 and hBD3 expression.  
 
The results for hBD2, in Figure 3.24, showed that both flagellin and estrogen pretreatment plus 
flagellin significantly increased hBD2 expression compared to control samples (p<0.0001). Mean 
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hBD2 expression in the control samples was 0.7AU, and this increased significantly to 100AU 
and 93AU following flagellin and estrogen pretreatment plus flagellin, respectively. However, 
compared to flagellin challenge alone, estrogen pretreatment prior to flagellin challenge did not 
significantly alter hBD2 expression.  
 
 
Figure 3.24: Effects of estrogen pretreatment and flagellin on hBD2 expression in primary vaginal epithelial 
cells grown in DMEM medium. PVECs were harvested from vaginal tissue samples and seeded into 6-well plates 
in DMEM containing 10% FCS. The cells were treated with 4nM estrogen, or cyclodextrin vehicle, for 
approximately 7 days, and then challenged with 50ng/ml flagellin for 24 hours. RNA was extracted and analysed by 
qPCR for hBD2 expression. The data represent 7 patient samples with 14 replicates. Symbols are colour coded 
according to patient. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. 
 
The results for hBD3 showed more variability than those for hBD2. The mean hBD3 expression 
in the control samples was 35AU. This increased significantly to 100AU and 86AU following 
flagellin challenge and estrogen pretreatment plus flagellin challenge, respectively (p<0.001). Six 
of the 14 replicates showed increased expression with estrogen pretreatment plus flagellin 
challenge compared to flagellin alone, however, eight replicates showed reduced expression 
following estrogen pretreatment plus flagellin. Thus, overall, hBD3 expression showed a 14% 
decrease in expression following estrogen pretreatment plus flagellin challenge, compared to 
flagellin challenge alone, but this difference in expression was not statistically significant 
(p=0.6789).  
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Figure 3.25: Effects of estrogen pretreatment and flagellin on hBD3 expression in primary vaginal epithelial 
cells grown in DMEM. PVECs were harvested from vaginal tissue samples and seeded into 6-well plates in 
DMEM containing 10% FCS. The cells were treated with 4nM estrogen, or cyclodextrin vehicle, for approximately 7 
days, and then challenged with 50ng/ml flagellin for 24 hours. RNA was extracted and analysed by qPCR for hBD3 
expression. The data represent 7 patient samples with 14 replicates. Symbols are colour coded by patient. Statistical 
analysis was performed by one-way ANOVA with Tukey’s post hoc test. 
 
3.8.4 Cultured human primary cells express cytokeratins 
The data obtained with PVECs cultured in DMEM with 10% FCS showed a different pattern to 
the data obtained with PVECs cultured in EpiLife medium. Thus, it was important to analyse the 
authenticity of the cells and confirm they were indeed epithelial. To investigate this the 
cytokeratin expression of the PVECs cultured in DMEM was investigated. Cytokeratins 
constitute the intermediate filaments of all epithelial cells and thus can be used as epithelial cell 
markers. End-point PCR was performed for cytokeratin 8 and 18 in the PVECs and VK2 cells to 
confirm that the primary cells were indeed epithelial. Cytokeratin 8 and 18 are typically co-
expressed in many epithelial cells, including vaginal cells209,210. The end-point PCR detected 
products at 190bp and 207bp, representative of cytokeratin 8 and cytokeratin 18, respectively, in 
both VK2 cells and PVECs. This indicated that the PVECs cultured from human vaginal tissue 
samples were true epithelial cells (Figure 3.26).  
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Figure 3.26: End-point PCR for cytokeratins 8 and 18. End-point PCR products for (A) cytokeratin 8 at 190bp 
and (B) cytokeratin 18 at 207bp in VK2 and primary cells. Lane 1 shows the Generuler 100bp ladder (Thermo Fisher 
Scientific, USA), lanes 2-4 show PCR products from VK2 cells, and lanes 5-7 show PCR products amplified from 
primary vaginal epithelial cells (PVECs).  
 
The presence of cytokeratins in the PVECs was also confirmed by immunocytochemistry using a 
C-11 anti-cytokeratin antibody that detected cytokeratins 4, 5, 6, 8, 10, 13 and 18. For 
immunocytochemistry, the PVECs were seeded onto sterile glass coverslips in DMEM with 10% 
FCS, and were grown until confluent. The cells were fixed using methanol and stained using the 
mouse C-11 anti-pan cytokeratin primary antibody (Abcam, UK) and the Alexa Fluor 488 rabbit 
anti-mouse secondary antibody (Thermo Fisher Scientific, USA). 
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Figure 3.27: Cytokeratin staining in VK2 and primary vaginal epithelial cells. VK2 and PVECs were stained 
using the mouse C-11 anti-pan cytokeratin primary antibody (1:20, Abcam, UK) and the Alexa Fluor 488 (green) 
rabbit anti-mouse secondary antibody (1:500, Thermo Fisher Scientific, USA). Nuclei were stained with DAPI (blue). 
(A) Alexa Fluor 488 and (B) Alexa Fluor 488 +DAPI staining of VK2 cells stained without the primary antibody, as 
a negative control. (C) Alexa Fluor 488 and (D) Alexa Fluor 488 + DAPI staining of VK2 cells stained with both 
primary and secondary antibodies. (E) Alexa Fluor 488 and (F) Alexa Fluor 488 + DAPI staining of primary vaginal 
epithelial cells stained with both primary and secondary antibodies. All images were taken on Zeiss Axio Imager II 
microscope at x40 magnification with exposure of 274.6ms for Alexa Fluor 488 and 13.8ms exposure for DAPI. 
 
VK2 cells were stained as a positive control, as these cells are known to be epithelial. The VK2 
cells stained with both primary and secondary antibodies (Figure 3.27C and D) demonstrated 
much stronger Alexa Fluor 488 (green) staining, compared to the negative control stained with 
secondary antibody only (Figure 3.27A and B). This indicated that the VK2 cells synthesised 
cytokeratins and were epithelial, as expected. The PVECs also stained positively for cytokeratins, 
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to a similar level as VK2 cells, confirming that the cells isolated from the human vaginal tissue 
samples were indeed epithelial (Figure 3.27E and F).  
 
3.9 Discussion 
It is hypothesised that estrogen has a protective role against UTIs due to the increased risk of 
women developing rUTI after the menopause13. One possible mechanism of protection by 
estrogen is prevention of uropathogen colonisation of the vagina by increasing vaginal glycogen. 
This encourages growth of commensal bacteria, such as Lactobacillus spp., which metabolise 
glycogen and produce lactic acid. Although colonisation with Lactobacillus spp. has been shown to 
limit UPEC growth in numerous ways, the primary mechanism of action is thought to be 
through lowering the pH of the vagina184,189. A pH below 4.5 has been shown to prevent the 
growth of uropathogens190. However, few studies have considered the effect of estrogen on 
innate defences of the urogenital tract.  
 
Data presented in this chapter showed that estrogen has a role in priming the innate immune 
response to infection, when given as a long-term treatment. Acute estrogen treatment of VK2 
cells, an immortalised vaginal epithelial cell line, had no effect on hBD2 expression and a minimal 
effect on hBD3 expression after 24 hours. However, estrogen pretreatment of VK2 cells prior to 
challenge with flagellin upregulated both hBD2 and hBD3 expression by greater than 2-fold 
compared to cells challenged with flagellin without estrogen pretreatment. This potentiation by 
estrogen was evident after 8 hours challenge for both AMPs. Furthermore, estrogen pretreatment 
plus flagellin induced hBD3 expression 16 hours earlier than flagellin challenge alone, suggesting 
that estrogen pretreatment not only promotes a greater antimicrobial response, but also brings 
about this response quicker than cells not pretreated with estrogen. The qPCR data was 
supported by hBD2 luciferase reporter assay data, which showed that estrogen pretreatment plus 
flagellin challenge resulted in greater reporter activity than flagellin challenge alone. Thus, the 
effects of estrogen on hBD2 expression were confirmed by two separate approaches.  
 
Taken together, these data suggest that vaginal epithelial cells require the presence of estrogen 
prior to infection for the antimicrobial effects of estrogen to be observed. One possible 
explanation for the differences observed between acute and long-term estrogen is that estrogen 
may upregulate components of the flagellin signalling pathway, such as TLR5 and NF-ĸB. 
Upregulation of components such as these by estrogen pretreatment prior to challenge would 
result in greater TLR5 pathway activation upon challenge with flagellin, thus increasing hBD2 
and hBD3 expression. Whereas, upregulation of TLR5 pathway components by acute estrogen 
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would occur too late for any effects to be seen. Broader gene expression analysis of pathway 
constituents is needed to determine whether this is the mechanism of estrogen action and was 
conducted using microarray analysis in the next chapter.  
 
Both hBD2 and hBD3 have been shown to have potent killing activity against Gram-negative 
bacteria. Thus increased expression of these AMPs may promote UPEC clearance from the 
urogenital tract. In vivo activity of AMPs is determined by their salt sensitivity, and the literature 
reports conflicting findings over the salt sensitivity of hBD2 and hBD3. Some studies suggest 
that hBD2 is sensitive to physiological concentrations of sodium chloride (0-200mM), limiting its 
ability to kill E. coli211,212. However, a study by Zhao et al. (2011), showed that transfection of a 
plasmid containing the hBD2 gene downstream of a CMV promoter into bladder cells of live rats 
resulted in much faster clearance of UPEC from the bladder than rats transfected with a vector 
control213. This clearly suggests that hBD2 is functional at physiological salt concentrations of the 
urogenital tract and facilitates bacterial killing. hBD3 is often reported as salt insensitive, 
however, studies that reported this typically used a maximum of 150mM sodium chloride214. 
More recently, Scudiero et al. (2010) used higher concentrations of sodium chloride and found 
that hBD3 was inactivated by 200mM sodium chloride215. Interestingly, a study by Jung et al. 
(2011) reported that at high salt concentrations (>100mM) hBD3 was inactive against E. coli, but 
retained activity against S. aureus, whereas, at the same sodium chloride concentrations hBD2 
displayed activity against E. coli, but not S. aureus216. This suggests that the salt concentration at 
the site of antimicrobial peptide action has a role in determining which bacteria AMPs are active 
against. The vaginal sodium chloride concentration is in the region of 60mM, and thus it is likely 
that both peptides maintain E. coli killing capabilities within the vagina217–219. However, further 
work is required in this area to further understand hBD2 and hBD3 activity during vaginal 
colonisation with UPEC.  
  
Previous work from our laboratory showed a reduction in hBD2 and hBD3 concentration in 
vaginal douches of postmenopausal women, compared to premenopausal women60. Furthermore, 
the vaginal concentration of both hBD2 and hBD3 was significantly increased in postmenopausal 
women receiving estrogen treatment, compared to postmenopausal women not receiving 
estrogen treatment. This is supportive of the work presented in this chapter as these data suggest 
regulation of hBD2 and hBD3 by estrogen in vivo. Additional evidence of a role for estrogen in in 
vivo AMP regulation comes from a paper by Luthje et al. (2013) who measured AMP expression 
in exfoliated cells from the urine of postmenopausal women before and after a two week course 
of 25μg/day topical vaginal estrogen treatment134. Luthje et al. reported an increase in hBD2, 
hBD3 and psoriasin in exfoliated urothelial cells following estrogen supplementation. The 
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expression of hBD1, RNase7 and LL-37 were also enhanced by estrogen in immortalised bladder 
epithelial cells. Thus, this work is intriguing as it not only supports the notion of estrogen 
regulation of other AMPs, in addition to hBD2 and hBD3, but also suggests that topical estrogen 
treatment of the vagina may also have protective effects in the bladder. In vitro work by Han et al. 
(2010) has also shown that physiological estrogen concentrations increased hBD2 expression 
from human PVECs during challenge with LPS, supporting a role for estrogen in the vaginal 
antimicrobial response. However, a conflicting paper from Patel et al. (2013) reported that 48 
hour treatment of human PVECs with 50nM estrogen reduced hBD2 secretion by approximately 
50% compared to PVECs that were not treated with estrogen199,220. These differences may 
perhaps be attributed to the method of vaginal cell collection; Han et al. collected vaginal 
epithelial cells from vaginal tissue removed during surgery, whereas Patel et al. collected sloughed 
vaginal cells in a menstrual cup. The latter is less representative of intact cells in the vaginal 
epithelium. Furthermore, Patel et al. report data from only 2-3 patients and used an estrogen 
concentration much greater than physiological concentrations, suggesting these data should be 
interpreted with caution. Analysis of hBD2 and hBD3 expression in PVECs was attempted in 
this chapter, but proved difficult. Initial results obtained with PVECs cultured in EpiLife medium 
appeared to mirror VK2 cell data, however, generally this medium was not sufficient to promote 
primary cell growth and typically resulted in adhesion of primary cells to the culture plate but no 
cell division. Thus, the cells were cultured in DMEM containing 10% FCS, which did facilitate 
growth of the PVECs to a confluent monolayer. However, cells cultured in this medium did not 
show increased hBD2 and hBD3 expression with estrogen pretreatment prior to flagellin 
challenge. The DMEM contained phenol red and FCS, which are both estrogenic, and therefore, 
it cannot be excluded that culturing the primary cells in this medium diminished the effects of 
estrogen supplementation. Further optimisation of the PVEC culture technique is clearly required 
before conclusions can be drawn from the primary cell data presented here.  
 
The secretion of hBD2 and hBD3 by VK2 cells was measured by ELISA. The hBD2 ELISA 
showed increased secretion of hBD2 into the cell culture medium following challenge with 
flagellin. However, estrogen pretreatment prior to flagellin challenge did not increase hBD2 
secretion further. In-plate replicates of the cell culture medium samples and recombinant hBD2 
standards below 125pg/ml displayed variability in the reported peptide concentration, suggesting 
the ELISA may not be sufficiently sensitive for this application despite the kit stating the lower 
limits of detection as 8pg/ml. It is, therefore, possible that the assay is not sensitive enough to 
detect differences in hBD2 concentration between the flagellin and estrogen pretreatment plus 
flagellin samples. The hBD3 ELISA showed no increase in hBD3 secretion with any of the 
treatments. However, the hBD3 standard curve demonstrated a correlation between hBD3 
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concentration and signal detected, indicating that there was not an issue with the capture or 
detection antibodies. The mRNA data showed that flagellin only begins to induce hBD3 
expression at the 24 hour time point, thus, the 24 hour time point may be too early to detect 
changes in hBD3 secretion from VK2 cells. Future work should include analysis of both mRNA 
and peptide levels at later time points, to fully establish the effects of estrogen pretreatment and 
flagellin on hBD3 secretion. Previous work from our laboratory has utilised these ELISAs to 
measure the hBD2 and hBD3 concentration of vaginal douches of postmenopausal women. 
Postmenopausal women who were not receiving topical estrogen treatment had vaginal hBD2 
and hBD3 concentrations of 626pg/ml (SEM) and 869pg/ml (SEM), respectively60. Whereas, 
the vaginal concentration of hBD2 and hBD3 in postmenopausal women who were receiving 
topical estrogen treatment was 11913pg/ml (SEM) and 13917pg/ml (SEM), respectively. 
These data indicate that estrogen significantly increased hBD2 and hBD3 secretion from vaginal 
epithelial cells in vivo. Furthermore, Han et al. (2010) demonstrated that 2nM estrogen increased 
hBD2 peptide secretion from PVECs in vitro199. Taken together these data suggest that estrogen 
increases hBD2 and hBD3 secretion from vaginal epithelial cells and that further investigation 
and optimisation of the ELISAs used here is needed to confirm this in the VK2 cell model. 
 
The data presented in this chapter is supported by other work showing estrogen has a role in 
upregulation of AMPs, and especially hBD2 and hBD3, indicating validity of the data60,134,199. 
However, the mechanism behind this upregulation has not been investigated. Understanding the 
regulation of innate immune defences in response to UTIs is important, as this is the hosts 
primary defence against uropathogens since an acquired immune response is not protective 
against rUTIs136,221,222. Furthermore, as Luthje et al. identified upregulation of multiple other 
AMPs, it is of interest to investigate the effect of estrogen on other innate immune defences of 
the urogenital tract and whether the mechanism of estrogen regulation is common among AMPs. 
This, along with regulation of upstream signalling pathway components, will be investigated in 
more detail in the next chapters. 
 
Overall, data presented in this chapter identify a role for estrogen in augmenting the innate 
immune response to vaginal colonisation with UPEC, exemplified here by hBD2 and hBD3. 
Thus, the benefits of estrogen treatment may go beyond increased vaginal glycogen production, 
by increasing the vaginal antibacterial response to infection. Hence loss of estrogen following the 
menopause results in decreased vaginal AMP expression, along with a decrease in vaginal 
lactobacilli colonisation, facilitating establishment of vaginal colonisation with UPEC, and 
exacerbating the cycle of rUTI. Identification of other innate immune effectors regulated by 
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estrogen and the mechanism of regulation may aid development of future therapeutics to prevent 
rUTI and will be investigated further in the following chapters.  
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4 Analysis of global gene expression by microarray 
4.1 Introduction 
Data presented in this thesis has shown that estrogen pretreatment of a vaginal epithelial cell line 
prior to challenge with flagellin potentiated the expression of the AMPs hBD2 and hBD3, 
compared to the expression levels measured for flagellin challenge without estrogen 
pretreatment. Acute estrogen treatment did not potentiate hBD2 expression and only resulted in 
minimal potentiation of hBD3 expression. This suggested that estrogen pretreatment primes the 
vaginal epithelial cells prior to exposure to bacterial PAMPs. It is possible that estrogen 
pretreatment enhanced hBD2 and hBD3 expression by upregulating expression of the signalling 
pathway components for these genes. Upregulation of signalling pathway components by 
estrogen pretreatment could facilitate greater activation of the pathway upon flagellin challenge. 
Thus, it was of interest to utilise microarrays to conduct broad gene expression analysis to 
investigate the mechanism of hBD2 and hBD3 upregulation by estrogen pretreatment. In 
addition, whole transcriptome analysis by microarray would identify other genes associated with 
innate immunity that were upregulated by estrogen pretreatment, such as other AMPs.  
 
For the analysis conducted in this thesis, the Illumina HumanHT-12 v4 Expression Beadchip was 
used. This microarray chip utilises more than 47,000 50mer probes attached to silica beads to 
analyse the expression level of 31,000 annotated genes derived from the NCBI RefSeq Release 
38. The cDNA samples to be analysed were labelled with biotin and following hybridisation the 
bound cDNA was visualised by streptavidin-Cy3 staining. Each gene probe is hybridised to a 
known location on the chip, thus the signal from each probe can be measured. The hybridisation 
of biotin labelled cDNA to the probe is shown in Figure 4.1.   
 
 
Figure 4.1: Diagram of biotin labelled cDNA binding to probe. 50mer probes are attached to the microarray 
chip by silica beads. Biotin labelled cDNA hybridises with complementary probes sequences and can be visualised to 
determine the level of gene expression. 
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4.2 Sample selection and analysis of RNA quality 
To perform microarray analysis RNA samples previously analysed by qPCR were selected. 
Control cells along with estrogen pretreatment, flagellin, and estrogen pretreatment plus flagellin 
challenged cells at the 12 and 24 hour time points were selected for microarray analysis, based 
upon the qPCR results obtained for hBD2 and hBD3. Three technical replicates of each 
treatment from one biological repeat were analysed. Following RNA extraction, RNA samples 
were sent to Service XS, The Netherlands for microarray analysis.  
 
Before microarrays were performed the RNA samples were analysed using the Agilent RNA 6000 
Nano Kit and the Agilent 2100 Bioanalyser to ensure the RNA was of high enough quality to 
achieve accurate and reliable results. The kit analyses the quality of the 18S and 28S ribosomal 
RNA and calculates an RNA integrity number (RIN) out of ten for each sample. An RIN above 
7 indicates high quality RNA. The ribosomal RNA quality was very good for all 24 samples 
(Figure 4.2) and the RIN was calculated to be 10 for each sample. Thus, the RNA was very high 
quality and was suitable for microarray analysis. 
 
 
Figure 4.2: RNA quality analysis by ServiceXS. The Agilent RNA 6000 Nano Kit and Agilent 2100 Bioanalyser 
were used to check the quality of the 18S and 28S ribosomal RNA of the RNA samples.  
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Microarrays were performed using an Illumina HumanHT-12 v4 Expression Beadchip and the 
resultant raw expression values were analysed in collaboration with the Bioinformatics Support 
Unit, Newcastle University, where the raw data was normalised and converted into fold changes 
relative to the control at each time point using the R software platform with Bioconductor223,224. 
This resulted in six datasets for further analysis and these are shown in Table 4.1. Genes were 
considered to be significantly differentially expressed if they had a fold change greater than or 
equal to +2 or less than or equal to -2 and a p-value less than 0.05. The cut off of +/- 2 fold 
change is a commonly used cut off value which excludes genes with small fold changes and keeps 
gene lists to a manageable size for initial analysis. The full list of differentially expressed genes 
after 12 and 24 hours is shown in the Appendix Table 8.1 and Table 8.2, respectively.  
 
Table 4.1: Description of microarray dataset abbreviations. 
 
 
4.3 Venn diagram analysis 
Venn diagrams were constructed to show genes that were commonly differentially regulated by 
each of the treatments. Each entry in the Venn diagram represents a single probe set. On a 
microarray chip multiple probe sets may map to the same gene. Figure 4.3 shows the Venn 
diagram produced for each of the treatments after 12 hours. There were five genes that were 
differentially expressed by all three treatments (EP12, F12, and EP/F12) and these were lipocalin 
2 (LCN2), S100 calcium binding protein A8 (S100A8), S100A9, small proline rich protein 2A 
(SPRR2A) and SPRR2F. All five of these genes showed significant upregulation with each 
treatment.  
 
Dataset abbreviation Description
EP12 Estrogen pretreatment 12 hours vs control 12 hours
F12 Flagellin 12 hours vs control 12 hours
EP/F12 Estrogen pretreatment + flagellin 12 hours vs control 12 hours
EP24 Estrogen pretreatment 24 hours vs control 24 hours
F24 Flagellin 24 hours vs control 24 hours
EP/F24 Estrogen pretreatment + flagellin 24 hours vs control 24 hours
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Figure 4.3: Venn diagram of differentially regulated genes after 12 hours. Venn diagrams drawn using 
BioVenn201. 
 
LCN2 is an iron sequestering antimicrobial protein, S100 genes encode calcium binding proteins 
involved in many cellular response including differentiation and immune responses, and the 
SPRR genes encode proteins involved in keratinisation. Further examination of the microarray 
data revealed that for each of the five genes EP/F12 resulted in the highest level of expression 
(Figure 4.4), followed by F12, and then EP12. For each of the genes EP12 alone resulted in an 
approximate 2.0-fold increase in gene expression, compared to controls, F12 resulted in increased 
gene expression between 2.2-fold and 6.4-fold, and EP/F12 saw the highest increases in gene 
expression between 3.4-fold and 15-fold. This pattern was not as marked for S100A8, but was 
still present as fold changes of 2.0, 2.2, and 3.4 were observed with EP12, F12, and EP/F12 
treatments, respectively. In contrast, the increase in gene expression with EP/F12 was 
particularly notable for SPRR2A and SPRR2F, which exhibited 13- and 15-fold changes in gene 
expression, respectively, compared to 4.0- and 3.6-fold changes, respectively, with F12 treatment. 
These data indicate that estrogen pretreatment prior to flagellin challenge potentiated the 
expression of these genes.  
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Figure 4.4: Fold change in expression of genes upregulated by estrogen pretreatment, flagellin, and 
estrogen pretreatment plus flagellin, as determined by microarray. 
 
Previous qPCR data shown in Chapter 3 demonstrated that estrogen pretreatment alone had little 
effect on the expression of hBD2 and hBD3. Nevertheless, combined estrogen pretreatment plus 
flagellin challenge potentiated the expression of hBD2 and hBD3 compared to flagellin challenge 
alone. This may, therefore, be the case for other genes and thus it was important to consider the 
genes that were upregulated by both F12 and EP/F12, but not EP12.  
 
After 12 hours there were 124 gene probes that fell into this category. All 124 genes showed 
significant upregulation with the two treatments. Within this set of 124 genes, genes with 
substantially higher expression with EP/F12 compared to F12 alone were identified. After 12 
hours there were only six gene probes out of 124 that exhibited higher expression with EP/F12 
than with F12, suggesting potentiation of gene expression by estrogen. These six probes were 
DEFB4A, IL36G, SERPINB4, SPRR2D, and two probes for SPRR2E. The fold change in gene 
expression of each of these genes after F12 and EP/F12 treatment is shown in Table 4.2 and 
ranged from 2.1- to 3.1-fold change with F12 treatment to 4.3- to 13.5-fold change with EP/F12 
treatment. As mentioned previously, DEFB4A encodes the antimicrobial peptide hBD2 and the 
SPRR genes are involved in keratinisation. The SERPINB4 gene encodes the serpin peptidase 
inhibitor, clade B (ovalbumin), member 4 protein, which is involved in inflammation and 
immunity, and the IL36G gene encodes the proinflammatory cytokine interleukin 36 gamma.  
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Table 4.2: Fold change in gene expression of genes upregulated by flagellin and estrogen treatment plus 
flagellin, after 12 hours. 
 
 
Conversely, there were also genes from this group that showed higher expression with F12 
treatment than with EP/F12 treatment. Many of these genes have functions related to 
inflammation and the antiviral response. For example, the 2'-5'-oligoadenylate synthetase 1, 
40/46kDa (OAS1) gene, which is involved in inhibition of viral replication, exhibited 17.2-fold 
change in gene expression with F12 treatment, and 10.4-fold change with EP/F12 treatment. 
Likewise, the chemokines CXCL10 and CCL5 had fold changes of 42 and 9.6, respectively, after 
F12 treatment and 16 and 4.6, respectively, after EP/F12 treatment. Additionally, the Venn 
diagram identified 74 gene probes that were only upregulated by F12 treatment. These were also 
mostly antiviral and inflammatory genes such as 2'-5'-oligoadenylate synthetase-like (OASL, 4.8-
fold change with F12) and interferon-induced protein with tetratricopeptide repeats 3 (IFIT3, 
3.5-fold change with F12), which both inhibit viral replication and caspase 1, apoptosis-related 
cysteine peptidase (CASP1, 2.1-fold change with F12), which induces cell apoptosis. These data 
suggest a clear role for estrogen in modulating the innate immune response to infection. 
 
There were five genes that were upregulated by EP12 and EP/F12, but not by F12. These genes 
are shown in Table 4.3 and were cornifelin (CNFN), coagulation factor III (F3), late cornified 
envelope 3D (LCE3D), suprabasin (SBSN), and secretory leukocyte protease inhibitor (SLPI). 
These genes mostly have functions related to keratinisation and differentiation, except for F3, 
which is involved in blood coagulation, and SLPI, which is an AMP important in protecting 
epithelial cells from proteolytic enzymes. With the exception of F3, these genes show enhanced 
expression with EP/F12 than with EP12 indicating that the combined treatment amplified gene 
expression, despite there being no significant increase in the expression of these genes with F12 
alone. This expression pattern indicated that these genes are typically expressed in the presence of 
estrogen and that their expression is augmented by flagellin challenge (i.e. during infection), 
however, without estrogen these genes were not significantly upregulated following flagellin 
challenge.  
 
Gene ID Gene symbol Flagellin Estrogen pretreatment + flagellin
ILMN_2048043 DEFB4A 2.4 5.1
ILMN_2158713 IL36G 2.7 4.3
ILMN_1782716 SERPINB4 2.9 6.5
ILMN_2191967 SPRR2D 2.1 5.7
ILMN_1701239 SPRR2E 2.5 10.8
ILMN_2211018 SPRR2E 3.1 13.5
Fold change after 12 hours
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Table 4.3: Fold change in gene expression of genes upregulated by estrogen pretreatment and estrogen 
pretreatment plus flagellin, after 12 hours. 
 
 
There were three gene probes that were differentially regulated by EP12 and F12 but not 
EP/F12. These genes were lectin, galactose-binding, soluble, 7 (LGALS7) and two different gene 
probes for LGALS7B, and these genes are involved in cell-cell interactions in keratinocytes. 
Further examination of the microarray data revealed that these genes were all significantly 
downregulated by EP12 and F12 with approximately 0.38-fold change for each probe after each 
treatment. It is interesting that these genes were downregulated by both EP12 and F12, but not 
by EP/F12.  
 
Finally, the Venn diagram also showed 54 gene probes that were differentially expressed by 
EP/F12 treatment but not by EP12 or F12 (see Figure 4.3). All 54 of these genes showed 
significant upregulation. The fact that these genes were not upregulated by EP12 or F12 
suggested that neither of these treatments alone was sufficient to stimulate significant 
upregulation of these genes, however, when the two treatments were combined gene expression 
was significantly upregulated. Many of these genes, for example keratins (KRTs) and SPRR 
proteins are involved in keratinisation and differentiation, and may serve to strengthen the 
epithelial barrier during infection. However, this group of genes also contained the genes S100A7 
(also known as psoriasin), S100A12 and DEFB103A, which are antimicrobial peptides. Thus, this 
suggested that estrogen pretreatment prior to flagellin challenge resulted in upregulation of genes 
that are not upregulated by estrogen or flagellin alone. 
 
The 24 hour time point samples were also analysed using this method (Venn diagram shown in 
Appendix Figure 8.1) and this identified the genes RNASE7, SPRR2C, and SPRR2G as 
additional genes of interest as these genes also showed increased expression with EP/F24 
treatment than with EP24 and F24 treatments (see Figure 4.5). Furthermore, analysis of the 24 
hour datasets revealed that for many of the genes of interest EP/F24 treatment showed higher 
gene expression than EP/F12 treatment, whereas, F12 and F24 treatments exhibited similar fold 
changes in gene expression. These data suggested that estrogen pretreatment prior to flagellin 
challenge augmented the epithelial response to infection and the response continued to increase 
Gene ID Gene symbol Estrogen pretreatment Estrogen pretreatment plus flagellin
ILMN_1803838 CNFN 2.0 5.9
ILMN_1797009 F3 2.1 2.2
ILMN_1718395 LCE3D 2.1 5.8
ILMN_1712759 SBSN 2.1 4.4
ILMN_2114720 SLPI 2.2 3.2
Fold change after 12 hours
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up to at least 24 hours post-challenge, whilst flagellin challenge alone stimulated gene expression 
that did not increase from 12 to 24 hours. 
 
Overall, these analyses identified a number of genes, detailed in Table 4.4, that are of interest due 
to their pattern of expression (shown in Figure 4.5) following estrogen and flagellin treatments. 
Compared to the response seen for genes such as the SPRRs, the increased gene expression with 
EP/F treatment for some of the genes, such as S100A8 and SLPI, was comparatively small and 
may not be physiologically relevant with regards to infection. Nevertheless, a number of these 
genes show a substantial increase in expression with EP/F treatment compared with F treatment 
alone; the SPRR2G gene exhibited a 22.5-fold increase in expression with EP/F24 treatment 
compared to a 3.3-fold change with F24. These genes primarily have functions in the immune 
response to pathogens or the keratinisation/differentiation process.  
 
Table 4.4: Table of genes of interest and their functions after Venn diagram analysis. 
 
Gene symbol Gene name Gene function(s)
DEFB103A Human beta defensin 3 Antimicrobial peptide
DEFB4A Human beta defensin 2 Antimicrobial peptide
LCN2 Lipocalin 2 Antimicrobial peptide
RNASE7 Ribonuclease, RNase A family, 7 Antimicrobial peptide
SLPI Secretory leukocyte peptidase inhibitor Antimicrobial peptide
S100A7 S100 calcium binding protein A7/Psoriasin Antimicrobial peptide, keratinisation, inflammation
S100A12 S100 calcium binding protein A12 Antimicrobial peptide, keratinisation, inflammation
S100A8 S100 calcium binding protein A8 Keratinisation, inflammation
S100A9 S100 calcium binding protein A9 Keratinisation, inflammation
CNFN Cornifelin Keratinisation
LCE3D Late cornified envelope 3D Keratinisation
SBSN Suprabasin Keratinisation
SPRR2A Small proline-rich protein 2A Keratinisation
SPRR2C Small proline-rich protein 2C Keratinisation
SPRR2D Small proline-rich protein 2D Keratinisation
SPRR2E Small proline-rich protein 2E Keratinisation
SPRR2F Small proline-rich protein 2F Keratinisation
SPRR2G Small proline-rich protein 2G Keratinisation
IL36G Interleukin 36 gamma Inflammation
SERPINB4 Serpin peptidase inhibitor, clade B (ovalbumin), member 4 Inflammation
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Figure 4.5: Expression pattern of genes of interest identified by Venn diagram analysis. 
 
4.4 Validation of microarray data by qPCR 
To validate the microarray data, qPCR was performed for LCN2 and RNASE7 as the encoded 
proteins have antimicrobial properties. The development of the qPCR assays for these genes is 
detailed in Chapter 5 section 5.4.1. The qPCR results for LCN2 and RNASE7, and the previous 
qPCR results for DEFB103A and DEFB4A were compared to the microarray data for these 
genes (Figure 4.6). The results for DEFB4A are shown on a separate graph, as the fold change in 
expression of this gene, as measured by qPCR, was substantially greater than the other genes. The 
data for each of the genes resulted in an R2 of between 0.9865 and 0.9999 indicating that there 
was good agreement between the microarray results and the qPCR results for all genes measured. 
This agreement between the two methods provided confidence that the values measured by 
microarray for the other genes in the dataset were reliable. 
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Figure 4.6: Comparison of fold change in gene expression obtained by microarray and qPCR. (A) Fold 
change in expression of LCN2, DEFB103A, and RNASE7 genes. (B) Fold change in expression of DEFB4A. 
 
4.4.1 Discussion of gene analysis 
Analysis of individual genes from the microarray data revealed several genes that may have 
important roles in innate defence of the urogenital tract during infection and may also be 
regulated by estrogen. Most of these genes have functions relating to either inflammation, 
keratinisation, or function as a host defence peptide.  
 
Many genes identified by the microarray contribute to the keratinisation process and are encoded 
on the epidermal differentiation complex on human chromosome 1q21. This includes the SPRR, 
S100 and LCE genes. 
 
SPRR genes are a multigene family that are differentially expressed in different types of epithelia. 
They are a component of the cornified cell envelope and it is thought the differential expression 
of these genes results in the production of different types of barrier at the epithelial surface225. 
The SPRR genes identified by the microarray all belong to the SPRR2 family. This family of 
genes has been previously shown to be regulated by estrogen226. 
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S100 proteins are calcium binding proteins with a diverse range of functions. One of these 
functions is thought to be keratinocyte differentiation; the expression of S100A7, A8, and A9 
increases during differentiation of primary human keratinocytes124,227. Furthermore, treatment of 
primary human keratinocytes with recombinant S100A7 resulted in upregulation of 
differentiation markers, such as keratins, and increased expression of tight junction proteins 
resulting in a stronger tight junction barrier228. Similarly overexpression of S100A8 and A9 in a 
human keratinocyte cell line also increased expression of differentiation markers229. Altogether, 
these results indicate a role for S100 proteins in keratinocyte differentiation and thus, increased 
expression of these genes following estrogen and flagellin treatment suggested that these 
treatments caused increased differentiation and strengthening of the tight junction barrier 
between cells, which may not occur to the same extent with estrogen or flagellin alone. 
 
The late cornified envelope (LCE) genes encode cornified envelope constituents with protein 
cross-linking abilities and are very similar to SPRR genes230. These genes are expressed much later 
than other keratinisation genes, hence their name. The LCE family are divided into six 
subgroups, which show tissue specific expression in the skin and contribute to the barrier 
function of the skin231. LCE expression is regulated by stimuli such as ultraviolet light and 
calcium232. Estrogen binding to the GPER receptor results in increased intracellular calcium, 
indicating a potential mechanism of estrogen regulation of these genes. 
 
Many factors can affect the keratinisation of the vaginal epithelium, one of these being the 
menopause. After the menopause the vaginal epithelium thins and is less keratinised203. It is 
thought that increased keratinisation protects against infection by preventing penetration of the 
epithelial layer by pathogens. Increased keratinisation following estrogen treatment has been 
reported previously and topical estrogen is currently used to treat vaginal atrophy in 
postmenopausal women. Using topical estrogen treatment to increase keratinisation of the 
foreskin is also currently being trialled as a preventative to HIV infection233. Additionally, 
research has shown that peptide fragments derived from keratins also have antimicrobial activity 
and these fragments have been named keratin-derived antimicrobial peptides (KDAMPs)234. 
Keratin 6A-derived peptides from human corneal epithelial cells displayed bactericidal activity 
against multiple pathogens. The upregulation of numerous genes involved in keratinisation 
following estrogen pretreatment plus flagellin may therefore serve to protect the vaginal 
epithelium from infection in a number of ways. Firstly, by strengthening the epithelial barrier to 
infection and preventing penetration by pathogens. Secondly, by increasing the glycogen content 
of the vaginal lumen, which supports the growth of Lactobacillus spp., which in turn prevents the 
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growth of pathogenic bacteria. Finally, increased keratinisation may protect the vaginal epithelium 
from infection by potentially increasing the production of KDAMPs in the vagina to aid in 
elimination of bacteria from the site of infection. Further examination into the role of 
keratinisation in protecting against UTIs, and the effect of estrogen on this will be an important 
area to study further in the future.  
 
Many of the genes upregulated after estrogen and flagellin treatments also have functions related 
to inflammation. Of the genes highlighted as being of interest due to their expression patterns, 
IL36G, S100A7, S100A8, S100A9, S100A12 and SERPINB4 have all been reported to play a role 
in inflammation. IL36G is a proinflammatory cytokine produced by keratinocytes that stimulates 
MAP kinase and NF-ĸB signalling upon binding to its receptor and induces the expression of 
other proinflammatory cytokines235–238. S100 proteins are calcium binding proteins with a diverse 
range of functions, including inflammation. S100A7, also known as psoriasin, has been shown to 
stimulate proinflammatory cytokine production from neutrophils239. Moreover, S100A8 and 
S100A9 are chemotactic for neutrophils and thus, these proteins together may act to recruit 
neutrophils to the site of infection and activate the neutrophils to secrete proinflammatory 
cytokines to promote an immune response240. Similarly, S100A12 is chemotactic for mast cells 
and monocytes and induces the production of proinflammatory cytokines from mast cells241–244. 
However, it has also been reported that S100A8 and S100A9, which work both independently 
and as a heterodimer, are anti-inflammatory and act to supress acute inflammation by neutralising 
proinflammatory cytokines produced by neutrophils and macrophages, such as IL-1β, IL-6, and 
TNF-α, and reducing inflammation245. Therefore, as inflammation is a complex area and many 
proteins involved can function both to stimulate and dampen an immune response, it is difficult 
to conclude what effect estrogen pretreatment may have on the level of inflammation during a 
UTI. However, many of the same genes have been reported to be upregulated in inflammatory 
skin conditions such as atopic dermatitis and contact eczema suggesting that these genes are 
indeed proinflammatory, and furthermore, that EP/F treatment promotes an inflammatory 
response238. 
 
The microarray data also identified several AMPs that showed potentiated expression with 
estrogen pretreatment plus flagellin than flagellin alone. These were DEFB103A, DEFB4A, 
LCN2, RNASE7, S100A7, S100A12 and SLPI.  
 
LCN2 is an iron binding protein with antimicrobial properties246. A role for LCN2 in defence 
against UTIs has recently been identified; transurethral inoculation of LCN2 deficient mice with 
E. coli resulted in significantly higher CFUs in the bladder 3 days postinoculation than mice that 
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were LCN2 competent247. LCN2 is also elevated in the urine of women with acute cystitis, 
suggesting this protein is expressed during episodes of UTI and has an important role in 
protection against uropathogenic bacteria247. 
 
RNase 7 was initially identified in skin from healthy individuals in 2002121. It was found to have 
high sequence similarity to the RNase A superfamily of ribonucleases and indeed was found to 
have high ribonuclease activity. RNase 7 was found to have broad-spectrum antimicrobial activity 
against Gram-positive bacteria, Gram-negative bacteria and yeast, and thus was deemed to be an 
AMP. RNase 7 is expressed by epithelial cells throughout the urinary tract and is constitutively 
present in the urine of healthy patients248. Furthermore, in 2013 Kline et al. demonstrated that 
urinary RNase 7 concentrations increase during infection and that RNase 7 facilitates rapid killing 
of uropathogens by membrane disruption123. Altogether, these data suggest that RNase 7 is an 
important AMP with a role in protecting the urogenital tract from infection. RNase 7 expression 
has previously been reported in the vulvar, however, the microarray data presented in this thesis 
is, to the best of our knowledge, the first demonstration of RNase 7 expression in the vaginal 
epithelium249. Furthermore, the microarray data suggested an increase in RNase 7 expression with 
estrogen pretreatment plus flagellin, compared to flagellin challenge alone indicating a role for 
estrogen in the regulation of this AMP. Regulation of RNase 7 by estrogen has been reported 
once previously by Luthje et al. (2013); the authors demonstrated that estrogen supplementation 
increased RNase 7 expression in an immortalised bladder epithelial cell line134. Thus, the 
microarray findings for RNase 7 in the vagina are novel, but supported by observations of RNase 
7 expression in the bladder. 
 
The S100 proteins S100A7, S100A8, S100A9 and S100A12 also have antimicrobial 
properties127,250,251. These peptides have been reported to exert their antimicrobial properties 
through sequestration of metal ions, such as Zn2+ and Mn2+250–252. S100A8 and S100A9 have 
previously been identified in both the human and murine vagina however, the microarray data 
presented in this thesis also demonstrated S100A7 and S100A12 expression in vaginal epithelial 
cells253,254. S100A7 and S100A8/A9 have previously been shown to be upregulated by bacterial 
flagellin in foreskin-derived keratinocytes255,256. Despite having antimicrobial properties these 
proteins have mainly been studied as chemotactic factors in the context of inflammation, as 
discussed previously126. However, potentiation of the expression of these genes with estrogen 
pretreatment prior to flagellin challenge indicates that estrogen boosts the antimicrobial 
properties of the vagina upon exposure to pathogens. 
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The AMP SLPI was initially identified in lung epithelial cells. The C-terminal domain of SLPI is a 
protease inhibitor, which protects epithelial cells from serine proteases, and the N-terminal has 
antimicrobial activity257. SLPI has been demonstrated to have broad-spectrum antimicrobial 
activity against Gram-positive, Gram-negative and fungal pathogens257–260. SLPI is expressed in 
numerous epithelial cells and has been detected in the bladder, kidney, and female reproductive 
tract261–264. However, the role of SLPI in protecting against UTIs has not been studied and thus, 
the importance of this AMP during UPEC colonisation is not known. Fahey and Wira (2002) 
previously demonstrated that uterine secretions from premenopausal women contained 
significantly higher SLPI concentrations than postmenopausal women265. This suggested 
hormonal regulation of SLPI expression and supports the findings of estrogen regulation of SLPI 
presented here.  
 
In the literature other AMPs have been identified in the urogenital tract and are thought to be 
important in defence against UTIs. Cathelicidin, with active molecule LL-37, is expressed in the 
vagina, bladder and kidney, and is upregulated in the urine of during UTIs263,266–268. Furthermore, 
transgenic mice lacking the LL-37 gene had significantly higher levels of bacteria attached to the 
bladder epithelium following transurethral injection of UPEC, compared to LL-37 competent 
mice267. These data suggest that LL-37 is important in protecting against UTIs. Similarly, the 
urinary concentrations of lactoferrin and HD5 are increased during UTI episodes96,269,270. In 
addition, treatment of mice with oral lactoferrin significantly reduced the bacterial load in the 
bladder following transurethral UPEC injection, compared to mice that did not receive oral 
lactoferrin. However, the effects of deleting the lactoferrin and HD5 genes on the susceptibility 
of mice to UTIs has not been investigated, so their importance in bacterial clearance from the 
urinary tract has not been fully substantiated. The microarray data indicated that these AMPs 
were not upregulated by estrogen pretreatment in vaginal epithelial cells. This demonstrates that 
topical estrogen treatment may not upregulate all innate factors that may be protective against 
UTIs.  
 
The Venn diagram identified downregulation of the genes LGALS7 and LGALS7B by EP12 and 
F12 treatment, but not EP/F12 treatment. Some galectins have been shown to be important in 
the immune response to bacterial infection, by binding bacteria directly and having a 
bacteriostatic or bactericidal effect and by recruiting macrophages and neutrophils to the site of 
infection271. Thus, inhibition of these genes by EP12 and F12 treatments may reduce the 
antimicrobial response of vaginal epithelial cells to infection. Downregulation of these genes was 
not observed with combined EP/F12 treatment, nor with any treatment at the 24 hour time 
point making it difficult to speculate on the mechanism behind this regulation pattern and the 
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importance of this finding. Furthermore, the Venn diagram highlighted that for some genes 
estrogen pretreatment prior to flagellin challenge resulted in reduced gene transcription, 
compared to flagellin alone. For example, there were 74 gene probes that were significantly 
upregulated by F12 treatment, but not by EP/F12 treatment. Many of these genes related to 
inhibition of viral infection and replication. Flagellin treatment has been shown previously to 
activate antiviral responses and conferred protection against Cytomegalovirus272. Further 
investigation is required to determine whether downregulation of these antiviral genes is 
detrimental to clearance of bacterial pathogens from the vagina, or whether downregulation of 
the host antiviral response is due to the immune response being driven towards antibacterial 
activity. Chemokines such as CXCL10 and CCL5 also showed increased gene expression with 
F12 treatment than with EP/F12 treatment. Flagellin induced CXCL10 expression in the cornea 
has been reported as a crucial factor in innate defence to Pseudomonas aeruginosa infection273. Thus, 
reduced expression of CXCL10 after EP/F12 treatment, compared to F12 treatment, may result 
in reduced bacterial killing and elimination from the vagina. These data, therefore, highlight the 
importance of understanding the mechanism of action of estrogen, so that key signalling 
pathways which promote innate immunity may be targeted with novel therapeutics. 
 
The microarray data was verified by qPCR for several AMP genes and the two methods of 
quantifying mRNA showed good agreement (R2>0.9865 for each gene). Reporting of validation 
results varies in the literature, with some groups considering results to be valid if both microarray 
and qPCR data reported a fold change greater than 2, whilst other groups consider more carefully 
the magnitude of the difference between the two reported results274,275. Furthermore, a 2-fold 
change has been reported as a cut off below which microarray and qPCR data begin to lose 
correlation. Thus, consideration of genes with a fold change above 2 should ensure better 
correlation between microarray and qPCR data. The fold changes measured by qPCR in this 
thesis are generally consistent with the fold changes measured by microarray however, it is 
notable that the microarray underestimated the fold change of some samples, particularly those 
where qPCR reported high fold changes. Svaren et al. (2000) also reported greater fold change in 
gene expression by qPCR than was measured by microarray and found this to be most prevalent 
for genes where the control sample exhibited low expression of that gene275. Examination of the 
raw gene expression values for the 12 and 24 hour control samples showed that this was indeed 
the case for hBD2, perhaps indicating why the microarray analysis reported lower fold changes 
for these genes than qPCR analysis. However, overall there was good agreement between the fold 
change values reported by microarray and qPCR, providing confidence in the microarray data. 
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Altogether, initial analysis of the microarray data by Venn diagram highlighted several genes of 
interest, the expression of which was potentiated in vaginal epithelial cells by estrogen 
pretreatment prior to exposure to flagellin – a bacterial PAMP important in establishing a UTI. 
The genes identified have functions relating to three areas: keratinisation, inflammation and 
microbial killing. However, many of the genes have multiple functions within these. These data 
suggest, therefore, that estrogen functions to improve innate immunity to infection by increasing 
the antimicrobial characteristics of the vagina, strengthening the epithelial barrier to pathogens 
and increasing expression of chemotactic genes involved in migration of immune cells, such as 
neutrophils and macrophages. All of these functions are involved in facilitating bacterial clearance 
from the vagina.  
 
 
4.5 Ingenuity Pathway Analysis 
To investigate areas identified by initial microarray analysis in more detail the microarray data was 
analysed using Ingenuity Pathway Analysis (IPA) software. This allows analysis of the 
downstream effects of each treatment, the canonical pathways that are involved in producing 
these effects and the upstream regulators potentially responsible for target gene expression. This 
type of analysis is useful in beginning to identify potential mechanisms of target gene regulation. 
 
4.5.1 Downstream effects analysis 
Using IPA the effects of a treatment on various downstream functions can be predicted. This 
type of analysis allows a hypothesis to be generated for how a function is regulated by a given 
treatment. The downstream effect of a treatment is calculated by IPA using interactions 
published in the literature. For example, the literature may identify a particular set of genes that 
causes a particular outcome or function, for instance cell cycle activation. The expression values 
of those genes in any given dataset can then be used to predict the activation state of that 
function (see Figure 4.7), i.e. to determine whether cell cycle activation is an outcome of a given 
treatment. This activation state is reported in IPA as a z-score. A z-score is only significant and 
reported for a function if it is above +2 or below -2276. A z-score above +2 shows the function is 
likely to be activated as a result of the treatment and the higher the z-score the more activated 
that function is expected to be. Whereas, a z-score below -2 indicates the function may be 
inhibited in the dataset. Considering the previous example, if genes X, Y and Z are known in the 
literature to cause cell cycle activation, and these genes are upregulated in a dataset the function 
“Cell cycle activation” would have a z-score greater than +2 and therefore be predicted to be a 
downstream effect of the treatment. A p-value is also calculated for each function, however, IPA 
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typically reports the p-value as –log(p-value). Reporting the p-value in this way means that small 
p-values are represented by large numbers, whereas large p-values are represented by small 
numbers. This allows smaller, more significant p-values to be displayed on a graph more clearly. 
Thus, a significant p-value of less than 0.05 is the equivalent of –log(p-value) of greater than 1.30. 
 
Each of the microarray datasets were analysed with IPA to determine the functions with the 
highest and lowest z-scores after each treatment (EP, F and EP/F) in VK2 cells. 
 
 
Figure 4.7: Diagram of how the z-score of each function is calculated by IPA. Each function is known to be 
regulated by a selection of genes (A-E) documented in the literature. The activation state of these genes within a 
dataset determines the predicted overall activation state of the downstream function. The z-score is calculated for 
each function based upon the expression values of each of the upstream genes. 
 
4.5.1.1 Most highly activated functions 
EP12 treatment did not result in any functions with z-scores above 2. EP24 treatment also 
resulted in no functions with z-scores greater than 2. This suggested EP treatment alone was not 
predicted to activate any functions in VK2 cells by IPA. After F12 treatment 85 functions had a 
z-score above 2 and thus were predicted to be activated. Almost all 85 of the functions were 
relating to immune cell activation and chemotaxis. However, there were also two relating to 
transactivation of RNA, two relating to quantity of metal ions, and activation of four diseases 
(multiple sclerosis, relapsing-remitting multiple sclerosis, inflammatory demyelinating disease and 
progressive motor neuropathy). The ten functions with the highest z-score after F12 treatment 
are shown in Figure 4.8A and the differentially expressed genes associated with each of the 
functions are shown in Table 4.5. In this table groups of genes that are associated with multiple 
functions are colour coded. 
 
Analysis of the F24 dataset showed predicted activation of similar functions, 64 in total, mostly 
related to cell movement and migration. The function ‘Cell movement of myeloid cells’ had the 
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highest z-score, of 3.664, after F24 treatment, which is comparable with the z-score of 3.710 for 
the same function after F12 treatment. The ten functions with the highest z-scores after F24 
treatment are shown in Figure 4.8B and the differentially expressed genes associated with each 
function are shown in Table 4.6. 
 
 
Figure 4.8: Functions with highest z-score after (A) F12 treatment and (B) F24 treatment. Graph shows the 
ten functions with the highest z-score after (A) 12 hours flagellin (F) treatment and (B) 24 hours F treatment, as 
calculated by Ingenuity Pathway Analysis. The z-score is calculated based upon the expression values of certain genes 
within the dataset.  
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Table 4.5: Table of functions with highest z-score after F12 treatment. 
 
 
 
Table 4.6: Table of functions with highest z-score after F24 treatment. 
 
 
 
After EP/F12 treatment 63 functions had a z-score above 2 and, similarly to F12 treatment, 
almost all 63 functions related to immune cell activation and chemotaxis. However, one function 
related to ‘Transactivation of RNA’, one to ‘Damage of liver’ and five to multiple sclerosis and 
similar diseases. The ten functions with the highest z-score after EP/F12 treatment are shown in 
Figure 4.9A with the z-score after F12 treatment represented by blue bars. Observing only the 
ten functions with the highest z-scores for F12 and EP/F12, EP/F12 resulted in higher z-scores 
for many of these functions. For example, ‘Cell movement by myeloid cells’ had a z-score of 
3.710 and 4.069 with F12 and EP/F12 treatment, respectively, although it was not possible to 
determine if this difference was significant. This suggested that EP/F12 treatment resulted in 
Number of
molecules
CASP1,CCL20,CCL5,CEACAM1,CFB,CXCL10,CXCL8,
DEFB4A/DEFB4B,ICAM1,IL1RN,LCN2,LTB,MMP9,
S100A8,S100A9,SAA1,SERPINA3,VEGFC = (a)
Cell movement of  phagocytes 3.700 19 (a),CXCL11
Cell movement of  leukocytes 3.686 23 (a),CXCL11,DDX58,FYB,STAT1,STAT2
Leukocyte migration 3.544 24 (a),CXCL11,DDX58,FYB,OLR1,STAT1,STAT2
Transactivation 3.511 15 (c),MARKCKSL1
Cell movement of  granulocytes 3.485 14 (d),CEACAM1
CCL20,CCL5,CEACAM1,CXCL10,CXCL11,CXCL8,
DDX58,DEFB4A/DEFB4B,FYB,ICAM1,LTB,
MMP9 = (b)
CXCL8,DDX58,DDX60L,EIF2AK2,HERC5,IFI16,
IRF1,IRF9,LMO2,MMP9,MX1,STAT1,STAT2,
TNFSF10 = (c)
CASP1,CCL5,CFB,CXCL10,CXCL8,
DEFB4A/DEFB4B,ICAM1,IL1RN,LCN2,MMP9,
S100A8,S100A9,SAA1 = (d)
Cell movement of  lymphocytes 3.254 13 (b),SAA1
Cell movement of  myeloid cells 183.710
Cell movement of  neutrophils
Transactivation of  RNA
Migration of  mononuclear 
leukocytes
133.334
3.376 14
123.394
MoleculesFunction z-score
Number of
molecules
Cell movement of  myeloid cells 3.664 17 (b),(c),CFB,LTB
Cell movement of  phagocytes 3.653 17 (b),(c),CFB,LTB
Cell movement of  granulocytes 3.488 13 (a),S100A7
Cell movement of  neutrophils 3.328 12 CCL5,CFB,CXCL10,CXCL8,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,LCN2,MMP9,PTGS2,S100A8,
S100A9,SAA1 = (a)
Migration of  cells 3.299 24 (b),(c),CFB,CYP2J2,EIF2AK2,LTB,NT5E,PARP9,
SOD2,SP100,STAT1
Chemotaxis of  cells 3.282 15 (b),LCN2,S100A7,SERPINA3,THBS1 = (c)
Chemotaxis 3.282 16 (b),(c),TYMP
Migration of  phagocytes 3.184 11 CCL20,CCL5,CXCL10,CXCL8,
DEFB103A/DEFB103B,DEFB4A/DEFB4B,
MMP9,PTGS2,S100A8,S100A9,SAA1 = (b)
Cell movement of  leukocytes 3.164 19 (b),(c),CFB,LTB,NT5E,STAT1
Function z-score Molecules
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stronger activation of immune related pathways. However, considering all 63 functions activated 
by EP/F12, 52 of these functions were common with F12. Of these 26 had a higher z-score with 
EP/F12 than with F12, 7 had equal z-scores with both treatments and 19 had higher z-scores 
with F12 than with EP/F12. Furthermore, functions such as ‘Cell movement of neutrophils’ 
exhibited a higher z-score with EP/F12 than F12, but the function ‘Migration of neutrophils’ had 
a higher z-score with F12 rather than EP/F12. Thus from these data it was difficult to conclude 
whether estrogen pretreatment prior to flagellin challenge resulted in increased activation of 
immune functions, as the functions activated by F12 and EP/F12 and their z-scores were mostly 
comparable. The differentially expressed genes associated with the ten functions with the highest 
z-scores after EP/F12 treatment are shown in Table 4.7. 
 
Analysis of the EP/F24 dataset once again showed activation of similar functions to the F24 
dataset, with ‘Cell movement of myeloid cells’ having the highest z-score (3.323) followed by 
‘Cell movement of phagocytes’ (3.295). The ten functions with the highest z-scores after EP/F24 
treatment are shown in Figure 4.9B, with the data from F24 represented by blue bars. The 
differentially expressed genes associated with each function are shown in Table 4.8. 
 
Figure 4.9: Functions with highest z-score after (A) EP/F12 treatment and (B) EP/F24 treatment. Graph 
shows ten functions with highest z-score after (A) estrogen pretreatment plus flagellin for 12 hours (EP/F12) and 
(B) estrogen pretreatment plus flagellin for 24 hours (EP/F24). Blue lines indicate values for (A) F12 treatment and 
(B) F24 treatment. 
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Table 4.7: Table of functions with the highest z-score after EP/F12 treatment. 
 
 
Table 4.8: Table of functions with highest z-score after EP/F24 treatment. 
 
 
 
Number of
molecules
CASP1,CCL20,CCL5,CFB,CXCL10,CXCL14,CXCL8,
DEFB103A/DEFB103B,DEFB4A/DEFB4B,FABP4,
GJB2,IL1RN,LCN2,LTB,MMP9,S100A12,S100A7,
S100A8,S100A9,SAA1,SERPINA3,THBS1 = (a)
Cell movement of  phagocytes 4.058 22 (a)
CASP1,CCL20,CCL5,CFB,CXCL10,CXCL14,CXCL8,
CYP2J2,DDX58,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,EGR1,EIF2AK2,F3,FABP4,GJB2,
ID1,IFIT2,IGFBP3,IL1RN,KRT10,LAMA3,LCN2,
LTB,MMP9,OLR1,PARP9,S100A12,S100A7,S100A8,
S100A9,S100P,SAA1,SERPINA3,SERPINB3,SLPI,
SOD2,SP100,STAT1,STAT2,THBS1,TSC22D3,
ZC3H12A = (b)
Cell movement of  granulocytes 3.879 18 (c),S100A7
Cell movement 3.765 46 (b),IL32,MX1,TYMP
CASP1,CCL5,CFB,CXCL10,CXCL14,CXCL8,
DEFB103A/DEFB103B,DEFB4A/DEFB4B,FABP4,
GJB2,IL1RN,LCN2,MMP9,S100A12,S100A8,S100A9,
SAA1 = (c)
(d),CASP1,CFB,DDX58,F3,FABP4,GJB2,IL1RN,
KRT10,LTB,SERPINB3,STAT1,STAT2,
ZC3H12A = (e)
Inflammatory response 3.312 21 (d),FABP4,IL1RN,ISG15,OLR1,STAT1
TYMP,CCL20,CCL5,CXCL10,CXCL14,CXCL8,
DEFB103A/DEFB103B,DEFB4A/DEFB4B,LCN2,
MMP9,S100A12,S100A7,S100A8,S100A9,
SAA1,SERPINA3,THBS1 = (d)
Leukocyte migration 3.212 31 (d),(e),OLR1,SLPI
Function z-score Molecules
Chemotaxis
Cell movement of  leukocytes
Cell movement of  neutrophils
Migration of  cells
Cell movement of  myeloid cells
173.260
293.352
173.731
433.960
224.069
Number of
molecules
Cell movement of  myeloid cells 3.323 19 (a),(b),CFB,FABP4,NFKBIZ,PRDM1 = (c)
Cell movement of  phagocytes 3.295 19 (a),(b),(c)
(a),CFB,FABP4,LCN2,MMP9,PRDM1,S100A12,
S100A7
Chemotaxis 3.157 16 (a),(b),TYMP
Homing of  cells 3.055 16 (a),(b),IGFBP3
Homing 3.055 17 (a),(b),IGFBP3,TYMP
(a),CCL20,LCN2,MMP9,S100A12,S100A7,
SERPINA3,THBS1 = (b)
Cell movement of  neutrophils 3.038 14 (a),CFB,FABP4,LCN2,MMP9,PRDM1,S100A12
CCL20,MMP9,CCL5,CXCL10,CXCL2,
DEFB103A/DEFB103B,DEFB4A/DEFB4B,S100A8,
S100A9,SAA1 = (a)
Chemotaxis of  phagocytes 2.971 14 (a),CCL20,LCN2,S100A12,S100A7,SERPINA3,THBS1
Chemotaxis of  leukocytes 3.042 15
Migration of  phagocytes 3.036 10
Cell movement of  granulocytes 3.258 15
Function z-score Molecules
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4.5.1.2 Most strongly inhibited functions 
EP12 and EP24 treatments did not result in any functions with a z-score below -2. This 
suggested that EP treatment alone was not predicted to inhibit any functions. F12 treatment 
resulted in 14 functions with a z-score below -2. Other than one function relating to organismal 
death, all of the inhibited functions after F12 treatment related to replication of pathogens. Thus, 
F12 treatment resulted in inhibition of pathogen replication within VK2 cells. The ten functions 
with the lowest z-scores after F12 treatment are shown in Figure 4.10A. F24 treatment resulted in 
inhibition of seven functions, all relating to viral replication, and these are shown in Figure 4.10B. 
The genes associated with each function after F12 and F24 treatment are shown in Table 4.9 and 
Table 4.10, respectively. 
 
 
Figure 4.10: Functions with lowest z-score after (A) F12 and (B) F24 treatment. Graph shows the ten 
functions with the lowest z-score after (A) 12 hour flagellin treatment (F12) and (B) 24 hour flagellin treatment 
(F24), as calculated by Ingenuity Pathway Analysis. 
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Table 4.9: Table of functions with lowest z-scores after F12 treatment. 
 
 
Table 4.10: Table of functions with lowest z-scores after F24 treatment. 
 
 
 
After EP/F12 treatment 12 functions had a z-score below -2 (ten functions with lowest z-scores 
shown in Figure 4.11A with the F12 data overlaid in blue). Eleven of these functions related to 
infection and replication of pathogens and one function related to organismal death. Of these 12 
functions only two had a lower z-score with EP/F12 than with F12, three had an equivalent z-
Number of
molecules
Replication of  virus -4.474 38 (a),BIRC3,MX2
(a),BIRC3,DDX60L,DEFB4A/DEFB4B,HLA-B,
ICAM1,IFI35,IFIT2,IFIT3,IL1RN,IL32,IL36G,LCN2,
MX2,PARP9,PI3,PSME2,SAMD9,SP100,TRIM22
ADAR,BST2,CCL5,CEACAM1,CXCL10,CXCL8,
DDX58,EIF2AK2,GBP1,IFIH1,IFIT1,IFITM1,IFITM2,
IFITM3,IRF1,IRF9,ISG15,ISG20,MMP9,MX1,OAS1,
OASL,PARP12,RSAD2,S100A8,S100A9,SP110,
STAT1,STAT2,TAP1,TNFSF10,TRIM21,TRIM25,
TRIM5,UBE2L6,ZC3HAV1 = (a)
DDX58,IFIH1,IFITM2,IFITM3,IRF1,IRF9,ISG20,
OAS1,OASL,PARP12,SP110,STAT2,TAP1,TRIM25
CCL5,EIF2AK2,IFIT1,ISG15,MX1,OAS1,OAS3,OASL,
PLSCR1,TNIP1
ADAR,CXCL10,DDX58,IFIH1,IRF1,ISG20,MX2,
OAS1,PARP12 = (b)
Replication of  Herpesviridae -2.874 13 (b),IRF9,RSAD2,STAT1,STAT2
(c),ADAR,CD68,CFB,CXCL10,CXCL8,
DEFB4A/DEFB4B,IL1RN,IRF7,IRF9,MARCKSL1,
NINJ1,SDC4,SOD2,STAT2,TNIP1,TRIM21,VEGFC
CXCL10,EIF2AK2,IFIT1,IFITM1,IFITM3,ISG15,
RSAD2,UBE2L6
LCN2,PI3,CASP1,DDX58,EIF2AK2,IFIH1,ISG15,
MMP9,STAT1,USP18 = (c)
-3.422
-3.858
-4.036
z-scoreFunction Molecules
Infection of  mammalia
Replication of  Flaviviridae
Organismal death
Replication of  Murine
herpesvirus 4
Replication of  viral replicon
Replication of  vesicular 
stomatitis virus
Replication of  RNA virus
Viral infection
10
8
25
9
10
14
36
55
-2.372
-2.582
-2.729
-3.000
-3.138
Number of
molecules
Replication of  virus -3.404 23 (a),BIRC3,MX2
BST2,CCL5,CXCL10,CXCL8,EIF2AK2,IFITM1,
IFITM2,IFITM3,IRF9,ISG15,MMP9,MX1,OAS1,
PARP12,RSAD2,S100A8,S100A9,SP110,STAT1,TAP1,
UBE2L6 = (a)
(a),BIRC3,C1R,DDX58,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,HLA-B,IFI35,IL32,IL36G,LCN2,
MX2,PARP9,PTGS2,SP100,TRIM22
IFITM2,IFITM3,IRF9,OAS1,PARP12,SP110,TAP1
CXCL10,EIF2AK2,IFITM1,IFITM3,ISG15,RSAD2,
UBE2L6
EIF2AK2,IFITM1,IFITM2,IFITM3,ISG15,MMP9,
MX1,RSAD2,STAT1
CXCL10,MX2,OAS1,PARP12Replication of  Murine
herpesvirus 4
-2.000 4
Replication of  vesicular 
stomatitis virus
-2.630 7
Function z-score Molecules
Replication of  RNA virus
Viral infection
Replication of  Influenza A
virus
-2.978 21
-2.924 36
-2.082 9
Replication of  Flaviviridae -2.382 7
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score after both treatments and seven had a lower z-score after F12 treatment than after EP/F12. 
For example, “Replication of virus” was the most inhibited function after both treatments, 
however, the z-score was -4.474 and -3.645 for F12 and EP/F12, respectively. Although it was 
not possible to test whether this was a significant difference, these data suggested that F12 
treatment may result in stronger inhibition of pathogen replication than EP/F12 treatment. 
EP/F24 treatment resulted in inhibition of nine functions (Figure 4.11B with F24 data overlaid in 
blue), once again all related to replication of viral pathogens. Of the seven commonly inhibited 
functions by F24 and EP/F24, four had a lower z-score with EP/F24 than F24, two had equal z-
scores with both treatments and one had a lower z-score with F24 than EP/F24. Thus, these data 
suggested that although at the 12 hour time point F12 treatment potentially resulted in greater 
inhibition of viral replication, by 24 hours EP/F24 treatment displayed the strongest inhibition of 
these functions. It is not clear whether regulation of these antiviral responses is important for 
driving bacterial clearance from the site of infection.  
 
The differentially expressed genes associated with each function after EP/F12 and EP/F24 
treatments are shown in Table 4.11 and Table 4.12, respectively. 
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Figure 4.11: Functions with lowest z-score after (A) estrogen pretreatment plus flagellin for 12 hours 
(EP/F12) and (B) EP/F24 treatment. Blue bars represent the z-score after F12 and F24 treatment. 
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Table 4.11: Table of functions with lowest z-scores after EP/F12 treatment. 
 
 
 
Table 4.12: Table of functions with lowest z-score after EP/F24 treatment. 
 
 
Number of
molecules
(b),DDX58,IFIH1,IFITM2,IFITM3,IRF9,MX2,OAS1,
OASL,PARP12,SP110,STAT2,TAP1 = (a)
(a),(b),DDX60L,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,EGR1,HLA-B,IFI35,IFIT2,IFIT3,
IL1RN,IL32,IL36G,KLK12,LCN2,PARP9,PI3,S100P,
SAMD9,SERPINB3,SP100,TRIM22
CCL5,EIF2AK2,IFIT1,ISG15,MX1,OAS1,OAS3,OASL,
PLSCR1,SLPI,TNIP1
(c),ADAR,BST2,CCL5,CXCL10,CXCL8,EIF2AK2,
GBP1,IFIT1,IFITM1,ISG15,MMP9,MX1,RSAD2,
S100A12,S100A8,S100A9,SLPI,STAT1,TRIM21,TRIM5,
UBE2L6 = (b)
DDX58,IFIH1,IFITM2,IFITM3,IRF9,OAS1,OASL,
PARP12,SP110,STAT2,TAP1 = (c)
(e),ADAR,CFB,CLDN1,CXCL10,CXCL8,
DEFB4A/DEFB4B,F3,HOPX,IGFBP3,IL1RN,IRF7,
IRF9,SLPI,SOD2,STAT2,TGM1,TNIP1,TRIM21
ADAR,CXCL10,DDX58,IFIH1,MX2,OAS1,
PARP12 = (d)
CXCL10,EIF2AK2,IFIT1,IFITM1,IFITM3,ISG15,
RSAD2,UBE2L6
Replication of  Herpesviridae -2.525 11 (d),IRF9,RSAD2,STAT1,STAT2
LCN2,PI3,CASP1,DDX58,EIF2AK2,IFIH1,ISG15,
MMP9,STAT1,USP18 = (e)
10
8
26
11
Replication of  viral replicon
Viral infection
Replication of  virus
-2.372
-2.582
-2.902
-2.975
-3.293
-3.409
-3.645
Infection of  mammalia
7-2.646
Replication of  Murine
herpesvirus 4
Molecules
Replication of  Flaviviridae
Organismal death
Function z-score
11
54
33
Replication of  vesicular
stomatitis virus
Replication of  RNA virus -3.183 32
Number of
molecules
Replication of  virus -3.718 26 (a),BIRC3,MX2
BST2,CCL5,CXCL10,EIF2AK2,IFITM1,IFITM2,
IFITM3,IRF9,ISG15,MMP9,MX1,OAS1,PARP12,
RSAD2,S100A12,S100A8,S100A9,SLPI,SP110,STAT1,
STAT2,TAP1,TRIM5,UBE2L6 = (a)
(a),BIRC3,CYSRT1,DDX60L,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,HLA-B,IFI35,IFIT3,IL36G,
KLK12,LCE3D,LCN2,MX2,NFKBIZ,PARP9,PI3,
S100P,SAMD9,SERPINB3,SP100,TRIM22
Replication of  viral replicon -2.804 8 CCL5,EIF2AK2,ISG15,MX1,OAS1,OAS3,PLSCR1,SLPI
Replication of  vesicular IFITM2,IFITM3,IRF9,OAS1,PARP12,SP110,STAT2,
stomatitis virus TAP1
CXCL10,EIF2AK2,IFITM1,IFITM3,ISG15,RSAD2,
UBE2L6
Replication of  Influenza A EIF2AK2,IFITM1,IFITM2,IFITM3,ISG15,MMP9,
virus MX1,RSAD2,SLPI,STAT1
Infection by DNA virus -2.170 5 DEFB103A/DEFB103B,NFKBIZ,PI3,SAMD9,STAT1
Replication of  Murine CXCL10,MX2,OAS1,PARP12
herpesvirus 4
Function z-score Molecules
-2.000 4
10
7
8
45
24
-2.270
-2.382
-2.804
-2.884
-3.319Replication of  RNA virus
Viral infection
Replication of  Flaviviridae
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4.5.1.3 Most significantly affected functions  
In some cases IPA predicts that a function is affected by genes within the dataset, but cannot 
determine in which direction the function is affected based upon what has been reported in the 
literature. To consider where this may be the case the functions were sorted by p-value, to 
establish which were most significantly affected by EP, F and EP/F treatments. 
 
After EP12 treatment the ten most significantly affected functions are shown in Figure 4.12A. 
Once again, many of the functions related to immune cell activation, however, the most 
significantly affected function was ‘Plaque psoriasis’. Similarly, the function ‘Psoriasis’ was also 
the third most significantly affected function for EP12. There were seven differentially expressed 
genes from the EP12 dataset that were linked to the ‘Plaque psoriasis’ function and these 
included LCN2, SLPI, and S100A8/A9 – genes highlighted as potential genes of interest. The full 
list of differentially expressed genes associated with each function after EP12 and EP24 
treatments are shown in Table 4.13 and Table 4.14, respectively. EP24 treatment showed similar 
most significantly affected functions to EP12 treatment, with ‘Plaque psoriasis’ being the most 
significantly affected function with both treatments (Figure 4.12B). 
 
 
Figure 4.12: Functions with the smallest p-value after (A) estrogen pretreatment at 12 hours and (B) 
estrogen pretreatment at 24 hours. The p-value is represented as –log(p-value). Grey bars indicate no z-score was 
calculated for these functions. 
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Table 4.13: Table of most significantly affected functions after EP12 treatment. 
 
 
Table 4.14: Table of most significantly affected functions after EP24 treatment. 
 
 
 
The ten most significantly affected functions after F12 treatment are shown in Figure 4.13A. Six 
of these ten functions had a z-score associated with them that was above 2 or below -2, but a z-
score was not reported for the remaining four functions. ‘Psoriasis’ was the most significantly 
affected function and 60 differentially expressed genes from the F12 dataset were linked to this 
function, once again including previously identified genes of interest DEFB4A, LCN2, 
S100A8/A9, and SERPINB4 (full list of associated genes in Table 4.15). The three remaining 
functions without a z-score from the ten most significantly affected functions in the F12 dataset 
all related to autoimmune diseases, and linked to numerous genes related to inflammation such as 
interferon-induced proteins. 
 
F24 treatment significantly affected similar functions to F12 treatment, with ‘Psoriasis’ being the 
most significantly affected function with both treatments (Figure 4.13B). The genes associated 
with each function after F24 treatment is shown in Table 4.16. 
Number of
molecules
Plaque psoriasis 9.10 6 KRT15,LCN2,S100A8,S100A9,SLPI,SPRR2A = (a)
Papilloma 7.67 5 CNFN,LCN2,S100A8,S100A9,SLPI
Psoriasis 5.89 7 (a),LCE3D
Inflammatory response of  cells 5.64 3 CD14,S100A8,S100A9
Dissemination of  cells 5.34 3 CD14,S100A9,SLPI
Phagocytosis of  bacteria 5.30 3 CD14,LCN2,S100A9
Carotid atherosclerosis 5.29 2 S100A8,S100A9
Apoptosis of  endothelial cell lines 5.07 3 S100A8,S100A9,TFRC
Immune response of  phagocytes 5.01 4 CD14,F3,LCN2,S100A9 = (b)
Response of  myeloid cells 5.00 4 (b)
Function -log(p-value) Molecules
Number of
molecules
Plaque psoriasis 5.66 4 LCN2,S100A7,SPRR2A,TXNIP = (a)
AKR1C1/AKR1C2,AKR1C3 = (b)
Reduction of  hormone 4.87 2 (b)
Proliferation of  cancer cells 4.63 4 LGALS7/LGALS7B,RCAN1,S100A7,TXNIP
Psoriasis 3.84 5 (a),LCE3D
Reduction of  lipid 3.83 2 (b)
Metastasis of  mammary tumor 3.75 2 LCN2,S100A4
Metastasis 3.63 5 (b),LCN2,S100A4,TXNIP
Apoptosis of  heart cell lines 3.59 2 LCN2,TXNIP
Chronic psoriasis 3.58 3 LCN2,S100A7,SPRR2A
MoleculesFunction -log(p-value)
25.19
Conversion of
dihydrotestosterone
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Figure 4.13: Functions with the smallest p-value after (A) 12 hour flagellin treatment (F12) and (B) F24 
treatment. The graph shows the ten functions with the most significant p-values after (A) F12 and (B) F24 
treatment. Green bars indicate functions with a z-score <-2, red bars indicate functions with a z-score >2, and grey 
bars indicate functions where no z-score was calculated. The p-value is given as –log(p-value). 
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Table 4.15: Table of most significantly affected functions after F12 treatment. 
 
Number of
molecules
(c),ADAR,ALDH1A3,CASP4,CXCL10,CXCL11,CXCL8,
DDX58,EPSTI1,GBP1,HERC6,ICAM1,IFI16,IFI35,
IFI44,IFI44L,IFIT3,IL36G,IRF7,ISG15,ISG20,LAMP3,
LCN2,LGALS3BP,MMP9,NAMPT,OAS1,OAS2,OAS3,
OASL,PARP9,PI3,PLSCR1,PSMB10,RSAD2,S100A8,
SAMD9,SCO2,SERPINB1,SERPINB2,SERPINB4,
SOD2,SPRR2A,SPRR2D,SPRR2E,STAT1,TNC,
TNFAIP6,TNIP1,TRIM22,UBE2L6
Replication of  virus 21.29 38 (a),BIRC3,MX2
ADAR,BST2,CCL5,CEACAM1,CXCL10,CXCL8,
DDX58,EIF2AK2,GBP1,IFIH1,IFIT1,IFITM1,IFITM2,
IFITM3,IRF1,IRF9,ISG15,ISG20,MMP9,MX1,OAS1,
OASL,PARP12,RSAD2,S100A8,S100A9,SP110,STAT1,
STAT2,TAP1,TNFSF10,TRIM21,TRIM25,TRIM5,
UBE2L6,ZC3HAV1 = (a)
ADAR,BIRC3,BST2,CCL5,DDX58,EIF2AK2,IFI44,
IFIH1,IFIT1,IFIT2,IRF7,ISG20,LCN2,MX1,OAS1,
OAS2,OAS3,OASL,STAT1,TRIM22,ZC3HAV1
(b),CCL20,CD68,CEACAM1,HELZ2,IFIT1,IL1RN,LAP3,
LCN2,LTB,MMP9,MX1,NAMPT,S100A8,S100A9,SAA1,
SDC4,SLFN5,TNFAIP6,TNFSF10,TRIM21,UBE2L6
CASP1,CASP4,CCL5,CFB,CXCL10,CXCL8,DDX60,
GBP4,HERC6,ICAM1,IFI16,IFI44,IFIH1,IFIT2,IFIT3,
IRF7,OAS1,PARP14,PSMB9,SAMD9L,STAT1,STAT2,
TAP1,TMEM140,XAF1 = (b)
DDX58,IFIH1,IFITM2,IFITM3,IRF1,IRF9,ISG20,
OAS1,OASL,PARP12,SP110,STAT2,TAP1,TRIM25
Replication of  Herpesviridae 15.29 13 (d),IRF9,RSAD2,STAT1,STAT2
HLA-B,IFITM2,IFITM3,IRF1,LAP3,LTB,CCL20,
DEFB4A/DEFB4B,IFI27,IFI6,IFIT1,IFITM1,MX1,
PSME2,S100A9,TYMP = (c)
ADAR,CXCL10,DDX58,IFIH1,IRF1,ISG20,MX2,
OAS1,PARP12 = (d)
15.04
20.23
2120.43
3620.44
MoleculesFunction -log(p-value)
Replication of  Murine
herpesvirus 4
Lichen planus
Replication of  vesicular
stomatitis virus
Insulin-dependent diabetes 
mellitus
Systemic autoimmune 
syndrome
Antiviral response
Replication of  RNA virus
Psoriasis
1416.05
2517.19
46
6043.09
914.76
16
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Table 4.16: Table of most significantly affected functions after F24 treatment. 
 
 
 
The ten most significantly affected functions after EP/F12 treatment are shown in Figure 4.14A. 
Of these 10 functions, only two had an associated z-score. Three out of ten functions related to 
psoriasis with ‘Psoriasis’ being the most significantly affected function for this dataset linked to 
74 differentially expressed genes within the dataset. ‘Plaque psoriasis’ and ‘Chronic psoriasis’ were 
the second and third most significantly affected functions for EP/F12, and these were linked to 
25 and 23 genes in the dataset, respectively. Once again the genes linked to the psoriasis 
functions included many of the genes highlighted as potential genes of interest due to 
potentiation of their expression after estrogen treatment. The full list of differentially expressed 
genes associated with each function after EP/F12 treatment is shown in Table 4.17. The 
remaining functions mostly related to immune responses, such as ‘Antiviral response’ and were 
linked to many interferon-induced genes. 
 
EP/F24 treatment significantly affected similar functions to EP/F12 treatment (Figure 4.14B). 
Of the ten functions with the smallest p-value after EP/F24 treatment eight functions related to 
skin diseases such as psoriasis and dermatitis, and these involved genes such as AMPs (hBD2, 
Number of
molecules
(b),CCL20,DEFB103A/DEFB103B,DEFB4A/DEFB4B,
EPSTI1,HERC6,IFI16,IFI27,IFI35,IFI44L,IFI6,IFITM1,
IL36G,IRF7,ISG15,LAMP3,LCE3D,LCN2,LGALS3BP,
OAS2,OAS3,PARP9,PLSCR1,PTGS2,RSAD2,S100A7,
SERPINB2,SOD2,SPRR2A,SPRR2C,SPRR2E,SPRR2G,
TNFAIP6,TRIM22,TYMP,
IFI6,IFITM2,IFITM3,LAP3,TYMP,CCL20,
DEFB4A/DEFB4B,HLA-B,IFI27,IFITM1,LCE3D,
LTB,MX1,S100A7,S100A9 = (a)
(c),C1R,CCL20,CCL5,CD68,CFB,DDX60L,HELZ2,
HERC6,IFI16,IRF7,LAP3,LCN2,LTB,NT5E,PSMB9,
PTGS2,SAA1,TAP1,THBS1,TNFAIP6,XAF1
BIRC3,BST2,CCL5,CXCL10,CXCL8,EIF2AK2,
IFITM1,IFITM2,IFITM3,IRF9,ISG15,MMP9,MX1,
MX2,OAS1,PARP12,RSAD2,S100A8,S100A9,SP110,
STAT1,TAP1,UBE2L6 = (b)
(a),CCL5,CXCL8,DEFB103A/DEFB103B,EIF2AK2,
LGALS3BP,PLSCR1,PTGS2,S100A8,SOD2,STAT1
BST2,CCL5,EIF2AK2,IFITM1,IFITM2,IFITM3,IRF9,
ISG15,PARP12,RSAD2,SP110,TAP1,CXCL10,CXCL8,
MMP9,MX1,OAS1,S100A8,S100A9,STAT1,UBE2L6 = (c)
(b),C1R,DDX60L,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,HLA-B,IFI35,IL32,IL36G,LCN2,
PARP9,PTGS2,SP100,TRIM22
BIRC3,BST2,CCL5,EIF2AK2,IRF7,LCN2,MX1,OAS1,
OAS2,OAS3,STAT1,TRIM22 = (d)
Antimicrobial response 11.58 14 (d),DEFB103A/DEFB103B,S100A7
CCL5,EIF2AK2,ISG15,MX1,OAS1,OAS3,PLSCR1,
PTGS2
Replication of  viral replicon 11.04 8
Hypersensitive reaction 13.50 20
Replication of  RNA virus 12.56 21
Systemic autoimmune
syndrome
15.48 30
Replication of  virus 13.92 23
Viral infection 12.08 36
Antiviral response 11.92 12
Psoriasis 36.64 43
Lichen planus 17.60 15
Function -log(p-value) Molecules
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hBD3, LCN2), inflammatory genes (interferon-induced genes and chemokines), and epithelial 
barrier genes (SPRR genes and keratins). The full list of genes associated with each function after 
EP/F24 treatment is shown in Table 4.18.  
 
Figure 4.14: Most significantly affected functions after EP/F treatment. Graph shows ten most significantly 
affected functions after (A) estrogen pretreatment plus flagellin treatment at 12 hours (EP/F12) and (B) EP/F24 
treatment. The p-values are represented by –log(p-value). Green bars indicate functions with z-scores <-2, and grey 
bars indicate functions where no z-score was calculated. 
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Table 4.17: Table of most significantly affected functions after EP/F12 treatment. 
 
Number of
molecules
(a),(b),ADAR,ALOX12B,DDX58,DEFB103A/DEFB103B,
DSG1,EGR1,EPSTI1,GBP1,HERC6,IFI16,IFI27,IFI35,
IFI44,IFI44L,IFI6,IFIT3,IGFBP3,IL36G,ISG15,KLK11,
KRTDAP,LAMP3,LCE3D,MMP9,OAS1,OAS2,OAS3,
OASL,PARP9,RSAD2,S100P,SAMD9,SERPINB2,SPRR2C,
SPRR2G,TNIP1,TRIM22,TYMP,UBE2L6
CCL20,CXCL10,CXCL8,DEFB4A/DEFB4B,GJB2,KRT1,
KRT10,KRT6C,LCN2,LOR,PI3,S100A12,S100A7,S100A8,
S100A9,SERPINB3,SERPINB4,SLPI,SPRR1A,SPRR1B,
SPRR2A,SPRR2B,SPRR2D,SPRR2E,STAT1 = (a)
DEFB4A/DEFB4B,GJB2,ID1,IFIT1,IFITM1,IRF7,KLK7,
KRT6C,LCN2,MX1,PI3,PLSCR1,S100A12,S100A7,S100A9,
SERPINB3,SERPINB4,SOD2,SPRR1B,SPRR2A,STAT1,
SULT2B1,TGM1 = (b)
ADAR,BST2,CCL5,DDX58,EIF2AK2,IFI44,IFIH1,IFIT1,
IFIT2,IRF7,LCN2,MX1,OAS1,OAS2,OAS3,OASL,
SERPINB3,STAT1,TRIM22 = (c)
CCL20,CCL5,CXCL8,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,EIF2AK2,FABP4,HLA-B,IFI27,
IFITM1,IL1RN,KLK7,KRT1,KRT10,KRT6C,LCE3D,LOR,
LTB,MX1,PI3,PLSCR1,S100A7,S100A8,S100A9,SERPINB3,
SERPINB4,SOD2,SPRR1B,STAT1
ADAR,BST2,CCL5,CXCL10,CXCL8,DDX58,EIF2AK2,
GBP1,IFIH1,IFIT1,IFITM1,IFITM2,IFITM3,IRF9,ISG15,
MMP9,MX1,OAS1,OASL,PARP12,RSAD2,S100A12,
S100A8,S100A9,SLPI,SP110,STAT1,STAT2,TAP1, TRIM21,
TRIM5,UBE2L6 = (d)
Replication of  virus 17.10 33 (d),MX2
Antimicrobial response 17.06 22 (c),DEFB103A/DEFB103B,S100A12,S100A7
CASP1,CCL20,CCL5,CFB,CXCL10,CXCL14,CXCL8,
DDX60,FABP4,GBP4,HELZ2,HERC6,IFI16,IFI44,IFIH1,
IFIT1,IFIT2,IFIT3,IL1RN,IRF7,LAP3,LCN2,LTB,MAFB,
MMP9,MX1,OAS1,PARP14,PSMB9,S100A12,S100A8,
S100A9,SAA1,SAMD9L,STAT1,STAT2,TAP1,THBS1,
TRIM21,UBE2L6,XAF1
CCL20,DEFB4A/DEFB4B,HLA-B,IFI27,IFI6,IFIT1,
IFITM1,IFITM2,IFITM3,LAP3,LCE3D,LTB,MX1,S100A7,
S100A9,TYMP
23
25
74
16
41
32
29
19
Chronic psoriasis
Plaque psoriasis
Psoriasis
15.31
16.78
17.15
17.15
17.98
21.17
27.17
63.12
Lichen planus
Systemic autoimmune
syndrome
Replication of  RNA virus
Hypersensitive reaction
Antiviral response
MoleculesFunction -log(p-value)
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Table 4.18: Table of most significantly affected functions after EP/F24 treatment. 
 
 
 
4.5.1.4 Discussion of functions 
Analysis of the downstream effects using IPA provides an insight into the functions being 
activated in cells as a response to a given treatment. Analysis of EP, F and EP/F treatment of 
VK2 cells at 12 and 24 hour time points revealed that EP treatment alone neither significantly 
activated nor inhibited any functions within the cells. Furthermore, F and EP/F treatments 
resulted in activation and inhibition of very similar functions – primarily relating to activation and 
migration of immune cells. Thus, from these data it was not possible to discern whether estrogen 
treatment prior to flagellin challenge resulted in stronger activation of the immune system and, 
therefore, enhanced protection from infections such as UTIs. F and EP/F treatment also 
significantly affected similar functions; IPA could not determine z-scores for these functions as 
the software did not have enough information available to make a reliable prediction. It was 
interesting that functions relating to psoriasis were significantly affected by all three treatments. 
The pathways and functions linked to psoriasis involved genes such as AMPs, as many AMPs 
were discovered in psoriatic patients and are often studied within this context, and genes 
involved in keratinisation. However, AMPs and other related genes are also important for 
Number of
molecules
(a),(b),ALOX12B,ARG1,CALML5,CDSN,DSC2,DSG1,
DEFB103A/DEFB103B,EPSTI1,FLG,HERC6,IFI27,IFI35,
IFI44,IFI44L,IFI6,IFIT3,IFITM1,IGFBP3,IL36G,ISG15,
KLK11,KLK7,LAMP3,LCE2B,LCE3D,LCE3E,LGALS3BP,
MMP9,MX1,OAS1,OAS2,OAS3,PARP9,PLSCR1,RSAD2,
S100P,SAMD9,SCO2,SERPINB2,SOD2,SPRR2C,SPRR2G,
TRIM22,TYMP,UBE2L6
(c),CST6,ID1,IRF7,LCN2,S100A12,SPRR2A,STAT1,
SULT2B1,TGM1,TGM3 = (a)
CCL20,CST6,CXCL10,DEFB4A/DEFB4B,KRT1,
KRT6C,LCN2,LOR,PI3,S100A12,S100A7,S100A8,S100A9,
SERPINB3,SERPINB4,SLPI,SPRR1B,SPRR2A,SPRR2B,
SPRR2D,SPRR2E,STAT1 = (b)
Hypersensitive reaction 19.02 31 (c),(d),EIF2AK2,HLA-B,
ARG1,DEFB4A/DEFB4B,IFITM1,KLK7,KRT6C,
LGALS3BP,MX1,PI3,PLSCR1,S100A7,S100A9,SERPINB3,
SERPINB4,SOD2,SPRR1B = (c)
CALML5,CCL20,DEFB4A/DEFB4B,HLA-B,IFI27,IFI6,
IFITM1,IFITM2,IFITM3,LAP3,LCE3D,MX1,S100A7,
S100A9,TYMP
Dermatitis 13.85 27 (d),DSC1,EIK2AK2,IRF9,PRDM1,SERPINB4,SLPI,THBS1
CCL20,CCL5,CST6,DEFB103A/DEFB103B,
DEFB4A/DEFB4B,FABP4,FLG,IFI27,KLK7,KRT1,
LCE3D,LOR,MX1,NFKBIZ,S100A7,S100A8,S100A9,
SERPINB3,STAT1,TGM3 = (d)
BIRC3,BST2,CCL5,EIF2AK2,IFI44,IRF7,LCN2,MX1,OAS1,
OAS2,OAS3,SERPINB3,STAT1,TRIM22 = (e)
Antimicrobial response 11.30 17 (e),DEFB103A/DEFB103B,S100A12,S100A7
2011.53
1411.38
-log(p-value) Molecules
Lichen planus
Atopic dermatitis
Antiviral response
7361.15
2523.80
2222.46
1515.98
1513.86
Psoriasis
Chronic psoriasis
Plaque psoriasis
Delayed hypersensitive
reaction
Function
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elimination of bacterial pathogens and, as previously discussed, keratinisation of cells prevents 
pathogen invasion. Therefore upregulation of psoriasis-related genes after exposure of VK2 cells 
to flagellin was perhaps not surprising. After 12 hours EP, F and EP/F treatments resulted in 
differential regulation of 6, 60, and 74 genes linked to the ‘Psoriasis’, respectively. Other than one 
gene (KRT15) downregulated by EP12, all of the genes linked to ‘Psoriasis’ were significantly 
upregulated. Thus, the increased number of upregulated genes linked to psoriasis after EP/F12 
treatment, compared to F12 treatment, was suggestive of EP/F12 treatment increasing the 
antimicrobial response of VK2 cells to infection. A similar pattern was observed for the 24 hour 
time point, with EP24, F24 and EP/F24 treatments resulting in upregulation of 4, 43 and 73 
genes linked to the function ‘Psoriasis’, further supporting this theory. 
 
4.5.2 Canonical pathways 
In comparison to the downstream effects analysis which predicts functions that are activated and 
inhibited downstream of the genes within a dataset, canonical pathway analysis determines 
potential pathways upstream of the differentially expressed genes within a given dataset and 
reveals interactions between genes. Canonical pathways are different to predicted functions; data 
relating to predicted functions in IPA is regularly updated whereas canonical pathways are more 
stable and represent well established pathways in the literature. IPA analyses which canonical 
pathways are overrepresented in a given dataset by calculating a ratio and –log(p-value). The ratio 
is the number of genes from a specific canonical pathway that are significantly affected in a 
dataset and is calculated as follows: 
 
𝑅𝑎𝑡𝑖𝑜 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑒𝑛𝑒𝑠 𝑓𝑟𝑜𝑚 𝑑𝑎𝑡𝑎𝑠𝑒𝑡 𝑖𝑛 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑝𝑎𝑡ℎ𝑤𝑎𝑦 𝑡ℎ𝑎𝑡 𝑚𝑒𝑒𝑡 𝑡ℎ𝑒 𝑐𝑢𝑡𝑜𝑓𝑓 𝑐𝑟𝑖𝑡𝑒𝑟𝑖𝑎
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑒𝑛𝑒𝑠 𝑡ℎ𝑎𝑡 𝑚𝑎𝑘𝑒 𝑢𝑝 𝑡ℎ𝑒 𝑝𝑎𝑡ℎ𝑤𝑎𝑦 𝑎𝑛𝑑 𝑎𝑟𝑒 𝑖𝑛 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒 𝑠𝑒𝑡
 
 
Thus, a higher ratio indicates that more genes within the pathway are significantly upregulated. 
The reference gene set for this analysis was the genes included on the Illumina HumanHT-12 v4 
Expression Beadchip. 
 
The top 10 canonical pathways after EP12 treatment are shown in Figure 4.15. The grey bars 
represent the ratio and the orange line shows the –log(p-value) for each canonical pathway. The 
pathway with the highest ratio after EP12 treatment was ‘Role of IL-17A in Psoriasis’ with a ratio 
of 0.154. There were two other pathways relating to IL-17A in the top ten canonical pathways 
after EP12 treatment, these were ‘Differential Regulation of Cytokine Production in Intestinal 
Epithelial Cells by IL-17A and IL-17F’ and ‘IL-17A Signalling in Fibroblasts’. EP12 treatment 
also resulted in several pathways related to innate immunity, such as ‘MIF Regulation of Innate 
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Immunity’ and ‘MIF-mediated Glucocorticoid Regulation’. Both of these pathways involve 
activation of NF-ĸB and result in production of cytokines. The ‘iNOS Signalling’ pathway is also 
related to innate immunity and results in production of nitric oxide, which inhibits bacterial DNA 
replication. The pathways ‘Extrinsic Prothrombin Activation Pathway’ and ‘Coagulation System’ 
are activated by tissue damage and result in secretion of coagulation factors to form a clot and 
repair the tissue. All ten of the top upregulated pathways by EP12 treatment shown in Figure 
4.15 have a significant p-value (p<0.05 or –log(p-value)>1.30). The genes associated with each 
pathway that were upregulated after EP12 treatment are shown in Table 4.19. Similar pathways 
were upregulated after EP24 treatment and are shown in Table 4.20.  
 
Figure 4.15: Top ten canonical pathways after EP12 treatment. The graph shows the ten canonical pathways 
with the highest ratio after estrogen pretreatment at 12 hours (EP12), as calculated by Ingenuity Pathway Analysis. 
Grey bars represent the ratio of each pathway, and orange symbols represent the –log(p-value) which must be >1.30 
to be equivalent to a p-value of <0.05. Significance cut off for the –log(p-value) is shown as a dotted orange line. 
 
Table 4.19: Canonical pathways after EP12 treatment. 
 
 
Number of
molecules
Role of  IL-17A in Psoriasis 0.1540 4.18 2 S100A9,S100A8
Extrinsic Prothrombin Activation Pathway 0.0625 1.82 1 F3
Differential Regulation of  Cytokine Production 
in Intestinal Epithelial Cells by IL-17A and IL-17F
MIF-mediated Glucocorticoid Regulation 0.0312 1.52 1 CD14
Coagulation System 0.0286 1.48 1 F3
IL-17A Signaling in Fibroblasts 0.0286 1.48 1 LCN2
MIF Regulation of  Innate Immunity 0.0250 1.43 1 CD14
iNOS Signaling 0.0233 1.40 1 CD14
Atherosclerosis Signaling 0.0168 2.25 2 S100A8,F3
LXR/RXR Activation 0.0165 2.24 2 CD14,S100A8
Function Ratio Molecules
LCN2
-log(p-value)
11.660.0435
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Table 4.20: Canonical pathways after EP24 treatment. 
 
 
 
The top 10 canonical pathways after F12 treatment are shown in Figure 4.16A. The most 
upregulated pathway after F12 treatment was ‘Interferon Signalling’. This pathway is activated by 
interferons binding to cell surface receptors, initiating transcription of interferon regulated genes, 
and therefore stimulating an immune response. The ‘Activation of IRF by Cytosolic Pattern 
Recognition Receptors’ pathway is similar to the ‘Interferon Signalling’ pathway, as it results in 
activation of the interferon regulatory factor (IRF) transcription factor in the cell in response to 
double-stranded RNA or DNA of viral/bacterial origin. Activation of IRF causes transcription of 
interferon-stimulated genes (ISGs), which generates an innate immune response. The ‘Role of IL-
17A in Psoriasis’ pathway was once again upregulated with a ratio of 0.385 (compared to 0.154 
after EP12 treatment). This pathway involves binding of IL-17 to the IL-17 receptor, which 
activates transcription of AMPs (including hBD2 and S100A7) and chemokines, which are 
immune cell attractants. The genes associated with each of the canonical pathways that were 
upregulated after F12 treatment are shown in Table 4.21. All of the pathways in Figure 4.16A 
have significant p-values, except for ‘Superoxide Radicals Degradation’, which had a –log(p-
value) of 1.27, equating to a p-value of 0.053 (3dp) (shown in Table 4.21). 
 
The top 10 canonical pathways after EP/F12 treatment are shown in Figure 4.16B. The pathway 
with the highest ratio after EP/F12 treatment was ‘Role of IL-17A in Psoriasis’ with a ratio of 
0.462. This pathway was also activated by EP12 and F12 treatment, with ratios of 0.154 and 
0.385, respectively. Thus, a larger number of genes in this pathway were significantly upregulated 
after EP/F12 treatment than after EP12 or F12 treatment. Two other pathways relating to IL-17 
appeared in the top ten after EP/F12 treatment and these were ‘Differential Regulation of 
Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F’ and ‘IL-17A Signalling 
in Gastric Cells’. All three of these pathways involve IL-17A binding to the IL-17 receptor and 
cause transcription of immune related genes and inflammatory mediators, such as cytokines, 
chemokines and AMPs. Other immune related pathways were also upregulated, such as 
Number of
molecules
Methylglyoxal Degradation III 0.2000 4.54 2 AKR1C1/AKR1C2,AKR1C3
Bile Acid Biosynthesis, Neutral Pathway 0.1540 4.30 2 AKR1C1/AKR1C2,AKR1C3
Androgen Biosynthesis 0.0833 2.00 1 AKR1C3
Role of  IL-17A in Psoriasis 0.0769 1.97 1 S100A7
Differential Regulation of  Cytokine Production 
in Intestinal Epithelial Cells by IL-17A and IL-17F
Retinoate Biosynthesis I 0.0333 1.61 1 AKR1C3
MIF-mediated Glucocorticoid Regulation 0.0312 1.58 1 CD14
IL-17A Signaling in Fibroblasts 0.0286 1.54 1 LCN2
Estrogen Biosynthesis 0.0278 1.53 1 AKR1C3
MIF Regulation of  Innate Immunity 0.0250 1.48 1 CD14
MoleculesRatioFunction -log(p-value)
0.0435 1.72 1 LCN2
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‘Interferon Signalling’, ‘Activation of IRF by Cytosolic Pattern Recognition Receptors’ and 
‘Antigen Presentation Pathway’. The genes associated with the canonical pathways that were 
upregulated after EP/F12 treatment are shown in Table 4.23. The ‘Superoxide Radicals 
Degradation’ and ‘Salvage Pathways of Pyrimidine Deoxyribonucleotides’ pathways had –log(p-
values) of 1.29 and 1.17, respectively (equating to p-values of 0.051 and 0.067) which did not pass 
the significance threshold. All of the remaining pathways had significant p-values (shown in 
Table 4.23).  
 
The canonical pathways upregulated after F24 and EP/F24 treatments are shown in Table 4.22 
and Table 4.24, respectively, and were similar to that of the 12 hour time point with upregulation 
of interferon and IL-17 related pathways. 
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Figure 4.16: Top ten canonical pathways after F12 and EP/F12 treatments. The graphs show the top ten 
canonical pathways by ratio after (A) 12 hours flagellin treatment (F12) and (B) estrogen pretreatment plus flagellin 
treatment at 12 hours (EP/F12). The grey bars represent the ratio for each pathway and the orange symbols 
represent the –log(p-value). The significance cut off of 1.30 for the –log(p-value) is shown with a dotted orange line.   
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Table 4.21: Table of canonical pathways upregulated after F12 treatment. 
 
 
 
Table 4.22: Table of canonical pathways upregulated after F24 treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of
molecules
IFIT3,OAS1,MX1,IFI35,IRF9,PSMB8,
TAP1,IFITM2,IRF1,IFIT1,IFITM3,
STAT2,STAT1,IFITM1
CXCL8,S100A9,CCL20,S100A8,
DEFB4A/DEFB4B
Pathogenesis of  Multiple Sclerosis 0.3330 4.22 3 CXCL10,CXCL11,CCL5
1,25-dihydroxyvitamin D3 Biosynthesis 0.3330 1.56 1 CYP27B1
Airway Pathology in Chronic Obstructive 
Pulmonary Disease
NAD Biosynthesis III 0.2500 1.44 1 NAMPT
IL-17A Signaling in Gastric Cells 0.2000 5.56 5 CXCL10,CXCL8,CXCL11,CCL20,CCL5
Activation of  IRF by Cytosolic Pattern DHX58,IFIH1,IRF7,DDX58,STAT2,
Recognition Receptors IRF9,STAT1,ADAR,IFIT2,ISG15
Superoxide Radicals Degradation 0.1670 1.27 1 SOD2
Bile Acid Biosynthesis, Neutral Pathway 0.1540 2.22 2 AKR1C1/AKR1C2,AKR1C4
-log(p-value)RatioFunction Molecules
Interferon Signaling
Role of  IL-17A in Psoriasis
19.70 140.4120
57.130.3850
0.2500 22.65 CXCL8,MMP9
109.800.1670
Number of
molecules
S100A7,CXCL8,S100A9,CCL20,S100A8,
DEFB4A/DEFB4B
Glutathione Redox Reactions II 0.3330 1.82 1 TXNDC12
IFITM3,OAS1,MX1,IFI35,IRF9,STAT1,
TAP1,IFITM2,IFITM1
Airway Pathology in Chronic Obstructive
Pulmonary Disease
Pathogenesis of  Multiple Sclerosis 0.2220 3.04 2 CXCL10,CCL5
Differential Regulation of  Cytokine Production DEFB103A/DEFB103B,LCN2,CCL5,
in Intestinal Epithelial Cells by IL-17A and IL-17F DEFB4A/DEFB4B
Superoxide Radicals Degradation 0.1670 1.52 1 SOD2
IL-17A Signaling in Gastric Cells 0.1600 5.13 4 CXCL10,CXCL8,CCL20,CCL5
Salvage Pathways of  Pyrimidine 
Deoxyribonucleotides
Prostanoid Biosynthesis 0.1110 1.35 1 PTGS2
4
1
Molecules
9
2 CXCL8,MMP9
Interferon Signaling
-log(p-value)RatioFunction
Role of  IL-17A in Psoriasis
13.100.2650
3.150.2500
5.280.1740
1.400.1250
610.600.4620
TYMP
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Table 4.23: Table of canonical pathways upregulated after EP/F12 treatments. 
 
 
 
Table 4.24: Table of canonical pathways upregulated after EP/F24 treatments. 
 
 
 
The ‘Role of IL-17A in Psoriasis’ pathway diagram in Figure 4.17 shows the molecules involved 
with this pathway. Red shading of a molecule indicates upregulation in the dataset and the 
intensity of the colour indicates the degree of fold change in gene expression. The pathway shows 
IL-17A acting upon the IL-17 receptor, which is made up of IL-17RA and IL-17RC subunits, 
and causing transcription of genes involved in either an antimicrobial response, such as hBD2, or 
genes involved in psoriasis, such as CCL20. After EP12 treatment S100A8 and S100A9 are the 
only molecules in this pathway that were upregulated, by 2.03 and 2.13-fold respectively (Figure 
4.17A). However, after F12 treatment S100A8/9 were upregulated but hBD2, CCL20 and IL-8 
were also upregulated (Figure 4.17B). After EP/F12 treatment these molecules and S100A7 were 
all upregulated (Figure 4.17C). Furthermore, as shown in Figure 4.5 in section 4.3 the expression 
of genes S100A7, S100A8, S100A9, and hBD2 was higher with EP/F treatment than just F 
treatment and this is reflected in Figure 4.17 by more intense colouring on the pathway. Thus, the 
Number of
molecules
S100A7,CXCL8,S100A9,CCL20,S100A8,
DEFB4A/DEFB4B
IFITM3,IFIT1,IFIT3,OAS1,MX1,STAT2,
IRF9,IFI35,PSMB8,STAT1,IFITM2,TAP1,
IFITM1
Airway Pathology in Chronic Obstructive
Pulmonary Disease
Pathogenesis of  Multiple Sclerosis 0.2220 2.57 2 CXCL10,CCL5
Differential Regulation of  Cytokine Production DEFB103A/DEFB103B,LCN2,CCL5,
in Intestinal Epithelial Cells by IL-17A and IL-17F DEFB4A/DEFB4B
Superoxide Radicals Degradation 0.1670 1.29 1 SOD2
IL-17A Signaling in Gastric Cells 0.1600 4.20 4 CXCL10,CXCL8,CCL20,CCL5
Activation of  IRF by Cytosolic Pattern IFIH1,IRF7,DDX58,STAT2,IRF9,STAT1,
Recognition Receptors ADAR,IFIT2,ISG15
Antigen Presentation Pathway 0.1390 4.82 5 PSMB9,HLA-B,PSMB8,HLA-F,TAP1
Salvage Pathways of  Pyrimidine
Deoxyribonucleotides
-log(p-value)Function Ratio Molecules
2.680.2500
TYMP
CXCL8,MMP9
11.170.1250
98.600.1500
44.350.1740
2
Interferon Signaling 0.3820 18.10 13
69.160.4620Role of  IL-17A in Psoriasis
Number of
molecules
S100A7,S100A9,CCL20,S100A8,
DEFB4B/DEFB4B
Ascorbate Recycling (Cytosolic) 0.3330 1.58 1 GLRX
Glutathione Redox Reactions II 0.3330 1.58 1 GLRX
IFIT3,IFITM3,OAS1,MX1,IFI35,STAT2,
IRF9,STAT1,TAP1,IFITM2,IFITM1
Arginine Degradation I (Arginase Pathway) 0.2500 1.45 1 ARG1
Pathogenesis of  Multiple Sclerosis 0.2220 2.56 2 CXCL10,CCL5
Differential Regulation of  Cytokine Production DEFB103A/DEFB103B,LCN2,CCL5,
in Intestinal Epithelial Cells by IL-17A and IL-17F DEFB4A/DEFB4B
Urea Cycle 0.1670 1.28 1 ARG1
Arginine Degradation VI (Arginase 2 Pathway) 0.1670 1.28 1 ARG1
Superoxide Radicals Degradation 0.1670 1.28 1 SOD2
RatioFunction -log(p-value) Molecules
Interferon Signaling
Role of  IL-17A in Psoriasis
44.320.1740
1114.300.3240
57.190.3850
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‘Role of IL-17A in Psoriasis’ canonical pathway was on the whole more upregulated with EP/F 
treatment than with EP or F treatment separately.  
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Figure 4.17: ‘Role of IL-17A in Psoriasis’ pathway diagram. The data from (A) Estrogen pretreatment at 12 
hours, EP12, (B) Flagellin treatment after 12 hours, F12, and (C) Estrogen pretreatment plus flagellin after 12 hours, 
EP/F12, is overlaid on the pathway diagram for the ‘Role of IL-17A in Psoriasis’ pathway, using Ingenuity Pathway 
Analysis. The intensity of the red colouring indicates the degree of upregulation. 
 
4.5.2.1 Discussion of canonical pathways 
IPA was used to analyse the six microarray datasets for canonical pathways that were 
overrepresented after each treatment. Canonical pathways associated with interferon production 
and signalling were upregulated after F and EP/F treatments. However, perhaps more notable, 
all three treatments resulted in upregulation of multiple pathways associated with IL-17. The 
‘Role of IL-17A in Psoriasis’ pathway was overrepresented in every dataset indicating that after 
EP, F and EP/F treatments at both the 12 and 24 hour time points genes from this pathway 
were significantly upregulated. In the case of psoriasis, activation of this pathway resulting in 
expression of chemokines that attract immune cells aggravates the condition by promoting influx 
of proinflammatory cytokine-producing immune cells to the psoriatic lesion, driving 
inflammation. However, in the case of an infection, such as a UTI, activation of this pathway 
may stimulate both an innate (AMP) immune response and an adaptive immune response. Thus, 
it is possible that increased activation of this pathway may improve bacterial clearance from the 
133 
 
site of infection. However, IL-17 is not produced by epithelial cells, and hence, expression of this 
gene in VK2 cells was not detected by the microarray. IL-17 is mainly produced by Th17 cells. 
Th17 cells are recruited to sites of infection by secretion of the chemokine CCL20, which was 
significantly upregulated by F12 and EP/F12 treatment277,278. The expression of IL-36G, a 
proinflammatory cytokine identified as a potential gene of interest, was also potentiated by EP/F 
treatment and has been shown to stimulate IL-17 production from CD4+ T cells237. Thus, 
increased IL-36G expression following estrogen pretreatment may result in increased IL-17 
secretion from CD4+ T cells at the site of infection. Furthermore, the downstream functions 
analyses indicated that immune cell migration was activated in all datasets. Even though IL-17 
was not present in the VK2 cell model, the genes downstream of this cytokine show 
upregulation. Consequently, it is possible to hypothesise that addition of IL-17 to VK2 cells 
would further increase the expression of the AMPs, cytokines, and chemokines in this pathway. 
Furthermore, addition of IL-17 to the VK2 cells would more accurately model the cytokine 
environment that vaginal epithelial cells are exposed to during infection, as IL-17 secreting Th17 
cells would likely be recruited to the site of infection by CCL20. 
 
4.5.3 Upstream regulator analysis 
Upstream regulator analysis identifies molecules, such as transcription factors, that are upstream 
of the genes in a given dataset and may be responsible for the observed gene expression changes. 
IPA uses the gene expression data to predict which upstream regulators are activated or inhibited 
in a dataset. For example, if it is reported in the literature that a set of genes are transcribed by a 
particular transcription factor, and these genes are upregulated in a given dataset, IPA predicts 
that the upstream regulator is active. However, if the gene expression mostly contradicts the 
literature IPA predicts that the upstream regulator is inhibited. If the gene expression data do not 
follow a clear pattern with the literature a prediction of the upstream regulator activity cannot be 
made. Following identification of important upstream regulators, IPA also identifies mechanistic 
networks; these are used to determine which, if any, transcription factors are working together to 
regulate the genes within a dataset. 
 
The upstream regulators and mechanistic networks were analysed for each dataset. After EP12 
treatment only one transcription factor was predicted to be activated by IPA and this was E26 
transformation-specific (ETS) homologous factor (EHF) with an activation z-score of 2.00. This 
transcription factor belongs to the family of ETS transcription factors that possess a conserved 
DNA binding domain, the ETS domain279. No mechanistic network was predicted for this 
transcription factor. Four genes from the EP12 dataset were predicted to be downstream of this 
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transcription factor and these were cornifelin (CNFN), S100A8, S100A9 and SPRR2A. EHF is a 
member of the epithelial specific expression (ESE) family of transcription factors and is reported 
to have roles epithelial cell differentiation and barrier function280,281. Therefore, this transcription 
factor may be involved in the keratinisation process of vaginal epithelial cells in response to 
estrogen treatment identified by downstream functional analysis.  
 
After F12 treatment 17 transcription factors were predicted to be upregulated (see Table 4.25) by 
IPA. Interferon regulatory factor 3 (IRF3) had the highest activation z-score (5.715) suggesting 
this was the most activated transcription factor for this dataset. IRF1, 5 and 7 were also predicted 
to be activated, with z-scores of 3.071, 4.383 and 5.381, respectively. These transcription factors 
are involved in transcription of interferon-induced genes and were upstream of several genes, 
such as IFIT3 and OAS1, involved in the ‘Interferon Signalling’ canonical pathway discussed 
previously. Three of the 17 transcription factors that were predicted to be activated after F12 
treatment also had increased gene expression in the dataset compared to controls (see Table 
4.25). These three transcription factors are IRF1, IRF7 and signal transducer and activator of 
transcription 1 (STAT1). Transcriptional upregulation of these transcription factors further 
indicated a role for these transcription factors after flagellin treatment.  
 
Table 4.25: Table of activated upstream regulators after flagellin treatment at 12 hours. The mechanistic 
network is shown as: number of target genes in network (number of transcription factors in network). 
 
 
 
Observation of the mechanistic networks associated with the transcription factors revealed that 
many of the mechanistic networks are in fact highly similar, and only differ by perhaps one or 
two transcription factors. For example, the IRF3, STAT1, tumour protein P53 (TP53) and V-rel 
avian reticuloendotheliosis viral oncogene homolog A (RELA) mechanistic networks, shown in 
Upstream Regulator Fold Change Predicted Activation State Activation z-score Mechanistic Network
IRF3 Activated 5.715 73 (8)
IRF7 7.41 Activated 5.381 61 (8)
STAT1 11.48 Activated 4.985 87 (16)
IRF5 Activated 4.383 47 (5)
NFATC2 Activated 3.606 65 (7)
RELA Activated 3.522 86 (16)
TP53 Activated 3.273 89 (19)
STAT3 Activated 3.075 75 (15)
IRF1 2.17 Activated 3.071 19 (2)
EZH2 Activated 2.926
EHF Activated 2.714
PPRC1 Activated 2.598
JUN Activated 2.491 45 (11)
SMARCB1 Activated 2.449
FOXO1 Activated 2.408 55 (9)
FOXO3 Activated 2.333 61 (11)
CTNNB1 Activated 2.000 11 (2)
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Figure 4.18, share many common transcription factors, such as STAT1, STAT3, NF-ĸB 
(complex) and forkhead box O1 (FOXO1), and result in transcription of similar groups of genes.  
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Figure 4.18: Examples of mechanistic networks after flagellin treatment for 12 hours.
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The transcription factor STAT1 was present in many of the mechanistic networks and was 
upregulated 11.48-fold after F12 treatment indicating that this was potentially a crucial 
transcription factor in VK2 cell response to flagellin challenge. The STAT1 mechanistic network 
after F12 treatment consisted of 16 transcription factors working together to upregulate 87 genes. 
These genes included interferon-induced genes, cytokines, chemokines and AMPs. The full list of 
genes downstream of the STAT1 mechanistic network after F12 treatment is shown in Table 
4.26.  
 
Table 4.26: Genes downstream of the STAT1 mechanistic network after flagellin treatment at 12 hours. 
 
 
The EHF transcription factor was also predicted to be activated for the F12 dataset with a z-
score of 2.714, compared to a z-score of 2.000 after EP12 treatment. Furthermore, after F12 
treatment 11 upregulated genes from the dataset were predicted to be downstream of the EHF 
transcription factor, when only four genes downstream of this transcription factor were 
upregulated after EP12 treatment. 
 
Upstream analysis of the EP/F12 revealed that IPA predicted activation of 20 transcription 
factors (see Table 4.27). IRF3 was once again the transcription factor with the highest z-score 
(5.355), and similar transcription factors were predicted to be activated for both F12 and EP/F12 
treatments (see Figure 4.19A). Furthermore, most of the transcription factors exhibited similar z-
scores after both F12 and EP/F12 treatments. EP/F12 treatment resulted in the predicted 
activation of four transcription factors that were not predicted to be activated after F12 
treatment; these were V-myc avian myelocytomatosis viral oncogene homolog (MYC), nuclear 
receptor coactivator 2 (NCOA2), STAT2 and CEBPB. 
 
Gene Fold Change Gene Fold Change Gene Fold Change Gene Fold Change
ALDH1A3 2.08 IFI27 16.47 LGALS3BP 2.13 SDC4 2.34
BIRC3 2.77 IFI35 6.84 LTB 10.91 SERPINA3 8.67
CASP1 2.30 IFI44 4.03 MARCKSL1 3.47 SERPINB2 2.80
CASP4 2.04 IFI44L 15.81 MMP9 3.72 SERPINB4 2.92
CCL20 2.68 IFI6 14.36 MX1 16.02 SERPINE2 2.28
CCL5 9.61 IFIH1 5.09 MX2 24.78 SLC15A3 5.56
CEACAM1 2.07 IFIT1 7.00 NAMPT 2.07 SLFN5 2.56
CFB 7.63 IFIT2 5.34 OAS1 17.20 SOD2 8.06
CMPK2 2.35 IFIT3 13.45 OAS2 14.99 SP100 2.70
CXCL10 41.73 IFIT5 2.34 OAS3 5.85 SP110 8.78
CXCL11 2.32 IFITM1 14.02 OASL 4.79 STAT1 11.48
CXCL8 3.59 IFITM2 3.19 PI3 2.05 STAT2 4.81
DDX58 4.66 IFITM3 3.50 PLSCR1 5.27 TAP1 5.37
DEFB4A/DEFB4B 2.35 IL1RN 2.66 PSMB10 2.23 TNFSF10 3.98
EIF2AK2 3.11 IL32 2.39 PSMB8 3.43 TNIP1 3.56
GBP1 8.84 IRF1 2.17 PSMB9 2.72 TRIM22 8.78
GBP4 4.03 IRF7 7.41 PSME2 2.10 TYMP 5.26
HERC6 3.13 IRF9 3.21 RSAD2 8.71 USP18 5.43
HLA-B 4.16 ISG15 4.89 S100A8 2.24 VEGFC 2.14
HLA-F 3.22 ISG20 3.40 S100A9 2.53 WARS 2.49
ICAM1 2.41 LAMP3 7.48 SAA1 3.65 XAF1 6.19
IFI16 2.71 LCN2 6.38 SAMD9 4.16
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Table 4.27: Table of transcription factors predicted to be activated after estrogen pretreatment plus flagellin 
treatment at 12 hours. The mechanistic network is shown as: number of target genes in network (number of 
transcription factors in network). 
 
 
Upstream Regulator Fold Change Predicted Activation State Activation z-score Mechanistic Network
IRF3 Activated 5.355 69 (10)
IRF7 5.47 Activated 4.902 54 (8)
EHF Activated 4.000
IRF5 Activated 3.918
STAT1 7.90 Activated 3.861 78 (15)
STAT3 Activated 3.339 65 (15)
NFATC2 Activated 3.162 42 (4)
RELA Activated 2.936 76 (16)
TP53 Activated 2.866 82 (21)
IRF1 Activated 2.742 30 (3)
SMARCB1 Activated 2.611  
PPRC1 Activated 2.598
MYC Activated 2.577
JUN Activated 2.397 50 (9)
FOXO1 Activated 2.395 42 (7)
NCOA2 Activated 2.383 63 (11)
EZH2 Activated 2.359 19 (3)
FOXO3 Activated 2.317 33 (8)
STAT2 3.31 Activated 2.234 52 (5)
CEBPB Activated 2.159 45 (7)
139 
 
 
 
Figure 4.19: Comparison of transcription factors predicted to be activated after estrogen pretreatment, 
flagellin, and estrogen pretreatment plus flagellin treatments. (A) transcription factors predicted to be activated 
after 12 hours and (B) transcription factors predicted to be activated after 24 hours. 
 
The transcription factor EHF was predicted to be most active after EP/F12 treatment with a z-
score of 4.000, compared to 2.714 after F12 treatment and 2.000 after EP12 treatment. 
Furthermore, after EP/F12 16 upregulated genes in this dataset were downstream of this 
transcription factor. These genes are mostly related to keratinisation and cell differentiation, such 
CNFN, S100 proteins and SPRR genes. The fold change in gene expression for these 16 genes 
and the genes downstream of EHF that were upregulated after EP12 and F12 treatments are 
shown in Table 4.28. 
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Table 4.28: Table of genes downstream of the EHF transcription factor that are upregulated after estrogen 
pretreatment (EP12), flagellin (F12), and estrogen pretreatment plus flagellin (EP/F12) at 12 hours. 
 
 
 
Analysis of the 24 hour datasets showed similar transcription factors were predicted to be 
activated to those of the 12 hour datasets (Figure 4.19B). After EP/F24 treatment there were five 
transcription factors that were predicted to be activated that were not predicted to be activated 
for F24 treatment. These were TP53, MYC, SYR box 2 (SOX2), Y-box binding protein 1 
(YBX1), and Kruppel-like factor 4 (KLF4). Altogether, there were eight transcription factors that 
were predicted to be activated by EP/F treatment at either the 12 or 24 hour time point that 
were not predicted to be activated by F treatment at the same time point. These were CEBPB, 
KLF4, MYC, NCOA2, SOX2, STAT2, TP53 and YBX1. The upregulated genes downstream of 
these transcription factors at each time point are shown in Table 4.29. Of note, from the genes of 
interest identified by Venn diagram analysis, DEFB4A, LCN2 and SLPI were identified 
downstream of YBX1, CEBPB and KLF4, respectively. Thus, increased activation of these 
transcription factors following EP/F treatment may result in increased transcription of these 
AMPs.  
 
Gene Symbol EP12 F12 EP/12
CCL20 2.68 2.54
CNFN 2.04 5.90
IL1RN 2.66 2.32
KLK7 2.02
S100A7 5.07
S100A8 2.03 2.24 3.39
S100A9 2.13 2.53 5.86
S100A12 2.69
SAA1 3.65 2.25
SERPINA3 8.67 8.92
SPRR1B 2.38
SPRR2A 2.06 3.95 14.74
SPRR2D 2.09 5.73
SPRR2E 3.14 13.54
SPRR2G 7.27
SPRR3 2.11
TNC 2.41
VEGFC 2.14
Fold Change
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Table 4.29: Genes downstream of transcription factors upregulated after EP/F treatment but not F 
treatment. 
 
 
4.5.3.1 Discussion of upstream regulator analysis 
Analysis of upstream regulators using IPA is utilised to predict which transcription factors may 
be activated depending on which genes are differentially expressed in a dataset. The activation 
state and associated z-score of a transcription factor is determined based upon known 
relationships in the literature. A transcription factor is predicted as being activated if it has a z-
score above +2. This type of analysis is useful as transcription factors may be highly activated in a 
sample but not show increased expression, as many transcription factors are activated by 
phosphorylation events, or by dissociation from an inhibitor. Therefore, the expression values of 
transcription factors are not sufficient to determine the activation state. 
The six microarray datasets were analysed in this way to examine whether particular transcription 
factors may be responsible for the observed potentiation of the expression of certain genes with 
estrogen pretreatment before flagellin challenge in VK2 cells.  
The analysis revealed that the EHF transcription factor is predicted to be activated after all three 
treatments. Furthermore, EHF is predicted to be most active following EP/F treatment. This 
transcription factor is upstream of several of the potential genes of interest. Increased activation 
of this transcription factor after EP/F12 treatment, compared to F12 treatment, may explain the 
substantial gene expression potentiation of genes such as the SPRR genes after EP/F12 
treatment (shown in section 4.3 in the Venn diagram analysis), as these genes are downstream of 
EHF. Thus, estrogen pretreatment prior to flagellin challenge may result in increased 
keratinisation and a strengthened epithelial barrier to infection through activation of this 
transcription factor, resulting in transcription of genes crucial to this process. Other transcription 
Transcription
factor
CEBPB ARG1,CCL5,FABP4,IGFBP3,IRF9,LCN2,SBSN,
SERPINB2
KLF4 ASPRV1,CNFN,CST6,LOR,PRDM1,SERPINB2,SLPI,SPRR3,TGM1,USP18
MYC (a),CASP1,EGR1,GBP4,IFI16,SPRR1A ARG1,ASPRV1,CST6,PRDM1,CNFN,FABP4,LOR,MMP9,PLSCR1,SPRR3,
TGM1,THBS1,USP18 = (a)
NCOA2 CCL5,CXCL10,EGR1,FABP4,IFIT2,ISG15,OASL
SOX2 ASPRV1,CNFN,CST6,HOPX,LOR,PRDM1,SPRR3,TGM1,USP18
STAT2 CCL5,GBP1,IFI27,IFI6,IFIT2,IFIT3,IFITM1,IRF7,
IRF9,ISG15,MX1,OAS1,OAS2,RSAD2
TP53 (b),CASP1,CXCL8,GBP1,IFI16,TSC22D3,ZC3H12A BIRC3,GLRX,PRDM1,SCO2,FABP4,ID1,IFI35,IGFBP3,IRF7,IRF9,ISG15,
MAFB,MMP9,OAS1,SERPINA3,SOD2,STAT1,TAP1,THBS1,TRIM22 = (b)
YBX1 CCL5,CXCL2,DEFB4A/DEFB4B,ID1,IGFBP3
12 hour downstream genes 24 hour downstream genes
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factors in the ETS family have been shown to be activated by hormones such as gonadotropin-
releasing hormone via a MAP kinase pathway. Binding of estrogen to GPER results in MAP 
kinase activation. This reveals a potential pathway of estrogen regulation of EHF and therefore, 
keratinisation and differentiation in VK2 cells. 
Similar transcription factors were predicted to be upregulated after both F12 and EP/F12 
treatments, and many of these transcription factors had similar z-scores, for example IRF3, 
STAT1 and RELA. Thus, it was difficult to determine from this analysis alone which 
transcription factors were involved in the potentiation of the expression of the AMPs identified 
by Venn diagram analysis following estrogen treatment. There were eight transcription factors 
that were predicted to be activated by EP/F treatment at either 12 or 24 hours that were not 
predicted to be activated by F treatment at the same time point. These were CEBPB, KLF4, 
MYC, NCOA2, SOX2, STAT2, TP53 and YBX1. KLF4, SOX2 and TP53 were identified as 
being upstream of genes mostly involved in keratinisation, such as CNFN and SPRR genes, and 
therefore may activate the keratinisation response alongside the EHF transcription factor. The 
AMP SLPI was also identified as being downstream of the transcription factor KLF4. CEBPB 
was identified as being upstream of genes involved in both keratinisation and inflammation, and 
the AMP LCN2. STAT2 and YBX1 were predicted to be upstream of genes that were mostly 
chemokines or interferon-induced genes. However, YBX1 was predicted to be upstream of 
hBD2, suggesting that activation of this transcription factor may be responsible for the observed 
increase in gene expression of hBD2 after EP/F treatment. NCOA2 is a transcription factor that 
interacts with nuclear hormone receptors to aid in DNA transcription. NCOA2 has been shown 
to co-localise with ER-α in nuclei after estrogen treatment282. Thus, EP/F treatment may increase 
gene expression through activation of NCOA2. Therefore, these analyses highlight transcription 
factors that were predicted to be more activated following EP/F treatment, compared to F 
treatment, and thus, may be involved in upregulation of the AMPs hBD2, LCN2 and SLPI. 
However, the upstream regulator analysis did not reveal potential transcription factors for all 
AMPs identified by Venn diagram analysis, such hBD3 and RNase 7. Hence for these AMPs 
other transcription factors not identified by IPA (such as the genomic ERs) may require further 
investigation.  
 
4.6 Summary 
This chapter focussed on the use of microarrays to perform whole transcriptome analysis, 
enabling the identification of both downstream effector genes and pathways involved in 
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regulating expression of target genes. Microarrays were performed upon eight conditions: 
control, estrogen pretreatment, flagellin, and estrogen pretreatment plus flagellin at the 12 and 24 
hour time points. This generated six datasets for analysis via examining the expression patterns of 
individual genes by employing Venn diagrams and utilising IPA for downstream effect, canonical 
pathway, and upstream regulator analyses.   
 
Initial analysis of the datasets by Venn diagram resulted in identification of 20 genes of interest. 
The expression of these genes was potentiated by estrogen pretreatment prior to challenge with 
flagellin, compared to flagellin challenge without prior estrogen treatment. The genes of interest 
are all either AMPs, or are involved in keratinisation, inflammation, or have multiple roles within 
these three areas. This suggested that pretreatment of vaginal epithelial cells with estrogen prior 
to exposure to the bacterial PAMP flagellin served to increase the keratinisation of the vaginal 
epithelial barrier, as well as the inflammatory and antimicrobial response of the vagina. Thus, 
these factors promote rapid clearance of bacteria from the site of infection.  
 
Analysis of the microarray data via IPA identified a potential role for IL-17 in the production of 
AMPs. This pathway has been predominantly studied in psoriasis and shows that binding of IL-
17 to the IL-17 receptor results in expression of AMPs and chemokines in keratinocytes. IL-17 is 
expressed by Th17 cells, not epithelial cells, and thus this element was absent from the VK2 cell 
model. However, the microarray data showed that F and EP/F treatments both caused 
expression of CCL20 – the chemokine responsible for Th17 cell migration. Therefore, it was 
possible to hypothesise that the presence of pathogenic bacteria in the vagina stimulates 
expression of CCL20, causing migration of Th17 to the vagina, which stimulates AMP 
production facilitating bacterial killing. This notion is supported by downstream function analysis 
of the microarray data showing that F and EF treatments activated immune cell migration. 
However, the literature suggests that estrogen and IL-17 levels may be conversely expressed in 
vivo, as serum IL-17 increases after the menopause when estrogen levels decline283. Initial 
investigations into the effect of IL-17 on vaginal AMP expression are presented in Chapter 6. 
 
It is difficult to conclude from the upstream regulator analysis which transcription factors may be 
involved in increasing gene expression with EP/F treatment as IPA predicted similar levels of 
activation for most of the transcription factors with both F and EP/F treatments. However, 
there were transcription factors that were only predicted to be activated after EP/F treatment 
that will need further investigation, along with the genomic ERs which can directly cause 
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transcription of target genes upon binding to estrogen. The role of the ERs in vaginal AMP 
expression is explored in the next chapter. 
 
Altogether, these microarray data indicated a role for estrogen in potentiation of AMP gene 
expression, in addition to genes involved in keratinisation and the inflammatory response. Thus, 
the data presented in this chapter have revealed that estrogen promotes a multipronged defence 
against vaginal UPEC colonisation.   
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5 Investigating the mechanisms of AMP regulation by estrogen 
5.1 Introduction 
Analyses of the microarray data in Chapter 4 revealed upregulation of several AMP genes, along 
with genes involved in keratinisation and inflammation, in response to estrogen pretreatment plus 
flagellin. The finding that estrogen upregulated many AMPs is supported by unpublished work 
from our laboratory that showed estrogen treatment of postmenopausal women significantly 
increased vaginal douche concentrations of hBD2, hBD3 and LCN2, compared to 
postmenopausal women not receiving estrogen treatment (unpublished data). Furthermore, 
Luthje et al. (2013) have also reported that estrogen treatment increased AMP expression in 
exfoliated bladder cells in the urine of postmenopausal women134. However, the mechanism 
behind this upregulation has not been investigated. Upstream regulator analysis of the microarray 
data predicted activation of many transcription factors as a result of flagellin and estrogen 
pretreatment plus flagellin. Specifically, YBX1, CEBPB and KLF4 were identified as being 
upstream regulators of hBD2, LCN2 and SLPI, respectively, and were predicted to be activated 
by estrogen pretreatment plus flagellin but not flagellin challenge alone. However, none of the 
transcription factors that were predicted by Ingenuity Pathway Analysis to be more activated by 
estrogen pretreatment plus flagellin than flagellin alone were upstream of other important AMPs, 
such as hBD3 and RNase 7. In addition, ER-α and –β can regulate gene transcription directly, by 
interacting with estrogen response elements in the promoter region of estrogen responsive genes. 
Thus, it was feasible that AMP gene regulation by ER-α and –β did not involve the transcription 
factors IPA predicted to be activated. It was, therefore, of interest to determine the contribution 
of ER-α/β and GPER to AMP expression, to establish their roles in the signalling pathways that 
upregulate AMP expression in response to estrogen.  
 
Understanding the mechanisms by which estrogen regulates AMP expression may aid in 
development of novel therapeutics for UTI, for example by highlighting common signalling 
molecules involved in AMP expression. Increased serum estrogen levels are associated with 
higher breast cancer risk and topical estrogen application has been shown to increase the serum 
estrogen concentration in postmenopausal women284,285. As a result, topical estrogen treatment is 
contraindicated for breast cancer patients, due to increased risk of cancer recurrence. This 
highlights concerns over the safety of estrogen therapy and indicates that there are patients for 
whom estrogen treatment is not suitable. Thus, there is a need for alternative treatments to 
estrogen; hence, greater understanding of the mechanisms by which estrogen is protective against 
UTIs may facilitate development of non-hormonal alternatives that function in the same manner.  
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To explore the effects of the different estrogen receptors an agonist and antagonist were used 
and the effects of estrogen receptor agonism/antagonism on AMP expression were measured. 
The microarray data identified upregulation of the AMPs hBD2, hBD3, LCN2, RNase 7, 
S100A7, S100A12 and SLPI by estrogen pretreatment plus flagellin. LCN2, RNase 7 and S100A7 
were chosen, in addition to hBD2 and hBD3, for initial investigations in this chapter into the 
mechanism of AMP regulation. LCN2 and RNase 7 have been identified as important 
antimicrobial effectors against UTIs and S100A7 has been shown to be an effective killer of E. 
coli in the vagina123,129,247,248.  
 
5.2 Mechanism of hBD2 expression regulation by estrogen 
5.2.1 Inhibition of ER-α and –β and VK2 cell growth 
To determine which estrogen receptors were involved in AMP upregulation following estrogen 
pretreatment, the ER-α and –β receptors were inhibited using ICI 182,780 (fulvestrant). 
Fulvestrant is a high affinity antagonist of ER-α and –β, with agonistic activity on the GPER 
receptor286. As the VK2 cells were to be pretreated with fulvestrant, the effect of 1μM fulvestrant 
on the growth of VK2 cells was determined using the CellTiter-Blue Cell Viability Assay 
(Promega, USA) as detailed in the materials and methods. The results showed (Figure 5.1) that 
estrogen, fulvestrant, or estrogen plus fulvestrant pretreatments did not significantly affect the 
growth of VK2 cells, compared to a vehicle treated control. Thus, after seven days there was 
approximately the same number of cells in the well, regardless of the pretreatment received. 
Thus, inhibition of ER-α and –β did not affect cell growth. 
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Figure 5.1: Effects of fulvestrant on VK2 cell growth. VK2 cells were seeded in 12-well plates and treated with 
4nM estrogen with and without 1μM fulvestrant, or vehicle, for seven days. CellTiter-Blue Cell Viability Assay 
(Promega, USA) was used to measure cell viability. Error bars represent standard error. Statistical analysis was 
performed by one-way ANOVA with Dunnett’s post hoc test. N=3, n=9. 
 
5.2.2 Effects of inhibition of ER-α and –β on hBD2 expression 
To investigate the effects of inhibiting ER-α and –β on hBD2 expression VK2 cells were treated 
with 4nM estrogen with and without 1μM fulvestrant (Tocris Bioscience, UK) for seven days and 
then challenged with 50ng/ml flagellin, or PBS, for 24 hours. This concentration of fulvestrant 
has been shown previously to inhibit estrogen challenge concentrations up to 10μM287,288. Hence, 
this concentration is argued to be sufficient to inhibit an estrogen challenge concentration of 
4nM. If the potentiation in hBD2 expression following estrogen pretreatment was regulated 
through ER-α and/or –β, then following inhibition of these receptors it was predicted that the 
potentiation would no longer be observed. Alternatively, if the potentiation of hBD2 expression 
by estrogen was regulated by GPER the potentiation would still occur and may even be slightly 
enhanced, as fulvestrant is a GPER agonist. After 24 hour flagellin challenge the RNA was 
extracted, reverse transcribed into cDNA and then analysed by qPCR for the expression of 
hBD2. The qPCR results were analysed relative to two housekeeping genes, GAPDH and 
ATP5B, using the geometric mean and the resultant values were normalised to 24 hour flagellin.  
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The results showed (Figure 5.2) that estrogen pretreatment prior to flagellin challenge resulted in 
a significant increase in hBD2 expression compared to flagellin challenge alone (p<0.0001). 
However, inhibition of ER-α and –β by fulvestrant abolished this effect, so that the difference in 
hBD2 expression between flagellin challenge with and without estrogen pretreatment was no 
longer significant. Following fulvestrant treatment, flagellin and estrogen pretreatment plus 
flagellin induced hBD2 expression from 0.8AU in the control to 25AU and 23AU, respectively. 
Thus, inhibition of ER-α and –β prevented potentiation of hBD2 expression by estrogen. 
Fulvestrant also appeared to reduce overall hBD2 expression, even in the absence of estrogen 
pretreatment; flagellin challenge without fulvestrant induced a 63-fold change in hBD2 
expression (from 1.6AU in the control to 100AU after flagellin challenge), whereas flagellin 
challenge with fulvestrant only induced a 31-fold change in hBD2 expression (from 0.8AU in the 
control to 25AU after flagellin). The CellTiter-Blue assay data showed fulvestrant did not affect 
the growth of VK2 cells, so this was not due to a reduced number of cells following fulvestrant 
treatment. It is not fully understood why this occurred but it may have been due to inhibition of 
background estrogen in the media, for example small amounts of estrogen in the bovine pituitary 
extract, which activated hBD2 expression. 
 
 
Figure 5.2: Effects of inhibition of ER-α and –β on hBD2 expression. VK2 cells were seeded into 12-well plates 
and then treated with 4nM estrogen and/or 1μM fulvestrant, or vehicle, for seven days before challenge with 
50ng/ml flagellin or PBS for 24 hours. The RNA was extracted, reverse transcribed into cDNA and analysed by 
qPCR for hBD2 expression. Results were normalised to 24 hour flagellin challenge. Error bars represent standard 
error. Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. ns=not significant, 
***=p<0.001. N=3, n=9. 
 
5.2.3 Effects of estrogen pretreatment on expression of TLR5 pathway components 
Regulation of hBD2 expression by ER-α and –β may occur directly, through ERs binding to the 
hBD2 promoter region and causing gene transcription, or indirectly, through upregulation of 
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TLR5 pathway components. The TLR5 signalling pathway is shown in Figure 5.3A and consists 
of activation of the adaptor protein MYD88 by TLR5. MYD88 then initiates the signal 
transduction by activating the IRAK1/IRAK2/IRAK4/TRAF6 complex, which in turn activates 
the TAB2/TAB3/TAK1 complex. This TAK1 kinase complex phosphorylates the IKKα/β 
complex, which results in NF-ĸB activation. Examination of the microarray data showed that 
estrogen pretreatment did not upregulate components of the TLR5 pathway (Figure 5.3B). 
Interestingly, flagellin and estrogen pretreatment plus flagellin did result in increased expression 
of the molecule IRAK2, however, overall estrogen pretreatment did not upregulate the TLR5 
signalling pathway. Thus, upregulation of hBD2 by estrogen is likely to occur through direct 
interaction of ER-α and/or –β with the hBD2 promoter, independently of the TLR5 pathway. 
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Figure 5.3: Effects of estrogen pretreatment and flagellin on expression of TLR5 pathway molecules. The 
figure shows (A) the molecules involved in the TLR5 signalling pathway and (B) the expression levels of these 
molecules after seven days estrogen pretreatment and flagellin challenge, relative to control samples. The expression 
was measured by microarray on an Illumina HumanHT-12 V4 Expression BeadChip.  
 
5.2.4 Effects of mutagenesis of estrogen response elements in hBD2 promoter on hBD2 
expression  
To establish whether ER-α and –β regulation of hBD2 occurred through direct interaction of the 
receptors with the promoter, the role of estrogen response elements (EREs) in the hBD2 
promoter was investigated. Following estrogen binding to ER-α/β the receptors dimerise, 
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migrate to the nucleus, bind EREs in the promoter of estrogen responsive genes and initiate 
transcription of the gene. An ERE typically consists of two palindromic ERE half-sites, with 
sequence GGTCA or TGACC, separated by three base pairs of any nucleotide sequence. Thus, 
EREs have the consensus sequence GGTCAnnnTGCAA. However, most estrogen responsive 
genes do not contain the consensus ERE sequence in their promoter289. One arm of the 
palindromic sequence is often imperfect. Furthermore, ERE half-sites have been reported to 
regulate gene transcription without a full ERE290,291. Therefore, PROMO software was used to 
search for ERE half-sites in the hBD2 promoter292,293. Six ERE half-sites were identified in the 
2032bp hBD2 promoter region in the phBD-2-luc plasmid engineered by Dr Marcelo Lanz106. 
These are shown in Figure 5.4 highlighted in red. The sequence highlighted in green is the start of 
the first exon.  
 
 
Figure 5.4: Estrogen response element half-sites in the 2032bp hBD2 promoter region. The sequence shown 
is the 2000bp hBD2 promoter region in the phBD-2-luc plasmid engineered by Dr Marcelo Lanz. ERE half-sites 
identified by PROMO are highlighted in red. The start of the first exon is shown in green. 
  
To assess the role of each ERE half-site in the regulation of hBD2 expression, each ERE half-
site of the parental, or wild type (WT), plasmid was mutated in turn by site-directed mutagenesis 
in collaboration with Tom Powell (MRes student, 2014), to produce six mutant plasmids. The 
results of the mutagenesis were confirmed by sequencing and are shown in Figure 5.5. 
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Figure 5.5: Sequencing of hBD2 promoter ERE mutants. Site-directed mutagenesis was used to mutate each of 
the six ERE half-sites in the 2032bp hBD2 promoter region in the phBD-2-luc plasmid. The figure shows the 
BLAST alignments of the sequencing results for (A) the WT plasmid, (B) ERE1 mutant, (C) ERE2 mutant, (D) 
ERE3 mutant, (E) ERE4 mutant, (F) ERE5 mutant, (G) ERE6 mutant. The ERE sites of the plasmids are 
highlighted in green, and the ERE sequence from the human genomic and transcript DNA database is highlighted in 
blue. The query sequence is the sequence of the PCR product as determined by sequencing and the subject (sbjct) 
sequence is the BLAST database sequence. 
153 
 
 
To analyse the effects of the ERE mutations, VK2 cells were pretreated with 4nM estrogen for 
seven days and then transiently transfected with each of the seven plasmids, using the conditions 
determined in Chapter 3 section 3.4.2.2. Following transfection, the VK2 cells were challenged 
with 50ng/ml flagellin, or PBS, for 24 hours. After challenge, the medium was removed, the cells 
were washed, lysed and the Luciferase Assay System (Promega, UK) used to determine the level 
of hBD2 luciferase reporter activity.  
 
After transfection with the WT phBD-2-luc plasmid, challenging the VK2 cells with flagellin 
resulted in a 12-fold change in hBD2 expression, compared to control (Figure 5.6). Estrogen 
pretreatment prior to flagellin challenge of VK2 cells transfected with WT phBD-2-luc plasmid 
induced a 27-fold change in hBD2 expression, compared to control. This represents a statistically 
significant 2.1-fold change in hBD2 expression (p=0.0012) with estrogen pretreatment plus 
flagellin, compared to flagellin challenge without estrogen pretreatment. Flagellin challenge of 
VK2 cells transfected with phBD-2-luc plasmids with mutations in ERE1-6 resulted in induction 
of hBD2 expression to a comparable level to that of the WT transfected cells. However, estrogen 
pretreatment of the VK2 cells transfected with ERE mutant phBD-2-luc plasmids did not result 
in statistically significant potentiation of hBD2 expression above that observed with flagellin 
challenge without estrogen pretreatment. Thus, estrogen regulation of hBD2 expression occurs 
through direct interaction of ER-α/β with the hBD2 promoter to stimulate gene transcription. 
Furthermore, these data suggested all EREs in the hBD2 promoter were necessary for 
potentiation of hBD2 expression by estrogen.  
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Figure 5.6: Effects of mutating estrogen response elements (EREs) in the hBD2 promoter on hBD2 
expression. VK2 cells were pretreated with 4nM estrogen, or cyclodextrin vehicle, for seven days and then 
transiently transfected with WT and mutant phBD-2-luc plasmids, before challenged with 50ng/ml flagellin or PBS 
for 24 hours. After challenge, the medium was removed, the cells were washed and lysed, and luciferase production 
was determined using the Luciferase Assay System (Promega, USA) and FLUOstar Omega Microplate Reader. The 
results were normalised to the cyclodextrin-treated control for each plasmid. Error bars represent standard error. 
Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. ns=not significant, **=p<0.01. 
N=4, n=8. 
  
5.2.5 Effects of GPER stimulation on hBD2 expression 
Data presented in this chapter indicated that regulation of hBD2 expression by estrogen was 
dependent on ER-α/β; inhibition of these receptors abolished the potentiation of hBD2 
expression observed with estrogen pretreatment plus flagellin challenge. To verify these data, 
VK2 cells were treated with G-1, a selective GPER receptor agonist with no activity against ER-α 
and –β. It was hypothesised that stimulation of GPER with G-1 would not affect hBD2 
expression with estrogen pretreatment plus flagellin, compared to flagellin alone. 
 
As the VK2 cells were to be pretreated with G-1, it was important to investigate any effects of G-
1 on VK2 cell growth. The cells were pretreated for one, five and seven days with 100nM G-1 or 
vehicle control. This concentration of G-1 has been shown previously to stimulate estrogenic 
effects294. At each time point the cells were imaged using an EVOS XL core digital light 
microscope and the cell viability was determined using the CellTiter-Blue Cell Viability Assay 
(Promega, USA). The results, shown in Figure 5.7, indicated that 100nM G-1 pretreatment did 
not affect the growth of VK2 cells. No statistically significant difference in the number of viable 
cells was observed between G-1 and vehicle treated VK2 cells at any time point up to seven days. 
In contrast, Mitomycin C significantly reduced the growth of VK2 cells, compared to the control 
cells, after five and seven days of pretreatment.   
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Figure 5.7: Effects of G-1 pretreatment on the growth of VK2 cells. VK2 cells were treated with 100nM G-1, 
DMSO vehicle, or 1mM Mitomycin C for 1, 5, and 7 days. (A) CellTiter-Blue Cell Viability Assay (Promega, USA) 
was used to measure cell viability after 1, 5, and 7 days of treatment. Error bars represent standard error. Statistical 
analysis was performed by two-way ANOVA with Dunnett’s post hoc test. ns=not significant, ***=p<0.001. At 
days 1 and 5 N=2, n=6, and at day 7 N=1, n=3. (B) Images taken on an EVOS XL Core digital light microscope 
(AMG, USA) at x20 magnification show the confluency of the cells at each time point with each treatment. Each 
image was representative of the well.  
 
Having established that G-1 did not affect VK2 cells growth, the VK2 cells were pretreated with 
100nM G-1, or DMSO vehicle, for one, five and seven days, and then challenged with 50ng/ml 
flagellin or PBS for 24 hours. RNA was extracted from these cells, reverse transcribed into 
cDNA and analysed by qPCR for hBD2 expression.  
 
Day 1 Day 5 Day 7 
Control 
G-1 
Mitomycin C 
(A) VK2 cell viability 
(B) VK2 cell growth images 
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The results from this experiment revealed that hBD2 expression was not significantly increased 
by G-1 pretreatment plus flagellin, compared to flagellin challenge alone, for any of the time 
points studied (Figure 5.8). Following one day pretreatment, flagellin challenge increased hBD2 
expression to 89AU, from 0.2AU in the control. G-1 pretreatment plus flagellin induced hBD2 
expression to 105AU, which was not statistically significant different from flagellin challenge 
alone (p=0.261). Similarly, after five days pretreatment flagellin challenge induced hBD2 to 
113AU, from 0.4AU in the control, and G-1 pretreatment plus flagellin resulted in hBD2 
expression of 105AU. Once again this did not represent a statistically significant difference 
(p=0.7851). After seven days pretreatment, flagellin induced hBD2 expression to 100AU from 
0.5AU in the control. Interestingly, G-1 pretreatment plus flagellin challenge resulted in hBD2 
expression of 74AU, a significant 26% reduction (p=0.0156) in hBD2 expression compared to 
flagellin challenge alone.  
 
 
Figure 5.8: Effects of G-1 pretreatment and flagellin on hBD2 expression. VK2 cells were pretreated with 
100nM G-1, or DMSO vehicle, for 1, 5, and 7 days, before challenged with 50ng/ml flagellin or PBS for 24 hours. 
The RNA was extracted, reverse transcribed, and analysed by qPCR for hBD2 expression. The results were 
normalised to 24 hour flagellin challenge after seven day vehicle pretreatment. Error bars represent standard error. 
Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. ns=not significant, *=p<0.05. 
N=2, n=6. 
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To summarise, inhibition of ER-α and/or -β abolished the potentiation of hBD2 expression by 
estrogen pretreatment plus flagellin, suggesting that hBD2 is regulated through ER-α and/or –β. 
Mutation of the six ERE half-sites in the hBD2 promoter also inhibited hBD2 potentiation by 
estrogen pretreatment plus flagellin. Moreover, these data indicated that all six ERE half-sites 
were needed for estrogen regulation of hBD2 expression. In support of this, stimulation of 
GPER with G-1 agonist did not result in potentiation of hBD2 expression. Thus, these data 
indicated that upregulation of hBD2 by estrogen pretreatment occurred via ER-α and/or –β and 
required all six ERE half-sites in the hBD2 promoter region.  
 
5.3 Mechanism of hBD3 expression regulation by estrogen 
5.3.1 Effect of inhibition of ER-α and ER-β on hBD3 expression 
Receptor agonists/antagonists were again used to determine the roles of ER-α, ER-β, and GPER 
in hBD3 induction by estrogen. VK2 cells were pretreated with 4nM estrogen and/or 1μM 
fulvestrant, or vehicle, for seven days and then challenged with 50ng/ml flagellin or PBS for 24 
hours. The RNA was extracted, reverse transcribed and analysed by qPCR for hBD3 expression.  
 
The results, presented in Figure 5.9, showed that flagellin challenge without fulvestrant induced 
hBD3 expression to 100AU from 56AU in the control, representative of a 1.8-fold increase in 
hBD3 expression (p=0.0171). Estrogen pretreatment prior to flagellin challenge resulted in hBD3 
expression of 169AU, representing a significant 3.0-fold change in hBD3 expression relative to 
the control (p<0.0001) and a significant 1.7-fold change compared to flagellin challenge 
(p<0.0001). Following fulvestrant pretreatment, flagellin challenge induced hBD3 expression to a 
comparable level as flagellin challenge without fulvestrant (1.6-fold change vs. 1.8-fold change). 
However, inhibition of ER-α and –β by fulvestrant attenuated the potentiation of hBD3 
expression by estrogen pretreatment plus flagellin. In fact, fulvestrant plus estrogen pretreatment 
prior to flagellin challenge induced hBD3 expression to 92AU, which was comparable to 
expression of 104AU observed with fulvestrant pretreatment plus flagellin challenge (p=0.8238). 
Hence, inhibition of ER-α and –β prevented potentiation of hBD3 expression by estrogen 
pretreatment.  
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Figure 5.9: Effects of inhibiting ER-α and –β on hBD3 expression. VK2 cells were treated with 4nM estrogen 
and/or 1μM fulvestrant, or vehicle, for seven days, and then challenged with 50ng/ml flagellin or PBS for 24 hours. 
The RNA was extracted, reverse transcribed, and analysed by qPCR for hBD3 expression. The results were 
normalised to 24 hour flagellin challenge. Error bars represent standard error. Statistical analysis was performed by 
two-way ANOVA with Tukey’s post hoc test. ns=not significant, ***=p<0.001. N=3, n=9.  
 
5.3.2 Development of a hBD3 promoter luciferase reporter plasmid 
To further explore the mechanisms of ER-α and –β upregulation of hBD3 expression, the role of 
EREs in the hBD3 promoter was investigated. Promoter analysis using the PROMO software 
identified one ERE half-site in the 2000bp hBD3 promoter region directly upstream of the first 
exon and this is highlighted in red in Figure 5.10. The sequence highlighted in green is the start of 
the first exon. 
 
Figure 5.10: Identification of EREs in the hBD3 promoter. PROMO software was used to identify ERE half-
sites in the 2000bp hBD3 promoter region directly upstream of the first exon292,293. ERE half-sites are highlighted in 
red. The start of the first exon is shown in green. 
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To analyse the effects of this ERE half-site on hBD3 expression attempts were made to engineer 
a luciferase reporter plasmid containing the hBD3 promoter region containing the ERE. Initially 
1000bp and 2000bp 5’ upstream regions of the hBD3 promoter were amplified from genomic 
DNA. The forward and reverse primers used to amplify the PCR products contained KpnI and 
HindIII restriction enzyme sites, respectively, to introduce these restriction enzyme sites at either 
end of the PCR products. The amplified 1kp and 2kb hBD3 promoter products are shown in 
Figure 5.11. Electrophoresis of the products after gel extraction is shown in Figure 5.11C. These 
products were digested, along with the pGL4.10 reporter plasmid, using KpnI and HindIII 
restriction enzymes, ligated and transformed into competent DH5α cells, as detailed in the 
materials and methods. Following transformation, plasmid DNA was isolated from the DH5α 
cells by miniprep. However, despite repeated attempts sequencing data showed that the 1kb and 
2kb hBD3 promoter products were not successfully cloned into the pGL4.10 luciferase reporter 
plasmid. 
 
 
 
Figure 5.11: Amplification of 1kb and 2kb hBD3 promoter region from genomic DNA. Amplification of (A) 
1kb and (B) 2kb region of the hBD3 promoter. The 1kb DNA ladder (New England BioLabs, USA) is shown in lane 
1 and the PCR products are shown in lanes 2-7. (C) The DNA bands were extracted from the gel and the gel 
extraction product was electrophoresed. The 1kb DNA ladder is shown in lane 1, the gel extraction products of the 
1kb and 2kb PCR are shown in lanes 2 and 3, respectively.  
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As attempts to clone 1kb and 2kb fragments of the hBD3 promoter into pGL4.10 were not 
successful, the forward primer for the hBD3 promoter region was redesigned to amplify a smaller 
500bp region of the hBD3 promoter containing the ERE half-site. End-point PCR was 
performed for the 500bp hBD3 promoter region (Figure 5.12A), and the product purified (Figure 
5.12B). Single and double digests of the pGL4.10 reporter vector were performed using the 
HindIII and SacI restriction enzymes. Gel electrophoresis of the digested products (Figure 
5.12C) showed that both double and single digests resulted in complete digestion of the plasmid, 
with no plasmid left uncut. This confirmed that the restriction digest reaction was efficient. 
 
Figure 5.12: Amplification, gel extraction and restriction digest of 500bp hBD3 promoter product. (A) The 
500bp hBD3 promoter region was amplified and gel electrophoresed. The 100bp DNA ladder (Thermo Scientific, 
USA) is shown in lane 1, and 500bp hBD3 promoter PCR products are shown in lanes 2-7. (B) The PCR products 
were extracted from the gel and electrophoresed to confirm extraction of the product. The 100bp DNA ladder is 
shown in lane 1, and the gel extraction product is shown in lane 2. (C) The pGL4.10 luciferase reporter plasmid and 
the 500bp hBD3 promoter product were digested with restriction enzymes HindIII and SacI. The 1kb DNA ladder 
(New England BioLabs, USA) is shown in lane 1. The uncut pGL4.10 plasmid is shown in lane 2. A double digest of 
pGL4.10 with HindIII and SacI is shown in lane 3. Single digests of pGL4.10 with HindIII and SacI are shown in 
lanes 4 and 5, respectively. A double digest of the 500bp hBD3 promoter product with HindIII and SacI is shown in 
lane 6.   
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The digested pGL4.10 vector and 500bp hBD3 promoter insert were ligated together, 
transformed into DH5α cells and plated onto LB/ampicillin plates as detailed in the materials and 
methods. Typically, less than five colonies grew on the LB/ampicillin plates after transformation 
and sequencing results revealed that the 500bp hBD3 insert was not successfully integrated into 
the pGL4.10 luciferase reporter vector. Control reactions were performed in parallel with the 
500bp hBD3 promoter insert reaction. As the pGL4.10 vector contains the gene for ampicillin 
resistance, only bacteria that have successfully taken up the pGL4.10 vector, with or without the 
500bp insert, are able to grow on LB/ampicillin plates. The first of the control reactions (V + L) 
included the doubly digested vector with DNA ligase, but with no 500bp insert. As expected, no 
colonies grew as a result of this transformation reaction indicating that minimal amounts of the 
vector were undigested, or religated without incorporating the insert (Figure 5.13C). The second 
control reaction consisted of doubly digested vector only (V), without DNA ligase and again the 
results showed (Figure 5.13D) that no colonies grew after this transformation reaction, 
supporting the notion that the vector was entirely digested during the restriction digest. The third 
reaction consisted of the pGL4.10 vector singly digested, by HindIII only, plus DNA ligase 
(Vsingle + L). The results (Figure 5.13E) showed that >100 colonies grew on the LB/ampicillin 
plates after this transformation reaction, indicating that the ligation reaction was functional. The 
final control reaction consisted of undigested pGL4.10 vector only (Vuncut) and the results (Figure 
5.13F) showed that >300 colonies grew on the LB with ampicillin plate following this reaction 
and thus, the transformation step was working efficiently. Thus, altogether the control reactions 
suggested that the vector was being fully digested by HindIII and SacI, and that both the ligation 
and transformation steps were working efficiently. Thus, it was not clear why cloning the hBD3 
promoter region (500bp, 1kb, or 2kb) into the pGL4.10 luciferase reporter vector was not 
successful, but the data were reproducible and hence, this experiment was not pursued any 
further.  
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Figure 5.13: Results of hBD3 promoter cloning. (A) shows the components of the ligation reactions for the 
500bp hBD3 insert and control reactions. (B)-(F) show the results of the transformation plated out on LB/ampicillin 
agar plates for each of the reactions.  
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5.3.3 Effects of GPER stimulation on hBD3 expression 
As previous data suggested that hBD3 expression in response to estrogen pretreatment was 
regulated through ER-α and/or –β, it was hypothesised that stimulation of GPER with the G-1 
agonist would not result in significant induction of hBD3 expression in the VK2 cells. VK2 cells 
were pretreated with 100nM G-1, or DMSO vehicle, for one, five and seven days, and then 
challenged with 50ng/ml flagellin or PBS for 24 hours. The RNA was extracted, reverse 
transcribed and analysed by qPCR for hBD3 expression. The results were normalised to 24 hour 
flagellin challenge. 
 
The results, shown in Figure 5.14, showed that none of the pretreatments with G-1 resulted in 
significant upregulation of hBD3 expression. After one day pretreatment, flagellin challenge 
induced hBD3 expression to 104AU, from 37AU in the control samples. This represented a 
significant 2.8-fold change in hBD3 expression (p<0.0001). One day G-1 pretreatment plus 
flagellin challenge resulted in hBD3 expression of 114AU, which was comparable to hBD3 
expression observed with flagellin challenge without G-1 (p=0.7275). Similarly, after five days 
pretreatment, flagellin challenge alone induced hBD3 expression to 110AU from 58AU in the 
control and G-1 pretreatment for five days prior to flagellin challenge resulted in hBD3 
expression of 87AU. This also did not represent a statistically significant change in hBD3 
expression compared to flagellin challenge without G-1 (p=0.1030). Following seven days 
pretreatment, flagellin challenge alone induced hBD3 expression to 100AU from 43AU in the 
control (p<0.0001), comparable to the level of induction with flagellin challenge after one and 
five day vehicle pretreatment. Interestingly, seven day G-1 pretreatment plus flagellin challenge 
resulted in hBD3 expression of 45AU, a level comparable with that of the control (p=0.99), and 
which represented a significant 55% reduction in hBD3 expression compared to flagellin 
challenge (p<0.0001). Consistently, seven day G-1 pretreatment alone also significantly reduced 
hBD3 expression 64% compared to the control (p=0.0231). Thus, this result suggested that long-
term stimulation of GPER resulted in downregulation of hBD3 expression, which was not seen 
with shorter G-1 treatments. 
164 
 
 
 
Figure 5.14: Effects of G-1 pretreatment on hBD3 expression. VK2 cells were pretreated with 100nM G-1, or 
DMSO vehicle, for one, five, and seven days and then challenged with 50ng/ml flagellin, or PBS, for 24 hours. The 
RNA was extracted, reverse transcribed, and then analysed by qPCR for hBD3 expression. The results were 
normalised to 24 hour flagellin challenge after 7 days vehicle pretreatment. Error bars represent standard error. 
Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. ns=not significant, ***=p<0.001. 
N=2, n=6. 
 
5.4 Mechanisms of LCN2, RNase 7, and S100A7 gene expression regulation by 
estrogen 
5.4.1 Development of LCN2, RNase 7 and S100A7 qPCR assays 
As microarray analysis in Chapter 4 identified upregulation of several antimicrobial peptide genes 
by estrogen pretreatment plus flagellin, compared to flagellin challenge alone, qPCR assays were 
developed for LCN2, RNase 7, and S100A7 so that expression of these AMP genes could be 
further investigated. These AMPs have been shown to be important in clearance of E. coli from 
the urogenital tract123,129,247,248. 
 
The qPCR assay for LCN2 and positive control plasmid was previously established by Dr Ased 
Ali60. The plasmid, containing the LCN2 PCR product, was used to produce a standard curve for 
the LCN2 assay and the melt curve confirmed that only one product was amplified (Figure 5.15). 
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Figure 5.15: Standard curve and melt peak of the LCN2 qPCR assay. The figure shows the standard curve and 
melt peak of the LCN2 qPCR assay designed by Dr Ased Ali60. The melt peak confirmed amplification of a single 
qPCR product.  
 
A qPCR assay was also developed for RNase 7. End-point PCR was performed for RNase 7 and 
the resultant PCR product was cloned into the pGEM-T easy vector as detailed in the materials 
and methods. Sequencing confirmed the presence of the PCR product in the plasmid (Figure 
5.16A). The plasmid insert had 98% identity to the BLAST subject sequence. This plasmid was 
serially diluted and used to produce a standard curve for the RNase 7 qPCR assay (Figure 5.16B). 
Melt peak analysis confirmed that only one product was amplified by the qPCR reaction (Figure 
5.16B). A slight shoulder was observed on the melt peak, however, this only occurred in very 
highly concentrated plasmid samples and was not observed for VK2 cDNA samples. 
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Figure 5.16: Sequencing data, standard curve, and melt peak of the RNase 7 qPCR assay. (A) Sequencing 
results confirmed the insertion of the RNase 7 PCR product into the pGEM-T easy vector. Sequencing was 
performed by Genevision (UK). The query sequence is the sequence of the PCR product as determined by 
sequencing and the subject (sbjct) sequence is the BLAST database sequence. (B) This vector was used to produce a 
standard curve and melt peak for the RNase 7 qPCR assay. The melt peak showed only one PCR product was 
amplified. 
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A similar approach was used to develop a qPCR assay for S100A7. End-point PCR was 
performed for S100A7 and the PCR product was cloned into the pGEM-T easy vector as 
outlined in the materials and methods. Sequencing, performed by Genevision (UK), confirmed 
the presence of the S100A7 PCR product in the pGEM-T easy vector (Figure 5.17A) with 97% 
identity to the BLAST subject sequence. The vector was serially diluted and used to produce a 
standard curve and melt peak for the S100A7 qPCR assay (Figure 5.17B). The qPCR reaction for 
the standard with the highest S100A7 concentration amplified multiple products, represented by 
multiple peaks on the melt curve, however, only one PCR product was amplified for the other 
standards and multiple products were not observed for the VK2 cDNA samples.  
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Figure 5.17: Sequencing data, standard curve, and melt peak of the S100A7 qPCR assay. (A) Sequencing 
results confirmed the insertion of the S100A7 PCR product into the pGEM-T easy vector. Sequencing was 
performed by Genevision (UK). The query sequence is the sequence of the PCR product as determined by 
sequencing and the subject (sbjct) sequence is the BLAST database sequence.  (B) This vector was used to produce a 
standard curve and melt peak for the S100A7 qPCR assay.  
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These qPCR assays were used to analyse expression of LCN2, RNase 7, and S100A7 in the next 
sections.  
 
5.4.2 Effects of estrogen pretreatment and flagellin on LCN2, RNase7 and S100A7 
expression 
To verify the microarray data, qPCR was performed for LCN2, RNase 7 and S100A7 following 
estrogen pretreatment for seven days followed by 50ng/ml flagellin challenge for 24 hours.  
 
The results for LCN2, presented in Figure 5.18A, showed that flagellin treatment significantly 
induced LCN2 expression to 100AU from 12AU in the control, representing an 8.5-fold change 
(p<0.0001). Estrogen pretreatment prior to flagellin challenge further increased LCN2 expression 
to 125AU, a significant 25% increase in LCN2 expression, compared to flagellin challenge 
without estrogen (p=0.0059). Similarly, flagellin challenge induced a significant 1.6-fold change in 
RNase 7 expression (Figure 5.18B), to 100AU from 62AU in the control. Estrogen pretreatment 
prior to flagellin challenge resulted in RNase 7 expression of 125AU, suggesting a trend towards 
increased expression with estrogen pretreatment. However, this difference was not statistically 
significant. Finally, flagellin challenge significantly increased S100A7 expression from 39AU in 
the control to 100AU (p<0.0001). Estrogen pretreatment prior to flagellin challenge increased 
S100A7 to 141AU, a significant 41% increase in expression, compared to flagellin challenge alone 
(p<0.0001). Thus, altogether, these data were supportive of the microarray findings, and 
suggested a role for estrogen potentiation of LCN2, S100A7 and potentially RNase 7.    
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Figure 5.18: Effects of estrogen pretreatment and flagellin on LCN2, RNase 7 and S100A7 expression. VK2 
cells were pretreated with 4nM estrogen, or cyclodextrin vehicle, for seven days and then challenged with 50ng/ml 
flagellin, or PBS, for 24 hours. After challenge the RNA was extracted, reverse transcribed, and analysed by qPCR 
for (A) LCN2, (B) RNase 7, and (C) S100A7 expression. The results were normalised to 24 hour flagellin challenge. 
Error bars represent standard error. Statistical analysis was performed using one-way ANOVA with Tukey’s post 
hoc test. ns=not significant, **=p<0.01, ***=p<0.001. For LCN2 and RNase 7 N=8, n=24 and for S100A7 N=5, 
n=15.  
 
5.4.3 Effects of ER-α and –β inhibition on LCN2, RNase 7, and S100A7 expression 
To investigate the potential role of ER-α and –β in the regulation of LCN2, RNase 7 and 
S100A7, the 2000bp promoter regions of these genes were analysed for the presence of ERE 
half-sites using PROMO. Several ERE half-sites were identified in the promoter region of each 
gene (highlighted in red in Figure 5.19); nine ERE half-sites were identified in the LCN2 
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promoter, eight in the RNase 7 promoter and eight in the S100A7. These data demonstrated the 
potential for interaction of ER-α and –β with binding sites in the promoter region of these genes.  
 
 
Figure 5.19: Identification of EREs in the promoter regions of LCN2, RNase 7, and S100A7. The figure 
shows the 2000bp promoter region of (A) LCN2, (B) RNase 7 and (C) S100A7. Estrogen response element half-sites 
identified by PROMO software are shown in red292,293. The start of the first exon is shown in green. 
 
To investigate the roles of ER-α and –β in LCN2, RNase 7 and S100A7 expression, the 
expression of these genes was analysed following inhibition of ER-α and –β. VK2 cells were 
pretreated with 4nM estrogen with and without 1μM fulvestrant, or vehicle, for seven days, and 
(A) 
(B) 
(C) 
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then challenged with 50ng/ml flagellin or PBS for 24 hours. After the challenge the RNA was 
extracted, reverse transcribed and analysed by qPCR for LCN2, RNase 7 and S100A7 expression. 
The results were normalised to 24 hour flagellin. 
 
The results for LCN2, shown in Figure 5.20A, revealed that flagellin challenge induced LCN2 
expression to 100AU, from 11AU in the controls (p<0.0001). Estrogen pretreatment prior to 
flagellin challenge significantly increased LCN2 expression, to 110AU, compared to flagellin 
challenge (p=0.0006). However, following inhibition of ER-α and –β by fulvestrant, potentiation 
of LCN2 expression by estrogen was not observed. Following fulvestrant pretreatment, flagellin 
challenge induced LCN2 expression to 20AU, from 3.6AU in the control, and estrogen 
pretreatment plus flagellin resulted in LCN2 expression of 17AU. This did not represent a 
significant change in LCN2 expression (0.5218). These results also reflected the results for hBD2 
(Figure 5.2), which showed an approximate 50% decrease in the level of induction of gene 
expression with flagellin following fulvestrant pretreatment. For LCN2, without fulvestrant 
pretreatment flagellin challenge resulted in a 9.4-fold increase in expression, whereas, after 
fulvestrant pretreatment flagellin challenge induced a 5.6-fold increase in LCN2 expression. 
Again this may have been due to potential estrogenic compounds in components of the cell 
culture medium, such as bovine pituitary extract, which induced a baseline level of LCN2 
expression. Inhibition of ER-α and –β with fulvestrant may have, therefore, reduced this 
exogenous effect. 
 
The results for RNase 7 (Figure 5.20B) showed that estrogen pretreatment prior to flagellin 
challenge did not significantly increase RNase 7 expression, compared to flagellin challenge alone, 
with or without fulvestrant treatment. Furthermore, inhibition of ER-α and –β by fulvestrant 
increased baseline expression of RNase 7, from 59AU in the control samples without fulvestrant 
pretreatment, to 173AU in the control samples with fulvestrant pretreatment. These data 
suggested that inhibition of ER-α and –β increased RNase 7 expression. 
 
Without fulvestrant pretreatment expression of S100A7 was significantly induced 2.4-fold to 
100AU by flagellin challenge, compared to 42AU in the control (p<0.0001, Figure 5.20C). 
Estrogen pretreatment prior to flagellin challenge further increased S100A7 expression to 
134AU, a significant 1.3-fold change compared to flagellin alone (p<0.0001). Following 
fulvestrant pretreatment the potentiation of S100A7 expression by estrogen pretreatment plus 
flagellin challenge was attenuated, and no statistically significant difference was observed between 
S100A7 expression with flagellin challenge (32AU) and estrogen pretreatment plus flagellin 
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(30AU). Once again fulvestrant pretreatment resulted in a reduced baseline gene expression in 
the control samples, with S100A7 expression determined as 42AU in controls without fulvestrant 
and 13AU in controls plus fulvestrant pretreatment. Nevertheless, the level of induction of 
S100A7 gene expression by flagellin was comparable with and without fulvestrant treatment; 
flagellin challenge without fulvestrant treatment resulted in a 2.4-fold change in S100A7 
expression, whilst flagellin challenge with fulvestrant pretreatment resulted in a 2.5-fold change, 
compared to the controls.  
 
Thus, taken together these data did not suggest that estrogen pretreatment upregulated RNase 7 
expression and thus, these results did not reflect the microarray findings for RNase 7. 
Nevertheless, these data did indicate a role for ER-α and –β in upregulation of LCN2 and 
S100A7 by estrogen, as inhibition of these receptors blocked potentiation of LCN2 and S100A7 
expression by estrogen.  
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Figure 5.20: Effects of ER-α and –β inhibition on LCN2, RNase 7 and S100A7 expression. VK2 cells were 
pretreated with 4nM estrogen with and without 1μM fulvestrant (Tocris, UK), or vehicle, for seven days and then 
challenged with 50ng/ml flagellin or PBS for 24 hours. The RNA was extracted, reverse transcribed, and analysed by 
qPCR for (A) LCN2, (B) RNase 7, and (C) S100A7 expression. The results were normalised to 24 hour flagellin 
challenge. The error bars represent standard error. Statistical analysis was performed by two-way ANOVA with 
Tukey’s post hoc test. ns=not significant, ***=p<0.001. N=3, n=9. 
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5.4.4 Effects of GPER stimulation on LCN2, RNase 7 and S100A7 expression 
Inhibition of ER-α and –β by fulvestrant attenuated the potentiation of LCN2 and S100A7 gene 
expression by estrogen, which indicated that expression of these AMP genes was regulated in 
part through the genomic estrogen receptors. To verify these results VK2 cells were treated with 
G-1, a GPER agonist, and it was hypothesised that activation of GPER would not affect LCN2 
and S100A7 expression. Although the previous experiments with fulvestrant did not suggest that 
RNase 7 was upregulated by estrogen through ER-α and –β, the effects of G-1 on RNase 7 
expression were also investigated, to determine whether RNase 7 is upregulated by activation of 
GPER. VK2 cells were pretreated with 100nM G-1, or DMSO vehicle, for one, five and seven 
days and then challenged with 50ng/ml flagellin or PBS for 24 hours. The RNA was extracted, 
reverse transcribed and analysed by qPCR for LCN2, RNase 7 and S100A7 expression. 
 
The results for LCN2, presented in Figure 5.21A, showed that for one, five and seven day 
pretreatments flagellin challenge alone induced LCN2 expression to approximately 100AU, from 
approximately 15AU in the control samples. However, G-1 pretreatment plus flagellin challenge 
resulted in significant downregulation of LCN2 expression at one, five and seven days 
pretreatment (p-values<0.05). The level of downregulation increased with the length of 
pretreatment; one day G-1 pretreatment plus flagellin resulted in a significant 25% decrease in 
LCN2 expression compared to flagellin (p=0.0104), five day G-1 pretreatment plus flagellin 
resulted in a significant 41% decrease in LCN2 expression compared to flagellin (p=0.0001), and 
seven day G-1 pretreatment plus flagellin resulted in a significant 66% reduction in LCN2 
expression compared to flagellin (p<0.0001).  
 
Following one day pretreatment, flagellin induced RNase 7 expression to 103AU, compared to 
41AU in the control (p=0.0023). G-1 pretreatment plus flagellin further increased this to 127AU, 
suggesting potentiation of RNase 7 expression by G-1 after one day pretreatment, however, this 
increase was not statistically significant (p=0.4377). Five and seven day G-1 pretreatment plus 
flagellin resulted in reduced RNase 7 expression by approximately 30%, compared to flagellin 
alone, however, again these results were not statistically significant (p-values of 0.2252 and 
0.1207, respectively).  
 
The results for S100A7 expression following G-1 pretreatment echoed the results for LCN2 and 
RNase 7, whereby, G-1 pretreatment resulted in downregulation of S100A7 expression. After 
one day pretreatment, flagellin induced S100A7 expression to 121AU, compared to 36AU in the 
control. One day G-1 pretreatment plus flagellin induced S100A7 expression to 111AU, which 
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did not represent a statistically significant difference in S100A7 expression compared to flagellin 
challenge. Five and seven day G-1 pretreatment plus flagellin resulted in significant 34% and 29% 
decreases in S100A7 expression, respectively, compared to flagellin challenge alone (p=0.0025 
and p=0.0297, respectively). 
 
Therefore, a similar pattern was seen for LCN2, RNase 7 and S100A7 expression whereby G-1 
pretreatment plus flagellin resulted in lower AMP expression than flagellin challenge.  
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Figure 5.21: Effects of G-1 pretreatment and flagellin on LCN2, RNase 7, and S100A7 expression. VK2 cells 
were pretreated with 100nM G-1 (Tocris, UK), or DMSO control, for one, five, or seven days and then challenged 
with 50ng/ml flagellin or PBS for 24 hours. The RNA was extracted, reverse transcribed, and analysed by qPCR for 
(A) LCN2, (B) RNase 7, and (C) S100A7 expression. The results were normalised to 24 hour flagellin challenge with 
7 day vehicle pretreatment. Error bars represent standard error. Statistical analysis was performed by two-way 
ANOVA with Tukey’s post hoc test. ns=not significant, *=p<0.05, **=p<0.01, ***=p<0.001. N=2, n=6.   
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5.5 Discussion 
This chapter investigated potential mechanisms of estrogen regulation of AMP expression in 
VK2 cells. Data presented in this thesis indicated upregulated expression of a number of AMP 
genes in response to estrogen pretreatment prior to flagellin challenge, and this finding is 
supported by other published literature134,199. However, prior to this no investigation into the 
mechanism by which estrogen upregulates AMP gene expression had been conducted. To 
determine the contribution of estrogen receptors to AMP expression, estrogen receptor 
agonists/antagonists were used. 
 
The ER-α and –β agonist, fulvestrant, was used to inhibit ER-α and –β during seven day 
pretreatment of VK2 cells with estrogen. Fulvestrant is a pure antagonist of ER-α and –β, with 
agonistic activity on GPER286,295. Thus, expression of AMPs regulated through ER-α/β would not 
be potentiated with estrogen and fulvestrant pretreatment plus flagellin challenge. Whereas, 
following fulvestrant pretreatment AMPs regulated through GPER would still show increased 
gene expression with estrogen pretreatment plus flagellin compared to flagellin challenge alone. It 
is of interest to note that patients receiving fulvestrant treatment for breast cancer experience a 
greater incidence of UTIs, hinting at an important role for ER-α and -β in protection against 
UTIs296. Analysis of hBD2 expression revealed that the potentiation observed with estrogen 
pretreatment plus flagellin was indeed inhibited by fulvestrant treatment, suggesting regulation of 
hBD2 by ER-α/β. The classical mechanism of hBD2 induction is through activation of NF-ĸB, 
which binds to NF-ĸB binding sites in the hBD2 promoter60,106,297–300. Data obtained by 
microarray revealed that estrogen pretreatment did not upregulate components of the TLR5 
pathway, indicating that ER-α/β regulation of hBD2 expression was likely to be through direct 
interaction of the ERs with EREs in the hBD2 promoter region. ERE half-sites were identified 
in the 2032bp hBD2 promoter region inserted into the phBD-2-luc vector, engineered by Dr 
Marcelo Lanz, using PROMO software106,292,293. Although EREs are reported as having the 
consensus sequence GGTCAnnnTGACC, most estrogen responsive genes contain imperfect, 
non-palindromic EREs in their promoter. For example, functional EREs were identified in the c-
fos and lactoferrin gene promoters with sequences of CGGCAgcgTGACC and 
GGTCAaggCGATC, respectively301,302. EREs with mutations in both sides of the palindrome 
have much lower transcriptional activity than EREs with mutations in only one side289,303. Thus, 
searching for ERE half-sites, rather than full ERE sequences, was a valid approach for identifying 
potential EREs in a gene promoter region. PROMO identified six ERE half-sites in the hBD2 
promoter region and mutation of these six ERE half-sites by site-directed mutagenesis resulted in 
attenuation of hBD2 gene expression by estrogen pretreatment. Thus, these data indicated that 
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hBD2 is regulated through ER-α/β, and that all six ERE half-sites are required for potentiation 
by estrogen. Interestingly, a similar result has been found previously for the chicken ovalbumin 
gene, whereby four ERE half-sites, separated by more than 100bp were identified in the 
promoter region and all contributed to induction of gene expression by estrogen290. Furthermore, 
evidence suggested that ER dimers could cause a conformational change in the ovalbumin 
promoter region and bind to two widely spaced ERE half-sites. This therefore, suggests a 
mechanism by which the ERE half-sites may regulate hBD2 expression in response to estrogen. 
Examination of the hBD2 promoter region showed that two of the six ERE half-sites, ERE3 and 
ERE4, were separated from imperfect palindromes by 3bp, suggesting that two full EREs may 
exist within the hBD2 promoter. The six ERE half-sites are highlighted in red in Figure 5.22, 
with the imperfect palindromes of ERE3 and ERE4 highlighted in blue. Thus, hBD2 may be 
regulated through ER dimers binding to two separate ERE half-sites, and/or by interaction of 
ER dimers with imperfect EREs in the hBD2 promoter, but further work is needed to determine 
the precise mechanism of ER-α/β regulation of hBD2 through the ERE half-sites identified here.  
 
 
Figure 5.22: Position of potential imperfect full EREs in the 2032bp hBD2 promoter region. ERE half-sites 
identified by PROMO software are shown in red. Imperfect ERE half-sites separated from these by 3bp are shown 
with consensus base pairs highlighted in blue and imperfect base pairs underlined in black. The start of the first exon 
of hBD2 is shown in green.  
 
Analysis of hBD3 expression also revealed inhibition of gene expression following fulvestrant 
treatment. This suggested that hBD3, in addition to hBD2, may be regulated by ER-α/β. 
PROMO software identified one ERE half-site in the hBD3 promoter and to investigate the 
contribution of this ERE half-site to hBD3 expression attempts were made to engineer a 
luciferase reporter plasmid containing the hBD3 promoter region. However, these attempts were 
not successful for reasons that were not clear, as the control reactions did not highlight any 
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technical issues with the experiment protocols. Thus, this avenue was not explored further. 
Future attempts to engineer a hBD3 luciferase reporter plasmid could involve the use of a 
different bacterial strain for transformation, such as JM109, or a strain suitable for transformation 
by electroporation rather than chemical transformation. The genotype of the bacterial 
transformation strain and the transformation method may affect the efficiency of the cloning 
reaction. Examination of the DNA sequence flanking the ERE half-site in the hBD3 promoter 
did not reveal any further imperfect ERE sequences. Furthermore, as only one ERE half-site was 
identified, cooperative binding of an ER dimer to separate ERE half-sites is implausible. Thus, 
the bioinformatics analysis does not support regulation of hBD3 by ER-α/β. To investigate the 
role of GPER in hBD3 expression, VK2 cells were pretreated with the GPER agonist G-1 for 
one, five and seven days prior to flagellin challenge. Interestingly, seven day pretreatment of VK2 
cells with G-1 followed by flagellin challenge resulted in significant downregulation of hBD3 
expression of 55% compared to flagellin challenge without G-1 pretreatment. This suggested that 
stimulation of GPER resulted in a reduction in hBD3 expression and was unexpected. This result 
may be explained by desensitisation of GPER. Desensitisation of G protein-coupled receptors 
(GPCRs) is the loss of response due to prolonged administration of an agonist. During 
desensitisation the GPCR is endocytosed and then either recycles back to the membrane or is 
targeted for degradation. Desensitisation has been reported previously with GPER, whereby the 
receptor was endocytosed and degraded by the ubiquitin-proteasomal pathway304. Thus, it is 
possible that seven day stimulation of GPER with G-1, at a concentration much higher than that 
used for the estrogen pretreatment, resulted in desensitisation and degradation of the GPER in 
the VK2 cells. This notion was also supported by the fulvestrant data. Pretreatment of the VK2 
cells with fulvestrant inhibited the potentiation of hBD3 expression by estrogen. This initially 
indicated that hBD3 was regulated through ER-α/β. However, as fulvestrant also has agonistic 
effects on GPER, fulvestrant treatment of the VK2 cells for seven days may also have resulted in 
GPER desensitisation. Therefore, paradoxically, downregulation of hBD3 expression following 
G-1 and fulvestrant treatments may indicate regulation of hBD3 through GPER. This premise is 
supported by the findings from the hBD3 promoter analysis, which did not support regulation of 
hBD3 by ER-α and ER-β. As G-1 treatment did not cause an increase in hBD3 expression even 
after only one day pretreatment, it is possible that desensitisation began within the first 24 hours 
following G-1 treatment. Hence, further experiments may indicate whether G-1 treatment at this 
concentration (100nM) significantly induces hBD3 expression at earlier time points than one day 
G-1 pretreatment.   
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Induction of hBD3 expression has previously been reported to occur through activation of the 
epidermal growth factor receptor (EGFR) and MAP kinases305. Interestingly, GPER has been 
shown to activate MAP kinase signalling through transactivation of EGFR306. Thus, a mechanism 
is proposed whereby estrogen binding to GPER results in activation of EGFR, MAP kinases and 
consequently, increases hBD3 expression. Further work using EGFR inhibitors is needed to fully 
investigate this hypothesis. 
 
The results for LCN2 and S100A7 were similar to that of hBD3. Pretreatment of VK2 cells with 
fulvestrant prevented potentiation of LCN2 and S100A7 expression by estrogen pretreatment 
plus flagellin. In addition, G-1 pretreatment prior to flagellin challenge also resulted in significant 
downregulation of LCN2 and S100A7 expression compared to flagellin challenge without G-1 
pretreatment. However, unlike hBD3, several ERE half-sites and at least two imperfect full ERE 
sequences are present in the promoter regions of LCN2 and S100A7 (Figure 5.23). Thus, for 
these AMP genes it is difficult to determine which estrogen receptor(s) were responsible for 
increasing AMP expression in response to estrogen. The downregulation in response to G-1 may 
be attributed to GPER desensitisation, however, further work examining GPER protein levels 
following G-1 treatment is required to confirm this. Furthermore, the loss of gene expression 
potentiation with fulvestrant may either be due to inhibition of ER-α and –β, or may be due to 
agonism of GPER causing desensitisation of this receptor. Thus, these data alone are not 
sufficient to ascertain the role of each estrogen receptor in LCN2 and S100A7 expression.  
 
qPCR analysis to verify the microarray data showed a trend towards potentiation of RNase 7 
expression with estrogen pretreatment plus flagellin, compared to flagellin alone. However, 
repetition of this challenge with and without fulvestrant pretreatment, showed that estrogen 
pretreatment plus did not enhance RNase 7 expression, compared to flagellin challenge without 
estrogen pretreatment, even when fulvestrant was not present. Thus, these data do not fully 
support previous findings suggesting a role for estrogen in RNase 7 regulation. Furthermore, 
following fulvestrant pretreatment, baseline expression of RNase 7 appeared to be increased 
from 59AU in control samples without fulvestrant to 172AU in control samples with fulvestrant. 
These data suggested that inhibition of ER-α and –β and potential desensitisation of GPER 
resulted in increased RNase 7 expression. Contradictory to this, a decrease in RNase 7 expression 
was observed following seven day G-1 pretreatment plus flagellin challenge, compared to flagellin 
challenge without G-1 pretreatment, which did suggest a role for estrogen receptors in regulation 
of RNase 7 gene expression. However, this downregulation was not statistically significant. Eight 
ERE half-sites and one imperfect full ERE was also identified in the RNase 7 promoter (Figure 
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5.23). Therefore, the results of these experiments are complex and it is not possible to determine, 
from these experiments alone, the role of the estrogen receptors in RNase 7 expression. 
 
Figure 5.23: Identification of imperfect ERE sequences in the 2000bp LCN2, RNase 7, and S100A7 
promoter regions. ERE half-sites in identified by PROMO in the (A) LCN2, (B) RNase 7, and (C) S100A7 
promoters are highlighted in red. Imperfect ERE half-sites within 3bp of another ERE half-site are shown with 
consensus base pairs in blue and mismatched base pairs underlined in black. The start of the first exon is shown in 
green. 
 
It is possible to speculate, from findings published in the literature, how estrogen treatment may 
increase expression of LCN2, RNase 7 and S100A7. LCN2 has been reported to be regulated 
through induction of NF-ĸB in epithelial cells307. A recent paper has also shown collaboration of 
(A) 
(B) 
(C) 
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NF-ĸB with the ETS transcription factor E74-like factor 3 (ELF3) to induce LCN2 expression, 
although this work was performed in chondrocytes from cartilage tissue and not epithelial cells308. 
Analysis of the microarray data in Chapter 4 identified upregulation of another ETS transcription 
factor, ETS homologous factor (EHF) by estrogen pretreatment plus flagellin. Thus, LCN2 
regulation by EHF is a potential avenue for further work. NF-ĸB can be activated by EGFR, 
which can be transactivated by GPER306,309. Thus, this suggests a mechanism by which estrogen 
may increase NF-ĸB activation, and consequently induce expression of downstream genes, such 
as LCN2. The microarray data did not show increased expression of NF-ĸB following estrogen 
treatment, however, this does not rule out that estrogen increases NF-ĸB activation at the protein 
level, rather than mRNA level, and is an area that warrants further research. The literature reports 
conflicting findings with some papers reporting that estrogen activates NF-ĸB and others 
reporting that estrogen inhibits NF-ĸB310–314. Cerillo et al. (1998) reported cell-type specific 
differences in the cross-talk between estrogen receptors and NF-ĸB signalling. Thus, the effects 
of estrogen on NF-ĸB activation in vaginal epithelial cells provide an interesting area for future 
investigations. In addition, the microarray data identified LCN2 downstream of the transcription 
factor CEBPB. CEBPB was predicted to be more activated following estrogen pretreatment plus 
flagellin than following flagellin challenge without estrogen. Furthermore, CEBPB has been 
shown to be activated by EGFR, through MAP kinase signalling, suggesting a mechanism 
whereby estrogen binding to GPER may cause upregulation of CEBPB, and hence, LCN2 
expression315. Overall, there are several pathways by which estrogen may upregulate LCN2, 
including potential NF-ĸB and CEBPB activation and direct interaction of ER-α/β with the 
LCN2 promoter. Further work is required to determine the contribution of these pathways to 
LCN2 expression in response to estrogen.  
 
RNase 7 is reported to be regulated through activation of MAP kinases, ERK1 and ERK2, but 
not NF-ĸB316. RNase 7 activation through STAT3 has also been reported317. STAT3 was 
highlighted in the microarray pathway analysis as being a strongly activated transcription factor 
following flagellin and estrogen pretreatment plus flagellin. ERK1/2 and STAT3 are all 
downstream of the EGFR, indicating that estrogen binding to GPER may result in increased 
RNase 7 gene expression via activation of EGFR and, in turn, MAP kinases and STAT3306,318. 
However, promoter analysis identified several ERE half-sites, as well as one imperfect ERE, in 
the promoter region of RNase 7. Thus, potential pathways exist for induction of RNase 7 
expression by GPER and ER-α/β. 
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Finally, the regulation of S100A7 is less clear, however, S100A7 has been shown to be induced by 
IL-1β, which is upstream of both NF-ĸB and MAP kinase signalling pathways319. As discussed for 
LCN2 and RNase 7, both NF-ĸB and MAP kinase signalling pathways may be activated by 
binding of estrogen to GPER. The promoter region of S100A7 showed multiple ERE half-sites, 
and two imperfect full EREs. Thus, potentiation of S100A7 expression by estrogen may occur 
through GPER or ER-α/β. ER-β regulation of S100A7 has been reported in breast cancer cells, 
and thus further work using site-directed mutagenesis may confirm this and reveal which of the 
ERE half-sites are important for S100A7 expression320.  
  
A diagram summarising potential pathways of estrogen regulation of LCN2, RNase 7, and 
S100A7 is shown in Figure 5.24. 
 
 
Figure 5.24: Regulatory pathways of hBD2, hBD3, LCN2, RNase 7, and S100A7. The figure shows potential 
pathways of hBD2, hBD3, LCN2, RNase 7, and S100A7 regulation by estrogen and flagellin.  
 
Interestingly, the microarray data in Chapter 4 also identified potentiation of the proinflammatory 
cytokine IL-36G by estrogen pretreatment plus flagellin, compared to flagellin challenge alone. 
IL-36G has been reported to activate NF-ĸB and MAP kinase signalling in T cells and breast 
cancer cells235,236. This indicates that upregulation of IL-36G by estrogen may activate pathways 
involved in AMP gene transcription. In support of this, stimulating primary human keratinocytes 
with exogenous IL-36G has been shown to upregulate the expression of S100A7321. 
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Further work to decipher the roles of the estrogen receptors in AMP expression should employ 
ER-α and –β inhibitors without agonist activity on GPER. Fulvestrant is the only combined ER-
α and –β inhibitor, which is why it was used here, however, MPP dihydrochloride and PHTPP 
are selective antagonists for ER-α and –β, respectively, and could be used separately, or in 
combination, to inhibit ER-α and –β without agonism on GPER. Inhibition of GPER with the 
selective antagonist G-15, which has no affinity for ER-α or –β, may also elucidate the role of 
GPER in AMP expression.   
 
To summarise, this chapter investigated the potential mechanisms by which estrogen regulates 
AMP expression. Although the results for some of the AMP genes were not clear-cut, data 
corresponding to mutagenesis of the ERE half-sites in the hBD2 promoter were strongly 
suggestive of a role for ER-α/β in hBD2 gene transcription, and this was a novel finding. 
Conversely, the presence of only a single ERE half-site in the hBD3 promoter and no imperfect 
full ERE sequence makes it unlikely that hBD3 is regulated by estrogen in the same manner as 
hBD2. Results relating to LCN2, RNase 7 and S100A7 were more ambiguous and require further 
experiments to clarify the regulation of these genes by estrogen. Nevertheless, the results for 
hBD2 and hBD3 indicate that multiple mechanisms for AMP expression by estrogen may exist, 
and that a broad range of cellular responses activated by estrogen, through GPER and ER-α/β, 
may be needed to mount an effective antimicrobial response to infection. This will be important 
to consider in the development of novel therapeutics for UTIs. In addition to this, the suggestion 
of GPER desensitisation in response to prolonged stimulation may have important repercussions 
on the use of long-term estrogen as a prophylactic treatment for UTIs, and should be explored 
further.  
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6 Role of IL-17 in antimicrobial peptide expression 
6.1 Introduction 
Analyses of the microarray data in Chapter 4 identified ‘The Role of IL-17A in Psoriasis’ as the 
canonical pathway most activated by estrogen pretreatment plus flagellin challenge (shown in 
Figure 6.1). This pathway consists of IL-17A binding to the IL-17 receptor complex (IL-
17RA/RC) and activating transcription of the AMPs hBD2 and S100A7, as well as genes such as 
S100A8/A9, CCL20 and IL-8, which are associated with an inflammatory response. This was 
suggestive of a role for IL-17 in AMP transcription in the vaginal epithelium and warranted 
further investigation.  
 
 
Figure 6.1: ‘Role of IL-17A in Psoriasis’ pathway. Shading of the molecules shows their upregulation following 
estrogen pretreatment plus flagellin after 12 hours, the darker red the more upregulation.  
 
IL-17 was initially identified in 1993 and was found to function as a proinflammatory 
cytokine322,323. Its discovery also lead to the identification of a new subset of T helper cells, named 
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T helper 17 (Th17) cells, which are the main source of IL-17 secretion. IL-17 is also secreted 
from other cell types, such as γδT cells and mast cells324,325. T helper cells secrete a specific 
cytokine profile that ensures the host mounts an appropriate immune response for the invading 
pathogen. For example, Th1 cells produce IFN-γ and TNF-α, which aid in the clearance of 
intracellular pathogens326. Th2 cells produce cytokines such as IL-4 and -5, which drive the 
immune system towards an anti-parasitic response. Th17 cells are a distinct subset from Th1 and 
Th2 cells, and produce cytokines such as IL-17 and IL-22327. Th17 cells protect mucosal surfaces 
from invading pathogens and promote extracellular bacterial killing328.  
 
There are six members of the IL-17 family, IL-17A to IL-17F, with IL-17A and IL-17F being the 
most well characterised members. IL-17A and IL-17F are encoded on the same gene locus on 
chromosome 6; the other four IL-17 family members are encoded elsewhere in the genome, but 
share structural similarity329. IL-17A and IL-17F can form homodimers or heterodimers of the 
two subunits. IL-17A is a more potent inducer of cytokine secretion than IL-17F, and IL-17A/F 
heterodimers have intermediate activity330. IL-17B, IL-17C, and IL-17D are also considered to be 
proinflammatory cytokines, but they are not well understood. Emerging evidence suggests IL-
17C can be expressed by epithelial cells, however microarray analysis in Chapter 4 did not 
identify IL-17C expression in VK2 cells331,332. IL-17E, also known as IL-25, shares the lowest 
homology with the rest of the family and is involved in Th2 cell responses to parasites and 
allergies333.  
 
To initiate cell signalling IL-17 binds to the IL-17 receptor, a cell membrane receptor 
ubiquitously expressed on many cells throughout the body334–338. The IL-17 receptor family 
consists of five members, IL-17RA to IL-17RE, the genes of which are mostly clustered on 
chromosome 3. IL-17RA and IL-17RC subunits form a receptor complex that binds IL-17A and 
IL-17F homodimers and heterodimers339. Binding of IL-17A/F to the IL-17RA/RC complex 
activates signalling through several pathways including NF-ĸB, MAPK and C/EPB, resulting in 
production of proinflammatory cytokines, chemokines, and other important immune response 
effectors such as antimicrobial peptides327,340–342. In addition to inducing expression of 
inflammatory genes, activation of MAPK by IL-17 also results in stabilisation of the mRNA of 
cytokines and chemokines, such as IL-6 and IL-8343,344. This increased stability prevents 
degradation of the mRNA before translation and thus results in greater production of these 
cytokines. Consequently, IL-17 has been identified as having an important role in host defence 
against pathogens.  
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Clinically, the importance of IL-17 signalling during an infection is demonstrated by patients with 
mutations in the IL-17F and IL-17RA genes345. These patients have recurrent infections of the 
skin, nails and oral and genital mucosa by C. albicans and S. aureus. This is supported by mouse 
models, which show that IL-17 signalling is crucial to protect against C. albicans and S. aureus, but 
also several other pathogens including Helicobacter pylori and Neisseria gonorrhoeae346–349. IL-17A has 
also been shown to be important for murine defence against uropathogenic E. coli during a UTI 
by stimulating a neutrophil migration response; mice lacking a neutrophil response were unable 
to clear E. coli from the bladder and kidney and suffered from a persistent infection79. 
Furthermore, neutrophil recruitment and bacterial clearance were attenuated in IL-17A null mice, 
indicating this as an important cytokine in bacterial clearance during a UTI350.  
 
The microarray data reported in Chapter 4 revealed upregulation of genes downstream of the 
‘Role of IL-17A in Psoriasis’ pathway following estrogen pretreatment plus flagellin challenge, 
despite the cells not being exposed to IL-17A during this experiment. This suggested that, in 
addition to estrogen, IL-17A may also have a role in AMP expression. Thus, production of IL-
17A by Th17 cells during an infection may affect the regulation of AMPs. It was, therefore, of 
interest to investigate the potential roles of IL-17A in vaginal AMP expression and consider the 
combined effects of estrogen and IL-17A on AMP expression during simulated infection. Such 
analyses were attempted to determine whether estrogen retains the ability to potentiate AMP 
expression in the presence of the proinflammatory cytokine IL-17A, or whether introduction of 
IL-17A to the VK2 cells negates the potentiation of AMP gene expression by estrogen.  
 
6.2 IL-17 receptor expression in VK2 cells 
To determine whether the VK2 cells were able to bind to IL-17A, end-point PCR was performed 
for the IL-17 receptor complex subunits IL-17RA and IL-17RC. These two members form a 
heterodimer on the cell surface, bind IL-17A and IL-17F homo/heterodimers, and initiate a 
signalling cascade339,351. PCR products of 132bp and 338bp, representing IL-17RA and IL-17 RC, 
respectively (Figure 6.2), were detected. The IL-17RA and IL-17RC PCR products were 
confirmed by sequencing and had 98% and 99% identity, respectively, to the BLAST database 
subject sequence. The VK2 cells were therefore expected to be responsive to IL-17A. 
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Figure 6.2: Expression of IL-17RA and IL-17RC in VK2 cells. End-point PCR performed on cDNA from VK2 
cells shows (A) IL-17RA PCR products at 132bp and (B) IL-17RC PCR products at 338bp. In each gel a 100bp 
DNA Ladder (New England BioLabs, USA) is in lane 1, and PCR products are shown in lanes 2-5. The PCR 
products were confirmed by sequencing (Genevision, UK) and the nucleotide BLAST alignment is shown. The 
query sequence is the sequence of the PCR product as determined by sequencing and the subject (sbjct) sequence is 
the BLAST database sequence. 
 
6.3 Effects of IL-17A concentrations on AMP expression 
To determine the effects of IL-17A on AMP expression, VK2 cells were treated with 
recombinant IL-17A (Sigma, USA) at concentrations ranging from 0.1ng/ml to 100ng/ml for 24 
hours. This broad range of concentrations was investigated, initially, to establish at what IL-17A 
concentration (if any) significant AMP induction was observed. Control cells were treated with 
vehicle only. After challenge the RNA was extracted, reverse transcribed into cDNA, and 
analysed by qPCR for the expression of hBD2, hBD3, LCN2, RNase7 and S100A7 (Figure 6.3). 
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The qPCR results were normalised to the two housekeeping genes GAPDH and ATP5B, and 
then to 100ng/ml IL-17A. These AMPs were identified by the microarray as being upregulated 
by estrogen pretreatment, and have been studied in previous chapters of this thesis. The ‘Role of 
IL-17A in Psoriasis’ pathway showed only hBD2 and S100A7 downstream of IL-17A, thus it was 
of interest to determine whether other AMPs were also regulated by IL-17A signalling.  
 
AMP expression typically exhibited an IL-17A dose dependent response, with higher 
concentrations of IL-17A resulting in higher expression of AMPs (Figure 6.3). For hBD2, IL-
17A at concentrations of 0.1ng/ml and 1ng/ml did not significantly increase expression 
compared to control (Figure 6.3A). However, 10ng/ml IL-17A significantly increased hBD2 
expression to 49AU from 4.7AU in the control samples (p<0.0001). This was representative of a 
10-fold increase in hBD2 expression compared to control. 100ng IL-17A further increased hBD2 
expression to 100AU, a 21-fold increase relative to control (p<0.001). In contrast, hBD3 
expression did not appear to be affected by exogenous IL-17A (Figure 6.3B), as none of the 
concentrations used resulted in a statistically significant increase in hBD3 expression. 
 
IL-17A induced a dose dependent response in LCN2 expression; 1ng/ml, 10ng/ml and 
100ng/ml IL-17A resulted in expression levels of 31AU, 78AU and 100AU, respectively. This 
was reflective of a significant 5.3-, 13- and 17-fold change in LCN2 expression, respectively, 
compared to the control (p=0.0252, p<0.0001 and p<0.001, respectively, Figure 6.3C). 
Interestingly, all of the concentrations of IL-17A administered to the VK2 cells resulted in a 
significant increase in RNase 7 expression, ranging from a 1.5-fold change with 0.1ng/ml IL-17A 
(p=0.0108) to a 1.9-fold change with 100ng/ml IL-17A (p<0.0001), compared to the control 
samples (Figure 6.3D). Conversely, S100A7 expression was only increased by 100ng/ml IL-17A, 
which resulted in a significant 2.0-fold upregulation of S100A7, compared to the control samples 
(p<0.0001). 
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Figure 6.3: Effects of IL-17A concentrations on antimicrobial peptide gene expression. VK2 cells were 
challenged with 0.1-100ng/ml IL-17A or vehicle only for 24 hours. RNA was then extracted and analysed by qPCR 
for the expression of (A) hBD2, (B) hBD3, (C) LCN2, (D) RNase 7, and (E) S100A7. Results were normalised to 
100ng/ml IL-17A challenge. Error bars represent standard error. Statistical analysis was performed by one-way 
ANOVA with Dunnett’s post hoc test. ns=not significant, *=p<0.05, **=p<0.01, ***=p<0.001. N=2, n=6. 
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Thus, all of the AMPs, with the exception of hBD3, were responsive to IL-17A, typically 
showing a dose dependent upregulation of gene expression. The AMPs hBD2 and LCN2 showed 
the strongest gene expression induction in response to IL-17A. These data indicated that, in 
addition to estrogen, IL-17A is also an inducer of AMP expression and may be an important 
regulator during infection. Therefore, it was of interest to establish whether estrogen and IL-17A 
work synergistically to further increase AMP expression, or whether either treatment results in 
maximal expression that is not increased by further treatments. As 100ng/ml IL-17A induced 
significant upregulation of all the AMPs measured, except hBD3, this concentration of 
recombinant IL-17A was used for further experiments. Additionally, use of this concentration 
examined whether high concentrations of proinflammatory cytokines, such as IL-17A, negated 
the beneficial effects of estrogen on AMP expression, or whether estrogen potentiated AMP 
expression over and above that observed with 100ng/ml IL-17A. 
 
6.4 Effects of estrogen pretreatment, IL-17A, and flagellin on AMP expression 
To examine potential synergistic effects of IL-17A and estrogen on AMP expression during 
infection VK2 cells were pretreated with 4nM estrogen, or cyclodextrin vehicle, for seven days 
and then challenged with 100ng/ml IL-17A and/or 50ng/ml flagellin for 24 hours. The RNA 
was extracted and qPCR analysis was performed for the AMPs hBD2, hBD3, LCN2, RNase 7 
and S100A7 to determine gene expression.  
 
Following the challenge, hBD2 expression increased from 0.3AU in the control samples to 23AU 
with IL-17A alone, and 41AU with estrogen pretreatment plus IL-17A. This represented a 77-
fold change with IL-17A without estrogen pretreatment and a 137-fold change with estrogen 
pretreatment plus IL-17A, compared to control, supporting increased gene expression following 
estrogen pretreatment (Figure 6.4A). A similar trend was seen with flagellin challenge, which 
increased hBD2 expression to 100AU (333-fold change compared to control) without estrogen 
pretreatment, and 159AU (531-fold change compared to control) with estrogen pretreatment 
prior to flagellin challenge. Statistical analyses of these data did not indicate this to be a significant 
difference, although this response was found to be significant in previous experiments in 
Chapters 3 and 5. Combined IL-17A and flagellin treatment without estrogen pretreatment 
resulted in a substantial 2307-fold change in gene expression, compared to the control samples. 
Nevertheless, estrogen pretreatment prior to combined IL-17A and flagellin challenge 
potentiated hBD2 expression and resulted in a 3712-fold increase in gene expression compared 
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to the control. This represented a significant 1.6-fold increase in hBD2 expression compared to 
IL-17A plus flagellin challenge without estrogen (p=0.014).  
 
A similar trend was also seen for hBD3 (Figure 6.4B), whereby there was a clear trend towards 
increased expression with estrogen pretreatment compared to the same challenges without 
estrogen pretreatment. IL-17A challenge without estrogen pretreatment increased hBD3 
expression to 51AU, from 30AU in the control. Estrogen pretreatment prior to IL-17A challenge 
further increased hBD3 expression to 85AU, representative of a 1.7-fold change compared to IL-
17A challenge without estrogen. Flagellin challenge alone resulted in a 3.3-fold change in 
expression to 100AU, from 30AU in the control. This again increased to 154AU when estrogen 
pretreatment was given prior to flagellin challenge, representative of 5.1-fold change in hBD3 
expression relative to control. This result supported the data shown in previous chapters. 
Combined IL-17A and flagellin challenge upregulated hBD3 expression to 238AU without 
estrogen pretreatment, representative of a 7.8-fold change compared to control samples. This 
increased to 331AU after estrogen pretreatment, IL-17A and flagellin, representative of an 11-
fold change compared to control, and a significant 1.4-fold change compared to IL-17A plus 
flagellin without estrogen pretreatment (p=0.014). 
 
The results also suggested an increase in LCN2 expression in response to estrogen pretreatment 
prior to IL-17A and/or flagellin challenge, although the difference was not statistically significant 
for any of the challenges (Figure 6.4C). Combined IL-17A and flagellin challenge without 
estrogen pretreatment induced LCN2 expression from 8.8AU in the control to 189AU, a 22-fold 
change in LCN2 expression. This further increased to 227AU with estrogen pretreatment, IL-
17A and flagellin, representing a 26-fold change in LCN2 expression, compared to the control. 
Thus, the results for LCN2 were suggestive of potentiation of gene expression by estrogen 
pretreatment, although these results were not statistically significant. 
 
Likewise, the results for RNase 7 suggested increased expression with estrogen pretreatment 
prior to each challenge compared to the same challenge without estrogen, but again these 
differences were not statistically significant (Figure 6.4D). IL-17A challenge without estrogen 
pretreatment resulted in RNase 7 expression of 67AU, compared to 35AU in the control 
samples, representative of a 1.9-fold change. Estrogen pretreatment plus IL-17A increased RNase 
7 expression to 99AU, which represented a 2.9-fold change compared to control samples, and a 
1.5-fold change compared to IL-17A without estrogen pretreatment. Flagellin challenge without 
estrogen pretreatment resulted in RNase 7 expression of 100AU, which rose to 136AU following 
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estrogen pretreatment plus flagellin, representative of 2.9 and 3.9-fold changes, respectively, 
when compared to the control. RNase 7 showed further induction to 183AU with combined IL-
17A and flagellin challenge, which represented a 5.3-fold change in RNase 7 expression 
compared to the control. Estrogen pretreatment prior to IL-17A plus flagellin challenge resulted 
in the greatest induction of RNase 7 expression to 246AU, which represented a 7.1-fold change 
in gene expression compared to control samples and a 1.3-fold change compared to IL-17A plus 
flagellin without estrogen pretreatment.  
 
Finally, induction of S100A7 expression by IL-17A was also augmented by estrogen pretreatment 
(Figure 6.4E). S100A7 expression was determined as 34AU for control samples. This increased to 
62AU with IL-17A challenge without estrogen pretreatment and 80AU with estrogen 
pretreatment plus IL-17A challenge, representative of 1.8- and 2.4-fold changes in S100A7 
expression compared to controls, respectively. Similarly, flagellin challenge induced S100A7 
expression to 100AU, which increased to 150AU following estrogen pretreatment plus flagellin 
challenge, representative of a significant 1.5-fold change (p=0.0126). In addition, IL-17A plus 
flagellin challenge resulted in S100A7 expression of 166AU, representative of a 4.9-fold change 
compared to control samples. However, this increased by a significant 1.5-fold to 255AU 
following estrogen pretreatment, IL-17A and flagellin (p<0.0001). 
 
195 
 
 
 
Figure 6.4: Effects of estrogen pretreatment, IL-17A, and flagellin on antimicrobial peptide expression. 
VK2 cells were pretreated with 4nM estrogen or 14.8nM cyclodextrin for 7 days and challenged with 100ng/ml IL-
17A and/or 50ng/ml flagellin for 24 hours. The RNA was extracted and analysed by qPCR for the expression of (A) 
hBD2, (B) hBD3, (C) LCN2, (D) RNase 7, and (E) S100A7. Error bars represent standard error. Statistical analysis 
was performed by two-way ANOVA using Sidak’s post hoc test. ns=not significant, *=p<0.05, ***=p<0.001. N=2, 
n=6. 
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Altogether, these results clearly indicated that there was a trend for increased AMP expression 
with estrogen pretreatment prior to challenging the cells with IL-17A and/or flagellin. Estrogen 
pretreatment, IL-17A and flagellin resulted in the greatest induction of gene expression for all of 
the AMPs measured. Thus, these data are indicative of a beneficial role for estrogen, by 
enhancement of AMP gene expression, even in the presence of proinflammatory cytokines such 
as IL-17A. 
 
6.5 Effects of estrogen pretreatment, IL-17A and flagellin on AMP secretion 
ELISAs were performed to examine the effect of estrogen pretreatment, IL-17A and flagellin on 
AMP peptide levels. As AMPs effectuate bacterial killing extracellularly, the AMP concentrations 
in the cell culture media were measured. Following pretreatment with estrogen for seven days, 
the VK2 cells were challenged with IL-17A and/or flagellin for 24 hours, the cell culture media 
was removed and stored at -80oC prior to quantification of peptide concentration by ELISA. 
ELISAs were performed for hBD2, hBD3 and LCN2.  
 
The ELISA results for hBD2 are shown in Figure 6.5. Combined data from two biological 
repeats of the experiment (with three technical replicates of each treatment within each repeat) 
showed the concentration of hBD2 in control samples was 23571pg/ml. This increased to a 
mean peptide concentration of 713101pg/ml for IL-17A and flagellin without estrogen 
pretreatment. Estrogen pretreatment prior to combined IL-17A and flagellin challenge resulted in 
a mean hBD2 concentration of 1433310pg/ml, which represented a significant 2.0-fold increase 
in hBD2 peptide concentration compared to IL-17A and flagellin without estrogen pretreatment 
(p=0.0048, Figure 6.5A). However, variability was detected between the two repeats of the 
experiment (shown in Figure 6.5B and Figure 6.5C). The first repeat showed that IL-17A plus 
flagellin resulted in a mean hBD2 concentration of 88547pg/ml, which increased significantly to 
1950174pg/ml with estrogen pretreatment, IL-17A and flagellin challenge (p=0.0004). Whereas, 
the second repeat resulted in mean hBD2 concentrations of 54111pg/ml with IL-17A plus 
flagellin challenge and 915104pg/ml after estrogen pretreatment, IL-17A and flagellin challenge. 
The increase in peptide concentration following the addition of estrogen in the second repeat was 
not statistically significant. Thus, the concentration of hBD2 after a given challenge varied 
between experimental repeats. Variability was also observed between in-plate replicates of the 
same sample; for example, the hBD2 concentration following IL-17A plus flagellin challenge was 
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determined as 721pg/ml and 955pg/ml for in-plate replicates of the same sample. As discussed 
in Chapter 3 this variability was also reflected in the standard curve and probably reflected 
reduced sensitivity of the ELISA. 
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Figure 6.5: Effects of estrogen pretreatment, IL-17A, and flagellin on hBD2 secretion. VK2 cells were 
pretreated with 4nM estrogen or 14.8nM cyclodextrin for 7 days and then challenged with 100ng/ml IL-17A and/or 
50ng/ml flagellin for 24 hours. The medium was removed from the cells and analysed by ELISA for hBD2 
secretion. (A) shows combined results from two experiments, N=2, n=4. (B) and (C) show the results from each 
biological repeat of the experiment separately, N=1, n=2. Error bars represent standard error. Statistical analysis was 
performed by two-way ANOVA with Sidak’s post hoc test. **=p<0.01, ***=p<0.001. 
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The data for hBD3 is shown in Figure 6.6. Similar to data reported in Chapter 3, the ELISA 
results did not show a significant change in hBD3 protein concentrations for any of the 
treatments. These data did not fit with mRNA data, which showed an 11-fold increase in hBD3 
expression with estrogen pretreatment, IL-17A, plus flagellin after 24 hours, compared to control 
samples.  
 
 
Figure 6.6: Effects of estrogen pretreatment, IL-17A, and flagellin on hBD3 secretion. VK2 cells were treated 
with 4nM estrogen or 14.8nM cyclodextrin for 7 days and then challenged with 100ng/ml IL-17A and/or 50ng/ml 
flagellin for 24 hours. The medium was removed from the cells and analysed by ELISA for hBD3 secretion. Error 
bars represent standard error. Statistical analysis was performed by two-way ANOVA with Sidak’s post hoc test. 
N=1, n=3. 
 
The ELISA results for LCN2 are shown in Figure 6.7. Combined data from two repeats of the 
experiment showed that IL-17A plus flagellin both with and without estrogen pretreatment 
significantly increased LCN2 protein secretion compared to control samples (p=0.0048 and 
p=0.0166, respectively). However, the addition of estrogen did not significantly increase the 
protein concentration compared to IL-17A plus flagellin challenge without estrogen (Figure 
6.7A). Flagellin challenge did not significantly increase LCN2 protein concentration compared to 
control, and once again no significant differences in LCN2 protein concentrations were observed 
between flagellin challenge with and without estrogen pretreatment.  IL-17A challenge with and 
without estrogen also did not significantly increase LCN2 concentrations compared to the 
control. Variability was detected in the LCN2 peptide concentration measured in the two repeats 
of the experiment. The first repeat showed a mean peptide concentration of 1217184pg/ml in 
the control samples which increased to 857423pg/ml following estrogen pretreatment, IL-17A 
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and flagellin (Figure 6.7B). The second repeat exhibited a mean LCN2 concentration of 
1538163pg/ml in the control samples, which was comparable with the level measured in the 
first repeat (Figure 6.7C). However, following estrogen pretreatment, IL-17A and flagellin the 
peptide concentration in the second repeat was determined as 3692432pg/ml, which was 
substantially lower than the 8574pg/ml measured for the first repeat following the same 
treatment. The trend of lower AMP secretion in the second repeat was also seen for hBD2, 
suggesting this difference may have reflected technical issues in the repetition of the experiment.  
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Figure 6.7: Effect of estrogen pretreatment, IL-17A, and flagellin on LCN2 secretion. VK2 cells were treated 
with 4nM estrogen or 14.8nM cyclodextrin for 7 days and then challenged with 100ng/ml IL-17A and/or 50ng/ml 
flagellin for 24 hours. The medium was removed from the cells and was analysed by ELISA for LCN2 secretion. (A) 
shows the combined results from two biological repeats, N=2, n=4. (B) and (C) show the results from each 
biological repeat separately, N=1, n=2. Error bars represent standard error. Statistical analysis was performed by 
two-way ANOVA with Sidak’s post hoc test. *=p<0.05. 
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Unlike the hBD2 and hBD3 ELISAs, the LCN2 ELISA showed good agreement between in-
plate replicates of the samples. This was reflected in the standard curve (Figure 6.8), which 
demonstrated that the LCN2 ELISA assay accurately detected the LCN2 concentration of the 
standards. This suggested that the assay was very sensitive and reliable.  
 
The peptide data for hBD2, hBD3 and LCN2 is summarised in Table 6.1. 
 
 
Figure 6.8: LCN2 ELISA standard curve. A standard curve was included on each LCN2 ELISA plate and 
consisted of recombinant LCN2 serially diluted 1:2 from 5000pg/ml to 20pg/ml. (A) shows the standard curve line 
of best fit. (B) shows the measured concentration of each of the standard replicates. 
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Table 6.1: Summary of hBD2, hBD3 and LCN2 peptide data. The table shows the peptide concentration 
measured for each repeat of the experiment and the overall average and standard error of the mean (SEM).  
 
 
6.6 Discussion 
Analyses of microarray data in Chapter 4 revealed that IL-17A may be an important regulator of 
AMP expression in epithelial cells through interaction with the IL-17 receptor IL-17RA/RC. 
Examination of the activated canonical pathways showed that after estrogen pretreatment plus 
flagellin challenge the most activated pathway was the ‘Role of IL-17A in Psoriasis’ (Figure 6.1). 
This pathway involves IL-17A binding to the IL-17A receptor (IL-17RA/RC) and initiating 
transcription of antimicrobial genes (DEFB4A, S100A7, S100A8, S100A9) and inflammatory 
genes (CCL20, CXCL1, CXCL3, CXCL5, CXCL6, IL-8). IL-17A was not present in the VK2 cell 
challenge with estrogen pretreatment plus flagellin, as IL-17A is not produced by epithelial cells. 
Nevertheless, qPCR data showed that estrogen pretreatment plus flagellin challenge potentiated 
the expression of a number of these genes compared to flagellin challenge alone. Taken together, 
these qPCR and microarray data suggest that both estrogen and IL-17A have a role in AMP 
regulation. Thus, it is possible that production of IL-17A by Th17 cells during a UTI may alter 
AMP expression. It was, therefore, of interest to challenge the cells with IL-17A, with and 
without estrogen pretreatment and flagellin, to investigate the combined effect of these 
treatments on the expression of AMPs in the urogenital tract. 
 
It is well established in the literature that IL-17A exerts its actions by binding to the IL-17 
receptor, both subunits of which (IL-17RA and IL-17RC) are required for IL-17A signalling351. 
Thus, end-point PCR was used to confirm that VK2 cells do indeed express both the IL-17RA 
and RC subunits (Figure 6.2). Previous studies have used transgenic mice lacking the IL-17RA 
gene to study vaginal infections, however IL-17RA expression in the vagina was not explicitly 
shown as part of these studies352,353. Furthermore, tissue expression of IL-17RC was extensively 
analysed by Ge and You (2008) and was found to be expressed in numerous tissues throughout 
the body, including many epithelial cells335. However, vaginal expression was not investigated by 
Repeat 1 Repeat 2 Average (SEM) Repeat 1 Repeat 1 Repeat 2 Average (SEM)
n=2 n=2 n=4 n=3 n=2 n=2 n=4
Control - Estrogen 137 334 235 (71) 143 15 1217 1538 1377 (137)
+ Estrogen 174 404 289 (71) 138 14 1734 1467 1601 (155)
IL-17A - Estrogen 254 319 286 (34) 151 23 2150 1064 1607 (326)
+ Estrogen 325 638 481 (145) 138 14 3568 1451 2510 (623)
Flagellin - Estrogen 786 646 716 (99) 142 5 4455 2173 3314 (687)
+ Estrogen 810 696 753 (73) 144 10 5428 2451 3940 (898)
IL-17A + Flagellin - Estrogen 885 541 713 (101) 131 6 8058 2996 5527 (1464)
+ Estrogen 1950 915 1433 (310) 160 7 8574 3692 6133 (1420)
LCN2 (pg/ml)
SEM
hBD2 (pg/ml) hBD3 (pg/ml)
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Ge and You, suggesting that the discovery of IL-17RA and IL-17RC expression in vaginal 
epithelial cells is novel. 
 
The VK2 cells were challenged with a range IL-17A concentrations, from 0.01ng/ml to 
100ng/ml, and qPCR was performed to determine the effect of increasing IL-17A concentrations 
on AMP expression. The literature is conflicting with regards to physiological IL-17A 
concentrations, with reported serum values for healthy patients varying 1000-fold, ranging from 
4.4pg/ml to 2.88ng/ml283,354,355. The average urine IL-17A concentration in patients with greater 
than 5x105 CFU E. coli (the number of E. coli required to clinically diagnose a UTI) was 
5.05pg/ml (Lauren Drage, PhD thesis in preparation). However, as this was IL-17A measured in 
the urine the concentration is likely to be much more dilute than that which is present at the 
surface of the bladder epithelium. It can be argued therefore, that dilution of IL-17A would not 
occur to the same extent in the vaginal fluids as there is a much smaller volume of liquid in the 
vaginal lumen than the volume of urine in the bladder, thus the concentration of IL-17A in the 
vaginal lumen during infection may be higher than that of the bladder. However, to quantify 
vaginal IL-17A concentrations a vaginal douche or brush sample would be needed, and both of 
these methods result in sample dilution in the collection fluid. Indeed, measurement of IL-17 
concentration in cervicovaginal lavages of women with chlamydia reported an average 
concentration of approximately 3pg/ml, however, the samples were diluted in 10mls of sterile 
saline solution, once again making the concentration at the epithelial surface difficult to 
determine356. This result, however, suggests that vaginal concentrations of IL-17A are greater 
than 3pg/ml during infection. Furthermore, to accurately determine IL-17A concentrations in 
response to UPEC colonisation the sample would have to be taken during an infection, or 
alternatively an in vivo model, using mice for example, would need to be employed. Thus, in the 
future it would be of interest to determine the concentration of IL-17A in the vaginal epithelium 
of both healthy patients and patients during an active UTI. Other researchers have employed IL-
17A concentrations ranging from 20-200ng/ml to study the effects of IL-17A on epithelial cells 
and thus, for the dose response experiments VK2 cells were initially treated with 0.1ng-100ng/ml 
IL-17A for 24 hours to observe the effect on AMP expression317,327,357. The trend seen with each 
AMP was that expression was IL-17A dose dependent, with 100ng/ml IL-17A resulting in the 
highest level of gene expression for each AMP (Figure 6.3). hBD3 was the only AMP which was 
not significantly upregulated by IL-17A, however, a recent paper by Burgey et al. (2016), showed 
that IL-17 did not induce hBD3 expression in immortalised human keratinocytes and nasal 
epithelial cells, but was able to induce hBD3 expression in primary human nasal epithelial cells358. 
Thus, it will be important to repeat this work using primary vaginal epithelial cells.  
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To investigate whether IL-17A and estrogen work synergistically on AMP expression, VK2 cells 
were pretreated with estrogen for seven days and then challenged with IL-17A and/or flagellin. 
This modelled IL-17 production in the vagina during an infection, with and without estrogen, to 
determine which conditions best promote AMP expression. An IL-17A concentration of 
100ng/ml was selected as this was the most potent inducer of AMP expression. Thus, without 
knowing the true epithelial concentration of IL-17A, initial investigations examined whether 
estrogen pretreatment potentiated AMP expression above that seen with 100ng/ml IL-17A, or 
whether high concentrations of the proinflammatory cytokine IL-17A negated the beneficial 
effects of estrogen pretreatment on AMP expression. The results showed that the expression of 
hBD2, hBD3 and S100A7 was significantly increased when IL-17A and flagellin were given 
following estrogen pretreatment, compared to the same treatment without estrogen (Figure 6.4). 
hBD2 expression exhibited the most dramatic induction, with a 2307-fold change in gene 
expression following IL-17A plus flagellin treatment, increasing to a 3711-fold change after the 
same challenge with estrogen pretreatment. S100A7 and hBD3 displayed more modest fold 
changes of 4.9 and 7.9, respectively, following IL-17A plus flagellin challenge. The expression of 
S100A7 and hBD3 increased to 7.5- and 11-fold change, respectively, following estrogen 
pretreatment, IL-17A plus flagellin challenge. The same trend was also seen for LCN2 and 
RNase 7, with increased expression following estrogen pretreatment, IL-17A plus flagellin 
challenge compared to IL-17A plus flagellin challenge, however, these data were not statistically 
significant. These data are important as they indicate that even following proinflammatory 
cytokine production during an infection, which substantially increases AMP expression, the 
presence of estrogen results in further upregulation of gene expression. Thus, if estrogen 
potentiates AMP gene expression at high concentrations of IL-17A, it can be speculated that 
even if the physiological concentration of IL-17A is lower than 100ng/ml, estrogen is important 
for AMP gene expression. Hence, it can be argued that the production of proinflammatory 
cytokines, such as IL-17A, during an infection in postmenopausal women does not result in the 
same level of AMP expression as that in premenopausal women.  
 
Peptide quantification by ELISA was also performed for hBD2, hBD3 and LCN2 (Figure 6.5, 
Figure 6.6, and Figure 6.7). The results for the hBD2 ELISA showed a significant increase in 
hBD2 concentration in the cell culture media following estrogen pretreatment with IL-17A plus 
flagellin, compared to IL-17A plus flagellin without estrogen pretreatment. However, there was 
variability in the results seen with each repeat experiment. As discussed previously, the hBD2 
ELISA standard curve also suggested that the commercial assay is not particularly sensitive, 
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despite the kit stating the lower limits of detection as 8pg/ml and thus, these data should be 
interpreted with caution. Further work is needed to firmly establish the effect of these treatments 
on hBD2 secretion. In agreement with data shown in Chapter 3, the hBD3 ELISA showed no 
significant increase in hBD3 protein secretion with any of the treatments. This does not fit with 
the mRNA data which showed an approximate 11-fold increase in gene expression following 
estrogen pretreatment, IL-17A and flagellin challenge. It is possible that the 24 hour time point 
was too early to detect changes in hBD3 peptide levels. In Chapter 3 hBD2 and hBD3 expression 
was measured at 8, 12 and 24 hours after challenge with estrogen pretreatment and/or flagellin 
and increases in hBD3 expression were delayed in comparison to hBD2; flagellin treatment 
resulted in increases in hBD2 expression by the 8 hour time point, but hBD3 expression did not 
increase with flagellin challenge until the 24 hour time point. Thus, it is feasible that changes in 
hBD3 peptide levels may not be observed until later collection time points. The LCN2 ELISA 
showed that IL-17A plus flagellin significantly increased LCN2 protein levels, both with and 
without estrogen, compared to control. However, no difference in protein concentration was 
seen between the estrogen positive and estrogen negative samples. The standard curve 
demonstrated that the LCN2 ELISA was extremely sensitive and thus provided reliable data. 
Previous work in our laboratory has measured LCN2 peptide concentrations in vaginal douches 
from postmenopausal women. These data revealed that women receiving topical estrogen 
treatment had a significantly higher mean vaginal LCN2 concentration (6211ng/ml) than 
postmenopausal women who did not receive topical estrogen treatment (244ng/ml). Thus, the 
ELISA data presented here were not reflective of the mRNA data, or of in vivo data obtained by 
our laboratory, which suggest that estrogen does indeed increase AMP secretion from vaginal 
epithelial cells. Further experiments including additional time points are required to investigate 
this discrepancy further, and to fully establish the role of estrogen in AMP secretion in the VK2 
cell model.  
  
Overall, the data in this chapter indicated that IL-17A is an important regulator of AMP 
expression, and that estrogen pretreatment prior to IL-17A plus flagellin challenge upregulated 
expression of all AMPs measured. In vivo it is predicted that IL-17A would be produced by Th17 
cells recruited to the site of infection by CCL20, which binds to the CCR6 receptor on Th17 cells 
and stimulates migration277,278,359. Microarray data showed that the cytokine CCL20 was expressed 
following flagellin and estrogen pretreatment plus flagellin challenges (Figure 6.1), indicating that 
vaginal UPEC colonisation results in a CCL20 concentration gradient towards which Th17 cells 
could migrate. Moreover, downstream effects analysis of the microarray data revealed many 
functions relating to immune cell migration, such as “Cell movement of leukocytes”, were 
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upregulated by flagellin and estrogen pretreatment plus flagellin challenges, further supporting 
the notion that infection of the urogenital tract would result in Th17 cell migration. This premise 
is also supported by the literature, which reports that IL-17 has been detected in vaginal fluid 
from mice infected with C. albicans353. Furthermore, treatment with halofuginone, which inhibits 
Th17 cell differentiation, lowered vaginal IL-17 production in mice infected with C. albicans, 
demonstrating that the source of vaginal IL-17 is Th17 cells349. Masson et al. (2015) also showed 
that IL-17 was increased in cervicovaginal lavages of women with bacterial sexually transmitted 
diseases, such as chlamydia, compared to healthy controls356. Thus, taken together, these results 
support the hypothesis that Th17 cell migration and IL-17 production occurs in the vagina 
following infection. 
 
IL-17 production by Th17 cells at the site of infection is important for bacterial clearance and has 
been shown to have multiple antimicrobial roles. Firstly, as demonstrated here and by others, IL-
17 increases AMP expression317,327,357. Secondly, Th17 cells recruit neutrophils to the site of 
infection through CXCL8, a process that has been shown to be vital to the clearance of a UTI. 
Mice lacking the IL-17A gene were shown to have significantly fewer neutrophils in their urine 
following transurethral infection with E. coli than WT mice350,360. Furthermore, mice with a 
neutrophil migration deficiency that were infected transurethrally with E. coli were unable to clear 
the infection and the bacteria persisted longer in the urinary tract than in neutrophil migration 
competent mice79.  Thus, migration of neutrophils to the urogenital tract during a UTI is crucial 
for bacterial clearance and is linked to IL-17A production. In addition, estrogen pretreatment 
plus flagellin resulted in greater expression of S100A8 and S100A9 than flagellin challenge alone, 
according to the microarray data. These proteins have been reported to be important chemotactic 
factors for neutrophil migration240. Upregulation of these genes by estrogen is suggestive of a role 
for estrogen in increasing neutrophil migration to the site of infection, and thus, enhancing 
bacterial clearance. Finally, IL-17A null mice have also been shown to have significantly reduced 
IL-4 expression in the bladder, in response to UPEC stimulation, than wild type mice350. As IL-4 
has a role in B cell activation, this suggests IL-17 may also be an important link between innate 
and adaptive immunity361. Therefore, despite the name, activation of the ‘Role of IL-17A in 
Psoriasis’ pathway, highlighted by microarray analysis, is likely to be important for antimicrobial 
responses in other tissues and conditions besides psoriasis, for example in protection against 
UTIs.   
 
The role of IL-17A in UTIs is a relatively novel area, and the initial findings are encouraging. 
However, further work is clearly needed to expand upon this hypothesis and further elucidate the 
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interplay between estrogen and IL-17 in protection against UTIs. Further work should involve 
measurement of IL-17A in the vagina during a UTI. This would not only show that Th17 cells 
are recruited to the vagina during a UTI and secrete IL-17 in the area, but would also determine 
the concentration of IL-17 in the vagina during UPEC colonisation. It would also be of great 
interest to investigate whether there is an effect of estrogen on Th17 cell migration and IL-17 
production in the vagina in response to colonisation, to determine whether estrogen also acts to 
promote IL-17 mediated responses. Such work could not be achieved within the timeframe of 
this thesis and would either require the use of human vaginal tissue from women with an 
infection at time of collection or mouse models. The interplay between estrogen and Th17 cells 
has been studied somewhat in the context of rheumatoid arthritis (RA). Th17 cell migration to 
the synovial fluid of joints has been shown to exacerbate RA, and IL-17 has been identified as a 
key molecule in driving inflammation and the destruction of joints in RA360,362,363. Similarly to 
UTIs, RA worsens following the menopause, which brought about the idea of hormonal 
regulation of RA and the hypothesis that the reduction in estrogen after the menopause promotes 
increased Th17 cell migration to joints, driving inflammation. This suggests that estrogen and IL-
17 have an inverse correlation. However, evaluation of the literature in this area shows that 
estrogen actually increases the expression of CCL20 (the chemokine responsible for Th17 cell 
migration), but that this increase occurs within lymph nodes and thus prevents migration of Th17 
cells to the site of inflammation364. Loss of estrogen following the menopause, therefore, results 
in reduced CCL20 expression in the lymph node and consequently, Th17 cell migration to the 
joints. Murine models of arthritis employ systemic estrogen treatment of ovariectomised mice to 
simulate the premenopausal state, whereas topical estrogen treatment would be employed for 
treatment of UTIs after the menopause. Therefore, it would be of interest to investigate whether 
localised application of estrogen increases Th17 cell migration to the site of topical treatment, or 
whether estrogen interferes with Th17 cell migration as shown for systemic estrogen in RA. 
Indeed, the microarray data showed that estrogen pretreatment plus flagellin upregulated CCL20 
expression in VK2 cells, suggesting that topical estrogen treatment may stimulate Th17 cell 
migration to the vagina during UPEC colonisation. Furthermore, a recent paper published in 
2016 reported that estrogen treated mice showed a higher proportion of IL-17+ T cells in the 
vagina following herpes simplex virus infection than infected mice given placebo treatment, 
despite the estrogen treatment being systemic365. Altogether these data suggest that estrogen 
treatment not only increases the antimicrobial response to UTIs by potentiating AMP expression, 
but may also promote Th17 cell migration to the vagina during colonisation with UPEC, which 
in turn increases vaginal IL-17A production and AMP expression. 
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To summarise, this chapter has presented preliminary findings on the role of IL-17A in AMP 
expression from vaginal epithelial cells and demonstrated synergistic effects between IL-17A and 
estrogen on AMP expression. A model is proposed whereby upon infection of the vagina with E. 
coli from the bowel, AMP expression is induced resulting in bacterial killing (Figure 6.9A). The 
addition of estrogen treatment to the vagina primes the epithelium so that during infection AMP 
expression is increased, and therefore augments bacterial killing (Figure 6.9C). This prevents 
bacterial migration to the urethra where it may ascend to the bladder causing cystitis. 
Furthermore, infection stimulates CCL20 expression from epithelial cells which recruits Th17 
cells to the site of infection, resulting in production of IL-17A in the vagina which further 
increases AMP expression (Figure 6.9B). Th17 cells also act to recruit neutrophils through the 
cytokine CXCL8, which aid in bacterial killing, thus expediting bacterial clearance. Estrogen 
treatment of vaginal cells further potentiates the AMP expression induced by IL-17 and flagellin, 
thus further increasing bacterial killing (Figure 6.9D). This theoretical model therefore 
demonstrates how estrogen pretreatment and IL-17 production during infection may both 
contribute to effective clearance of E. coli from the vaginal reservoir, and hence prevent 
progression to UTI.  
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Figure 6.9: Model showing the role of estrogen and IL-17A in bacterial clearance from the vagina. (A) 
infection with E. coli stimulate antimicrobial peptide (AMP) production from vaginal epithelial cells causing bacterial 
killing. (B) Infection also induces CCL20 secretion from vaginal epithelial cells which causes Th17 cell migration. 
Th17 cells produce IL-17A, which upregulates AMP expression, and CXCL8, which causes neutrophil migration to 
the site of infection. Increased AMP expression and neutrophil migration increase bacterial killing. (C) The addition 
of estrogen to the vaginal epithelium increases AMP expression upon infection with E. coli, increasing bacterial 
killing. (D) AMP expression induced by IL-17A is increased further still by the addition of estrogen to the vaginal 
epithelium, increasing bacterial killing and clearance from the vagina. 
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7 Final discussion 
Work presented in this thesis has shown that estrogen acts to upregulate AMP expression in the 
urogenital tract in response to UPEC colonisation. Data obtained by qPCR and microarray 
experiments indicated that pretreatment of vaginal epithelial cells with a physiological 
concentration of estrogen for seven days prior to flagellin challenge significantly upregulated 
several AMPs including hBD2, hBD3, LCN2 and S100A7. AMPs are a vital component of the 
innate immune defence to UTI, so upregulation of multiple AMPs by estrogen indicates a role 
for estrogen in enhancing the epithelial defence against infection.  
 
In addition to enhancing the antimicrobial defences of vaginal epithelial cells, the microarray data 
also indicated that estrogen upregulated genes involved in keratinisation and inflammation. Thus, 
estrogen may induce multiple responses in vaginal epithelial cells that help protect against UTIs. 
Genes involved in keratinisation, such as keratins, small proline rich protein (SPRR) genes and 
late cornified envelope (LCE) genes, were upregulated by estrogen pretreatment. Increased 
keratinisation protects against infection by strengthening the physical barrier against microbial 
invasion. Topical estrogen treatment of the male foreskin has been reported to improve 
keratinisation of the foreskin epithelia and protect against HIV infection233. Thus, enhancement 
of the vaginal epithelial barrier may be an important mechanism by which estrogen protects 
against UTIs. Furthermore, work by Tam et al. (2012) showed that keratin fragments in the 
cornea have antimicrobial properties234. Thus, upregulation of genes involved in keratinisation by 
estrogen may not only improve the physical barrier to infection, but may also improve the innate 
antimicrobial barrier to vaginal UPEC colonisation. 
 
Inflammatory genes such as IL-36G, SERPINB4 and S100A8/9 were also highlighted by the 
microarray as being upregulated by estrogen pretreatment. IL-36G and S100A8/9 have roles in 
recruiting immune cells, such as Th17 cells and neutrophils, to the site of infection. Neutrophils 
are vital to the clearance of UPEC from the urogenital tract; mouse models of UTI with mice 
deficient in neutrophil migration show prolonged bacterial persistence in the bladder than mice 
that were neutrophil migration competent79. Th17 cells secrete the proinflammatory cytokine IL-
17A, which was shown in this thesis to have an important role in upregulation of AMP 
expression. Furthermore, IL-17A has also been demonstrated to be important for neutrophil 
migration to the bladder during UPEC infection350,360. Thus, upregulation of IL-36G, S100A8 and 
S100A9 by estrogen pretreatment may indicate a role for estrogen in enhancing migration of 
important immune cells to the vagina during UPEC colonisation and promoting bacterial 
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clearance from the vaginal reservoir.  
 
Taken together, data from this thesis and the literature indicate that estrogen has several potential 
mechanisms by which it confers protection against UPEC invasion. Firstly, estrogen promotes 
the growth of lactobacilli in the vagina, which lower the vaginal pH through production of lactic 
acid and inhibit the growth of uropathogens. Secondly, estrogen increases the keratinisation of 
the vaginal epithelium to prevent bacterial invasion. Thirdly, estrogen potentiates AMP 
expression to facilitate rapid bacterial killing and clearance from the urogenital tract. Finally, 
estrogen may also improve immune cell migration to the site of infection, further aiding in 
bacterial clearance. These diverse actions of estrogen likely all contribute to effective protection 
against UTIs in premenopausal women.  
 
7.1 Moving forward: informing the development of alternative treatments 
The in vitro findings of this thesis are supported by clinical trials that have shown that topical 
vaginal estrogen treatment reduces the incidence of UTIs in postmenopausal women190,194. 
However, although the data relating to estrogen as a treatment for UTIs in postmenopausal 
women appears promising, there are safety concerns about the use of hormonal treatments. 
Postmenopausal women may be prescribed hormone replacement therapy (HRT) to alleviate 
symptoms of the menopause, however, studies have shown that estrogen HRT increases the risk 
of endometrial cancer. To combat this, estrogen and progestin are given together to reduce the 
risk of endometrial cancer, but nevertheless, estrogen-progestin HRT is still associated with an 
increased risk of breast cancer and cardiovascular events, such as coronary heart disease and 
stroke366,367. A recent study by Jones et al. (2016) found that postmenopausal women receiving 
estrogen-progestin HRT were 2.74 times more likely to develop breast cancer than 
postmenopausal women with no previous use of HRT368. In terms of UTIs, clinical trials have 
shown that topical vaginal estrogen treatment is more effective in reducing the incidence of UTIs 
than systemic estrogen treatment190,194. However, localised vaginal estrogen treatment still results 
in raised serum estrogen concentrations, which increases the risk of breast cancer284,285. In fact, 
vaginal estrogen treatment is contraindicated for women who have previously had breast cancer. 
Thus, a non-hormonal alternative therapeutic with a similar mechanism of action to estrogen 
would be beneficial to postmenopausal women with rUTIs.  
 
The data presented in this thesis sheds light on the mechanism of action of estrogen and can be 
used to inform the development of novel therapeutics for UTIs. For example, the data in this 
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thesis has revealed that estrogen upregulates the expression of AMPs that are vital to bacterial 
clearance from the urogenital tract. Thus, the effect of new UTI therapeutics on AMP expression 
should be considered during development, as this is an important factor of vaginal defence 
against UTIs. Development of therapeutics that upregulate the vaginal AMP expression may 
provide an effective alternative to antibiotics, as well as hormonal treatments. Alternative UTI 
treatments to estrogen will now be discussed with regards to their mechanism of action and how 
the new information about the mechanism of action of estrogen from this thesis may inform 
their development.    
 
7.1.1 Natural agents from diet 
7.1.1.1 Phytoestrogens 
The most obvious alternatives to estrogen are phytoestrogens, which are plant-derived xeno-
estrogens with estrogenic properties. Resveratrol and genistein are two common phytoestrogens 
found in the diet. Resveratrol is found in foods such as grapes, red wine and peanuts, whereas 
genistein is mainly found in soy. In 2011, Lee et al. showed that 25μM resveratrol treatment for 2 
hours followed by exposure to LPS and heat stress increased hBD2 expression in primary human 
dental pulp cells, compared to cells exposed to LPS and heat stress without resveratrol 
treatment369. This finding was supported by work by Lin et al. (2014); these authors demonstrated 
that resveratrol increased hBD2 expression in response to Streptococcus pneumoniae infection of an 
alveolar epithelial cell line370. Thus, these data suggest that the phytoestrogen resveratrol induces 
hBD2 expression during infection. However, previous data from our laboratory showed that 
resveratrol plus flagellin challenge significantly reduced hBD2 expression in VK2 cells, compared 
to flagellin challenge alone106. Thus, the effects of resveratrol on AMP expression require further 
research. Resveratrol has also been reported to have anti-cancer properties and thus, unlike 
estrogen treatment, would not pose a cancer risk371. However, resveratrol confers its anti-cancer 
properties through inhibition of cell proliferation and promotion of apoptosis. Accordingly, 
resveratrol has been reported to induce cell cycle arrest in keratinocytes and thus, may exacerbate 
vaginal atrophy in postmenopausal women372. As keratinisation is thought to be protective against 
infection, thinning of the vaginal epithelial by resveratrol may increase susceptibility to UTIs. 
Indeed, topical application of resveratrol to the skin is not advised due to its anti-proliferative 
effects on keratinocytes372. Nevertheless, Docherty et al. (2005) showed that topical vaginal 
application of resveratrol protected mice from herpes simplex virus infection373. However, 
Docherty et al. did not study the effects of resveratrol on the vaginal epithelium. Previous work 
from our laboratory revealed cytotoxic effects of resveratrol on an immortalised bladder epithelial 
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cell line106. Taken together these data suggest that resveratrol may be protective against vaginal 
infections, however, further research is needed to fully determine the effects of resveratrol on 
AMP expression and the vaginal epithelial barrier. The efficacy of resveratrol in specifically 
protecting against UTIs has not been studied and thus this is a potential area for both in vitro and 
in vivo studies.  
 
The phytoestrogen genistein has been investigated as a potential alternative to HRT in 
postmenopausal women. Consumption of genistein as part of the diet has been shown to 
increase the thickness of the vaginal epithelium in rats374. However, unlike estrogen, genistein did 
not increase the keratinisation of the vaginal epithelium. Research into the effects of genistein on 
AMP expression is limited; however, in 2006 Ouhara et al. demonstrated that induction of hBD2 
expression by Actinobacillus actinomycetemcomitans in human gingival epithelial cells was inhibited by 
genistein375. Thus, although genistein shows some estrogenic properties, it does not fully replicate 
the protective effects of estrogen and is unlikely to be a suitable candidate for a therapeutic for 
UTIs.  
 
7.1.1.2 Vitamin D 
As discussed in the introduction to this thesis, an initial study examining patients with type 2 
diabetes mellitus found that supplementation with vitamin D reduced the incidence of UTIs 
compared to patients receiving placebo treatment160. However, a clinical trial examining the 
efficacy of vitamin D in pre- and postmenopausal women who suffer from rUTIs has not been 
conducted. Interestingly, a correlation has been reported between serum vitamin D levels and 
hBD2 expression in vivo376. Furthermore, an in vitro study using a human primary keratinocytes 
showed induction of hBD2 by vitamin D377. Several studies have also shown upregulation of the 
AMP LL-37 by vitamin D in epithelial and keratinocyte cell lines378–380. LL-37 was not identified 
by the microarray analysis as being upregulated by estrogen and as LL-37 has been shown to be 
important in bacterial clearance during a UTI, these data suggest vitamin D may enhance 
expression of additional AMPs that estrogen does not268. Conversely, Hegyi et al. (2012) reported 
that vitamin D suppressed expression of S100A7; however, this research was conducted in 
psoriatic skin lesions and thus different results may be observed in the context of infection381. 
Nonetheless, the effects of vitamin D on AMP expression in the vagina in response to infection 
is an interesting area for future research. In addition to upregulating AMP expression, vitamin D 
has been reported to reduce vaginal pH and prevent vaginal atrophy382,383. Unpublished findings 
by our research group have also shown that vitamin D significantly reduced bacterial invasion of 
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vaginal epithelial cells, compared to untreated controls. These findings indicate that vitamin D 
may work in a similar manner to estrogen. Furthermore, adverse reactions are rarely reported in 
vitamin D supplementation, indicating that vitamin D is potentially a safe alternative to antibiotic 
and hormonal treatment of UTIs. Future work to investigate the potential for vitamin D to 
protect against UTIs should investigate the effects of vitamin D on AMP expression in vaginal 
epithelial cells both in vitro and in vivo. Furthermore, a clinical trial examining the effects of 
vitamin D on UTI incidence in pre- and postmenopausal women would further elucidate the 
clinical effectiveness of vitamin D.  
 
7.1.1.3 Other natural agents from the diet 
Other naturally occurring dietary compounds, such as cranberry extracts and vitamin C have also 
been proposed to reduce the incidence of UTIs. However, the protective nature of cranberry 
juice against UTIs has not been definitively shown156. Cranberry extracts are thought to prevent 
bacterial adhesion to epithelial cells, preventing penetration of the epithelial barrier384,385. To the 
best of my knowledge, the effects of cranberry extracts on vaginal pH, AMP expression, and 
keratinisation has not been studied. Similarly, vitamin C has been shown to acidify the urine and 
inhibit bacterial replication, however, the effects of vitamin C on vaginal acidity, AMP expression 
or keratinisation has not been investigated. Thus, further investigations into the effects of 
cranberry products and vitamin C on vaginal lactobacilli growth, AMP expression, and 
keratinisation will determine whether these may provide an alternative treatment option to 
estrogen. The effect of these compounds, and the previously mentioned vitamin D, on vaginal 
AMP production could initially be determined in vitro using the VK2 cell model established in this 
thesis. This would provide direct comparison of AMP induction following treatment with these 
agents to the AMP induction observed with estrogen pretreatment. 
 
7.1.2 Hyaluronic acid 
Hyaluronic acid is a promising therapeutic candidate for UTI treatment. Hyaluronic acid is 
currently marketed as a vaginal moisturiser for treatment of vaginal atrophy in postmenopausal 
women. A clinical trial comparing the efficacy of vaginal hyaluronic acid gel to estrogen cream 
for treating vaginal dryness found that although hyaluronic acid improved the symptoms of 
vaginal atrophy it did not reduce vaginal pH, whereas the estrogen cream did386. However, several 
trials have shown that hyaluronic acid treatment significantly reduced UTI incidence. 
Constantinides et al. (2004) demonstrated that premenopausal women with a history of rUTI had 
significantly fewer UTIs following bladder instillation of hyaluronic acid than before treatment387. 
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In the pretreatment phase (15.8 months) the 40 patients suffered 208 UTIs, however, post-
treatment (12.4 months) only 12 of these patients had 16 UTIs. This represented significantly 
fewer UTIs following treatment with hyaluronic acid than before treatment. Lipovac et al. (2007) 
conducted a similar study of UTI incidence in premenopausal women before and after bladder 
instillation with hyaluronic acid and also found that hyaluronic acid instillation significantly 
reduced UTI incidence388. A clinical trial comparing bladder instillation of hyaluronic acid plus 
chondroitin sulfate to placebo was conducted in premenopausal women in 2011389. In the 12 
month follow-up period after instillation the 29 women in the placebo group had 122 UTIs, 
whilst the 28 patients in the hyaluronic acid plus chondroitin sulfate group had only 17. Although 
these trials report promising effects with hyaluronic acid, none of the trials investigated the 
mechanism of action of hyaluronic acid. In vitro investigations by our laboratory group have 
shown that hyaluronic acid increased expression of hBD2, hBD3 and LCN2 in VK2 cells 
(Catherine Mowbray, unpublished data). In addition, these data showed that hyaluronic acid 
significantly reduced bacterial invasion of VK2 cells and formed a protective barrier, which 
reduced the leakage of mannitol through tight junctions between bladder epithelial cells. Thus, 
similarly to estrogen, hyaluronic acid may protect against UTIs by increasing innate immune 
defences and augmenting the epithelial barrier to UPEC invasion. Furthermore, our data suggests 
that hyaluronic acid is protective in the vagina, thus, vaginal application of hyaluronic acid should 
be explored as a UTI treatment as this may provide a more convenient alternative to bladder 
instillation. Thus, a clinical trial into the efficacy of topical vaginal hyaluronic acid treatment in 
protecting postmenopausal women from rUTI is warranted as hyaluronic acid is a promising 
alternative non-hormonal treatment for UTIs. 
 
7.1.3 Exogenous AMPs 
There is considerable effort within the AMP field to develop therapeutic synthetic AMPs. 
However, despite in vitro screening of hundreds of thousands of synthetic peptides, only a 
handful have ever made it to clinical trials. Notably, Pexiganan, developed as a treatment for 
diabetic foot ulcers, made it to phase 3 clinical trials, but was denied approval by the Food and 
Drug Administration (FDA) and development was halted. Pexiganan has now been renamed 
Locilex (Dipexium Pharmaceuticals) and has reentered phase 3 clinical trials390. However, the 
FDA is yet to approve a synthetic AMP for therapeutic use of any infection. Thus, the 
development of synthetic AMPs for clinical use is still in its infancy. Furthermore, development 
of potential targets is difficult as although many synthetic AMPs show activity in vitro, they only 
show activity in vivo at very high doses. These high doses are close to the toxic range of the 
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synthetic AMPs, and thus are often deemed unsafe. No synthetic AMPs are currently being 
developed specifically for treatment of UTIs. However, research into synthetic chimeric peptides 
of hBD1/hBD3 and hBD2/hBD3 have shown high in vitro antimicrobial activity against E. coli 
and low toxicity to erythrocytes and epithelial cells216,391. Thus, these synthetic peptides show 
promise for development for clinical use. However, clinical use of synthetic antimicrobial 
peptides should be approached with caution, as there is concern that therapeutic use of synthetic 
AMPs will induce the evolution of bacterial resistance in the same manner as bacterial antibiotic 
resistance emerged following clinical use of antibiotics392. Indeed, Perron et al. (2006) were able to 
experimentally induce Pexiganan resistance in E. coli through long-term exposure of the bacteria 
to the AMP393. Thus, enhancement of the host’s natural AMP response may be a more 
responsible long-term treatment option. 
 
In summary, there are a few promising therapeutic candidates (summarised in Table 7.1) that may 
have a similar mechanism of action to estrogen and that are safe to use. In particular, the results 
for vitamin D and hyaluronic acid are exciting as these agents have both demonstrated AMP 
induction and improved barrier function in epithelial cells. Nevertheless, further analysis of other 
less well studied agents, such as vitamin C, may also return promising results. In addition, these 
treatments may be used in combination to achieve maximal protection against UTIs. For 
example, combined vitamin C and D therapy may acidify the urine to prevent bacterial growth, 
whilst simultaneously enhancing the physical and antimicrobial barrier to infection in the vagina. 
Importantly, the molecular analyses performed in this thesis have identified mechanisms by 
which estrogen protects against UTIs. As topical estrogen treatment has been shown to 
significantly reduce the incidence of UTIs in postmenopausal women, the knowledge of how 
estrogen brings about this protection can be used to inform the identification and development 
of non-hormonal alternatives.  
 
Table 7.1: Summary of protective mechanisms of potential UTI therapeutics. 
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7.2 Future work 
The future work stemming from this project should cover two main areas. Firstly, continuing 
from the work presented in this thesis, further work should be conducted to further inform the 
mechanism of estrogen action. Secondly, experiments should be performed to begin to 
investigate the effects of estrogen alternatives on innate vaginal epithelial defences. 
 
With regards to further investigating the mechanism of estrogen action, several areas may be 
explored. To continue to investigate the roles of the estrogen receptors in AMP gene expression, 
ER-α and –β inhibitors that do not have agonistic effects on GPER could be employed. It is 
thought that the use of fulvestrant in Chapter 5 inhibited ER-α and ER-β and simultaneously 
caused GPER desensitisation, making it difficult to attribute the observed effects on AMP 
expression to a specific estrogen receptor. MPP dihydrocholride and PHTPP are selective 
antagonists for ER-α and ER-β, respectively, with no effect on GPER. Thus, the use of these 
separately, or in combination, should rule out the effects of potential GPER desensitisation on 
AMP expression. Such data may clearly indicate the role of the estrogen receptors in the 
expression of each of the AMPs.  
 
One limitation of this project was the difficulty in obtaining accurate protein secretion data for 
the AMPs. The hBD2 ELISA did not accurately detect peptide concentrations for the standards 
or for the VK2 cell samples. This area should be investigated further, and ELISAs optimised, in 
order to quantify AMP secretion in the VK2 cell model. Optimisation of the hBD2 protocol by 
increasing the concentration of detection antibody, for example, may improve results. The hBD3 
ELISA did not detect any increases in peptide concentration for any treatments. However, the 
increase in hBD3 mRNA following flagellin challenge was more delayed than the hBD2 
response, thus, measurement of hBD3 peptide levels at later time points should be considered 
for future experiments.  
 
A further limitation of the project was the measurement of AMP expression in PVECs. Culturing 
the PVECs proved difficult and although initial results were promising, changing the culture 
medium to DMEM with FCS to facilitate better PVEC growth appeared to abolish the effects of 
estrogen pretreatment on AMP expression. This may be due to the presence of phenol red in the 
DMEM and other estrogenic compounds in the FCS negating the effects of the 4nM estrogen 
supplementation. Thus, it would be beneficial to optimise the growth of the PVECs in medium 
that does not contain phenol red and FCS to more accurately study the effects of estrogen 
supplementation on AMP expression in vaginal epithelial cells. 
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The work presented in this thesis highlighted a role for estrogen in the keratinisation and 
inflammatory response of the vaginal epithelium, which was not further studied as part of this 
project. These provide exciting areas for further research into the effects of estrogen on the 
innate epithelial immune response to UPEC colonisation. The keratinisation response is 
particularly intriguing as in addition to strengthening the epithelial barrier to infection, Tam et al. 
(2012) have shown that keratin-derived fragments in the cornea have antimicrobial properties234. 
Thus, it would be of interest to determine whether increased keratinisation of the vaginal 
epithelium in response to estrogen pretreatment leads to production of keratin-derived AMPs 
(KDAMPs). To identify KDAMPs in the cornea, Tam et al. lysed corneal epithelial cells and 
fractionated the lysate by molecular mass. The fractions were tested for antimicrobial activity and 
mass spectrometry was utilised to identify potential KDAMPs. This process could, therefore, be 
used to investigate the production of KDAMPs in the vaginal epithelium in response to estrogen 
pretreatment. The microarray data also indicated that estrogen may increase the inflammatory 
response to infection; genes such as S100A8 and S100A9 were upregulated by estrogen 
pretreatment and have been reported to have roles in neutrophil migration to the site of 
infection. Furthermore, IPA analysis indicated that ‘The Role of IL-17A in Psoriasis’ pathway 
was activated by estrogen pretreatment plus flagellin. Utilising qPCR it was demonstrated that 
exogenous IL-17A upregulated the expression of AMPs, and that combined estrogen 
pretreatment, IL-17A and flagellin resulted in high AMP expression. Thus, it would be of interest 
to examine the effects of topical estrogen treatment on immune cell migration to the vagina 
during infection. Mouse models would be needed to study this effectively. Utilising such models, 
immune cell migration to the vagina following UPEC colonisation could be studied with and 
without topical estrogen treatment to determine whether estrogen acts to enhance migration of 
neutrophils and Th17 cells. 
 
Alongside these analyses, future work may also involve utilising the VK2 cell model to investigate 
the effects of novel therapeutics on vaginal AMP expression, keratinisation and inflammatory 
mediators. Our laboratory has used the VK2 cells to investigate the effects of hyaluronic acid and 
found that, similarly to estrogen, treatment of VK2 cells with hyaluronic acid improved AMP 
expression and barrier function. This suggests that hyaluronic acid is a promising candidate for 
treatment of UTIs. In vitro data for hyaluronic acid obtained using VK2 cell studies will be used to 
support an application for a clinical trial investigating the efficacy of hyaluronic acid in reducing 
UTI incidence in postmenopausal women. In addition to hyaluronic acid, the effects of vitamin 
D, vitamin C, and resveratrol could be investigated and compared with estrogen. The effects of 
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combined treatments could also be explored. Improved understanding of the mechanism of 
AMP regulation by estrogen may also result in the identification of other therapeutic candidates 
that could also be tested using VK2 cells.  
 
7.3 Summary 
In summary, the data presented in this thesis have highlighted a key role for estrogen in the 
innate epithelial defences of the urogenital tract. Previous investigations demonstrated that 
estrogen stimulates glycogen production in the vagina, promoting lactobacilli colonisation and 
lactic acid production, which results in a lower vaginal pH. However, the data within this thesis 
has shown that estrogen has additional roles in enhancing the vaginal innate immune response to 
UPEC colonisation by potentiating expression of AMPs, including hBD2, hBD3, LCN2 and 
S100A7. Furthermore, estrogen pretreatment was also shown to upregulate genes involved in 
keratinisation, inflammation and immune cell migration. Together these data suggest that 
estrogen protects the urogenital tract from infection in multiple ways. Firstly, stimulation of 
vaginal glycogen production by estrogen promotes growth of commensal bacteria, making the 
vagina inhospitable for uropathogens. Secondly, estrogen strengthens the physical epithelial 
barrier to infection to prevent pathogen invasion and finally, estrogen enhances the antimicrobial 
response to infection by promoting AMP production and potential immune cell migration to 
facilitate rapid bacterial killing and clearance from the vagina, and hence preventing progression 
to bladder infection. Therefore, loss of circulating estrogen following the menopause results in 
the loss of these protective mechanisms and results in uropathogen growth in the vaginal 
reservoir, facilitating infection of the urethra and bladder. Hence, these data provide scientific 
evidence that reveal how loss of estrogen after the menopause increases a women’s susceptibility 
to rUTIs and help inform future therapeutic strategies.  
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8 Appendix 
Table 8.1: List of differentially expressed genes after 12 hours challenge.
 
Probe Gene symbol Gene name EP12 F12 EP/F12
ILMN_1791759 CXCL10 chemokine (C-X-C motif) ligand 10 41.73 16.00
ILMN_1795359 SPRR2A small proline-rich protein 2A 2.06 3.95 14.75
ILMN_1662358 MX1 myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) 16.02 14.34
ILMN_2231928 MX2 myxovirus (influenza virus) resistance 2 (mouse) 24.78 14.09
ILMN_2058782 IFI27 interferon, alpha-inducible protein 27 16.48 13.76
ILMN_2211018 SPRR2E small proline-rich protein 2E 3.14 13.53
ILMN_1674367 SPRR2F small proline-rich protein 2F 2.20 3.60 13.08
ILMN_1723912 IFI44L interferon-induced protein 44-like 15.81 11.51
ILMN_1701239 SPRR2E small proline-rich protein 2E 2.46 10.84
ILMN_1805410 C15orf48 chromosome 15 open reading frame 48 14.52 10.46
ILMN_2410826 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 17.19 10.41
ILMN_1674063 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 14.99 10.38
ILMN_1692223 LCN2 lipocalin 2 2.18 6.38 9.47
ILMN_2347798 IFI6 interferon, alpha-inducible protein 6 14.36 9.43
ILMN_1675640 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 16.92 9.09
ILMN_1788874 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 8.67 8.92
ILMN_1735712 KRT1 keratin 1 8.82
ILMN_1801246 IFITM1 interferon induced transmembrane protein 1 14.01 8.44
ILMN_1658247 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 12.66 8.16
ILMN_1691364 STAT1 signal transducer and activator of  transcription 1, 91kDa 10.53 7.90
ILMN_1690105 STAT1 signal transducer and activator of  transcription 1, 91kDa 11.48 7.67
ILMN_1702127 SPRR2G small proline-rich protein 2G 7.27
ILMN_1782716 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 2.92 6.48
ILMN_1787509 HELZ2 helicase with zinc finger 2, transcriptional coactivator 10.48 6.45
ILMN_2415144 SP110 SP110 nuclear body protein 8.78 6.02
ILMN_2336781 SOD2 superoxide dismutase 2, mitochondrial 8.06 6.01
ILMN_1803838 CNFN cornifelin 2.04 5.90
ILMN_1750974 S100A9 S100 calcium binding protein A9 2.13 2.53 5.86
ILMN_2197577 SPRR2C small proline-rich protein 2C (pseudogene) 5.77
ILMN_1718395 LCE3D late cornified envelope 3D 2.11 5.76
ILMN_2191967 SPRR2D small proline-rich protein 2D 2.09 5.73
ILMN_1731418 SP110 SP110 nuclear body protein 7.79 5.68
ILMN_1777325 STAT1 signal transducer and activator of  transcription 1, 91kDa 7.24 5.65
ILMN_2239754 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 13.46 5.63
ILMN_1779252 TRIM22 tripartite motif  containing 22 8.78 5.61
ILMN_1798181 IRF7 interferon regulatory factor 7 7.41 5.47
ILMN_1731224 PARP9 poly (ADP-ribose) polymerase family, member 9 7.91 5.12
ILMN_2048043 DEFB4A defensin, beta 4A 2.35 5.11
ILMN_1757351 S100A7 S100 calcium binding protein A7 5.07
ILMN_2170814 LAMP3 lysosomal-associated membrane protein 3 7.48 5.03
ILMN_1745374 IFI35 interferon-induced protein 35 6.85 4.98
ILMN_1745397 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 5.85 4.92
ILMN_2406501 SOD2 superoxide dismutase 2, mitochondrial 7.63 4.83
ILMN_1701789 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 12.51 4.82
ILMN_2388547 EPSTI1 epithelial stromal interaction 1 (breast) 6.16 4.61
ILMN_2098126 CCL5 chemokine (C-C motif) ligand 5 9.60 4.56
ILMN_1796316 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 3.72 4.50
ILMN_2349061 IRF7 interferon regulatory factor 7 6.23 4.44
ILMN_1712759 SBSN suprabasin 2.06 4.44
ILMN_2158713 IL36G interleukin 36, gamma 2.70 4.34
ILMN_1745242 PLSCR1 phospholipid scramblase 1 5.28 4.26
ILMN_1774287 CFB complement factor B 7.62 4.21
ILMN_2148785 GBP1 guanylate binding protein 1, interferon-inducible 8.84 4.15
ILMN_1657871 RSAD2 radical S-adenosyl methionine domain containing 2 8.71 4.08
ILMN_2109708 TYMP thymidine phosphorylase 5.26 4.00
ILMN_2184373 IL8 interleukin 8 3.59 3.99
ILMN_2376205 LTB lymphotoxin beta (TNF superfamily, member 3) 10.91 3.88
ILMN_1794662 DSG1 desmoglein 1 3.70
ILMN_1703855 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 3.68
ILMN_1801216 S100P S100 calcium binding protein P 3.66
ILMN_1742618 XAF1 XIAP associated factor 1 6.19 3.66
ILMN_1723035 OLR1 oxidized low density lipoprotein (lectin-like) receptor 1 7.67 3.58
ILMN_1672661 SP110 SP110 nuclear body protein 5.17 3.54
ILMN_1691731 PARP14 poly (ADP-ribose) polymerase family, member 14 5.69 3.51
ILMN_1751079 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 5.37 3.48
ILMN_1770922 TMEM45A transmembrane protein 45A 3.46
ILMN_2054019 ISG15 ISG15 ubiquitin-like modifier 4.89 3.40
ILMN_1729801 S100A8 S100 calcium binding protein A8 2.03 2.24 3.39
ILMN_1730284 DSC1 desmocollin 1 3.34
ILMN_2085862 SLC15A3 solute carrier family 15 (oligopeptide transporter), member 3 5.56 3.34
ILMN_1690921 STAT2 signal transducer and activator of  transcription 2, 113kDa 4.81 3.31
ILMN_2402640 DSC1 desmocollin 1 3.28
ILMN_2148913 TMEM45A transmembrane protein 45A 3.26
ILMN_1736729 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 4.67 3.24
ILMN_1814305 SAMD9 sterile alpha motif  domain containing 9 4.16 3.22
ILMN_1713397 NCCRP1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 3.20
ILMN_1781373 IFIH1 interferon induced with helicase C domain 1 5.09 3.20
ILMN_3240420 USP18 ubiquitin specific peptidase 18 5.43 3.17
ILMN_2079042 WFDC5 WAP four-disulfide core domain 5 3.17
Fold change
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Probe Gene symbol Gene name EP12 F12 EP/F12
ILMN_1704972 TRIM5 tripartite motif  containing 5 5.72 3.16
ILMN_2114720 SLPI secretory leukocyte peptidase inhibitor 2.16 3.16
ILMN_1773352 CCL5 chemokine (C-C motif) ligand 5 6.30 3.12
ILMN_1760062 IFI44 interferon-induced protein 44 4.03 3.08
ILMN_1778401 HLA-B major histocompatibility complex, class I, B 4.16 3.04
ILMN_2053527 PARP9 poly (ADP-ribose) polymerase family, member 9 4.72 3.04
ILMN_1743950 IGFL1 IGF-like family member 1 2.29 3.01
ILMN_1707695 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 5.47 2.98
ILMN_1693192 PI3 peptidase inhibitor 3, skin-derived 2.05 2.96
ILMN_1754576 KRT6C keratin 6C 2.95
ILMN_1718558 PARP12 poly (ADP-ribose) polymerase family, member 12 3.91 2.93
ILMN_1752548 KRTDAP keratinocyte differentiation-associated protein 2.92
ILMN_1708303 CYP4F22 cytochrome P450, family 4, subfamily F, polypeptide 22 2.89
ILMN_1745471 IRF9 interferon regulatory factor 9 3.21 2.89
ILMN_3223126 TYMP thymidine phosphorylase 3.97 2.86
ILMN_1769520 UBE2L6 ubiquitin-conjugating enzyme E2L 6 3.80 2.86
ILMN_1654639 HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 3.13 2.77
ILMN_1805750 IFITM3 interferon induced transmembrane protein 3 3.50 2.74
ILMN_1692332 ALOX12B arachidonate 12-lipoxygenase, 12R type 2.73
ILMN_1700583 ZNF750 zinc finger protein 750 2.71
ILMN_1835092 IFI44L interferon-induced protein 44-like 3.47 2.71
ILMN_1665832 ID1 inhibitor of  DNA binding 1, dominant negative helix-loop-helix protein 2.70
ILMN_3243928 DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 4.39 2.70
ILMN_1806059 SPRR2B small proline-rich protein 2B 2.70
ILMN_1845037 TRIM69 tripartite motif  containing 69 3.32 2.69
ILMN_1716591 SPRR1A small proline-rich protein 1A 2.69
ILMN_1748915 S100A12 S100 calcium binding protein A12 2.69
ILMN_1797001 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 4.65 2.67
ILMN_1773006 FABP4 fatty acid binding protein 4, adipocyte 2.66
ILMN_2262044 PARP10 poly (ADP-ribose) polymerase family, member 10 4.13 2.65
ILMN_3297126 TYMP thymidine phosphorylase 3.79 2.65
ILMN_1701114 GBP1 guanylate binding protein 1, interferon-inducible 4.97 2.63
ILMN_1763666 ALDH3B2 aldehyde dehydrogenase 3 family, member B2 2.61
ILMN_1699331 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 7.00 2.60
ILMN_1718387 LOR loricrin 2.59
ILMN_1705814 KRT80 keratin 80 2.57
ILMN_1703108 UBE2L6 ubiquitin-conjugating enzyme E2L 6 3.39 2.55
ILMN_1784364 STARD5 StAR-related lipid transfer (START) domain containing 5 4.76 2.54
ILMN_1657234 CCL20 chemokine (C-C motif) ligand 20 2.68 2.54
ILMN_1746085 IGFBP3 insulin-like growth factor binding protein 3 2.52
ILMN_1723480 BST2 bone marrow stromal cell antigen 2 2.66 2.50
ILMN_2150856 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.73 2.49
ILMN_1750400 C19orf66 chromosome 19 open reading frame 66 3.61 2.49
ILMN_1706502 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 3.11 2.49
ILMN_1681526 SLC5A1 solute carrier family 5 (sodium/glucose cotransporter), member 1 2.47
ILMN_1695924 KLK11 kallikrein-related peptidase 11 2.47
ILMN_1673352 IFITM2 interferon induced transmembrane protein 2 3.19 2.46
ILMN_1748323 CXCL14 chemokine (C-X-C motif) ligand 14 2.45
ILMN_2390586 SP100 SP100 nuclear antigen 2.44 2.45
ILMN_2150851 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.80 2.44
ILMN_1771385 GBP4 guanylate binding protein 4 4.03 2.44
ILMN_1724686 CLDN1 claudin 1 2.42
ILMN_1784380 DTX3L deltex 3-like (Drosophila) 3.33 2.41
ILMN_1690939 TYMP thymidine phosphorylase 3.04 2.40
ILMN_1711174 SPRR1B small proline-rich protein 1B 2.38
ILMN_2284998 SP100 SP100 nuclear antigen 2.70 2.35
ILMN_2390162 PHF11 PHD finger protein 11 3.21 2.34
ILMN_2170813 LAMP3 lysosomal-associated membrane protein 3 3.17 2.34
ILMN_2396875 IGFBP3 insulin-like growth factor binding protein 3 2.32
ILMN_1774874 IL1RN interleukin 1 receptor antagonist 2.66 2.32
ILMN_1705241 TDRD7 tudor domain containing 7 3.55 2.32
ILMN_1776723 PHF11 PHD finger protein 11 3.02 2.31
ILMN_1716093 KRT10 keratin 10 2.29
ILMN_1762899 EGR1 early growth response 1 2.29
ILMN_2368530 IL32 interleukin 32 2.39 2.27
ILMN_1767006 PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 3.43 2.26
ILMN_2304512 SAA1 serum amyloid A1 3.65 2.25
ILMN_2320964 ADAR adenosine deaminase, RNA-specific 2.84 2.24
ILMN_1788017 HSH2D hematopoietic SH2 domain containing 4.42 2.24
ILMN_1797009 F3 coagulation factor III (thromboplastin, tissue factor) 2.06 2.23
ILMN_1799467 SAMD9L sterile alpha motif  domain containing 9-like 3.54 2.21
ILMN_1743412 SIAE sialic acid acetylesterase 2.21
ILMN_1686116 THBS1 thrombospondin 1 2.20
ILMN_1764709 MAFB v-maf  avian musculoaponeurotic fibrosarcoma oncogene homolog B 2.20
ILMN_1795181 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 2.87 2.20
ILMN_1678054 TRIM21 tripartite motif  containing 21 3.62 2.19
ILMN_1725912 KLK12 kallikrein-related peptidase 12 2.18
ILMN_2412336 AKR1C2 aldo-keto reductase family 1, member C2 3.18 2.18
ILMN_1684308 DEFB103A defensin, beta 103A 2.17
ILMN_1727589 SULT2B1 sulfotransferase family, cytosolic, 2B, member 1 2.16
ILMN_2404665 TRIM5 tripartite motif  containing 5 4.22 2.16
ILMN_1762861 HLA-F major histocompatibility complex, class I, F 3.22 2.16
ILMN_1710937 IFI16 interferon, gamma-inducible protein 16 2.71 2.15
ILMN_1683792 LAP3 leucine aminopeptidase 3 2.78 2.14
ILMN_2136495 A2ML1 alpha-2-macroglobulin-like 1 2.13
ILMN_1776777 ADAR adenosine deaminase, RNA-specific 2.46 2.12
ILMN_1672295 ZC3H12A zinc finger CCCH-type containing 12A 2.12
ILMN_1803452 CRCT1 cysteine-rich C-terminal 1 2.11
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Probe Gene symbol Gene name EP12 F12 EP/F12
ILMN_1758731 CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 2.82 2.11
ILMN_1810835 SPRR3 small proline-rich protein 3 2.11
ILMN_1703650 TNIP1 TNFAIP3 interacting protein 1 3.56 2.10
ILMN_1759598 DLX5 distal-less homeobox 5 2.09
ILMN_2390299 PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 3.01 2.08
ILMN_1721134 TGM1 transglutaminase 1 2.08
ILMN_1666733 IL8 interleukin 8 2.01 2.08
ILMN_1769388 GJB2 gap junction protein, beta 2, 26kDa 2.06
ILMN_2316236 HOPX HOP homeobox 2.04
ILMN_1674811 OASL 2'-5'-oligoadenylate synthetase-like 4.47 2.04
ILMN_2129572 F3 coagulation factor III (thromboplastin, tissue factor) 2.04
ILMN_1688892 LAMA3 laminin, alpha 3 3.08 2.03
ILMN_1745570 KLK7 kallikrein-related peptidase 7 2.02
ILMN_2376108 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 2.72 2.02
ILMN_1709333 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 3.00 2.01
ILMN_2406035 LAMA3 laminin, alpha 3 2.57 2.01
ILMN_1739428 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 5.34 2.01
ILMN_1763520 SULT2B1 sulfotransferase family, cytosolic, 2B, member 1 2.01
ILMN_2326512 CASP1 caspase 1, apoptosis-related cysteine peptidase 2.30 2.01
ILMN_2376403 TSC22D3 TSC22 domain family, member 3 0.45
ILMN_2276952 TSC22D3 TSC22 domain family, member 3 0.45
ILMN_1681721 OASL 2'-5'-oligoadenylate synthetase-like 4.79
ILMN_3253787 LOC100128274 putative p150 4.26
ILMN_1801307 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 3.98
ILMN_1815086 NINJ1 ninjurin 1 3.47
ILMN_1714433 MARCKSL1 MARCKS-like 1 3.47
ILMN_1664543 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 3.47
ILMN_1659913 ISG20 interferon stimulated exonuclease gene 20kDa 3.40
ILMN_1653466 HES4 hairy and enhancer of  split 4 (Drosophila) 3.25
ILMN_1678422 DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58 3.00
ILMN_1701621 SCO2 SCO2 cytochrome c oxidase assembly protein 2.98
ILMN_1755173 PLEKHA4 pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4 2.90
ILMN_1747195 PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 2.84
ILMN_1776181 BIRC3 baculoviral IAP repeat containing 3 2.77
ILMN_2376204 LTB lymphotoxin beta (TNF superfamily, member 3) 2.72
ILMN_1728224 OGFR opioid growth factor receptor 2.59
ILMN_1667068 ZC3HAV1 zinc finger CCCH-type, antiviral 1 2.56
ILMN_1769550 SLFN5 schlafen family member 5 2.56
ILMN_1727689 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 2.55
ILMN_1679133 SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 2.51
ILMN_1727271 WARS tryptophanyl-tRNA synthetase 2.49
ILMN_1778321 SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6 2.42
ILMN_1812226 ICAM1 intercellular adhesion molecule 1 2.41
ILMN_1719759 TNC tenascin C 2.41
ILMN_1691717 RHBDF2 rhomboid 5 homolog 2 (Drosophila) 2.39
ILMN_2337655 WARS tryptophanyl-tRNA synthetase 2.38
ILMN_1745148 ZNFX1 zinc finger, NFX1-type containing 1 2.37
ILMN_1783621 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 2.35
ILMN_1663042 SDC4 syndecan 4 2.34
ILMN_1696654 IFIT5 interferon-induced protein with tetratricopeptide repeats 5 2.34
ILMN_1682336 MASTL microtubule associated serine/threonine kinase-like 2.33
ILMN_1740418 CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1 2.33
ILMN_2067890 CXCL11 chemokine (C-X-C motif) ligand 11 2.32
ILMN_1751886 REC8 REC8 meiotic recombination protein 2.31
ILMN_1714861 CD68 CD68 molecule 2.30
ILMN_1655595 SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 2.28
ILMN_1681644 BIRC3 baculoviral IAP repeat containing 3 2.27
ILMN_1715684 LAMB3 laminin, beta 3 2.26
ILMN_1687768 NCOA7 nuclear receptor coactivator 7 2.25
ILMN_1690365 USP41 ubiquitin specific peptidase 41 2.24
ILMN_1729749 HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 2.24
ILMN_1785732 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 2.24
ILMN_1683026 PSMB10 proteasome (prosome, macropain) subunit, beta type, 10 2.23
ILMN_1813625 TRIM25 tripartite motif  containing 25 2.22
ILMN_1810608 PNPT1 polyribonucleotide nucleotidyltransferase 1 2.20
ILMN_1790472 SLC25A28 solute carrier family 25 (mitochondrial iron transporter), member 28 2.20
ILMN_1737599 TRIM5 tripartite motif  containing 5 2.19
ILMN_1687757 AKR1C4 aldo-keto reductase family 1, member C4 2.18
ILMN_1800078 LMO2 LIM domain only 2 (rhombotin-like 1) 2.18
ILMN_1708375 IRF1 interferon regulatory factor 1 2.17
ILMN_2248970 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 2.17
ILMN_1792455 TMEM158 transmembrane protein 158 (gene/pseudogene) 2.16
ILMN_1701204 VEGFC vascular endothelial growth factor C 2.14
ILMN_1769734 NT5C3A 5'-nucleotidase, cytosolic IIIA 2.14
ILMN_2326509 CASP1 caspase 1, apoptosis-related cysteine peptidase 2.14
ILMN_2145670 TNC tenascin C 2.13
ILMN_1720083 EHD4 EH-domain containing 4 2.13
ILMN_1659688 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 2.13
ILMN_2370573 XAF1 XIAP associated factor 1 2.12
ILMN_1858599 RBM43 RNA binding motif  protein 43 2.10
ILMN_1786612 PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 2.09
ILMN_1808501 SH3KBP1 SH3-domain kinase binding protein 1 2.09
ILMN_1807439 ALDH1A3 aldehyde dehydrogenase 1 family, member A3 2.08
ILMN_1716815 CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 2.07
ILMN_1753111 NAMPT nicotinamide phosphoribosyltransferase 2.07
ILMN_1654696 C15orf48 chromosome 15 open reading frame 48 2.06
ILMN_2130441 HLA-H major histocompatibility complex, class I, H (pseudogene) 2.06
ILMN_1729095 PDZD2 PDZ domain containing 2 2.06
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Probe Gene symbol Gene name EP12 F12 EP/F12
ILMN_2352121 NT5C3A 5'-nucleotidase, cytosolic IIIA 2.06
ILMN_1724837 ZC3HAV1 zinc finger CCCH-type, antiviral 1 2.05
ILMN_1678454 CASP4 caspase 4, apoptosis-related cysteine peptidase 2.04
ILMN_1796537 FYB FYN binding protein 2.04
ILMN_1736863 TMEM140 transmembrane protein 140 2.03
ILMN_2373062 RHBDF2 rhomboid 5 homolog 2 (Drosophila) 2.01
ILMN_2082209 TOX2 TOX high mobility group box family member 2 0.46
ILMN_1661708 LGALS7 lectin, galactoside-binding, soluble, 7 0.38 0.42
ILMN_2064860 LGALS7B lectin, galactoside-binding, soluble, 7B 0.38 0.39
ILMN_3243690 LGALS7B lectin, galactoside-binding, soluble, 7B 0.38 0.39
ILMN_2396444 CD14 CD14 molecule 0.46
ILMN_1770612 KRT15 keratin 15 0.39
ILMN_1712112 RCAN1 regulator of  calcineurin 1 0.46
ILMN_1693912 SLC47A2 solute carrier family 47 (multidrug and toxin extrusion), member 2 0.49
ILMN_1674243 TFRC transferrin receptor (p90, CD71) 0.41
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Table 8.2: Differentially expressed genes after 24 hour challenge.
 
Probe Gene symbol Gene name EP24 F24 EP/F24
ILMN_1702127 SPRR2G small proline-rich protein 2G 3.25 22.46
ILMN_2058782 IFI27 interferon, alpha-inducible protein 27 23.86 21.18
ILMN_2197577 SPRR2C small proline-rich protein 2C (pseudogene) 2.77 19.52
ILMN_1795359 SPRR2A small proline-rich protein 2A 3.13 3.60 17.04
ILMN_1801246 IFITM1 interferon induced transmembrane protein 1 20.20 13.40
ILMN_1674367 SPRR2F small proline-rich protein 2F 2.68 2.79 12.32
ILMN_1806059 SPRR2B small proline-rich protein 2B 11.96
ILMN_2347798 IFI6 interferon, alpha-inducible protein 6 13.69 11.75
ILMN_1701239 SPRR2E small proline-rich protein 2E 2.43 11.50
ILMN_1757351 S100A7 S100 calcium binding protein A7 2.53 2.50 10.66
ILMN_1723912 IFI44L interferon-induced protein 44-like 9.32 10.42
ILMN_1718395 LCE3D late cornified envelope 3D 2.28 2.64 10.37
ILMN_1692223 LCN2 lipocalin 2 2.66 4.89 9.87
ILMN_2211018 SPRR2E small proline-rich protein 2E 2.59 9.65
ILMN_1690105 STAT1 signal transducer and activator of  transcription 1, 91kDa 10.50 9.53
ILMN_2231928 MX2 myxovirus (influenza virus) resistance 2 (mouse) 7.86 9.51
ILMN_1691364 STAT1 signal transducer and activator of  transcription 1, 91kDa 9.53 9.07
ILMN_2048043 DEFB4A defensin, beta 4A 2.94 8.43
ILMN_1662358 MX1 myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) 8.19 8.32
ILMN_1684308 DEFB103A defensin, beta 103A 2.02 7.00
ILMN_1803452 CRCT1 cysteine-rich C-terminal 1 6.80
ILMN_1674063 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 6.28 6.76
ILMN_1803838 CNFN cornifelin 6.50
ILMN_1791759 CXCL10 chemokine (C-X-C motif) ligand 10 9.82 6.46
ILMN_3238649 LCE6A late cornified envelope 6A 6.43
ILMN_1808220 LCE3E late cornified envelope 3E 5.96
ILMN_1780649 KPRP keratinocyte proline-rich protein 5.59
ILMN_1728632 LCE3C late cornified envelope 3C 5.55
ILMN_1777325 STAT1 signal transducer and activator of  transcription 1, 91kDa 6.89 5.45
ILMN_1712849 RNASE7 ribonuclease, RNase A family, 7 2.08 5.41
ILMN_1712759 SBSN suprabasin 5.25
ILMN_1748915 S100A12 S100 calcium binding protein A12 5.23
ILMN_1731418 SP110 SP110 nuclear body protein 4.41 5.19
ILMN_1714587 DEFB103A defensin, beta 103A 5.17
ILMN_1735712 KRT1 keratin 1 5.13
ILMN_1829555 LCE6A late cornified envelope 6A 5.05
ILMN_1762284 ASPRV1 aspartic peptidase, retroviral-like 1 5.00
ILMN_2410826 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 5.85 4.84
ILMN_2349061 IRF7 interferon regulatory factor 7 5.64 4.69
ILMN_1745374 IFI35 interferon-induced protein 35 5.17 4.67
ILMN_2158713 IL36G interleukin 36, gamma 2.08 4.65
ILMN_1779252 TRIM22 tripartite motif  containing 22 5.64 4.62
ILMN_2402640 DSC1 desmocollin 1 4.57
ILMN_2415144 SP110 SP110 nuclear body protein 4.43 4.57
ILMN_1718387 LOR loricrin 4.56
ILMN_1730284 DSC1 desmocollin 1 4.55
ILMN_1727880 CDSN corneodesmosin 4.45
ILMN_1794662 DSG1 desmoglein 1 4.43
ILMN_1798181 IRF7 interferon regulatory factor 7 5.87 4.41
ILMN_3223126 TYMP thymidine phosphorylase 4.90 4.38
ILMN_1788874 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 5.14 4.13
ILMN_2388547 EPSTI1 epithelial stromal interaction 1 (breast) 3.73 4.13
ILMN_1805410 C15orf48 chromosome 15 open reading frame 48 6.78 4.12
ILMN_2191967 SPRR2D small proline-rich protein 2D 4.10
ILMN_1658247 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 4.92 4.06
ILMN_1774287 CFB complement factor B 5.09 3.97
ILMN_1675640 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 4.81 3.95
ILMN_1750974 S100A9 S100 calcium binding protein A9 2.25 3.79
ILMN_1787509 HELZ2 helicase with zinc finger 2, transcriptional coactivator 3.56 3.78
ILMN_2170814 LAMP3 lysosomal-associated membrane protein 3 4.65 3.75
ILMN_2109708 TYMP thymidine phosphorylase 4.68 3.74
ILMN_2316236 HOPX HOP homeobox 3.74
ILMN_1745397 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 4.45 3.65
ILMN_1796316 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 3.18 3.61
ILMN_1686116 THBS1 thrombospondin 1 3.51 3.53
ILMN_1782716 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 3.42
ILMN_1656706 LCE2D late cornified envelope 2D 3.40
ILMN_3297126 TYMP thymidine phosphorylase 3.55 3.33
ILMN_1708303 CYP4F22 cytochrome P450, family 4, subfamily F, polypeptide 22 3.31
ILMN_1745242 PLSCR1 phospholipid scramblase 1 3.36 3.31
ILMN_1713397 NCCRP1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 3.31
ILMN_2150851 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.72 3.27
ILMN_2148913 TMEM45A transmembrane protein 45A 3.25
ILMN_1805750 IFITM3 interferon induced transmembrane protein 3 3.64 3.23
ILMN_1778401 HLA-B major histocompatibility complex, class I, B 3.64 3.22
ILMN_1709708 LCE2C late cornified envelope 2C 3.14
ILMN_1692332 ALOX12B arachidonate 12-lipoxygenase, 12R type 3.11
ILMN_2304512 SAA1 serum amyloid A1 4.30 3.08
ILMN_2098126 CCL5 chemokine (C-C motif) ligand 5 4.22 3.04
ILMN_1795181 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 2.37 2.99
ILMN_1770922 TMEM45A transmembrane protein 45A 2.97
ILMN_2150856 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.57 2.94
ILMN_2079042 WFDC5 WAP four-disulfide core domain 5 2.94
ILMN_1786847 TGM3 transglutaminase 3 2.92
ILMN_1723480 BST2 bone marrow stromal cell antigen 2 2.92 2.87
ILMN_1731224 PARP9 poly (ADP-ribose) polymerase family, member 9 2.87 2.87
ILMN_1776181 BIRC3 baculoviral IAP repeat containing 3 2.46 2.86
ILMN_1736729 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 2.68 2.85
Fold change
226 
 
 
 
Probe Gene symbol Gene name EP24 F24 EP/F24
ILMN_1743412 SIAE sialic acid acetylesterase 2.83
ILMN_1735570 HOPX HOP homeobox 2.81
ILMN_2114720 SLPI secretory leukocyte peptidase inhibitor 2.79
ILMN_2239754 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 2.78
ILMN_1760062 IFI44 interferon-induced protein 44 2.77
ILMN_1690939 TYMP thymidine phosphorylase 2.89 2.75
ILMN_1655077 PRDM1 PR domain containing 1, with ZNF domain 2.74
ILMN_1673352 IFITM2 interferon induced transmembrane protein 2 3.37 2.73
ILMN_1725912 KLK12 kallikrein-related peptidase 12 2.72
ILMN_1672661 SP110 SP110 nuclear body protein 2.43 2.70
ILMN_1791545 KRT23 keratin 23 (histone deacetylase inducible) 2.70
ILMN_1769520 UBE2L6 ubiquitin-conjugating enzyme E2L 6 3.62 2.69
ILMN_1742618 XAF1 XIAP associated factor 1 2.69 2.69
ILMN_1695924 KLK11 kallikrein-related peptidase 11 2.69
ILMN_1703108 UBE2L6 ubiquitin-conjugating enzyme E2L 6 3.63 2.68
ILMN_1762861 HLA-F major histocompatibility complex, class I, F 2.96 2.66
ILMN_2262044 PARP10 poly (ADP-ribose) polymerase family, member 10 2.83 2.65
ILMN_1679960 LCE1A late cornified envelope 1A 2.63
ILMN_3243928 DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 2.54 2.61
ILMN_2336781 SOD2 superoxide dismutase 2, mitochondrial 3.99 2.60
ILMN_3249101 SDR9C7 short chain dehydrogenase/reductase family 9C, member 7 2.59
ILMN_1700081 FST follistatin 2.07 2.58
ILMN_1724686 CLDN1 claudin 1 2.58
ILMN_1698666 CST6 cystatin E/M 2.57
ILMN_2085862 SLC15A3 solute carrier family 15 (oligopeptide transporter), member 3 4.05 2.55
ILMN_1703855 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 2.53
ILMN_1705814 KRT80 keratin 80 2.52
ILMN_1690921 STAT2 signal transducer and activator of  transcription 2, 113kDa 2.51
ILMN_1814106 C9orf169 chromosome 9 open reading frame 169 2.50
ILMN_1754576 KRT6C keratin 6C 2.50
ILMN_1812281 ARG1 arginase 1 2.49
ILMN_1665832 ID1 inhibitor of  DNA binding 1, dominant negative helix-loop-helix protein 2.49
ILMN_1701789 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 2.48
ILMN_1654639 HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 2.77 2.47
ILMN_1835092 IFI44L interferon-induced protein 44-like 2.40 2.46
ILMN_1773352 CCL5 chemokine (C-C motif) ligand 5 3.23 2.46
ILMN_1709725 PAPL iron/zinc purple acid phosphatase-like protein 2.45
ILMN_1718558 PARP12 poly (ADP-ribose) polymerase family, member 12 2.07 2.44
ILMN_1719695 NFKBIZ nuclear factor of  kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 2.42
ILMN_1729801 S100A8 S100 calcium binding protein A8 2.10 2.41
ILMN_1706502 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 2.81 2.41
ILMN_1657234 CCL20 chemokine (C-C motif) ligand 20 2.61 2.40
ILMN_2134130 FLG filaggrin 2.39
ILMN_1697629 JMJD7-PLA2G4B JMJD7-PLA2G4B readthrough 2.38
ILMN_1745471 IRF9 interferon regulatory factor 9 2.27 2.38
ILMN_2170813 LAMP3 lysosomal-associated membrane protein 3 2.79 2.38
ILMN_2054019 ISG15 ISG15 ubiquitin-like modifier 2.24 2.36
ILMN_1773006 FABP4 fatty acid binding protein 4, adipocyte 2.35
ILMN_1699989 BNIPL BCL2/adenovirus E1B 19kD interacting protein like 2.34
ILMN_1776723 PHF11 PHD finger protein 11 2.34 2.34
ILMN_2390162 PHF11 PHD finger protein 11 2.44 2.34
ILMN_1795711 LCE2B late cornified envelope 2B 2.33
ILMN_2381257 DSC2 desmocollin 2 2.31
ILMN_1784294 CPA4 carboxypeptidase A4 2.30
ILMN_1687384 IFI6 interferon, alpha-inducible protein 6 2.51 2.30
ILMN_1814305 SAMD9 sterile alpha motif  domain containing 9 2.30
ILMN_1744923 WFDC5 WAP four-disulfide core domain 5 2.29
ILMN_1764709 MAFB v-maf  avian musculoaponeurotic fibrosarcoma oncogene homolog B 2.29
ILMN_2376108 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 2.62 2.26
ILMN_1657871 RSAD2 radical S-adenosyl methionine domain containing 2 2.20 2.25
ILMN_2053527 PARP9 poly (ADP-ribose) polymerase family, member 9 2.10 2.24
ILMN_3240420 USP18 ubiquitin specific peptidase 18 2.14 2.24
ILMN_1681644 BIRC3 baculoviral IAP repeat containing 3 2.24
ILMN_1659688 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 2.44 2.23
ILMN_1749118 CALML5 calmodulin-like 5 2.23
ILMN_1801216 S100P S100 calcium binding protein P 2.22
ILMN_1763666 ALDH3B2 aldehyde dehydrogenase 3 family, member B2 2.21
ILMN_1711174 SPRR1B small proline-rich protein 1B 2.20
ILMN_1700583 ZNF750 zinc finger protein 750 2.19
ILMN_1721134 TGM1 transglutaminase 1 2.18
ILMN_1845037 TRIM69 tripartite motif  containing 69 2.18
ILMN_1745964 IRAK2 interleukin-1 receptor-associated kinase 2 2.18
ILMN_3248032 NCCRP1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 2.17
ILMN_1788017 HSH2D hematopoietic SH2 domain containing 2.17
ILMN_1723035 OLR1 oxidized low density lipoprotein (lectin-like) receptor 1 2.17
ILMN_1745570 KLK7 kallikrein-related peptidase 7 2.15
ILMN_1746085 IGFBP3 insulin-like growth factor binding protein 3 2.15
ILMN_1704972 TRIM5 tripartite motif  containing 5 2.15
ILMN_1739882 SDR9C7 short chain dehydrogenase/reductase family 9C, member 7 2.13
ILMN_1663119 DSC2 desmocollin 2 2.12
ILMN_1701621 SCO2 SCO2 cytochrome c oxidase assembly protein 2.11
ILMN_1784364 STARD5 StAR-related lipid transfer (START) domain containing 5 2.11
ILMN_1682636 CXCL2 chemokine (C-X-C motif) ligand 2 2.08
ILMN_1751079 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2.31 2.08
ILMN_2396875 IGFBP3 insulin-like growth factor binding protein 3 2.07
ILMN_1727589 SULT2B1 sulfotransferase family, cytosolic, 2B, member 1 2.07
ILMN_1770338 TM4SF1 transmembrane 4 L six family member 1 2.06
ILMN_1693192 PI3 peptidase inhibitor 3, skin-derived 2.06
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Figure 8.1: Venn diagram of differentially expressed genes after 24 hours. 
Probe Gene symbol Gene name EP24 F24 EP/F24
ILMN_1718033 LYPD5 LY6/PLAUR domain containing 5 2.06
ILMN_2390586 SP100 SP100 nuclear antigen 2.07 2.06
ILMN_1793537 MUC15 mucin 15, cell surface associated 2.06
ILMN_1683792 LAP3 leucine aminopeptidase 3 2.36 2.05
ILMN_1810835 SPRR3 small proline-rich protein 3 2.05
ILMN_1741014 SLC28A3 solute carrier family 28 (concentrative nucleoside transporter), member 3 2.04
ILMN_2406501 SOD2 superoxide dismutase 2, mitochondrial 2.76 2.04
ILMN_2133090 SDR9C7 short chain dehydrogenase/reductase family 9C, member 7 2.03
ILMN_1737308 GLRX glutaredoxin (thioltransferase) 2.03
ILMN_1774901 GDPD3 glycerophosphodiester phosphodiesterase domain containing 3 2.02
ILMN_1758731 CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 2.19 2.01
ILMN_1697220 NT5E 5'-nucleotidase, ecto (CD73) 2.14 2.01
ILMN_2366445 KRT80 keratin 80 2.00
ILMN_1687757 AKR1C4 aldo-keto reductase family 1, member C4 0.45
ILMN_1677511 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 2.35
ILMN_1714861 CD68 CD68 molecule 2.31
ILMN_2054297 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 2.28
ILMN_2368530 IL32 interleukin 32 2.25
ILMN_2184373 IL8 interleukin 8 2.23
ILMN_2139100 SHISA5 shisa family member 5 2.23
ILMN_2376205 LTB lymphotoxin beta (TNF superfamily, member 3) 2.21
ILMN_1781966 OSBP2 oxysterol binding protein 2 2.03 2.18
ILMN_1710937 IFI16 interferon, gamma-inducible protein 16 2.07
ILMN_1755173 PLEKHA4 pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4 2.04
ILMN_1785732 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 2.01
ILMN_1764109 C1R complement component 1, r subcomponent 2.00
ILMN_1783753 TXNDC12 thioredoxin domain containing 12 (endoplasmic reticulum) 0.48
ILMN_1750800 ACO1 aconitase 1, soluble 0.48
ILMN_1790211 C7orf57 chromosome 7 open reading frame 57 2.31
ILMN_1697448 TXNIP thioredoxin interacting protein 2.12
ILMN_1661708 LGALS7 lectin, galactoside-binding, soluble, 7 0.49
ILMN_2064860 LGALS7B lectin, galactoside-binding, soluble, 7B 0.48
ILMN_1713124 AKR1C3 aldo-keto reductase family 1, member C3 0.45
ILMN_2412336 AKR1C2 aldo-keto reductase family 1, member C2 0.41
ILMN_1684306 S100A4 S100 calcium binding protein A4 0.40
ILMN_2396444 CD14 CD14 molecule 0.40
ILMN_2367239 RCAN1 regulator of  calcineurin 1 0.38
ILMN_1712112 RCAN1 regulator of  calcineurin 1 0.31
Fold change
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